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CHAPTER ONE 
REVIEW OF LITERATURE 
Hemostasis 
 The maintenance of blood flow through the circulation is critical to adequately 
supply oxygen and nutrients to organs and tissues and thereby maintain life. The ability 
to recover from disruptions to the integrity of the vascular system is critical to this 
function. Hemostasis is the process by which blood within the vasculature remains a free-
flowing liquid while also permitting the rapid formation of solid clots to plug defects in 
ruptured or injured blood vessels. This physiological response to vascular injury prevents 
excessive blood loss from a damaged blood vessel through vascular constriction, platelet 
plug formation, and blood coagulation, forming a plug to block the vascular leakage site. 
This process is accomplished through the combined actions of the vascular wall 
(including the endothelial and subendothelial layers), platelets, and the coagulation and 
fibrinolytic systems. Disruption of this process, resulting in either excessive bleeding or 
excessive clotting, can have severe and potentially fatal consequences.  
The initial response to vascular injury is vasoconstriction, mediated through 
neurogenic reflexes. This restricts blood flow through the damaged vessel, minimizing 
blood loss. Primary hemostasis is mediated by platelets and results in the formation of an 
initial platelet plug. This is followed by secondary hemostasis, in which the coagulation 
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cascade is activated and a fibrin clot is formed. The fibrinolytic system ultimately 
degrades this clot as tissue healing occurs.  
Coagulation. 
 The coagulation cascade, shown in Figure 1, is a network of circulating zymogen 
proteins as well as cofactors, activators, and inhibitors. Coagulation factor proteases are 
produced in the liver and circulate in inactive, proenzyme forms. When a coagulation 
factor is activated by enzymatic cleavage, it gains the ability to proteolytically activate 
the next factor in the coagulation cascade. This system is responsible for the production 
of an insoluble, gel-like fibrin clot. Coagulation can be initiated through either the 
intrinsic (contact activation) or extrinsic (tissue-factor mediated) pathway. These 
pathways converge at the conversion of Factor X to its active form, FXa.  
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Figure 1. The Coagulation Cascade. The coagulation cascade is commonly discussed 
in terms of the intrinsic or contact activation pathway (shown in blue), the extrinsic 
pathway, initiated by tissue factor (shown in green). The intrinsic and extrinsic 
pathways converge at the activation of factor X in the common pathway (shown in 
orange), which ultimately leads to the formation of a crosslinked fibrin clot. 
Endogenous anticoagulants (shown in red) including protein C, activated protein C 
(APC), thrombomodulin (TM), antithrombin (AT), and tissue factor pathway inhibitor 
(TFPI), act at various points on the coagulation cascade to prevent inappropriate or 
excessive coagulation. The fibrinolytic pathway (shown in purple) is responsible for 
the degradation of the fibrin clot.  
  
The extrinsic pathway is activated by the presence of tissue factor (TF) in the 
circulation. TF is a cell surface protein expressed on subendothelial cells and can 
therefore be exposed to the circulation following endothelial damage. Other conditions, 
including inflammation, can increase the expression of TF on intravascular cells. TF 
functions as a cell surface receptor for FVII and catalyzes the conversion of FVII to 
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FVIIa. The TF/FVIIa complex then catalyzes the conversion of FX into the active 
protease FXa.  
 The intrinsic pathway is initiated upon exposure of subendothelial collagen to the 
circulation by the formation of a complex of high molecular weight kininogen (HMWK), 
prekallekrein, and FXII on a collagen scaffold. This leads to the conversion of FXII to its 
active form FXIIa. The generation of FXIIa leads to an activation cascade, ultimately 
resulting in the generation of FXa.  
 The common pathway begins where the intrinsic and extrinsic pathways converge 
at the conversion of FX to FXa. FXa is responsible for the conversion of prothrombin 
(FII) to thrombin (FIIa). Thrombin is a serine protease with the ability to convert soluble 
fibrinogen into insoluble fibrin. Thrombin also exerts positive feedback on the 
coagulation cascade, activating factors XI, VII, V, and XIII. Factor XIII crosslinks fibrin 
strands, stabilizing the clot.  
 Endogenous anticoagulants, including antithrombin (AT), tissue factor pathway 
inhibitor (TFPI), and protein C, serve to prevent excessive or inappropriate coagulation. 
These anticoagulants act at different points throughout the coagulation cascade, 
preventing excessive coagulation initiated by either the intrinsic or extrinsic pathway. AT 
is an inhibitor of factors XIa, Xa, IXa, and IIa. TFPI inhibits the conversion of FVII to 
FVIIa as well as FXa. Protein C is an inhibitor of FVIIIa and FVa. 
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Fibrinolysis. 
 The fibrinolytic system consists of the enzymes responsible for clot dissolution. 
Like the coagulation factors, the main fibrinolytic enzyme, plasmin, is produced as a 
proenzyme, plasminogen, in the liver and activated when cleaved into its enzymatic form. 
The breakdown of a clot is a necessary part of the healing and tissue repair process. 
Plasmin cleaves the fibrin meshwork, degrading the clot. This forms fibrin split products, 
including D-Dimer, which can be detected in the blood as biomarkers of clot breakdown. 
Fibrinolysis is regulated by promotors such as tissue plasminogen activator (t-PA) and 
inhibitors including plasminogen activator inhibitor 1 (PAI-1), α2-antiplasmin, and 
thrombin activatable fibrinolysis inhibitor (TAFI). 
Platelets. 
 Platelets are small, discoid, anucelear cells derived from megakaryocytes that 
react to subendothelial proteins and can aggregate to form a primary hemostatic plug. 
Following endothelial injury, platelets adhere to subendothelial collagen. vWF serves as a 
molecular bridge between the collagen and the platelet membrane receptor glycoprotein 
(GP)Ib. Adhesion via GPIb works to platelets from the circulation and slow their flow to 
allow for activation and firmer adhesion mediated by GPIIb/IIIa. Activated platelets 
release granules. Light (α) granules contain fibrinogen, fibronectin, coagulation factors 
(F)V, and FVIII, platelet factor 4 (PF-4), platelet derived growth factor (PDGF), and 
transforming growth factor β (TGFβ). Dark (β) granules contain ADP, ATP, Ca2+, 
histamine, serotonin, and epinephrine. The release of granule contents leads to the 
aggregation and activation of additional platelets. In addition to forming the primary 
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hemostatic plug, the phospholipid surface of activated platelets provides a site for 
coagulation factors to combine with ionized calcium to activate the intrinsic pathway of 
the coagulation cascade.  
Endothelium. 
 Under normal physiological conditions, the endothelium has anticoagulant 
properties. Endothelial cells secrete prostaglandins and nitric oxide (NO), both of which 
inhibit platelet aggregation. Additionally, endothelial cells produce endogenous 
anticoagulants, including protein C, antithrombin (AT), thrombomodulin, protein S, and 
tissue factor pathway inhibitor (TFPI). The endothelial cell layer also prevents the 
exposure of circulating blood to subendothelial collagen. When the endothelium is 
damaged, collagen is exposed and initiates platelet aggregation and coagulation. 
Endothelial cells also produce von Willebrand Factor (vWF), which acts as a molecular 
bridge between platelets and collagen. In addition to causing the loss of the anticoagulant 
properties of the endothelium, activation or damage can cause a procoagulant response, 
mediated through the expression of the coagulation activator tissue factor (TF). The 
endothelium is also responsible for the production of many of the regulators of 
fibrinolysis.  
White Blood Cells. 
White blood cells (WBCs), also known as leukocytes, are the chief mediators of 
the immune system. Several distinct types of leukocytes develop in the bone marrow 
from hematopoietic stem cells, each with a district role in immunity. The WBC count is 
measured clinically as part of the complete blood count (CBC). The normal range for 
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WBC in a CBC is approximately 4,000-10,000 cells/μl. An elevated WBC count, known 
as leukocytosis, can be indicative of inflammation or infection.  
The immune response can be broadly divided into two categories; innate and 
acquired. Innate immunity is the set of nonspecific mechanisms that respond rapidly to 
pathogen exposure. Several cell types are involved in innate immunity, including natural 
killer cells, dendritic cells, basophils, eosinophils, mast cells, and the phagocytes; 
macrophages, monocytes, and neutrophils. Adaptive immunity develops throughout an 
individual’s life based on exposure to pathogens. B and T lymphocytes are the primary 
mediators of adaptive immunity.  
Neutrophils are of particular importance in the response to infections such as 
sepsis. Neutrophils are the most abundant circulating leukocyte and are the first 
responder in the case of bacterial or fungal infection. Neutrophils are often described as 
polymorphonuclear (PMN) leukocytes on the basis of their multilobed nucleus. In 
response to infection or inflammatory mediators such as interleukin 8 (IL-8), neutrophils 
migrate through the blood vessel wall towards the site of infection. At the site of 
infection, neutrophils release cytokines in order to recruit additional WBCs. Neutrophils 
also have several direct anti-infectious activities: phagocytosis, degranulation, and the 
release of neutrophil extracellular traps (NETs). In phagocytosis, neutrophils internalize 
and subsequently kill bacteria. Neutrophils can also degranulate, releasing a variety of 
antimicrobial proteins into the extracellular environment to kill or neutralize bacteria. 
NETosis, or the production of NETs, describes the process by which neutrophils can 
expel their nuclear contents, including chromosomal DNA, as well as antimicrobial 
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proteins, into the extracellular environment in order to trap or kill invading bacteria. As 
NETs have been shown to exhibit pro-inflammatory and pro-thrombotic properties, this 
process is particularly relevant to sepsis-associated coagulation dysfunction. 
Monocytes are a type of leukocyte capable of differentiation into macrophages or 
dendritic cells. Macrophages are phagocytes located primarily in the tissue that consume 
pathogens and cellular debris. Macrophages can secrete both pro-inflammatory and anti-
inflammatory cytokines in order to modulate the immune system. Macrophages and 
dendritic cells are also involved in the initiation of the adaptive immune response to a 
specific pathogen. In response to inflammation, monocytes and macrophages can also 
express TF, contributing to a procoagulant state. 
Abnormal Hemostasis. 
 Numerous pathological conditions can result in abnormal hemostasis, leading to 
either excessive bleeding or pathological clot formation. Thrombosis is the pathological 
formation of a clot, known as a thrombus, within an intact blood vessel. A thrombus 
blocks blood flow through the affected vasculature. Additionally, a thrombus can break 
free from its location of origin through a process known as embolization and become 
lodged in a distant vessel. Embolization of a clot can be fatal, particularly if lodged in the 
lungs (pulmonary embolism), heart (myocardial infarction), or brain (thromboembolic 
stroke).  
 The conditions required for thrombosis to occur are described by Virchow’s 
Triad, shown in Figure 2. Thrombosis occurs under conditions of endothelial damage, 
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stasis, and hypercoagulability. Endothelial damage or dysfunction results in the 
expression of TF, exposure of collagen, and the loss of endothelial anticoagulant 
properties. Low flow rates facilitate clot formation, and therefore coagulation is also 
favored in locations where blood is static in the vasculature. This commonly includes the 
atria of patients with atrial fibrillation or the veins of the lower legs, particularly in 
sedentary or immobilized individuals. Consequently, hospitalized patients often require 
prophylactic anticoagulation. Hypercoagulability can occur due to genetic factors, 
including mutations in coagulation factors or endogenous anticoagulants, or can be 
acquired due to situations including inflammation, smoking, oral contraceptive use, 
sepsis, cancer, or trauma. When endothelial damage, stasis, and hypocoagulability co-
occur, there is potential for thrombus formation. Anticoagulant therapy is often indicated 
in these situations.  
 In addition to thrombosis, abnormal hemostasis can also result in bleeding. 
Thrombocytopenia can occur due to platelet consumption, platelet destruction, splenic 
sequestration, or reduced production due to hereditary or acquired alterations in bone 
marrow. Qualitative platelet disorders such as Glanzmann’s thrombasthenia or Bernard-
Soulier disease can also predispose patients to bleeding. Reductions in circulating 
coagulation factors, through excessive consumption, pharmacologic modulation, or 
genetic disorders such as hemophilia (deficiencies in FVIII or FIX), can also contribute to 
bleeding risk. Bleeding can also occur secondary to excessive activation of the 
fibrinolytic system due to decreased circulating fibrinogen and the anticoagulant effects 
of fibrinogen degradation products.  
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Figure 2. Virchow’s Triad. Virchow’s Triad describes the three conditions that must 
be met for thrombosis to occur.  
 
Inflammation. A significant, bi-directional relationship exists between 
inflammation and thrombosis. Inflammation and inflammatory factors including the 
multi-protein inflammasome complex, have been implicated in the pathogenesis of many 
thrombotic disorders including sepsis, atherosclerosis, coronary artery disease, and atrial 
fibrillation. Several of the prototypical proinflammatory cytokines including IL-6, IL-1β, 
and TNFα induce the expression of TF on intravascular cells, particularly monocytes and 
endothelial cells, resulting in the development of a procoagulant state. Coagulation can 
also contribute to systemic inflammation. Thrombin and FXa activate protease activated 
receptors (PARs), G-protein coupled cell surface receptors, which have diverse effects 
including pro-inflammatory activities.  
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Sepsis 
Sepsis is a severe systemic response to infection characterized by an 
overwhelming inflammatory response, and is a complex and potentially devastating 
clinical scenario with high mortality. Sepsis often develops from the spread of a localized 
infection, such as pneumonia, urinary tract infection, or a skin or surgical site infection, 
but can also occur due to direct entry of bacteria into the bloodstream. The defining 
pathophysiologic feature of sepsis is the overwhelming host response to infection. 
Although a robust immune response is necessary to overcome infection, the immune 
response in sepsis can occur to excess. This leads to the derangement of multiple 
physiological processes and can cause dysfunction and failure of most major organ 
systems. The immune dysfunction observed in sepsis is not limited to the initial 
hyperinflammatory response, typically characterized by elevated plasma cytokine levels. 
Septic patients may experience qualitative defects in the function of neutrophils and other 
immune cells. Patients may also progress into a state of “immune paralysis” in which the 
resources of the immune system are exhausted and a patient can no longer mount an 
effective defense against infection. Clinical manifestations of sepsis include hypo- or 
hyperthermia, tachycardia, increased respiratory rate or reduced oxygen saturation, 
altered mental status, and hypotension. This hypotension may progress to shock and 
contribute to organ failure and death through impaired perfusion. However, numerous 
other processes, such as coagulation dysfunction, are involved in the development and 
progression of sepsis and contribute greatly to patient outcome.   
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Clinical Definitions of Sepsis. 
For clinical and research purposes, scoring systems incorporating clinical and 
laboratory parameters are used to describe and diagnose sepsis patients. The most recent 
set of guidelines (SEPSIS-3) was published by the Society for Critical Care Medicine 
(SCCM) in 2016 (Singer2016). These guidelines, summarized in flow chart form in 
Figure 3, present a process to be used in the diagnosis of sepsis in patients with a 
documented or suspected source of infection. Using these guidelines, patients are first 
screened with the Quick Sequential Organ Failure Assessment (qSOFA) tool. Patients 
meeting qSOFA criteria, defined as two or more of: respiratory rate ≥ 22 breaths per 
minute, altered mentation, and systolic blood pressure ≤ 100 mmHg, are then evaluated 
with the Sequential Organ Failure Assessment (SOFA) score, shown in Table 1. Patients 
with a SOFA score of two or greater, or a change of 2 or greater from baseline status in 
the case of pre-existing organ dysfunction, are considered to have sepsis. Patients with 
sepsis are then further evaluated for septic shock on the basis of the requirement for 
vasopressors to maintain mean arterial pressure (MAP) ≥65 mmHg and serum lactate 
levels >2 mmol/L.  
While new definitions for sepsis were published in 2016, the currently available 
literature describes sepsis according to the previous set of guidelines published in 1992 
(Bone 1992) and updated in 2001 (Levy 2003). Understanding of these guidelines is 
necessary to facilitate understanding of previous research, and these guidelines are 
detailed in Table 2. Patient samples used in this dissertation were collected prior to the 
publication of the 2016 guidelines and therefore were collected on the basis of the 1992 
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and 2001 guidelines. These guidelines define a spectrum of severity of illness ranging 
from sepsis to multiple organ dysfunction syndrome (MODS). These guidelines also 
define systemic inflammatory response syndrome (SIRS) as a sepsis-like inflammatory 
response in the absence of an infection.  
 
Figure 3. Summary of SEPSIS-3 Guidelines for the Diagnosis of Sepsis. Figure 
adapted from Singer et. al. 2016. In patients with confirmed or suspected sepsis, the 
qSOFA score is first evaluated as a screening mechanism. In patients with a qSOFA ≥ 
2, the more extensive SOFA score is then evaluated. Patients with sepsis are then 
further evaluated for the presence of shock.  
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Table 1. The Sequential Organ Failure Assessment (SOFA) Scoring System 
 
SOFA Score 1 2 3 4 
Respiration 
PaO2/FiO2, mmHg 
<400 <300 <200 
 (with respiratory 
support) 
<100 
 (with respiratory 
support) 
Coagulation 
Platelets, K/ml 
<150 <100 <50 <20 
Liver 
Bilirubin, mg/dl 
(μmol/l) 
1.2-1.9 
 (20-32) 
2.0-5.9 
 (33-101) 
6.0-11.9 
 (102-204) 
>12.0 
 (>204) 
Cardiovascular 
Hypotension 
 (Doses given in 
μg/kg*min) 
MAP < 
70 
mmHg 
Dopamine ≤ 5 
Or dobutamine, 
any dose 
Dopamine > 5 
Or epinephrine ≤ 
0.1 
Or 
norepinephrine ≤ 
0.1 
Dopamine > 15 
Or epinephrine > 
0.1 
Or 
norepinephrine > 
0.1 
Central nervous 
system 
Glasgow Coma Score 
13-14 10-12 6-9 <6 
Renal 
Creatinine, mg/dl 
(μmol/l) or urine 
output 
1.2-1.9 
 (110-
170) 
2.0-3.4 
 (171-299) 
3.5-4.9 
 (300-440) 
Or <500 ml/day 
>5 
 (>440) 
Or <200 ml/day 
Table adapted from the Working Group on Sepsis-Related Problems of the European 
Society of Intensive Care Medicine (Singer 2016; (Vincent1996) 
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Table 2. SCCM Definitions for Sepsis and Associated Conditions 
 
Condition Definition 
Bacteremia The presence of viable bacteria in the blood 
Systemic 
inflammatory 
response syndrome 
(SIRS) 
Systemic inflammatory response to a variety of severe clinical 
insults, manifested by two or more of the following conditions: 
 Temperature >38ºC or < 36ºC 
 Heart rate >90 BPM 
 Respiratory rate >20 breaths per minute or PaCO2 <32 
mmHg 
 White blood cell count >12,000/cu mm, <4,000/cu mm, 
or >10% immature forms 
Sepsis The systemic response to infection, manifested by two or more 
of the following as a result of the infection: 
 Temperature >38ºC or < 36ºC 
 Heart rate >90 BPM 
 Respirator rate >30 breaths per minute or PaCO2 <32 
mmHg 
 White blood cell count >12,000/cu mm, <4,000/cu mm, 
or >10% immature (band) forms 
Severe sepsis Sepsis associated with organ dysfunction, hypoperfusion, or 
hypotension, including but not limited to lactic acidosis, 
oliguria, or acute alteration in mental status 
Septic shock Sepsis-induced hypotension despite adequate fluid resuscitation 
along with perfusion abnormalities including but not limited to 
lactic acidosis, oliguria, or acute alteration in mental status. 
Patients receiving inotropic or vasopressive agents may not be 
hypotensive at the time perfusion abnormalities are measured 
Sepsis-induced 
hypotension 
Systolic blood pressure <90 mmHg or a reduction of ≥40 mmHg 
from baseline in the absence of other causes of hypotension 
Multiple organ 
dysfunction 
syndrome (MODS) 
Presence of altered organ function in an acutely ill patient such 
that homeostasis cannot be maintained without intervention 
Table adapted from the consensus guidelines set forth by the ACCP/SCCM consensus 
conference committee (Bone1992; Levy2003) 
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Epidemiology of Sepsis. 
Although it is clear that sepsis is a critical clinical condition with high mortality, 
precise estimation of the incidence of sepsis and associated mortality is difficult due to 
disease heterogeneity. However, it is clear that sepsis and associated illnesses are major 
causes of death in the United States and around the world. In 2010, “septicemia” was 
listed by the Centers for Disease Control (CDC) as the 11th most common cause of death 
(Murphy 2013). In that same year, more than 132,000 hospitalized patients in the US died 
with a first-listed diagnosis of sepsis (Hall 2013), and between 1999 and 2016, 2,470,666 
deaths (6% of total deaths in the United States) listed sepsis among the causes of death 
(Epstein 2016). Over 1 million cases of sepsis are estimated to occur in US hospital 
patients annually, with 2% of all hospitalized patients and 6-30% of ICU patients 
experiencing sepsis (Martin 2012). A 2016 meta-analysis estimated that 31.5 million 
cases of sepsis occur annually around the globe, including 19.4 million cases of severe 
sepsis and accounting for 5.3 million deaths (Fleischmann 2016).  
In addition to occurring with a high incidence worldwide, sepsis is associated 
with a high short-term mortality rate. The same 2016 analysis estimated in-hospital 
mortality in high-income countries at 17% for sepsis and 6% for severe sepsis 
(Fleischmann 2016). A separate study also published in 2016 reported the incidence of 
sepsis in the US in 2012 as 436 cases per 100,000 individuals, with an overall mortality 
of 17.3% (Stoller 2016). Using the 1992 definitions, mortality has been estimated at 10-
20% for sepsis, 20-50% for severe sepsis, and 40-80% for septic shock (Martin 2012). 
Other estimates for mortality for severe sepsis range from 14.7-29.9% (Gaieski 2013; 
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Hawiger 2015). Less data is available with regards to patient outcome using the 2016 
sepsis definitions. However, a French study published in 2017 reported 24% mortality for 
patients presenting to the emergency department with suspected infection and a qSOFA 
of ≥ 2 (Freund 2017). A retrospective analysis of 844 patients in the placebo arm of a 
large clinical trial in severe sepsis patients reported that those who die within the first 5 
days in the ICU are most likely to die of refractory shock, while those who die after more 
than 5 ICU days are more likely to die of respiratory failure (Macias 2004).  
The consequences of sepsis extend beyond short term in-hospital mortality. A 
study of 3195 patients with severe sepsis in 42 ICUs throughout Japan found a 26.4% 28 
day mortality rate but a 43.7% 90 day mortality rate (Hayakawa 2016). A Taiwanese 
study demonstrated that patients who recover from sepsis experience higher rates of 
severe adverse events, including: ischemic or hemorrhagic stroke, myocardial infarction, 
heart failure, and sudden cardiac death (Ou 2016). These patients also experienced higher 
all-cause mortality compared to age and gender matched non-septic hospitalized or 
healthy controls (Ou 2016). Even when patients survive, sepsis still places a significant 
financial burden. The median cost of a hospital stay for a patient with severe sepsis in 
2012 was estimated at $55,749 (Stoller 2016). In 2011 it was estimated that the annual 
cost of sepsis in the US is greater than $20 billion (Hawiger 2015).  
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Disseminated Intravascular Coagulation 
Disseminated intravascular coagulation (DIC) is an acquired coagulation disorder 
with high mortality that is characterized by both thrombotic and bleeding complications. 
In DIC, widespread activation of the coagulation cascade occurs, leading to fibrin 
deposition in the microvasculature and subsequent ischemia and organ failure. This 
inappropriate coagulation activity consumes platelets and coagulation proteins, leading to 
an elevated bleeding risk. Consequently, patients with DIC typically present with 
symptoms of both thrombosis, including organ dysfunction due to microthrombi in the 
vasculature, as well as bleeding, ranging from low-grade oozing from vascular access 
sites or surgical sites to potentially massive hemorrhage (Hunt 2014).  
DIC does not develop spontaneously but rather occurs as a complication of a 
number of predisposing conditions. DIC occurs most commonly in association with 
sepsis or trauma (Gando 2016), but can also occur in conjunction with cancer, obstetrical 
complications, vascular disorders, toxin exposure, aneurysm, liver disease, and 
immunological disorders (Levi 1999; Taylor 2001; Wada 2013). Although DIC 
secondary to each of these conditions may exhibit certain similarities, there are notable 
differences in DIC pathophysiology based on the underlying condition. For the purposes 
of this dissertation, discussion of DIC will be limited to cases occurring secondary to 
sepsis.  
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Pathophysiology of DIC. 
The pathophysiology of DIC is complex and involves multidirectional 
interactions between the coagulation cascade, platelets, the vascular endothelium, and the 
inflammatory and immune response. Excessive inflammation, dysregulation of the 
endogenous anticoagulant system, activation of platelets and endothelial cells, and 
bacterial and antibacterial processes contribute to a systemic prothrombotic state in DIC 
patients. Ongoing coagulation can lead to further dysregulation of these processes, 
amplifying disease development.  
Extensive cross-talk between inflammation and coagulation has been noted in 
DIC as well as in other clinical scenarios characterized by inflammation. In sepsis, 
bacterial components, particularly lipopolysaccharide (LPS), elicit a vigorous 
inflammatory response. This includes production of high levels of inflammatory 
cytokines such as interleukin (IL)-6, IL-1β, and tumor necrosis factor α (TNFα). These 
factors induce the expression of tissue factor (TF) on the surface of intravascular cells 
including monocytes and endothelial cells. The presence of high levels of TF in the 
circulation activates the extrinsic pathway of the coagulation cascade and is generally 
considered to be a major initiator of coagulation in sepsis-associated DIC (Esmon 2011; 
Gando2016; Levi 2017). 
Under homeostatic conditions, excessive coagulation is prevented by a set of 
endogenous anticoagulants, including thrombomodulin (TM), antithrombin (AT), 
activated protein C (APC), and tissue factor pathway inhibitor (TFPI) (Gando 2016; 
Ikezoe 2015). The endogenous anticoagulant system becomes dysregulated in DIC, 
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allowing inappropriate coagulation to occur. In addition to increasing the levels of 
procoagulant factors, high levels of inflammatory cytokines also downregulate 
endogenous anticoagulants, including TM, protein C, and endothelial cell protein C 
receptor (Esmon 2004). The reduction in protein C levels in DIC patients has been shown 
to correlate with poor outcomes (Levi 2001; ten Cate 2000). In addition to its 
anticoagulant activity, APC also possesses anti-inflammatory properties; these are also 
lost in DIC, further contributing to disease (Gando 2016). Although circulating levels of 
TM may not be markedly reduced in DIC patients, this is not due to upregulation but 
rather to shedding from the damaged endothelium, which further contributes to 
dysregulation of the endogenous anticoagulant system. Levels of AT are typically 
reduced in DIC patients, due to both reduced synthesis in the liver and increased 
consumption to combat excessive coagulation activation. 
Other factors that contribute to the pathophysiology of DIC include endothelial 
damage, platelet activation, and antibacterial response. In response to bacterial presence 
in the bloodstream, bactericidal factors such as neutrophil extracellular traps (NETs), 
composed of nuclear materials and bactericidal enzymes, are released into the 
bloodstream. While these components play a role in the eradication of bacteria, they are 
also prothrombotic and contribute to coagulation dysfunction and endothelial damage. 
Activation of the endothelium, including TF upregulation induced by inflammatory 
cytokines, as well as damage due to bactericidal factors provides favorable sites for 
thrombus initiation throughout the circulation. Inflammatory and bactericidal factors can 
also activate platelets, further perpetuating thrombus formation.  
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In order to fully understand the pathophysiology of DIC, it is important to 
appreciate the contribution of each of these dysregulated systems as well as their 
replication in animal models of DIC and modulation by therapeutic agents. 
Representative markers of these aspects of DIC will be discussed in an upcoming section.  
The Coagulation Cascade in DIC. In the clinical setting, coagulation is assessed 
through a set of standardized coagulation tests. These tests are also used to monitor 
coagulation status and response to therapy in patients treated with anticoagulants. Patients 
with sepsis and DIC have abnormal results on these standard coagulation screening tests, 
with prolonged clotting times indicating a hypocoagulable state. However, patients with 
sepsis and DIC also experience a propensity for clotting, indicating that the appropriate 
interpretation of these tests may differ between DIC patients and anticoagulated patients. 
The extrinsic pathway is monitored by prothrombin time (PT), and is commonly 
reported as international normalized ratio (INR), a standardized method to allow 
comparison of values between laboratories. INR is commonly elevated in sepsis patients 
and is used in the diagnosis of DIC. PT/INR is also used to monitor coagulation in 
patients taking warfarin, which reduces the synthesis of the vitamin K dependent factors 
II, VII, IX and X. A normal INR value is 1, and the therapeutic target range for patients 
taking warfarin is between 2 and 3. Functional and antigenic levels of FVII can also be 
measured to evaluate the function of the extrinsic pathway.  
The activated partial thromboplastin time (aPTT) is used to monitor the function 
of the intrinsic pathway and to monitor coagulation in patients receiving heparin. Factor 
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II, VI, IX, X, and XII antigenic and functional levels can be measured to assess this arm 
of the coagulation cascade.  
Fibrinogen, the soluble precursor to fibrin, can also be measured clinically. 
Reduced fibrinogen levels due to consumption is a component of the DIC scoring system. 
Fibrinogen is produced in the liver as an acute phase reactant. Accordingly, fibrinogen 
can also be elevated in DIC, particularly in the earlier stages. Factor X antigenic and 
functional levels can be measured as an alternative assessment of the function of the 
coagulation cascade 
The coagulation anomalies observed in sepsis patients range from slight 
perturbations in laboratory values to severe overt DIC. A study of 38 patients with severe 
sepsis reported an abnormal standard coagulation screen, including PT and aPTT, in 95% 
of patients (Collins 2006). As INR is one of the key parameters used clinically to identify 
patients with sepsis-associated coagulopathy, it is important to understand the appropriate 
interpretation of this measure in this specific patient population. Prolonged PT or 
elevated INR is generally indicative of a hypocoagulable state; however, patients 
presenting with SAC with an elevated INR are at risk of complications due to both 
thrombosis and bleeding. 
Elevated PT or INR is reported in 90% or more of sepsis patients with severe 
disease (Collins 2006; Kinasewitz 2004; Koami 2015). Prolonged PT and elevated INR 
are associated with increased mortality and poor clinical outcome in sepsis patients 
(Dhainaut 2005; Kinasewitz 2004) as well as other critically ill or injured patient 
populations (MacLeod 2003; Walsh 2010). Elevated PT-INR (typically INR ≥ 1.2) is 
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often a component of the inclusion criteria for clinical trials in patients with sepsis-
associated coagulation disorders (Abraham 2003; Vincent 2013). The majority of the 
elevated INRs within this patient population have been reported to fall into the range of 
1.6 to 2.5 (Walsh 2010). Other changes in global coagulation parameters, including aPTT 
(Bakhtiari 2004; Collins 2006; Daudel 2009; Johansson 2010; Kinasewitz 2004; Koami 
2015) and whole blood clotting ability as measured by thromboelastography (Daudel 
2009; Johansson 2010; Koami 2015), are also often reported in sepsis patients as well as 
in other critically ill patient populations.  
Despite clear evidence that significant changes to the overall coagulation profile 
occur in sepsis, changes in the levels of individual coagulation factors in sepsis and DIC 
patients are less well established. Reduced levels of coagulation factors including factors 
II, V, VII, X, and XII relative to those in normal individuals have been reported in sepsis-
associated coagulopathy (Collins 2006). However, these results demonstrated no 
discernible relationship to standard coagulation tests and are highly variable between 
studies (Collins 2006; Daudel 2009; Johansson 2010). 
PT/INR was designed to monitor the anticoagulation status in patients treated 
with warfarin and is widely used clinically for this purpose. Warfarin treated patients are 
typically considered appropriately anticoagulated with an INR of between 2 and 3, and 
regular adjustments to drug dosage are made to maintain the INR within this range. A 
study of the relationship of serial INR levels to severe bleeding in patients receiving 
warfarin anticoagulation found that warfarin patients hospitalized with severe bleeding 
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showed an elevated INR compared to non-bleeding patients (5.9 ± 5.9 vs. 2.3 ± 0.7) as 
well as higher INRs before the event of the bleed (3.0 ±1.2 vs. 2.1 ± 0.8) (Kucher 2004) 
The difference in INR levels at which bleeding occurs in warfarin treated and DIC 
patients as well as the fact that DIC patients with an elevated INR indicative of 
hypocoagulability experience both thrombotic and bleeding complications suggests that 
the information provided by this common laboratory test may be significantly different in 
these two patient populations. Accordingly, studies are required to compare the 
relationship of laboratory coagulation tests and levels of individual coagulation factors 
with INR in patients with DIC to the relationships observed in warfarin treated patients.  
Diagnosis of DIC. 
DIC is diagnosed through the application of a scoring system incorporating 
clinically available laboratory parameters describing coagulation dysfunction. For the 
purposes of this project, the International Society of Thrombosis and Hemostasis (ISTH) 
scoring system for overt DIC, shown in Table 3, will be used (Taylor 2001); however, the 
Japanese Association for Acute Medicine (JAAM) definition for DIC (Gando 2006), 
which incorporates a similar set of parameters, is used in some literature and is shown in 
Table 81 in Appendix C. The presence of a condition associated with DIC, including 
sepsis, trauma, organ destruction, malignancy, obstetrical calamity, vascular abnormality, 
severe hepatic failure, and severe toxic or immunologic reaction is a prerequisite for the 
application of this scoring system. For the purposes of this proposal, discussion of DIC is 
limited to cases associated with sepsis.  
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Table 3. ISTH Scoring System for DIC 
 
Variable Value Points 
Platelets (K/μl) 
>100 0 
50-100 1 
<50 2 
INR 
<1.3 0 
1.3-1.7 1 
>1.7 2 
D-Dimer (ng/ml) 
<400 0 
400-4000 2 
>4000 3 
Fibrinogen (mg/dl) 
>100 0 
<100 1 
 
Following the diagnosis of a condition associated with DIC, points are assigned 
based on clinical test results according to the above scoring system. Platelet count is 
typically reduced in DIC due to consumption. The international normalized ratio (INR), a 
standardized method of reporting the prothrombin time (PT), which is reflective of the 
status of the extrinsic coagulation pathway, is prolonged due to coagulation factor 
consumption. D-Dimer, a clinically validated marker of thrombosis, is elevated due to 
thrombus formation in the microvasculature. Fibrinogen, the soluble precursor of 
insoluble fibrin, is typically reduced in DIC due to consumption. However, in some 
patients, fibrinogen may be elevated due to its production in the liver as an acute phase 
reactant.  
Using this scoring system, a score of 5 or higher is indicative of overt or severe 
DIC. A score of 3-4 indicates the presence of an intermediate phenotype, typically 
referred to as non-overt DIC. A score of 0-2 indicates that DIC is not present. 
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DIC may be present in patients at the time of presentation to the emergency room 
or may develop in already hospitalized sepsis patients. In a study of 259 patients with 
septic shock actively monitored for DIC, 61 patients had DIC at admission, and 32 
additional patients developed DIC within 24 hours following admission despite the 
initiation of antibiotics and other therapies (Delabranche 2016). 
Epidemiology of DIC. 
Studies of DIC epidemiology and outcomes are complicated by the general 
heterogeneity of this disease as well as variants in the predisposing condition, diagnostic 
criteria used, and local standard of care. Coagulopathy is common in patients with sepsis. 
It has been estimated that changes in hemostasis become clinically significant in 50 to 
70% of sepsis patients, and that 35% of patients with sepsis will meet the criteria for DIC 
(Levi 2017). Another study identified DIC in 27% of patients with thrombocytopenia 
following diagnosis with severe sepsis or septic shock (Hawiger 2015). In a study of 77 
Japanese patients admitted to the ICU with a diagnosis of sepsis, 48.1% developed overt 
DIC according to the ISTH scoring system (Koyama 2014). Furthermore, these patients 
also experienced more severe illness, as quantified by higher Acute Physiology and 
Chronic Health Evaluation (APACHE) II and SOFA scores (Koyama 2014). In a study of 
259 patients with septic shock, 93 developed DIC as diagnosed by the ISTH score 
(Delabranche 2016). These patients had elevated mortality compared to those who did 
not develop DIC (45.2% vs. 28.3%) as well as elevated SOFA scores, incidence of acute 
kidney injury and hepatic failure, and increased requirement for renal replacement 
therapy, vasopressors, and blood products (Delabranche 2016). A study evaluating 
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consecutive critically ill patients with DIC diagnosed according to the ISTH criteria at 
Mayo Clinic found an incidence rate of 18.6 per 100,000 person years in 2010, with 
higher rates in men and the elderly (Singh 2013). Sepsis was a predisposing factor in 
59.7% of cases, and the overall in-hospital mortality ranged from 39%-58% in the years 
included in this study (Singh 2013)  
Development of DIC in a patient with sepsis is an independent predictor of 
mortality (Bakhtiari 2004; Levi 1999; Ogura 2014), and may double the risk of sepsis-
associated death (Levi 1999). Numerous studies have reported mortality due to DIC at or 
above 40% (Cauchie 2006; Delabranche 2016; Gando 2016; Gando 2008). Specifically, 
mortality has been reported at 56% in patients with overt and non-overt DIC by the ISTH 
diagnostic criteria (Cauchie 2006) or 21.9% in patients diagnosed by the JAAM criteria 
(Gando 2008).  
Biomarkers in DIC 
The scoring algorithms used to describe DIC incorporate only clinically available 
coagulation parameters. While this may effectively describe a developed coagulopathy, it 
does not provide significant insight into the underlying pathophysiology of DIC. In order 
to address this shortcoming, over 160 biomarkers have been assessed for relevance to 
sepsis (Pierrakos 2010), with many also assessed for their relevance to DIC, but no single 
marker has been established as diagnostic or prognostic for either condition (Annane 
2005; Bakhtiari 2004; Koyama 2014; Pierrakos 2010; Sims 2016; Wacker, 2013; Wada 
2013). Many studies have evaluated biomarkers of a single system, such as inflammation 
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or coagulation, or have not established relationships between biomarker levels and well-
defined coagulopathy.  
The studies outlined in this dissertation include profiling of an array of 
biomarkers representative of multiple facets of the pathophysiology of sepsis-associated 
DIC in a cohort of patients with well-defined illness. These markers will be used in 
combination to gather information about the underlying pathophysiology and its 
relationship to outcome. Additionally, use of these markers will be validated in an animal 
model and the response of these factors to treatment will be assessed. Hemostatic 
biomarkers analyzed include D-Dimer, Prothrombin Fragment 1.2 (F1.2), and 
Plasminogen Activator Inhibitor 1 (PAI-1). Inflammatory and infection biomarkers 
analyzed include nucleosomes, High Mobility Group Box 1 (HMGB-1), procalcitonin 
(PCT), the interleukins (IL) IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, and IL-10, Tumor 
Necrosis Factor α (TNFα), Interferon γ (IFNγ), Monocyte Chemoattractant Protein 1 
(MCP-1), Epidermal Growth Factor (EGF), and Vascular Endothelial Growth Factor 
(VEGF). Endothelial biomarkers analyzed include Tissue Factor Pathway Inhibitor 
(TFPI), Protein C, endocan, angiopoietin 2 (Ang-2), and von Willebrand factor (vWF). 
Platelet biomarkers analyzed include CD40L, platelet factor 4 (PF4), microparticles 
(MP), and microparticle-derived tissue factor (MP-TF). A description of each marker 
follows.  
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Hemostatic Biomarkers. 
 As DIC is a disorder defined by hemostatic dysfunction, evaluation of multiple 
hemostatic parameters is critical to the understanding of this disease. Aside from 
clinically used functional coagulation tests such as INR, the most commonly evaluated 
marker is D-Dimer, an indicator of thrombus breakdown. While this marker has been 
validated as an indicator of ongoing coagulopathy in patients with DIC, evaluation of 
other components of the coagulation system including the thrombin generation marker 
prothrombin fragment 1.2 (F1.2) fibrinolytic regulator plasminogen activator inhibitor 1 
(PAI-1) may provide further insight into the coagulopathy occurring in DIC.  
D-Dimer. D-Dimer is formed when the crosslinked fibrin mesh is cleaved by 
plasmin as a clot is degraded, and is therefore considered a fibrin degradation product. 
Structurally, D-Dimer is composed of 2 D domains, giving the factor its name, as well as 
a single E domain. Clinically, D-Dimer is used in the diagnosis of thrombotic conditions, 
such as deep vein thrombosis (DVT) or pulmonary embolism (PE), and is particularly 
useful in excluding thrombosis in situations with a low probability.  
D-Dimer is well established as a potential marker for sepsis and DIC and is a 
component of the ISTH DIC scoring algorithm (Taylor 2001). D-Dimer is elevated in 
patients with sepsis and DIC due to the breakdown of pathologically formed thrombi 
(Ishikura 2014; Singh 2015; Taylor 2001). As D-Dimer is formed from the breakdown of 
already formed thrombi, it may not be an optimal marker for early diagnosis of DIC but 
rather better suited for late-stage DIC (Singh 2015).  
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Prothrombin Fragment 1.2 (F1.2). Prothrombin Fragment 1.2 (F1.2) is 
produced when prothrombin, the precursor of thrombin, is cleaved to form active 
thrombin and is therefore measured as a marker of thrombin generation. Due to ongoing 
thrombin generation and thrombus formation, F1.2 is expected to be increased in sepsis-
associated DIC. F1.2 levels are also measured to assess coagulation activation in 
experimental settings, such as the administration of LPS to healthy volunteers (de Jonge 
2000).  
F1.2 levels may have prognostic implications for patients with sepsis-associated 
DIC. Elevated levels of F1.2 were observed in 77.5% of patients enrolled in the 
PROWESS study, a clinical trial of APC in patients with severe sepsis (Kinasewitz 
2004). Furthermore, F1.2 levels were significantly lower in survivors than non-survivors 
over the first 5 days after study enrollment (Kinasewitz 2004). In the Phase 2b study for 
rTM (ART-123), F1.2 levels changed significantly in response to treatment, with a 16% 
decrease from baseline to day 7 in the rTM treated group compared to an 8% increase 
from baseline in the placebo group (Hoppensteadt 2014). Preliminary data from the 
ongoing Phase 3 trial for ART-123, which is designed to enroll patients with more severe 
DIC than the Phase 2b study, has demonstrated elevated F1.2 at baseline in the Phase 3 
patients compared to the Phase 2b patients, indicating a correlation with disease severity 
(Hoppensteadt 2015). F1.2 has also been shown to be predictive of DIC development and 
thrombotic risk in patients with thermal burn injury (Kowal-Vern 2013). 
Plasminogen Activator Inhibitor 1 (PAI-1). Plasminogen activator inhibitor 1 
(PAI-1) is an endogenous suppressor of fibrinolysis, and increased PAI-1 levels can 
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result in impaired thrombus clearance (Esmon, 2004). Increased thrombin generation is 
the more common causative factor for DIC; however, impaired fibrinolysis is observed in 
some patients and contributes to disease pathophysiology. Patients with DIC with 
suppressed fibrinolysis often have increased PAI-1. These patients cannot break down the 
thrombi in their microvasculature, leading to disproportionately severe organ dysfunction 
compared to the thrombus load predicted by the D-Dimer level (Asakura 2003).  
In the PROWESS trial, elevated PAI-1 was only observed in 44% of patients at 
baseline, indicating that impaired fibrinolysis is not a universal phenomenon in patients 
with DIC (Kinasewitz 2004). However, in this same study, elevated PAI-1 correlated 
significantly with APACHE score and was associated with reduced survival (Kinasewitz 
2004). PAI-1 levels were also found to correlate with disease severity in a study of sepsis 
patients during evaluation in the emergency department (Shapiro 2010). A study 
examining fibrinolytic markers in 117 patients with sepsis-associated DIC demonstrated 
an inverse relationship between PAI-1 and D-Dimer levels and a direct relationship 
between PAI-1 and poor prognosis, elevated MODS score, and reduced survival 
(Madiowa 2006). A study of 77 patients admitted to the ICU with sepsis, including 37 
with DIC found that PAI-1 was elevated at baseline in non-survivors compared to 
survivors and in those with overt DIC compared to non-DIC patients on ICU days 0 
through 3 (Koyama 2014).  
Inflammatory and Infection Biomarkers. 
 The hyper-inflammatory response is one of the hallmarks of sepsis and 
contributes significantly to the pathophysiology of both sepsis and associated 
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coagulopathy. In addition to contributing directly to organ failure and shock, many of the 
inflammatory mediators produced at high levels in sepsis contribute to the procoagulant 
state. The relationship between inflammation and coagulation is bidirectional; 
coagulation is capable of inducing increased inflammation through several pathways, 
further emphasizing the importance of inflammation in sepsis-associated DIC.  
 While inflammation certainly plays a role in the pathophysiology of sepsis-
associated DIC, inflammatory cytokines are by no means specific to this disease. Markers 
of infection or infection response have recently emerged as important in sepsis and DIC 
as diagnostic or prognostic markers, components of DIC pathophysiology, and potential 
therapeutic targets. These factors include not only traditional markers of infection such as 
procalcitonin but also nuclear material present in the extracellular space. 
Materials typically restricted to the cell nucleus, including nucleosomes, histones, 
cell-free DNA (cfDNA), and DNA associated proteins such as HMGB-1 have recently 
been detected at elevated levels in the blood of patients with diverse pathologies 
including cancer, trauma, thrombosis, and sepsis. This phenomenon is thought to be the 
result of the immune response, particularly the generation of neutrophil extracellular traps 
(NETs). NETs consist of chromosomal DNA, associated histones, and various 
bactericidal factors expelled into the extracellular space by neutrophils through an active 
form of cell death (NETosis) in order to trap and neutralize bacteria (Brinkmann & 
Zychlinsky, 2012; Gould, Lysov, & Liaw, 2015). Nuclear components, including 
histones, cfDNA, and nucleosomes as well as DNA-associated proteins are commonly 
measured as surrogate markers of NET formation (Araujo 2016; Yost 2016). 
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Interestingly, NETs may also contain TF, leading to more direct induction of thrombin 
generation (Kambas 2017). Nucleosomes and HMGB-1 will be discussed in further detail 
in subsequent sections.  
NET formation and association with clot formation and vascular occlusion has 
been confirmed in sepsis using animal models. NETs, identified by the co-localization of 
histone H2 with thrombin, have been visualized using fluorescence microscopy in the 
microcirculation of the liver, lungs, spleen, and mesentery of mice challenged with LPS, 
S. aureus, or E. coli bacteria, has been visualized using fluorescence microscopy 
(McDonald 2017). In these mice, thrombin was located predominately in or immediately 
downstream of NET sites (McDonald 2017). In mice with LPS-induced sepsis, occlusion 
of hepatic sinusoids was visualized by intravital microscopy (McDonald 2017). In this 
study, PAD4-/- mice unable to form NETs as well as mice treated with DNase exhibited 
reduced microvascular occlusion (McDonald 2017). NET components, including DNA 
and histones have been detected via confocal microscopy in the vasculature of 
endotoxemic mice with kidney injury (Czaikoski 2016). 
In human sepsis patients, a higher proportion of polymorphonuclear leukocytes 
produced NETs than in healthy controls (Kambas 2017). Furthermore, treatment of 
healthy donor cells with serum from sepsis patients induced NET release (Kambas 2017). 
Another study demonstrated that platelets activated with LPS, but not with other platelet 
activators such as thrombin, are capable of stimulating NET formation (Clark 2007). In 
this study, platelets from septic patients, but not healthy individuals, also induced 
platelet-neutrophil binding (Clark 2007). In a study of 20 patients with septic shock, 10 
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with DIC and 10 without DIC diagnosed by the JAAM DIC score, NETs (detected by 
ELISA measurement of DNA-bound MPO as well as by neutrophil fluorescence, which 
is indicative of chromatin decompaction) were significantly elevated in DIC-patients 
compared to non-DIC patients (Delabranche 2017). NET formation has also been 
demonstrated in response to LPS, S. aureus, and dengue virus (Yost 2016). 
The formation of NETs in sepsis patients is an integral component of the host 
response and contributes to bacterial clearance (Araujo 2016). Conversely, inhibition of 
NET formation or degradation of NETs is associated with reduced bacterial clearance 
(Czaikoski 2016; Yost 2016). However, NET degradation may also lead to overall 
improved survival (Yost 2016). In particular, inhibition of NETosis may be beneficial in 
situations where bacteria can be controlled through antibiotic administration. In a mouse 
cecal ligation and puncture (CLP) model of sepsis, degradation of NETs by systemic 
administration of DNase did not lead to reduced liver or kidney damage and increased 
circulating bacteria; however, when administered in conjunction with systemic 
antibiotics, DNase treatment improved survival (Czaikoski 2016). Furthermore, in a 
mouse model of LPS-induced septic shock that did involve live bacteria, administration 
of DNase reduced organ damage and improved survival (Czaikoski 2016). This indicates 
that while NETs contribute to the clearance of bacteria, their presence may be mainly 
negative in situations in which bacterial growth can be controlled through other means.  
Numerous substances secreted in NETs, including nuclear materials, may 
contribute to the link between inflammation and thrombosis. Additionally, the fibrous 
NET meshwork can induce platelet activation and aggregation (Fuchs 2010). This 
35 
 
 
 
interaction is not entirely harmful; formation of a clot around bacteria, a phenomenon 
known as “immunothrombosis”, can help to halt the spread of infection. However, this 
can also contribute to the development of DIC.  
Individually, both DNA and histones contribute to the procoagulant state. 
Extracellular DNA is highly procoagulant and may incorporate into and strengthen fibrin 
clots as well as decrease the rate of fibrinolysis (Gould 2015). In vitro coagulation studies 
have demonstrated that histones dose-dependently decrease clotting time and enhance 
thrombin generation (Ammollo 2011). Histones have also been shown to enhance 
thrombin-thrombomodulin complex mediated APC generation both in vitro and in a 
mouse model (Kowalska 2014). Histones have been shown to promote thrombin 
generation in platelet rich plasma in the absence of a platelet agonist (Semeraro 2011; Xu 
2011; Yang 2016) and to contribute to platelet activation and depletion (Esmon 2011; 
Fuchs 2010; Gould 2015) in a TLR-2 and TLR-4 dependent manner. 
Histones can also contribute to the procoagulant state through less direct 
mechanisms. Histones H3 and H4 can also act through TLRs to promote the production 
of the pro-inflammatory cytokines TNFα and IL-6 (Ikezoe, 2015). Histones or histone-
rich plasma is also toxic to endothelial cells and can induce a procoagulant endothelial 
phenotype (Abrams 2013; Daigo 2014; Gould 2015; Kim 2016; Yang 2016). Histones 
induce endothelial TF expression at both the mRNA and protein levels and reduce 
surface TM expression in a partially TLR-2 and TLR-4 dependent manner (Kim 2016). 
At an organismal level, histones have been shown to contribute to DIC-like symptoms. 
Injection of histones into mice at a dose of 75 mg/kg induced pulmonary hemorrhage and 
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death with increased vascular permeability and consumptive coagulopathy similar to that 
seen in in DIC (Abrams 2013; Nakahara 2013). 
Elevated levels of histones and DNA have been detected and associated with 
disease severity and outcome in both human and animal studies. Elevated histone levels 
have been observed in a mouse E. coli injection model, in which anti-histone intervention 
also reduced the levels of cardiac injury markers (Alhamadi 2015; Xu 2009). In a study 
measuring plasma DNA in ICU patients, plasma DNA concentrations were highest in 
patients who ultimately developed sepsis and in non-survivors (Rhodes 2006). In a study 
of 31 patients admitted through the emergency department with sepsis, cfDNA was used 
as a surrogate marker for NET formation and correlated significantly with SOFA score as 
well as with lung injury, acute respiratory distress syndrome (ARDS), kidney injury, and 
elevated bilirubin (Czaikoski 2016). In a study of 43 sepsis patients, histone H3 levels 
were increased in non-survivors compared to survivors and had an inverse relationship 
with platelet counts and AT levels (Wildhagen 2015). Extracellular histones have also 
been shown to contribute to cell death in mouse models of inflammatory and chemical 
cellular injury (Xu 2011). 
Extracellular nuclear material is important not only for its role in the 
pathophysiology of sepsis-associated DIC but also for its potential role in the response to 
treatment. Potential therapeutics for DIC, including rTM (Iba 2014; Nakahara 2013; 
Osada 2017), APC (Kutcher 2012; Xu 2009), and AT (Iba 2017) may exert some of their 
therapeutic effect by dampening the production and effects of these materials, particularly 
histones. APC is capable of cleaving and thus inactivating histones H3 and H4 in the 
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extracellular environment and is protective in mice subjected to histone injection (Xu 
2009). In a study of 132 critically ill trauma patients, increasing levels of histone over 
time was a predictor of mortality; however, concomitant increase in APC mitigated this 
effect (Kutcher 2012). In vitro, recombinant thrombomodulin inhibited histone-induced 
thrombin generation and cell death and promoted protein C dependent histone cleavage 
(Osada 2017). In addition to activating protein C and therefore inducing histone cleavage, 
rTM may inhibit NET formation and the release of nuclear material. LPS-induced NET 
formation can be inhibited by rTM at concentrations of 2, 10, or 50 μg/ml (Shimomura 
2016). In a study of rTM administration to mice subjected to LPS challenge, 
administration of rTM at a dose of 3 mg/kg reduced the levels of circulating HMGB-1 
and nucleosomes as well as the inflammatory mediators IL-6, MCP-1, and TNFα 
(Takehara 2017). AT has also been shown to ameliorate some histone-mediated damage; 
treatment of endothelial cells treated with histone H4 with 300 μg/ml AT led to a 
reduction in histone-induced morphological changes including intracellular junction 
disruption and lactate dehydrogenase production (Iba 2017). However, treatment of the 
endothelial cells with lower doses of AT did not elicit this effect. Further research is 
necessary to determine how potential therapeutics for sepsis-associated DIC interact with 
extracellular nuclear material. 
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Nucleosomes. Nucleosomes are the basic physical unit of DNA organization, 
consisting of chromosomal DNA wrapped around a histone protein core. Like their 
component parts, nucleosomes are strongly pro-inflammatory and pro-thrombotic and 
may thus provide a significant link between infection, inflammation, and coagulopathy in 
patients with sepsis-associated DIC.  
In a study of 199 patients with sepsis-associated DIC, including 53 patients with 
overt DIC, high levels of nucleosomes were associated with poor prognosis and death, 
with better predictive values for death than conventional markers such as platelets or D-
Dimer (Kim 2015). In a study of 165 patients in medical and surgical ICUs, nucleosomes 
were found to be significantly elevated in septic versus non-septic ICU patients, with 
ability to differentiate sepsis with 86% sensitivity and 52% specificity (Chen 2012). 
Nucleosomes were also elevated in DIC patients compared to the non-DIC patients and 
showed a strong correlation with other indicators of NET formation (Delabranche 2017).  
High Mobility Group Box 1 (HMGB-1). High Mobility Group Box 1 Protein 
(HMGB-1) is a nuclear-associated protein with a physiological role in the physical 
organization of DNA. When detected in the extracellularly in sepsis, HMGB-1 exhibits 
pro-inflammatory and pro-thrombotic properties and is considered a late-phase mediator 
of sepsis. 
In vitro, HMGB-1 released from both endothelial cells (Bae 2011) and peritoneal 
macrophages (Kim 2009) has been reported in response to LPS exposure. Elevated 
circulating HMGB-1 levels have been reported in disease states including not only sepsis 
but also in other inflammatory diseases including chronic kidney disease (Bruchfeld 
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2008), acute appendicitis (Albayrak 2011), and heat stroke (Hagiwara 2010). Elevated 
HMGB-1 levels have been demonstrated in both LPS and CLP induced sepsis models in 
mice and rats (Li 2007; Nagato 2009; Yang 2004; Yin 2005). In a mouse model of CLP-
induced sepsis, HMGB-1 was not detectable until 18 hours following surgery and peaked 
after 24 hours, supporting the idea of HMGB-1 as a late-phase mediator (Yang 2004).  
Elevated HMGB-1 levels and their association with outcome and severity of 
illness has been reported in patients with sepsis, DIC-and related conditions. In a study of 
201 patients with suspected DIC of varied etiologies including but not limited to sepsis, 
plasma levels of HMGB-1 were significantly elevated in patients with DIC compared to 
those without DIC and correlated with DIC score (Hatada 2005). Elevated HMGB-1 was 
also associated with organ failure and non-survival (Hatada 2005). In a study of 122 
patients with community-acquired pneumonia, HMGB-1 levels were elevated compared 
to healthy controls, and were significantly elevated in survivors compared to non-
survivors, although no differences were seen in HMGB-1 levels between those who 
ultimately developed severe sepsis and those who did not (Angus 2007). In a study of 42 
patents with septic shock, baseline HMGB-1 levels were not significantly different 
between survivors and non-survivors but correlated positively with SOFA score, lactate, 
and procalcitonin (Gibot 2007). In this population, HMGB-1 levels held steady in non-
survivors and declined in survivors; on day 3, HMGB-1 levels were able to discriminate 
survivors from non-survivors with 66% sensitivity and 67% specificity (Gibot 2007). In a 
study of 26 patients with severe sepsis, 33 patients with sepsis shock, and 5 patients with 
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sepsis, HMGB-1 levels were elevated in all patients with no relationship with severity of 
sepsis (Sunden-Cullberg 2005).  
HMGB-1 contributes indirectly to the development of a pro-thrombotic state 
through increases in inflammation as well as synergistic interactions with thrombin. In a 
mouse stasis thrombosis model, HMGB-1 contributed to the pathogenesis of venous 
thromboembolism (VTE) as well as promoted NET formation, leading to further 
thrombosis and increases in HMGB-1 levels (Stark 2016). In vitro, HMGB-1 has been 
shown to induce monocyte cell surface TF expression (Ito 2006). In a rat model of 
thrombin-induced DIC, administration of HMGB-1 acted synergistically with thrombin to 
induce production of the proinflammatory cytokines IL-6 and TNFα (Ito 2006). Co-
administration of HMGB-1 with thrombin increased thrombin-induced mortality, fibrin 
deposition in the glomeruli, and alveolar hemorrhage as well as prolonged PT and aPTT 
compared to administration of thrombin alone, whereas treatment with HMGB-1 alone 
did not produce these effects (Ito 2006).  
HMGB-1 is of interest in sepsis-associated DIC not only as a pathophysiological 
mediator and biomarker but also as a therapeutic target. HMGB-1 neutralizing antibodies 
have been shown to increase survival in both rat (Suda 2006) and mouse (Yang 2004) 
models of CLP-induced sepsis. HMGB-1 may also interact with endogenous 
anticoagulants and therefore with therapeutics targeting these pathways. In an in vitro 
study, HMGB-1 did not modulate AT function, but concentration-dependently inhibited 
TM-mediated protein C activation (Ito 2006). In a separate in vitro study, APC inhibited 
LPS-mediated release of HMGB-1 from endothelial cells as well as HMGB-1 mediated 
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expression of endothelial cell adhesion molecules (Bae 2011). Reduction in circulating 
HMGB-1 levels in response to treatment with rTM has been demonstrated in rat models 
of both heat stroke (Hagiwara 2010) and LPS-induced sepsis (Nagato 2009). In a study of 
rTM administration to mice subjected to LPS challenge, administration of rTM at a dose 
of 3 mg/kg following LPS challenge reduced circulating HMGB-1 and nucleosome levels 
as well as IL-6, MCP-1, and TNFα (Takehara 2017).  
Procalcitonin (PCT). Procalcitonin (PCT) is a 116 amino acid, 13 kDa 
polypeptide often cited as an indicator of bacterial infection. Under normal physiological 
circumstances, PCT is produced by the C-cells of the thyroid and subsequently cleaved to 
the active hormone calcitonin, which is involved in calcium homeostasis. Blood levels of 
PCT are typically very low in healthy individuals (<0.1 ng/ml). In infectious conditions, 
PCT is produced by non-thyroid tissue and released into the blood in response to bacterial 
mediators and the associated inflammatory response (Sims 2016). Many studies have 
investigated PCT for its ability to distinguish between sepsis and non-infectious 
inflammatory conditions, such as non-infectious sterile inflammatory response syndrome 
(SIRS) (Annane 2005; Biron 2015; Harbarth 2001; Livaditi 2006; Pierrakos & Vincent, 
2010; Riedel 2011; Wacker 2013; Wunder 2004; Zakariah 2008). A 2013 meta-analysis 
on the ability of PCT to distinguish between sepsis and SIRS in 30 studies involving a 
total of 2344 patients demonstrated a sensitivity of 0.77 and a specificity of 0.78, with a 
recommended cutoff for the diagnosis of sepsis between 1 and 2 ng/ml (Wacker 2013). 
Studies have also shown that PCT is elevated in non-survivors compared to survivors in 
severe sepsis (Wunder 2004), predictive of death in SIRS and sepsis patients (Harbarth 
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2001), elevated in severe sepsis or septic shock compared to sepsis (Livaditi 2006), and 
higher in patients with positive blood cultures compared to those with negative blood 
cultures (Riedel 2011).   
Although PCT is a marker for infection, it may still be useful to assess the 
presence of coagulopathy in sepsis patients or to predict mortality in patients with sepsis-
associated DIC. In a study of 82 patients meeting SIRS criteria with suspected DIC, PCT 
had an area under the curve (AUC) of 0.904 for distinguishing sepsis from SIRS and an 
AUC of 0.785 for determining the presence of DIC (Ishikura 2014). In the ART-123 
phase 2b study, a non-significant trend towards elevated PCT was observed in the overt 
DIC group compared to the non-overt DIC group (Hoppensteadt 2015). 
IL-1α and IL-1β. Interleukins (IL) 1α and 1β are inflammatory cytokines that 
contribute to the development of a pro-coagulant state associated with severe 
inflammation. IL-α is produced largely by activated macrophages, neutrophils, 
epithelium, and endothelium. IL-1β is produced as a pro-protein by activated 
macrophages or activated platelets and is cleaved into its active form by caspase-1.  
IL-1, particularly IL-1β, promotes a procoagulant endothelial phenotype by 
increasing TF expression and downregulating anticoagulants. Infusion of IL-1 into 
rabbits led to a 10-fold increase in TF expression accompanied by a significant decrease 
in protein C activation in aortic endothelium over a 3 hour time period (Nawroth, 
Handley, Esmon, & Stern, 1986). Treatment with human IL-1α and IL-1β induced dose-
dependent increases in the procoagulant activity of human monocytes in vitro (Osnes, 
Westvik, Joo, Okkenhaug, & Kierulf, 1996). Additional studies have confirmed both the 
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IL-β-induced upregulation of TF expression (Abraham, 2000) and the downregulation of 
TM and endothelial cell protein C receptor gene activation (Esmon, 2004). Endothelial 
procoagulant response to IL-1 has been documented to have a rapid rise, peak activity at 
4 hours, and a decline towards basal levels by 24 hours (Bevilacqua 1986). Exposure of 
whole blood drawn from healthy volunteers to IL-1β at a concentration of 20 pg/ml 
significantly altered the viscoelastic properties of the clots as measured by 
thromboelastography. Specifically, IL-1β lowered the maximum amplitude of the clot as 
well as maximum velocity to reach clot growth, indicating a reduction in clot stability 
(Bester & Pretorius, 2016). The procoagulant response to IL-1 may have implications for 
survival in DIC. In a re-analysis of an unsuccessful 1997 trial of an IL-1 receptor 
antagonist in patients with severe sepsis, when patients were re-classified based on DIC 
status, improved survival with IL-1 receptor blockade was observed in the subgroup of 
patients with DIC and hepatobiliary dysfunction (Shakoory 2016). 
Previous work in our laboratory has demonstrated significant increases in IL-1α in 
patients with sepsis-associated DIC (Low 2016; Walborn 2017). However, 91% of 
patients in the PROWESS trial for APC had baseline levels of IL-1β below the threshold 
for detection (Kinasewitz 2004). IL-1β, along with TNFα, peaks early and transiently in 
response to infection and therefore may not be detectable in all sepsis patients 
(Kinasewitz 2004). The correlation of IL-1β with outcome in sepsis-associated DIC is 
also unclear. A study of 65 patients admitted to an intermediate care unit with sepsis 
showed no significant differences in IL-1β levels between survivors and non-survivors 
(Gogos 2000). In contrast, a study of 60 patients admitted to the ICU with SIRS criteria 
44 
 
 
 
and an obvious focus of infection found IL-1β to be significantly increased in septic 
shock compared with sepsis, positively correlated with SOFA score, and higher in non-
survivors than survivors (Bozza 2007).  
IL-2. IL-2 is an inflammatory cytokine involved in the differentiation of T cells. 
Although IL-2 is less commonly discussed in the sepsis and DIC literature, research from 
the 1990s investigating the use of IL-2 immunotherapy saw DIC or DIC-like syndromes, 
commonly known as “vascular leak syndrome”, as a consequence of high-dose IL-2 
therapy. IL-2 infusion into 7 cancer patients led to thrombocytopenia, elevated D-Dimer, 
and decreased plasminogen levels, without changes in PT, aPTT, or Factors VI or VII 
(Fleischmann 1991). IL-2 infusion into 9 tumor patients led to endothelial activation 
contributing to DIC development, indicated by elevated circulating levels of adhesion 
molecules, accompanied by increases in TPA and PAI-1, thrombocytopenia, increase in 
fibrin degradation products, prolonged aPTT, and decreased fibrinogen (Locker 1999). 
Previous work in our laboratory demonstrated significant elevation in IL-2 in patients 
with sepsis-associated DIC (Low 2016; Walborn 2017).  
IL-4. IL-4 is an anti-inflammatory cytokine involved in the development of TH2 
cells. IL-4 treatment has been shown to decrease the IL-1α, IL-1β, and LPS-induced 
procoagulant activity of human monocytes, including TF mRNA levels (Osnes 1996) and 
surface TF expression (Lindmark 1998). Another study demonstrated reduced TF 
expression on the surface of IL-1β, TNFα, or LPS-treated adult bovine aortic endothelial 
cell in response to IL-4 treatment (Herbert 1993). In a study of 60 patients admitted to the 
ICU with SIRS criteria and an obvious focus of infection, IL-4 was significantly elevated 
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in non-survivors compared to survivors and predictive of death within 48 hours (Bozza 
2007). Previous work in our laboratory has demonstrated increased levels of IL-4 in 
patients with sepsis-associated DIC (Low 2016; Walborn 2017). 
IL-6. IL-6 is the prototypical pro-inflammatory cytokine. It is necessary to mount 
a robust immune response, and to stimulate the production of acute phase reactants and 
inflammatory factors. However, excessively high levels of IL-6, such as those seen in 
sepsis, can injure the host through mechanisms including increased vascular leakage 
(Hawiger 2015) and increased thrombotic potential. IL-6 has been shown to induce 
mononuclear cell TF expression both in vitro and in vivo (Levi 2004). IL-6 is released in 
response to LPS injection into healthy human volunteers (de Jonge 2000). In a study of 
LPS injection into chimpanzees, anti-IL-6 antibody administration reduced activation of 
coagulation measured by levels of F1.2 and AT but did not impact fibrinolysis or the 
overall inflammatory state (van der Poll 1994). Stimulation of whole blood from healthy 
volunteers with 15 pg/ml IL-6 significantly altered the viscoelastic properties of the clots 
as measured by thromboelastography; specifically, IL-6 lowered the maximum amplitude 
of the clot, indicating a reduction in clot stability (Bester & Pretorius, 2016).  
The relationship between inflammation and coagulation is bidirectional, and 
coagulation can stimulate further IL-6 production. IL-6 expression can be induced 
through activation of the PAR-1 (Hawiger 2015) and PAR-2 (Levi 2004) receptors, 
which are activated by coagulation factor complexes and thrombin, as well as through 
treatment with histones H3 and H4 (Abrams 2013).  
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IL-6 is frequently measured in studies of sepsis and DIC patients and is well 
established to be significantly elevated in this patient population (Bozza 2007; Chen 
2012; Gogos 2000; Harbarth 2001; Iba 2006; Ishikura 2014; Kinasewitz 2004; Livaditi 
2006; Low 2016; Mauri 2010; Taniguchi 1999; Walborn 2017; Wunder 2004). Although 
IL-6 is a relatively non-specific inflammatory mediator, it may still provide information 
about disease state and prognosis. IL-6 rises rapidly in patients with sepsis and may 
correlate with disease severity, hypercoagulability, or non-survival (Iba 2006). In a study 
of 82 patients with SIRS criteria and suspected DIC, IL-6 had an AUC of 0.893 for 
distinguishing SIRS versus sepsis and an AUC of 0.765 for distinguishing between 
patients with and without DIC (Ishikura 2014). In a separate study of 78 patients with 
SIRS or sepsis, IL-6 had an AUC of 0.75 for distinguishing SIRS from infectious sepsis 
(Harbarth 2001) In a study of 60 patients admitted to the ICU with SIRS criteria and an 
obvious focus of infection, IL-6 was significantly increased in patients with septic shock 
compared to those with sepsis, correlated positively with SOFA score on day 0,was 
higher in non-survivors versus survivors, and was a good predictor of death within 48 
hours (Bozza 2007). However, other studies have demonstrated no association between 
IL -6 levels and mortality in sepsis patients (Gogos 2000; Wunder 2004). IL-6 levels may 
reflect response to therapy. In a study of rTM administration to mice subjected to LPS 
challenge, administration of rTM at a dose of 3 mg/kg reduced the levels of IL-6 as well 
as MCP-1, HMGB-1, nucleosomes, and TNFα (Takehara 2017). 
IL-8. IL-8, known as neutrophil chemotactic factor, is an inflammatory cytokine 
that is significantly elevated in sepsis (Bozza 2007; Claushuis 2016; Harbarth 2001; 
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Kinasewitz 2004; Livaditi 2006; Low 2016) and may have diagnostic or prognostic 
value. IL-8 interacts with coagulation in a somewhat different way than other commonly 
investigated inflammatory cytokines. Exposure of whole blood from healthy human 
volunteers to 40 pg/ml IL-8 altered clot viscoelastic properties as measured by 
thromboelastography to a greater extent than IL-1β or IL-6. Specifically, IL-8 decreased 
the R time, angle, maximum amplitude, MTRG, TMRTG, and TTG and increased the K 
time, indicating that IL-8 caused a rapid formation of an unstable clot (Bester 2016). IL-8 
expression may also be induced by coagulation. Administration of recombinant FVIIa to 
healthy volunteers produced small but statistically significant increases in plasma 
concentrations of IL-8 and IL-6 (de Jonge 2003). FVIIa, but not thrombin, was also 
shown to stimulate the production of IL-8 in vitro in a TF-expressing breast carcinoma 
cell line in a manner inhibited by PAR-2 blocking antibodies (Hjortoe 2004). 
IL-8 is elevated in sepsis and may have moderate diagnostic or prognostic value. 
In a study of 78 patients with SIRS or sepsis, IL-8 had an AUC of 0.71 for distinguishing 
SIRS from sepsis (Harbarth 2001). In a study of 60 patients admitted to the ICU with 
SIRS criteria and an obvious focus of infection, IL-8 was significantly elevated in septic 
shock compared to sepsis. In these patients, IL-8 correlated with SOFA score on day 0, 
was higher in non-survivors than survivors, and was a good predictor of death within 48 
hours (Bozza 2007). In a study of 47 patients with sepsis, significant differences were 
observed at baseline between patients with sepsis, severe sepsis, and septic shock, and IL-
8 had an AUC of 0.73 for the prediction of 28 day mortality (Livaditi 2006). In a study 
stratifying sepsis patients by platelet count upon ICU admission, patients with platelets 
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less than 100 K/μl showed significant elevation in IL-8 compared to those with higher 
platelet counts (Claushuis 2016). 
IL-10. IL-10 is an anti-inflammatory cytokine that acts in opposition to the pro-
inflammatory and pro-coagulant effects of other factors, including IL-6. IL-10 is 
upregulated in patients with sepsis in response to the elevated inflammatory state 
(Claushuis 2016; Kinasewitz 2004; Low 2016). In vitro, IL-10 treatment caused 
concentration-dependent decreases in IL-1α, IL-1β, and LPS-induced procoagulant 
activity of human monocytes and lowered the amount of TF mRNA detectable in these 
cells (Osnes 1996). IL-10 also inhibited LPS-induced TF expression, mRNA, and 
procoagulant activity in a whole blood in vitro stimulation protocol (Lindmark 1998). In 
a human model of mild DIC induced by LPS injection, administration of IL-10 reduced 
the activation of the coagulation, assessed using F1.2 and AT levels (Pajkrt 1997). In 
mouse models, IL-10 production has been detected in the liver as soon as 1 hour after 
CLP, and anti-IL-10 antibody administration resulted in higher TNF levels and mortality 
following CLP (T van der Poll 1995). IL-10 may also be upregulated through the 
interaction of thrombin with the PAR-1 receptor on monocytes (Naldini 2005). 
A study of 33 patients admitted to the ICU with severe sepsis found significantly 
higher levels of IL-10 in non-survivors than survivors on ICU days 1 and 2 but 
significantly higher IL-10 levels in survivors than non-survivors on day 3, suggesting that 
the time course of IL-10 in patients with sepsis is of particular importance (Wunder 
2004). IL-10 levels were also found to be elevated in non-survivors compared to 
survivors in a study of 65 patients with sepsis who were admitted to the intermediate care 
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unit (Gogos 2000). The IL-6:IL-10 ratio, representing the balance between pro- and anti-
inflammatory processes, has also been studied as a potential diagnostic or prognostic 
marker for patients with sepsis and DIC (Kellum 2007; Wunder 2004). In a study of 25 
patients meeting SIRS criteria, an increase of the ratio of IL-6/IL-10 over time due to a 
lack of decline in IL-6 coupled with a gradual decrease in IL-10 was associated with 
increased mortality (Taniguchi 1999). 
Tumor Necrosis Factor α (TNFα). Tumor Necrosis Factor (TNF) α is a pro-
inflammatory cytokine that rises rapidly in sepsis, with peak levels observed as soon as 2 
hours following LPS injection into rats (Kaspereit, Doerr, & Dickneite, 2004) or 1 hour 
following LPS challenge in mice (Remick 1990). TNFα contributes significantly to the 
procoagulant state both in vitro and in vivo. At an organismal level, administration of 
TNFα to healthy human volunteers induced a procoagulant state, measured by increased 
FX activity followed by increased F1.2 levels (van der Poll 1990) as well as inhibited 
fibrinolysis. Specifically, TNFα induces vascular TF expression, particularly by 
monocytes and endothelial cells (Abraham 2000; Bevilacqua 1986; Esmon 2004; Hezi-
Yamit 2005). TNFα has also been shown to downregulate thrombomodulin and 
endothelial cell protein C receptor gene expression (Esmon, 2004) and to increase levels 
of the inhibitor of fibrinolysis PAI-1 (Abraham, 2000; Ikezoe, 2015). TNFα may 
contribute significantly to DIC pathophysiology and response to therapy. Although a trial 
of anti-TNFα monoclonal antibody in patients with sepsis found no reduction in 28-day 
mortality, antibody-treated patients experienced more rapid reversal of septic shock and a 
delay in time to onset of first organ failure (Cohen & Carlet, 1996). In a study of rTM 
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administration to mice subjected to LPS challenge, administration of rTM at a dose of 3 
mg/kg suppressed TNFα production (Takehara 2017). 
TNFα is generally found to be elevated in sepsis and associated conditions (Low 
2016); however, analysis of severe sepsis patient samples from the PROWESS trial for 
APC could not detect TNFα in 47% of patients in this population. TNFα levels may be 
low in some sepsis patients due to the rapid and transient TNFα response in sepsis, with 
falling or normalized levels by the time of study enrollment (Kinasewitz 2004). 
Interferon γ (IFNγ). Interferon (IFN) γ is an activator of macrophages and an 
inducer of MHC class II expression. Relative to other inflammatory mediators, limited 
information is available regarding the role of IFNγ in sepsis and DIC. However, 
administration of anti-IFNγ antibody to mice either before or 24 hours after CLP resulted 
in improved survival, reduced inflammation, and decreased peritoneal bacterial load 
(Marquez-Velasco 2011; Qiu 2001). In contrast, a separate study found that IFNγ 
receptor knockout mice had reduced survival in a colon ascendens stent peritonitis 
(CASP) model of sepsis (Zantl 1998).  
Monocyte Chemoattractant Protein 1 (MCP-1). Monocyte Chemoattractant 
Protein 1 (MCP-1) is a potent chemotactic factor for monocytes and contributes to 
microvascular leakage through effects on endothelial cell tight junctions (Hawiger 2015). 
MCP-1 may be protective to the host in sepsis. In a mouse CLP model, blockade of 
MCP-1 decreased survival and increased bacterial presence in the peritoneum 
(Matsukawa 1999; Matsukawa 2000). Similar results were observed with the use of 
MCP-1 blocking antibodies in a mouse model of LPS injection, where administration of 
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exogenous MCP-1 was protective against endotoxin-induced lethality (Zisman 1997). In 
a study of rTM administration to mice subjected to LPS challenge, administration of rTM 
at a dose of 3 mg/kg reduced MCP-1 levels (Takehara 2017). Elevated levels of MCP-1 
occurred within 24 hours of surgery in a rat CLP model of sepsis (Qiu 2001). In 60 
patients admitted to the ICU with SIRS criteria and an obvious focus of infection, 
significant increases in MCP-1 were found, with greater elevation in non-survivors than 
in survivors (Bozza 2007).  
Epidermal Growth Factor (EGF). Epidermal Growth Factor (EGF) is a 
cytoprotective factor. Minimal information is available regarding the role of EGF in 
sepsis and DIC. However, levels of intestinal EGF were found to be elevated in a mouse 
model of CLP-induced sepsis, and IP injection of 150 μg/kg/day of EGF led to a 
reduction in mortality from 60% to 30% (J. A. Clark, Clark, Hotchkiss, Buchman, & 
Coopersmith, 2008). 
Vascular Endothelial Growth Factor (VEGF). Vascular Endothelial Growth 
Factor (VEGF) is a regulator of angiogenesis, neovascularization, and vascular 
permeability. In sepsis, VEGF may contribute to microvascular leakage through effects 
on tight junctions between endothelial cells (Hawiger 2015). Increased VEGF has also 
been observed in both CLP-induced and LPS-induced sepsis in mice and following LPS 
injection into human volunteers (Yano 2006). Potential mechanisms for increase in 
VEGF in DIC include release from activated platelets or LPS-induced production (Kim 
2008).  
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Both elevated and reduced VEGF levels have been reported in sepsis and DIC. 
Decreased VEGF levels were observed in patients with overt DIC, and VEGF was shown 
to correlate positively with platelet counts and negatively with SOFA score (Jesmin 
2012). A second study, including 57 severe trauma patients with or without DIC, also 
measured lower levels of VEGF in DIC patients (Wada 2012). In contrast, a study of 240 
patients with suspected DIC found elevated levels of VEGF in patients with overt DIC 
compared to those without (Joo 2010). A small study of 18 patients with severe sepsis 
also found elevated VEGF in patients compared to healthy controls and an association 
between VEGF and organ dysfunction (van der Flier 2005).  
Endothelial Biomarkers. 
 The endothelial cells lining the vasculature are in constant contact with the blood 
and are named in Virchow’s Triad as one of the critical contributors to thrombosis. In 
DIC, damage to the endothelium as well as functional changes induced by high levels of 
inflammatory factors or bacterial components can contribute to the development of 
coagulopathy. 
Under physiological conditions, the endothelium prevents inappropriate 
coagulation. Endothelial cells express or secrete an assortment of endogenous 
anticoagulants, including tissue factor pathway inhibitor (TFPI), protein C, 
thrombomodulin, and antithrombin. These molecules act at specific sites along the 
coagulation cascade to inhibit coagulation. The endogenous anticoagulant system is 
disrupted in DIC, and is a major focus of research both as a prognostic indicator and a 
therapeutic target.  
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In addition to endogenous anticoagulants, the endothelium is responsible for the 
production of an array of hemostatically active molecules, including von Willebrand 
Factor (vWF), TF, and PAI-1. Exposure to inflammatory mediators can modulate 
endothelial expression of these factors. Damage to the endothelium, such as that caused 
by exposure to histones, can also provide a site for clot initiation.  
The role of the endothelium in sepsis, as reviewed by Ince et. al. in 2016 (Ince ., 
2016), extends beyond coagulation. The endothelium produces vasoactive molecules, 
such as endothelin, which are involved in the regulation of vascular tone. These factors 
may be important in sepsis due to the role of shock and hypoperfusion in this disease 
process. The endothelium also produces and maintains the glycocalyx, a gel-like layer 
lining the vasculature. In conjunction with the endothelial cells themselves, the 
glycocalyx plays a role in the maintenance of the vascular barrier, hemostasis, adhesion, 
and anti-inflammatory effects. Inflammatory factors including TNFα can induce shedding 
of the glycocalyx, leading to loss of barrier function and subsequent edema. Other factors 
act on the junctions between endothelial cells themselves, also promoting vascular 
leakage. In addition to hemostatically active molecules, other indicators of general 
endothelial function such as endocan or angiopoietin 2 may provide insight into disease 
pathophysiology and prognosis.  
Tissue Factor Pathway Inhibitor (TFPI). Tissue Factor Pathway Inhibitor 
(TFPI) is an endogenous anticoagulant present on the surface of endothelial cells and 
released into circulation following heparin exposure or platelet and monocyte activation 
(Abraham 2003; Gando 2016; Maroney 2008; Wood 2014). TFPI is a reversible inhibitor 
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of FXa, and is capable of inhibiting the FVIIa-TF complex when in complex with FXa. 
Through models including TF administration to rabbits, experimental bacteremia in 
baboons, and endotoxin-induced coagulation in healthy human volunteers, TFPI was 
identified as important in preventing excessive coagulation and promoting survival 
(Gando 2016). Subsequently, administration of exogenous TFPI was shown to reduce 
DIC symptoms such as platelet and fibrinogen consumption and thrombus number in a 
rat model of LPS-induced DIC (Elsayed 1996b), and to reduce thrombin generation in 
healthy human volunteers injected with LPS (de Jonge 2000). The OPTIMIST clinical 
trial, completed in 2003, evaluated the safety and efficacy of recombinant TFPI 
(tifacogin) in the treatment of DIC (Abraham 2003). This study found no reduction in 
mortality and increase in bleeding in patients with severe sepsis and INR ≤ 1.2 treated 
with tifacogin and therapeutic use of TFPI was not pursued further (Abraham 2003). 
Changes in TFPI levels in DIC are unclear. In a rat model of CLP-induced sepsis, TFPI 
activity was significantly reduced at 24 hours (Ravindranath 2007). However, human 
TFPI levels did not vary with administration of LPS to healthy volunteers (de Jonge 
2000), in patients with trauma-associated DIC (Gando 2001), or in patients with DIC 
with or without INR greater than 1.2 (Abraham 2003).  
Protein C. Protein C is an endogenous anticoagulant that is of significant interest 
in DIC as both a biomarker and a therapeutic target. Protein C is activated in the presence 
of thrombin with activation greatly enhanced by thrombomodulin or the endothelial cell 
protein C receptor (EPCR). Activated Protein C (APC) proteolytically inactivates 
coagulation factors Va and VIIa. Additionally, APC has anti-inflammatory and 
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cytoprotective effects (Jong-Sup Bae & Rezaie, 2011). Protein C levels are significantly 
reduced in patients with sepsis-associated DIC, and restoration of this pathway has been 
pursued as a therapeutic approach for DIC. APC, known in drug form as drotrecogin alfa 
(activated) or by the brand name Xigris was developed for use in patients with severe 
sepsis and was ultimately approved for use in this population (Bernard 2001). Post-
approval data failed to show a reduction in mortality with APC treatment but did 
demonstrate an increase in bleeding, leading to the withdrawal of this drug from the 
market in 2011. Despite the lack of clinical success of APC as a therapeutic agent, the 
Protein C pathway is still of interest in DIC. Thrombomodulin, the activator of Protein C, 
is currently in clinical trials for DIC. Additionally, Protein C levels have the potential to 
be a strong diagnostic or prognostic marker for DIC. 
Data analysis from the severe sepsis patients included in the PROWESS and 
ENHANCE trials for APC demonstrated that low levels of Protein C, particularly below 
40% of normal levels, correlated with poor outcome (Macias 2004; Shorr 2008). Serial 
measurement of Protein C levels had better predictive ability for outcome throughout the 
hospitalization period than levels of IL-6 (Macias 2004). Furthermore, in a Phase 2 study 
for APC, increasing protein C levels with treatment was indicative of therapeutic efficacy 
(Shorr 2010). Other smaller studies, including a study of 80 ICU patients (Bouchard 
2015), a study of coagulation function in 38 patients with severe sepsis (Collins 2006), 
and a study of patients with B. pseudomallei sepsis infections (LaRosa 2006) have also 
demonstrated reduced protein C levels in critically ill patients and an association between 
low Protein C levels and poor outcome. Protein C level may also be a viable marker for 
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use in assessing the response to treatment of patients treated with recombinant 
thrombomodulin (Iba 2016).  
Endocan. Endocan was first described in 1996 as an endothelial cell factor, 
expressed in the lung and regulated by TNFα, IL-1β, and IFNγ (Lassalle 1996). Endocan 
levels also increase in response to LPS injection in healthy individuals, reaching average 
levels above 4 ng/ml (Cox 2015). Endocan was measured in 63 patients admitted to the 
ICU with sepsis as well as 20 healthy donors and 7 patients with SIRS, and was found to 
be elevated in sepsis with further elevation in patients with septic shock (Scherpereel 
2006). In a study of 60 patients with sepsis, endocan was found to be significantly 
elevated in patients with organ failure and in non-survivors compared to survivors with 
an AUC of 0.71 for the prediction of mortality (Mihajlovic 2014). Postmortem serum 
endocan concentrations have also been evaluated and found to be elevated in patients 
who died of sepsis compared to patients with a non-infectious cause of death (Palmiere 
2014). In a study of 175 patients with SIRS criteria and a known source of infection, 
endocan was the most effective marker investigated to evaluate worsening organ failure 
(AUC=0.77), defined by an increase in SOFA score of ≥ 2 in a 24 hour period 
(Ioakeimidou 2017). Furthermore, endocan decreased in patients who showed clinical 
improvement and increased in patients showing clinical decline (Ioakeimidou 2017). A 
patent has been granted for a method using endocan levels to predict the risk of 
respiratory failure, renal failure, or thrombocytopenia in a septic patient using endocan 
(Lassalle, 2014).  
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Angiopoietin 2 (Ang-2). Under physiological conditions, Angiopoietin 2 (Ang-2) 
is involved in vasculogenesis and acts as an antagonist to Angiopoietin 1 (Ang-1) at the 
Tie2 receptor on the endothelial cell surface. Ang-1 promotes vascular stability, preserves 
cell-cell contacts, and has anti-inflammatory effects, while Ang-2 acts in opposition to 
these effects.  
Ang-2 is relevant to the pathogenesis of sepsis for its role in the disruption of 
endothelial cell barrier function, which has been demonstrated both in vitro and in vivo. 
Treatment of endothelial cell monolayers with purified Ang-2 resulted in the 
development of stress fibers and intercellular gaps (Parikh 2006). In two separate in vitro 
studies, treatment of endothelial cell monolayers with serum from patients with elevated 
circulating Ang-2, but not patients with comparable pathological conditions and low 
Ang-2, led to increased intercellular gap formation and reduced endothelial barrier 
integrity (Gallagher 2008; Parikh 2006). These effects were reversed by co-treatment 
with Ang-1 (Gallagher 2008; Parikh 2006). In mice, administration of Ang-2 led to 
increased vascular permeability in the lung, liver, and intestine (Parikh 2006). 
Although the precise mechanism is not well understood, Ang-2 is upregulated in 
sepsis and may be a component of the endothelial response to ongoing coagulation. 
Injection of LPS into 22 healthy volunteers led to elevated circulating Ang-2 levels, 
peaking 4.5 hours after LPS injection (Kumpers 2009). However, treatment with LPS, 
TNFα, or IL-6 reduced Ang-2 release from human lung microvascular endothelial cells, 
while LPS and TNFα, but not IL-6, stimulated Ang-2 release from bovine lung 
microvascular endothelial cells (Orfanos 2007). Serum from patients with septic shock 
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stimulated the release of Ang-2 from the peripheral blood monocytes of healthy 
volunteers whereas serum from patients with sepsis without shock did not (Kranidioti 
2009). Neither stimulation of monocytes with LPS nor with serum from sepsis patient 
supplemented with LPS promoted Ang-2 release (Kranidioti 2009). In the absence of 
EPCR occupancy by protein C, stimulation of endothelial cell monolayers with thrombin 
led to increased Ang-2 and decreased Ang-1 and Tie2 production (Bae 2010). However, 
occupancy of the EPCR, even by catalytically inactive protein C mutants, led to Ang-1 
upregulation and Ang-2 downregulation following thrombin stimulation (Bae 2010). 
Elevated Ang-2 levels have been reported in septic patients as well as in patients 
with acute lung injury (ALI), ARDS (Gallagher 2008), or trauma (Ganter 2008). Ang-2 
elevation shows a particularly strong association with pulmonary dysfunction (Gallagher 
2008; Kumpers 2008; Lin 2015; Parikh 2006). A study of 341 patients with septic shock 
demonstrated associations between elevated Ang-2 and coagulation, hepatic and renal 
dysfunction, mortality, and levels of TNFα and IL-6 (Fisher 2016). Elevated Ang-2 has 
been demonstrated in severe sepsis patients compared to patients with mild sepsis or 
other hospitalized patients (Orfanos 2007; Parikh 2006; Siner 2009). Elevated Ang-2 has 
also been associated with impaired gas exchange (Parikh 2006), increased levels of 
inflammatory cytokines (Orfanos 2007; Siner 2009), increased organ failure (Davis 2010; 
Kranidioti 2009; Lin 2015; Orfanos 2007; Ricciuto 2011; Siner 2009), and poor outcome 
(Davis 2010; Kranidioti 2009; Lin 2015; Orfanos 2007; Ricciuto 2011; Siner 2009) in 
multiple cohorts of patients with sepsis and related conditions. 
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Although the association between Ang-2 and coagulopathy in sepsis has not been 
investigated, Ang-2 was associated with coagulopathy in a study of 208 adult trauma 
patients, where Ang-2 was significantly higher in patients with abnormal PT or aPTT 
than those without (Ganter 2008). Furthermore, D-Dimer increased with increasing Ang-
2 while Protein C decreased with increasing Ang-2 (Ganter 2008).  
von Willebrand Factor (vWF). Von Willebrand factor (vWF) is a glycoprotein 
produced in the endothelium as well as in megakaryocytes and the subendothelium. vWF 
is notable in hemostasis for its role in platelet adhesion as a link between the platelet 
receptor GPIb and the damaged endothelial wall. High or low molecular mass vWF 
multimers can be released into the circulation. Higher molecular weight vWF multimers 
are more prothrombotic than lower molecular weight multimers and can be secreted in 
response to inflammatory stimuli including TNFα, IL-6, or IL-8. Elevated circulating 
vWF or changes in vWF molecular weight profile in disease can indicate endothelial 
activation or damage.  
vWF may contribute to the development of coagulopathy in septic patients. In a 
porcine model of septic shock, vWF-rich thrombi were abundant in the glomeruli of the 
septic pigs (Bockmeyer 2011). In a mouse model of CLP-induced sepsis, vWF knockout 
mice demonstrated improved survival compared to WT mice (Lerolle 2009). 
Elevated vWF has been shown to correlate with severity of coagulopathy and 
mortality in septic patients. In a study of 40 patients with severe sepsis or septic shock, 
vWF activity and antigen levels were significantly elevated compared to age and gender 
matched healthy controls (Hovinga 2007). In a study of patients with severe sepsis or 
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septic shock, vWF levels were elevated in patients with a SOFA score ≥10 and in patients 
with an ISTH DIC score of ≥4 compared to those with lower scores (Claus 2009). vWF 
was also elevated in non-survivors compared to survivors (Claus 2009). vWF elevation 
also occurs in other illnesses characterized by endothelial activation or damage. vWF 
levels comparable to those seen in sepsis have been reported in patients with non-sepsis-
associated organ failure (Martin 2007) as well as in patients with ALI or ARDS (Ware 
2004). 
The size distribution of vWF multimers and the vWF activity level may influence 
the contribution of vWF to sepsis-associated DIC. Larger vWF multimers are more 
potent inducers of platelet aggregation and may occur with greater frequency in disease. 
In a porcine model of septic shock, septic animals had a higher molecular weight 
distribution of vWF multimers than controls (Bockmeyer 2011). The major regulator of 
vWF multimers size, ADAMTS-13, has also been investigated in some studies of sepsis 
and DIC. Decreases in ADAMTS-13 have been reported in non-survivors of sepsis or 
DIC compared to survivors (Claus 2009; Hyun 2009). Furthermore, elevated vWF 
antigen to ADAMTS-13 activity ratio has been reported in non-survivors compared to 
survivors (Claus 2009), and ADAMTS-13 has been reported to have an inverse 
relationship with DIC score in patients with DIC of varied etiology (Hyun 2009). 
Platelet Biomarkers. 
 Platelet abnormalities are almost always noted in DIC, as the development of 
thrombocytopenia due to consumption of platelets is one of the most readily available 
clinical indicators of DIC development. A study of 105 ICU patients revealed 
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thrombocytopenia in 53% of patients at the time of admission as well as an association 
between reduced platelet count and elevated mortality and a distinct cytokine profile 
including elevation of IL-8 and ICAM (Tsirigotis 2016). The role of platelets in DIC is 
not merely one of passive consumption. The primary function of platelets is hemostatic; 
platelets adhere to damaged endothelium, form the primary hemostatic plug to prevent 
blood loss, and ultimately contribute the formation of a stable clot. Platelets are also a 
crossroads between hemostasis, immunity, and inflammation. They are one of the first 
cell types to respond to compromised vasculature, invading pathogens, and sepsis. 
Studies have also shown that platelets may be involved in both the thrombotic and 
inflammatory aspects of disease through direct activity and the release of soluble 
mediators (de Stoppelaar 2014; Rondina 2011; Rondina 2012; Rondina 2015). In addition 
to responding to damaged endothelium, platelet aggregation can be induced by contact 
with a pathogen or by high levels of circulating inflammatory factors (Davis 2016). 
Platelets may also be activated through multiple mechanisms by NETs and their 
component parts (Davis 2016). Upon activation, platelets secrete their granule contents, 
releasing many factors into circulation, including insulin-like growth factor 1, platelet-
derived growth factor (PDGF), transforming growth factor β (TGFβ), platelet factor 4 
(PF-4), thrombospondin, fibronectin, Factor V, von Willebrand Factor (vWF), ATP, 
ADP, and serotonin. Accordingly, analysis of platelet function, including factors linking 
platelet function with inflammation and endothelial function, is relevant to the 
understanding of sepsis and DIC.  
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CD40L. CD40L (CD154) is a transmembrane protein expressed on the surface of 
CD4+ T cells and activated platelets. Platelets also release soluble CD40L into the 
circulation (Aukrust, Damas, & Solum, 2004). CD40L is a link between platelet and 
endothelial activation. Stimulation of endothelial cells with CD40L causes increased 
expression of adhesion molecules including as E-selectin, VCAM-1, and ICAM-1 on the 
endothelial cell surface as well as production of other inflammatory mediators including 
TF, IL-6, IL-8, and MCP-1 (de Stoppelaar 2014; Henn 1998; Semple 2011). CD40L also 
acts synergistically with FXa to induce endothelial TF expression (Hezi-Yamit 2005). 
Endothelial cell procoagulant activity can in turn lead to further CD40L production by 
inducing thrombin generation, which stimulates platelet CD40L production (Henn 1998). 
IL-1β activated human intestinal microvascular endothelial cells have also been shown to 
induce platelet CD40L expression and secretion (Danese 2003). 
Soluble CD40L has been detected in the plasma of patients with inflammatory 
conditions, but specific studies related to sepsis-associated DIC are lacking. Elevated 
soluble CD40L was detected in a study of 63 children with meningococcal sepsis 
compared to age matched controls, but no relationship was observed between the levels 
of soluble CD40L and disease severity (Inwald 2006).  
Platelet Factor 4 (PF4). Platelet factor 4 (PF4) is a chemokine released from α 
granules after platelet activation. PF4 binds to heparin and other glycosaminoglycans 
(GAGs) in a charge-dependent manner. This binding is notable for its role in heparin-
induced thrombocytopenia (HIT), a condition in which antibodies are formed against the 
heparin-PF4 complex. PF4 has also been shown to bind to bacteria, including Gram 
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positive S. aureus, S. pneumonia, and L. monocytogenes and Gram-negative E. coli and 
N. meningitides (Krauel 2011). Interestingly, anti-heparin-PF4 antibodies from HIT 
patients were also shown to bind to PF4-coated bacteria and enhance neutrophil-mediated 
bacterial clearance (Krauel 2011).  
In addition to binding to pathogens, PF4 may be relevant to DIC for its interaction 
with the APC system. In a purified system, PF4 enhanced histone-mediated APC 
generation in the presence of thrombin-thrombomodulin complexes (Kowalska 2014). 
Addition of heparin to this system reduced histone-mediated APC generation, but did not 
negate the ability of PF4 to induce APC generation (Kowalska 2014). PF4 was also 
shown to stimulate thrombin-induced APC generation in vivo (Kowalska, Mahmud, 
Lambert, Poncz, & Slungaard, 2007; Kowalska, Rauova, & Poncz, 2010), an effect which 
was negated by heparin administration (Kowalska 2010). PF4 injection in into mice was 
also shown to enhance histone and thrombin induced APC generation (Kowalska 2014). 
Whether through enhanced APC generation or another mechanism, PF4 may play a 
protective role in DIC. Mice with platelets overexpressing PF4 exhibited improved 
survival in an LPS-injection model of sepsis compared to both WT and PF4 knockout 
mice (Kowalska 2007). Furthermore, injection of platelets from PF4 knockout mice into 
WT mice with thrombocytopenia secondary to LPS challenge did not increase survival, 
whereas injection of platelets from mice overexpressing PF4 did (Kowalska 2007). 
Elevated PF4 has been reported in animal models of sepsis. In a study involving 
LPS or thrombin injection into mice, PF4 levels in the lungs were significantly elevated 
10 minutes after injection in both thrombin and LPS-treated mice compared to saline-
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injected controls (Kowalska 2007). Elevated PF4 has also been reported following LPS 
injection into rats (Tang 2010).  
Microparticles (MP) and MP-Associated Tissue Factor (MP-TF). 
Microparticles (MP) are small vesicles composed of cellular membrane and membrane 
proteins that are released into the circulation from numerous cell types, including 
endothelial cells, platelets, immune cells, and tumor cells. Based on their cellular origins, 
MPs have widely varied properties and thus play diverse roles in disease 
pathophysiology. Of greatest interest in DIC are the potential pro-coagulant properties of 
MP.  
MP have intrinsic procoagulant properties due to their phospholipid surface, and 
MP isolated from the blood of healthy volunteers without ongoing coagulation disorders 
have been shown to support coagulation in vitro in a TF-independent manner (Berckmans 
2001). It has been suggested that the role of these MP in healthy individuals is in fact 
anticoagulant, as the low-level thrombin generation promoted by these MP promotes 
protein C activation (Berckmans 2001). However, MP in disease states can also express 
abundant surface TF and thus exhibit significant procoagulant properties. Tumor cells are 
a notable source of circulating TF-bearing MP, and MP-associated TF was shown to be 
significantly elevated in patients with overt DIC secondary to malignancy (Langer 2008). 
Elevated levels of MP of platelet (Nieuwland 2000; Ogura 2001; Soriano 2005), 
granulocyte (Nieuwland 2000), endothelial (Delabranche 2016; Matsumoto 2015; 
Soriano 2005), and leukocyte (Fujimi 2002) origin have been reported in sepsis and DIC 
patients compared to healthy individuals, although the precise MP profile associated with 
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sepsis is not well established (Joop 2001). Elevation of platelet and endothelial MP has 
been associated with non-survival in sepsis patients (Soriano 2005). In a study of 259 
patients with septic shock with extensive follow-up to detect the development of DIC, 
procoagulant microparticles were elevated in all patients regardless of the ultimate 
development of DIC (Delabranche 2016). In this study, CD105+ microparticles, in 
conjunction with platelet count and PT, were found to have strong ability to predict the 
development of DIC in patients with septic shock early in disease progression before 
clinically relevant hemostatic signs (Delabranche 2016). Levels of endothelial-derived 
MP have been shown to correlate with ISTH DIC score (Matsumoto 2015). In addition, 
EPCR-positive MP correlated significantly with APACHE II score and TF and EPCR-
positive MP correlated with SOFA score (Matsumoto 2015).  
Experimental conditions replicating sepsis also increase MP number. In a study of 
LPS infusion into healthy volunteers, platelet-derived and total MPs increased compared 
to baseline levels (Mooberry 2016). CLP-induced sepsis led to production of increased 
numbers of MP of platelet, endothelial, and monocyte origin in mice (Zafrani 2012). 
In addition to changes in number, the procoagulant phenotype of MPs may be 
modified in disease states. A study of MP from patients with meningococcal sepsis found 
no absolute change in MP number but did observe alterations to the MP pattern of origin 
and procoagulant phenotype (Joop 2001). A second study of MP from patients with DIC 
secondary to meningococcal sepsis found that these MP supported in vitro thrombin 
generation more strongly than MP from healthy controls (Nieuwland 2000). 
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One of the main procoagulant mechanisms of MP is TF exposure. Procoagulant 
microparticles, defined by positive TF staining via flow cytometry, have been detected in 
the plasma of patients with sepsis and MODS (Delabranche 2013). TF-positive MP of 
endothelial origin also correlated significantly with levels of IL-6, soluble TF factor, D-
Dimer, and decreased platelet count (Matsumoto 2015). MP from healthy human 
volunteers injected with LPS exhibited increased TF activity as well as reduced MP-
dependent clotting time (Mooberry 2016). In a mouse model of LPS injection, injection 
of LPS led to a significant increase in total microparticle procoagulant activity, and the 
MP-TF activity correlated with levels of TAT in these mice (Wang 2009). 
MP production and procoagulant activity may be detrimental to the host in sepsis. 
Mice with reduced MP production due to increased calpastatin expression showed 
improved survival in a CLP model as well as reduced kidney, liver, and lung dysfunction 
(Zafrani 2012). This reduction in MP number was also associated with delayed thrombin 
generation, reduced depletion of platelets and coagulation factors, and reduced DIC 
(Zafrani 2012).  
Animal Models of Sepsis and DIC 
Sepsis and sepsis-associated DIC are complex clinical conditions with 
pathophysiology characterized by interactions between the immune system, blood-borne 
coagulation system components, and the endothelium. This pathophysiology cannot be 
effectively replicated by an in vitro system. Stimulation of whole blood with LPS 
(Lindmark 1998) or other factors such as histones can be performed to study the direct 
influence of these factors on coagulation; however, such approaches do not account for 
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the interactions with the endothelium or the mechanical influence of blood flow and 
cannot demonstrate the benefits of drugs that may occur through interactions with the 
endothelium. Although alternative in vitro systems are being developed to simulate DIC 
(Greineder 2015, 2016; Greineder 2017), animal model systems are the most viable 
methods to study DIC pathophysiology and drug mechanisms.  
 Several model systems are currently used for the study of sepsis, with the two 
most common being the infusion of exogenous toxins, typically LPS or more recently 
histones, or the induction of a polymicrobial infection through cecal ligations and 
puncture (CLP). These model systems may also induce coagulopathy and be appropriate 
for the study of DIC. Both model systems induce a sepsis-like inflammatory response and 
can lead to the development of coagulopathy. However, additional work is needed to 
determine how well these models truly replicate the DIC seen in human patients. 
Toxin Injection Models 
The LPS injection model is commonly used and presents minimal technical 
difficulties, simply involving the injection of LPS into a rat (Elsayed 1996a; Iba 2014; 
Iba 2014; Inoue 1991; Kaspereit 2004; Murakami 1996) or mouse (Abraham 1999; 
Standiford 1995; Wang 2009; Yano 2006). LPS injection has also been used to simulate 
sepsis or DIC in monkeys (van der Poll 1994) and in healthy human volunteers (de Jonge 
2000; Pajkrt 1997). This creates a transient model of sepsis, including full activation of 
inflammatory cytokines, but does not replicate the later or prolonged stages of disease 
(Doi 2009) and results in an earlier and lower peak level of TNFα and IL-6 than is 
observed in human sepsis and in other models (Rittirsch 2007). The underlying 
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assumption of the LPS injection model is that the majority of the pathophysiology of 
sepsis is due to the host inflammatory response to the pathogen, primarily due to highly 
pro-inflammatory components such as LPS, rather than to the pathogen itself (Rittirsch 
2007). Although this model is primarily used to study sepsis, development of symptoms 
consistent with DIC such as the formation of microthrombi in the organs, elevated 
markers of coagulation such as TAT and F1.2, and prolongations in PT or aPTT have 
been observed in the LPS injection model at doses ranging from 20 to 500 mg/kg in rats 
(Asakura 2003; Elsayed 1996a; Hasegawa 1996; Kaspereit 2004).  
 More recently, injection of histones has been used as an alternative model of DIC 
(Abrams 2013; Nakahara 2013). Injection of histones into mice at a dose of 75 mg/kg is 
sufficient to induce pulmonary hemorrhage and death accompanied by an elevation in 
TNFα, IL-6, and IL-10 and a consumptive coagulopathy similar to that seen in DIC 
(Abrams 2013; Nakahara 2013). Direct injection of a TF-containing reagent such as 
thromboplastin at a dose of 3.75 U/kg has also been used; however, this mimics cancer-
associated DIC, not sepsis-associated DIC, and is thus beyond the scope of this project 
(Asakura 2003).  
 While toxin injection models of sepsis and DIC are useful for the examination of 
certain aspects of the pathophysiology of DIC, they cannot accurately replicate prolonged 
disease and are therefore less appropriate for the study of drug treatments. Models 
involving a true infection provide a more accurate representation of the conditions seen in 
human DIC and are more appropriate for this purpose.  
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Cecal Ligation and Puncture 
The cecal ligation and puncture (CLP) model of sepsis is commonly used in both 
rats (Heuer 2004; Heur 2004; Hubbard 2005; Inoue 1991; Kim 2000; Laudes 2002; 
Otero-Anton 2001; Qiu 2001; Ravindranath 2007; Rittirsch 2007; Rittirsch 2008; 
Schabbauer 2012; Yang 1994; Yin 2005) and mice (Araujo 2016; Clark 2008; Cuenca 
2010; Ganopolsky 2004; Hubbard 2005; Li 2007; Marquez-Velasco 2011; Ono 2001; 
Song 2013; Uolla 2002; van der Poll 1995; Wang 2004; H. Yang 2004; Yano 2006). 
Many slight variations on the CLP model exist and variations in the model allow for the 
fine tuning of disease severity. This protocol is well described by Rittirsch et. al. 
(Rittirsch 2007) and is widely accepted as a model for sepsis (Zanotti-Cavazzoni 2009). 
In this surgical model, the cecum is ligated with a suture near to but not 
obstructing the ileocecal valve. The ligation of the cecum leads to ischemia and necrosis, 
adding a source of inflammation to the model (Schabbauer, 2012). Variations in the 
amount of the cecum ligated produce differing severities of sepsis and thus differing 
degrees of model lethality. Additionally, the cecum is punctured with a needle, allowing 
leakage of fecal matter into the peritoneum, creating a source of polymicrobial infection. 
Many variants on the needle puncture procedure exist, leading to varying severity of 
induced sepsis due to the number of punctures, size of feces droplet extruded, and gauge 
of the needle. 100% mortality has been reported with double puncture with an 18-gauge 
needle (Kim 2000), mid-grade sepsis with a survival rate of 40% with a single perforation 
with a 20-gauge needle (Laudes 2002), low grade sepsis with single perforation with an 
18-gauge needle (Kim 2000), and confirmed DIC with 7 punctures made with an 18-
70 
 
 
 
gauge needle with removal of the necrotic cecum after 12 hours (Inoue 1991). A single 
through-and-through puncture with an 18-gauge needle was used in this study to create 
sepsis and coagulopathy with low mortality to facilitate the study of drug mechanisms of 
action. This portion of the procedure has a high potential for inconsistency, and 
standardization of this method is necessary to obtain good experimental results.  
 Following puncture of the cecum and return to the peritoneal cavity, the incision 
is closed with clips or sutures. Fluid resuscitation practices are also highly variable and 
can have a significant impact on animal mortality (Kim 2000; Laudes 2002; Ravindranath 
2007; Rittirsch 2008) ranging from no resuscitation to 40 (Kim 2000) or 50 (Rittirsch 
2008) ml/kg of pre-warmed sterile normal saline injected subcutaneously immediately 
following surgery.  
Although the CLP model is typically used to study sepsis, it leads to the 
development of coagulopathy and can therefore be used to study DIC. Thrombin 
generation, thrombus formation, decreased platelet count, and changes in global 
coagulation status have been reported in CLP models, suggesting that DIC does develop 
in this system (Heuer 2004; Inoue 1991; Laudes 2002; Song 2013). In a mouse model of 
CLP, reduction in platelet count, and elevated PT, aPTT, and D-Dimer were observed 6 
hours following CLP, with extensive microthrombus formation within 12 hours (Song 
2013). 
The CLP model of sepsis provides several advantages for the study of the 
pathophysiology of DIC and modulation by therapeutic agents. This model replicates a 
common clinical scenario of polymicrobial infection with intestinal flora. Additionally, 
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CLP is adaptable and can be modified to induce sepsis and associated DIC along a 
spectrum of severity by altering the size or number of punctures made, amount of cecum 
ligated, and amount of fluid resuscitation used (Kim 2000; Rittirsch 2008). 
Alternative Approaches 
Although CLP or the injection of LPS are the most commonly used animal 
models for sepsis or DIC, several alternative models do exist. Several studies have used 
the direct injection of TF in order to model DIC (Asakura, 2014; Asakura2003). 
Differences in the nature of the coagulation dysfunction induced by LPS and TF injection 
have been described, and the direct injection of TF may be more appropriate for the study 
of cancer-associated DIC than sepsis-associated DIC. Direct injection of known 
quantities of viable live bacteria has also been used. Although these models do utilize live 
bacteria, they are often considered more similar to models of endotoxic shock than CLP 
models, as even high doses of bacteria may be rapidly destroyed and fail to establish 
lasting infection (Rittirsch 2007; Cross 1993; Lilley2015). 
Two main alternatives to CLP exist: the implantation of a bacterial clot or fecal 
pellet into the abdomen, or the colon ascendens stent peritonitis (CASP) model. The 
implantation of a fibrin clot containing viable bacteria (Mathiak2000) or a fecal pellet 
(Rittirsch2007) into the abdomen of a rat is considered similar to the CLP model and is 
not commonly used (Rittirsch2007). The CASP model, in which a stent is inserted into 
the ascending colon, leading to continued leakage of fecal matter into the peritoneal 
cavity, may represent a viable alternative to the CLP model Schabbauer, 2012; Zanotti-
Cavazzoni 2009; Zantl 1998). In this model, mortality is often controlled by removal of 
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the stent at a pre-determined time point. The added surgical complexity of this model was 
not warranted for these studies.  
Therapeutics for DIC 
Current clinical practice for the treatment of DIC does not involve any 
coagulopathy-specific treatment but rather is focused on resolution of the underlying 
condition. For sepsis-associated DIC, this involves treatment of the underlying infection 
with pathogen-appropriate antibiotics accompanied by supportive interventions such as 
fluids, vasopressors, and mechanical ventilation. Although some instances of DIC, such 
as those induced by obstetric complications, may resolve rapidly with resolution of the 
underlying condition, sepsis-associated DIC often results in extended illness that 
contributes substantially to patient morbidity and mortality. Additionally, the organ 
failure induced by the coagulopathy in DIC can have long-lasting complications. There is 
an unmet therapeutic need for a drug to treat the coagulopathy in sepsis-associated DIC. 
 The development of therapies for DIC is complicated by the propensity for both 
bleeding and thrombosis in DIC patients. While treatment with a conventional 
anticoagulant such as heparin may prevent systemic coagulation, this therapeutic 
approach carries a risk of significant and potentially fatal bleeding. Bleeding risk is 
heightened in patients with DIC, where consumptive coagulopathy leads to a risk of 
bleeding even in the absence of anticoagulant therapy. Conversely, replacement of 
coagulation factors and platelets to prevent bleeding associated with DIC and correct 
laboratory coagulation parameters through the administration of blood products may add 
fuel to the fire of ongoing systemic thrombosis. In a 2016 meta-analysis of 24 clinical 
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trials involving 14,767 patients, including trials of multiple exogenous or endogenous 
anticoagulants, anticoagulant therapy led to a reduction in mortality in patients with 
sepsis-associated DIC but not in patients with less severe coagulopathy or with sepsis 
alone (Umemura 2016). Other studies of anticoagulant use in DIC patients have yielded 
similar results (Dhainaut 2004; Kienast 2006; Yamakawa 2016). This suggests that 
anticoagulation of patients with sepsis and severe DIC may be appropriate and beneficial 
whereas anticoagulant treatment of patients with less severe coagulopathy may in fact 
prove detrimental. Accordingly, improved approaches for determining if patients are 
appropriate candidates for anticoagulant therapy are needed. Additionally, methods to 
monitor treatment and assess a patient’s response to therapy would also be beneficial.  
 A potential approach to DIC treatment is restoration of the endogenous 
anticoagulant system. Several endogenous anticoagulants have entered clinical trials for 
application in sepsis-associated DIC, including tissue factor pathway inhibitor (TFPI) 
(Abraham 2003; de Jonge 2000), activated protein C (APC) (Bernard 2004; J. Dhainaut 
2004; J.-F. Dhainaut 2003; Ranieri 2012; Shorr 2010), antithrombin concentrate (AT) 
(Allingstrup 2016; Iba 2016; Iba 2012; Kienast 2006; Tagami 2015; Warren 2001), and 
recombinant thrombomodulin (rTM) (Hayakawa2016; Hoppensteadt 2014; Ito 2015; 
Saito 2007; Vincent 2013). Heparin, often in combination with another agent, has also 
been evaluated for use in sepsis-associated DIC (do Toit 1991; Jaimes 2009; Kienast 
2006; Levi 2007; Pernerstorfer 1999). Treatment of DIC with TFPI was unsuccessful and 
did not lead to drug approval. APC, under the names drotrecogin alfa (activated) and 
Xigris, was successful in initial trials and was approved for use in patients with sepsis in 
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2001. However, post-approval studies showed low or no benefit to APC treatment 
coupled with an increased risk of severe bleeding, and APC was withdrawn from the 
market in 2011.  
The current focus for endogenous anticoagulant treatment in sepsis-associated 
DIC is antithrombin (AT) and recombinant thrombomodulin (rTM). Both AT and rTM 
are approved for use in the treatment of DIC in Japan, and an international Phase III trial 
of rTM is ongoing (ClinicalTrials.gov identifier NCT01598831). Although AT and rTM 
are not currently used in the United States, they are widely used to treat sepsis-associated 
DIC in Japan, with a study of 3195 patients with severe sepsis in Japan between 2011 and 
2013 reporting that 47% of these patients received treatment for DIC, with 31% receiving 
AT, 31% receiving rTM, and 16% receiving co-administration of the two agents 
(Hayakawa, Saito, 2016). In an analysis of anticoagulant therapy of 2663 sepsis patients 
in Japan, 1247 of whom received anticoagulants and 1416 of whom did not, 
administration of anticoagulants including AT, rTM, and heparin showed a benefit in 
those patients who were diagnosed with DIC, and a trend towards reduction in mortality 
in those with the highest SOFA scores (13-17) (Yamakawa 2016). However, this pattern 
was not observed in patients without DIC or with lower SOFA scores, underscoring the 
importance of targeting treatment to the most appropriate patients (Yamakawa 2016). In 
this cohort, bleeding risk, defined by the requirement for bleeding-related blood 
transfusions, ranged from 13-27% in the anticoagulant treated groups and from 6-10% in 
the control group (Yamakawa 2016).  
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Recombinant thrombomodulin, antithrombin, and heparin will be the focus of this 
research project. The following section provides a discussion of the mechanism of action 
and role of rTM, AT, and heparin in sepsis-associated DIC. Figure 4 illustrates the 
anticoagulant effects rTM, AT, and heparin. Table 4 summarizes the basic anticoagulant 
mechanisms and hypothesized additional activities of each agent with respect to their use 
in the treatment of sepsis-associated DIC.   
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Figure 4. Anticoagulant Actions of rTM, AT, and Heparin. Coagulation cascade 
components are shown in blue (intrinsic pathway), green (extrinsic pathway), and 
orange (common pathway). The actions of endogenous anticoagulants including 
Protein C, activated Protein C (APC), thrombomodulin (TM), and antithrombin (AT) 
are shown in red. Anticoagulant agents with potential use in DIC include recombinant 
thrombomodulin (rTM), antithrombin (AT), and heparin, and are shown in purple. rTM 
serves as a replacement for endogenous TM and converts Protein C to APC, which 
subsequently inhibits FVIIIa and FVa. Exogenous AT serves as a replacement for 
depleted endogenous AT and inhibits multiple coagulation factors including FIIa, FVa, 
FXa, FIXa, and FXIa. Heparin is an AT-dependent factor Xa and IIa inhibitor. Heparin 
binds to AT and enhances the AT-mediated inhibition of these factors.  
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Table 4. Summary of Mechanisms of Action of Recombinant Thrombomodulin, Antithrombin, and Heparin in DIC 
 
Drug Anticoagulant 
Mechanism 
Hypothesized Additional Mechanisms 
Recombinant 
Thrombomodulin  
 (rTM7; ART-
123) 
Replacement for 
dysregulated endogenous 
anticoagulant system; 
activates Protein C, 
leading to inhibition of 
FVIIIa and FVa 
 Direct anti-inflammatory effects including neutralization of LPS 
(Shi 2008)  
 Prevention of damage caused by circulating histones and other 
nuclear material (Hagiwara 2010; Iba 2014; Iba 2014; Nagato 
2009; Nakahara 2013; Osada 2017; Shimomura 2016; Takehara 
2017; Tanaka 2013)  
 Inhibition of NETosis (Shimomura 2016)  
 Anti-inflammatory and cytoprotective effects mediated through 
TAFI (Colucci 2012; Tawara 2016) and APC (Bae 2011; Xu 
2009) 
Antithrombin 
 (AT) 
Replaces physiological 
anticoagulant that 
becomes depleted in DIC; 
inhibitor of thrombin, 
FXa, FVIIa, FIXa, and 
FXIa 
 Reduction in inflammation through reduced coagulation (Iba 
2014; Levy 2016)  
 Preservation of the glycocalyx (Chappell 2009; Iba 2016) 
Increased prostacyclin synthesis and secretion, reduced 
neutrophil rolling and adhesion (Iba 2014; Levy 2015)  
Heparin 
 (UFH) 
Exogenous anticoagulant; 
antithrombin-dependent 
inhibitor of FXa and FIIa 
 Decreased TF expression (Ding 2011; Pernerstorfer 1999)  
 Increased TFPI release (Pernerstorfer 1999)  
 Reduced inflammation (Ding 2011)  
 Anti-histone effects (Kowalska 2014)  
 Reduced vascular permeability (Bentzer 2016) 
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The Protein C Pathway: Activated Protein C and Recombinant Thrombomodulin 
Activated Protein C (APC). Protein C is an endogenous anticoagulant that 
becomes depleted in DIC patients due to vascular leakage, reduced hepatic production, 
and excessive consumption. This acquired protein C deficiency is associated with 
hypercoagulability and increased mortality (Marcel Levi 2001; ten Cate, 2000). When 
converted to its active form, activated protein C (APC), APC proteolytically inactivates 
coagulation factors Va and VIIa in addition to exerting additional anti-inflammatory 
effects, potentially mediated through the cleavage of histones. 
Direct replacement of APC, known in drug form as drotrecogin alfa (activated) or 
by the brand name Xigris, was pursued as a therapeutic approach in patients with severe 
sepsis and coagulopathy. APC was approved by the FDA in 2001 as the first drug for use 
in this indication following the PROWESS trial (Bernard 2001). However, subsequent 
clinical trials showed significant bleeding risk associated with APC treatment (Abraham 
2005; Bernard 2004). Following the PROWESS-SHOCK study, which showed no 
reduction in mortality for patients treated with APC, the drug was ultimately removed 
from the market in 2011 (Ranieri 2012). Following the removal of APC from the market, 
drugs for the treatment of sepsis-associated coagulopathy represent an unmet medical 
need.  
Despite the overall clinical failure of APC, some evidence suggested that APC 
might have benefits outweighing the bleeding risk in the population of patients with overt 
DIC, which composed only a small portion of the severe sepsis patients enrolled in these 
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large clinical trials, ultimately leading to the development of rTM as a therapeutic agent 
(Dhainaut 2004).  
Recombinant Thrombomodulin (rTM). Recombinant thrombomodulin (rTM; 
also known as ART-123) was approved in Japan in 2008 for the treatment of sepsis-
associated DIC (Saito 2007). rTM is a soluble form of the endogenous protein 
thrombomodulin (TM). TM is expressed on the surface of endothelial cells and has a high 
affinity for thrombin. Thrombin-thrombomodulin complex formation changes the 
specificity of thrombin from procoagulant substrates towards the conversion of Protein C 
to Activated Protein C (APC) (Adams & Huntington, 2006). Once Protein C is activated 
by the thrombin-thrombomodulin complex, it inhibits FVa and FVIIa, ultimately leading 
to reduced thrombin generation (Kisiel, 1979). The anticoagulant effects of TM, mediated 
through Protein C, are illustrated in Figure 5 (Ikezoe, 2015). 
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Figure 5. Activity of Thrombomodulin on the Coagulation Cascade. Adapted from 
Ikezoe et. al. 2015. Thrombomodulin exerts its anticoagulant effects through the 
activation of Protein C. Once activated, APC inactivates coagulation factors Va and 
VIIIa, leading to reduced thrombin generation (TM, thrombomodulin; IIa, thrombin; 
PC, Protein C; EPCR, endothelial protein C receptor; APC, activated protein C) 
 
TM is dysregulated in DIC patients, which is hypothesized to contribute 
significantly to disease pathophysiology. Inflammation leads to reduced TM levels on 
endothelial cell surfaces (Moore, Andreoli, Esmon, Esmon, & Bang, 1987; Moore, 
Esmon, & Esmon, 1989). This in turn can lead to reduced activity of the Protein C system 
and increased coagulation as well as reduction in the non-anticoagulant effects of TM.  
The effects of TM are not limited to actions on specific proteins in the coagulation 
cascade. Both TM and Protein C have direct anti-inflammatory and cytoprotective 
effects. rTM has been shown to bind to and neutralize LPS, ameliorating the LPS-
induced inflammatory response (Shi 2008). The thrombin-thrombomodulin complex 
activates thrombin-activatable fibrinolysis inhibitor (TAFI), which itself has 
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antifibrinolytic and anti-inflammatory properties, including increased inactivation of 
complement factor C5a and decreased C5a-induced PMN migration (Colucci 2012; 
Tawara 2016).  
Interestingly, rTM may also be protective against histone induced damage and 
death (Iba 2014; Nakahara 2013; Osada 2017; Shimomura 2016). In vitro, rTM was 
shown to inhibit histone-induced thrombin generation and endothelial cell death and 
promote Protein C-mediated histone cleavage (Osada 2017). In a mouse model of histone 
H3 induced lethal thromboembolism, rTM was shown to bind to extracellular histones, 
suppress histone-induced platelet aggregation, and protect mice from histone induced 
DIC (Nakahara 2013). Administration of rTM also decreased detectable levels of histone 
H3 from 17.0 pg/ml to 5 pg/ml in rats subjected to an LPS-induced model of sepsis (Iba 
2014; Iba 2014). rTM at concentrations of 2, 10, or 50 μg/ml prevented LPS-induced 
NETosis in the presence of platelets (Shimomura 2016). APC was also capable of 
inhibiting histone-mediated damage through the cleavage of histone proteins H3 and H4 
(Xu 2009). rTM (Hagiwara 2010; Nagato 2009; Tanaka 2013) and APC (Bae 2011) may 
also prevent damage caused by other nuclear materials in the extracellular environment, 
such as the chromatin associated protein HMGB-1. In mice subjected to LPS challenge, 
administration of 3 mg/kg rTM reduced levels of nucleosomes and HMGB-1 as well as 
IL-6, MCP-1, and TNFα (Takehara 2017). The non-anticoagulant properties of 
thrombomodulin and Protein C are summarized in Figure 6.  
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Figure 6. Anti-Inflammatory and Cytoprotective Effects of Thrombomodulin. 
Adapted from Ikezoe et. al. 2015. .In addition to Protein-C mediated anticoagulant 
effects, both thrombomodulin and Protein C exert other anti-inflammatory and 
cytoprotective effects that may be highly beneficial to patients with sepsis-associated 
DIC. 
 
rTM was approved for use in patients with sepsis and DIC in Japan in 2008, and 
post-approval research has demonstrated a reduction in mortality without an increase in 
bleeding (Aota 2016; Hayakawa 2016; Ikezoe 2015; Ogawa 2011; Yamakawa 2015; 
Yamakawa 2011; Yamakawa 2013). Approval for rTM is currently being pursued in the 
United States and Europe, with a Phase II trial completed (Vincent 2013) and a Phase III 
trial is ongoing (ClinicalTrials.gov identifier NCT0158831).  
As with any drug with anticoagulant properties, treatment associated bleeding risk 
is a significant concern. In patients treated with rTM, lower bleeding rates have been 
observed compared to heparin-treated patients (Saito 2007). Pre-clinical studies of rTM 
demonstrated reduced peak thrombin generation in a thrombin generation assay (Mohri 
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1999) as well as effects on conventional coagulation assays including aPTT, PT, and TT 
in the presence of Protein C (Mohri 1999). However, no significant increases in bleeding 
have been reported in several clinical trials for rTM in DIC patients, suggesting that rTM 
is safe for use in this patient population (Ogawa 2011; Saito 2007; Vincent 2013).  
rTM is administered clinically at a dose of 60 μg/kg/day (Ogawa 2011; Saito 
2007; Vincent 2013; Yamakawa 2015; Yamakawa 2011; Yamakawa 2013) (0.06 
mg/kg/day) with a maximal dose of 6 mg per day (Vincent 2013). However, the IC50 
value of rTM on thrombin generation is much higher in rat plasma than in human plasma, 
and significantly higher doses of rTM must be used in rats to achieve comparable effects. 
The original preclinical studies of rTM in both LPS and TF-induced DIC in rats used 
rTM at doses of 0.3, 1, and 3 mg/kg, with the greatest effects seen at 3 mg/kg (Gonda 
1993; Mohri 1994). Experimentally, rTM is commonly administered to rats at doses of 
0.25 mg/kg (Iba 2013; Iba 2014; Iba 2014; Iba 2009) or 1 mg/kg (Aoki 1994; Aoki 1994; 
Gonda 1993; Hagiwara 2010; Iba 2013; Mohri 1994; Nagato 2009), with higher doses 
used in numerous studies (Aoki 1994; Gonda 1993; Hasegawa 1996; Iba 2013; Mohri 
1994; Tanaka 2013). rTM has also been co-administered with antithrombin in both 
animal (Iba 2014) and human (Iba 2009; Iba 2014; Iba 2016) studies, although 
combination approaches may result in increased bleeding.  
Antithrombin 
Antithrombin (AT) is a physiological anticoagulant capable of inhibiting 
thrombin, FVIIa, FIXa, FXa, FXIa, and FXIIa. Reduced AT levels have been observed in 
patients with sepsis-associated DIC and are correlated with increased mortality (Warren 
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2001). In sepsis, AT levels are reduced not only due to consumption but also due to 
leakage from the vasculature (Aibiki 2007; Iba 2016). AT has been pursued as therapy 
for patients with sepsis and coagulopathy, most notably through the large Phase III 
KyberSept trial, enrolling 2314 patients with severe sepsis (Warren 2001). In this trial, no 
overall reduction in 28-day mortality was observed, and an increase in clinically 
significant bleeding was observed in patients receiving AT and concomitant prophylactic 
doses of heparin (Warren 2001). Subsequent post-hoc analyses revealed that patients with 
confirmed DIC who did not receive concomitant heparin may in fact have benefitted 
from AT treatment; AT treatment in this population reduced mortality from 40% to 
25.4% in comparison to placebo (Kienast 2006). Additional smaller studies have also 
supported the safety and efficacy of AT in sepsis patients with confirmed DIC (Iba, 
Gando, 2016; Iba 2012; Tagami 2015). AT is used clinically as a therapeutic for DIC in 
Japan at doses of 3000 or 1500 IU/day (Iba 2012). While AT may be beneficial in the 
DIC patient population, use of this agent is associated with an increased risk of clinically 
significant bleeding (Allingstrup 2016). 
Although less commonly discussed, AT may have properties that extend beyond 
anticoagulation, including anti-inflammatory effects. AT may protect the endothelium by 
preserving the glycocalyx, which is essential for the regulation of endothelial 
permeability and leukocyte adhesion (Chappell 2009; Iba 2016). Other anti-inflammatory 
effects of AT are thought to be mediated through the inhibition of coagulation (Levy 
2016). In particular, the neutralization of thrombin by AT leads to reduced signaling 
through the PAR-1 receptor, which contributes to inflammatory activation (Iba 2014). 
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Inhibition of FXa and FVIIa may also decrease the induction of inflammation by 
coagulation (Levy 2016). Additionally, AT may be able to increase prostacyclin synthesis 
and secretion and prevent neutrophil rolling and adhesion (Iba 2014; Levy 2015).  
AT is typically administered to sepsis and DIC patients at doses of 3000 IU/day or 
1500 IU/day (Allingstrup 2016; Iba 2016; Iba 2012), although higher doses have been 
used in some clinical trials (Warren 2001). Based on the 70 kg “standard man”, this 
corresponds to a dose of 43 IU/kg/day or 21 IU/kg/day, with lower doses achieved in 
heavier patients. Some studies in rats have used AT at doses comparable to those used in 
humans, such as 50 IU/kg (Uchiba, Okajima, & Murakami, 1998) or 62.5 IU/kg (Iba 
2009). However, while this dose may be sufficient to reverse coagulation abnormalities, 
higher doses are required to have additional anti-inflammatory effects (Uchiba 1998). 
Consequently, AT is commonly administered to rats at doses of 125 IU/kg or 250 IU/kg 
(Uchiba 1998; Yamashiro 2001; Yang 1994). AT has also been co-administered with 
rTM in both animal (Iba 2014) and human (Iba 2009; Iba 2014; Iba 2016) studies, 
although combination approaches may result in increased bleeding. The co-
administration of AT with heparin in DIC patients has also been investigated as a 
therapeutic approach (Hoffmann 2002; Yang 1994), although co-administration of 
heparin may reduce the efficacy of AT supplementation. 
Heparin 
Heparin is an anticoagulant drug derived from porcine mucosa that is used in 
numerous medical and surgical applications. Heparin acts as an antithrombin-dependent 
inhibitor of factors Xa and IIa. The binding of heparin to AT induces a conformational 
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change in AT which increases the anticoagulant activities of AT more than 1,000 fold. As 
heparin requires AT to exert its anticoagulant effect, the effects of heparin will be 
reduced in a severely AT-deficient patient. In addition to its classical anticoagulant 
effects, heparin has additional mechanisms of action including induction of endothelial 
cell TFPI release.  
Unfractionated heparin (UFH), low molecular weight heparin (LMWH), or other 
heparin-derived products such as pentasaccharide (fondaparinux) or heparinoids may be 
used depending on the clinical scenario and desired benefits. UFH has traditionally been 
the focus of study in sepsis and DIC (Jaimes 2009; Y. Li 2011; Liu 2014). Prophylactic 
doses of UFH are commonly administered to hospitalized patients, while LMWH is the 
drug of choice for other applications. However, the non-anticoagulant activity and 
bleeding risks associated with UFH, LMWH, and heparinoids in sepsis-associated DIC 
may be different (Derhaschnig 2003; Iba 2009; van Bruggen 1996). Non-anticoagulant 
heparins have also been developed and may have relevance to sepsis and DIC (Ammollo 
2011; van Bruggen 1996; Wildhagen 2014; Zhang 2014). 
UFH is administered intravenously and is used to prevent or treat thrombosis in 
hospitalized patients, with significantly lower doses used for prophylaxis than for 
treatment of an established thrombus. Administration of prophylactic doses of heparin to 
hospitalized or immobilized patients is a common clinical practice. In addition to its 
antithrombotic effects, heparin may have non-anticoagulant effects that are beneficial to 
DIC patients.  
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The use of heparin in DIC has been studied in both animal models (do Toit 1991; 
Yang 1994) and in humans (Derhaschnig 2003; Kienast 2006; Levi 2007; Liu 2014; 
Pernerstorfer 1999; Saito 2007; Yang 1994). Heparin has been shown to inhibit 
coagulation in models of DIC. In a study of LPS administration to healthy human 
volunteers, administration of either UFH or LMWH decreased activation of coagulation, 
measured by blunted increase in F1.2 (Pernerstorfer 1999). However, it is less clear how 
well this contributes to increased survival. In general, clinical trials have failed to show a 
decrease in mortality with prophylactic UFH administration in DIC patients (Jaimes 
2009; Levi 2007). In a baboon model of thrombin-induced DIC, IV heparin 
administration at a low dose of 10 IU/kg/hour prevented the development of DIC and 
reduced mortality (do Toit 1991). In a study of administration of 70 IU/kg heparin per 
day to 37 sepsis patients, significant reduction in number of days in the ICU and days 
requiring a ventilator was observed, and the percentage of patients ultimately developing 
MODS or DIC were reduced in heparin-treated subjects compared to controls (Liu 2014). 
However, no reduction in mortality was observed (Liu 2014). 
Heparin may have benefits beyond anticoagulation in the treatment of DIC. UFH 
has been shown to decrease monocyte TF expression in response to LPS as well as 
increase TFPI levels (Pernerstorfer 1999). UFH pretreatment of mice subjected to LPS 
injection reduced inflammation and procoagulant phenotype, quantified by reduced levels 
of IL-1β, TNFα, and TF mRNA in blood cells as well as thrombus formation and fibrin 
deposition in the liver (Ding 2011). In a mouse model of histone injection, injection of 
UFH at 50 mg/kg, a dose sufficient to increase aPTT to greater than 150s compared to a 
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normal value of 20s, reduced histone-mediated APC generation; however, UFH also 
protected mice from histone-induced death (Kowalska 2014). Heparin administration 
may also prevent increased vascular permeability induced by elevated levels of heparin 
binding protein, which is associated with severity of shock and hypoxemia in patients 
with sepsis (Bentzer 2016).  
Heparin is used as part of the standard of care for DIC in Japan, and several 
animal studies and clinical trials for AT and rTM have used heparin as a comparator drug 
instead of placebo or have included heparin treatment concomitant with the 
investigational drug (Kienast 2006; Levi 2007; Saito 2007; Yang 1994). Despite 
theoretical mechanisms for benefit in DIC, clinical trials have failed to show a decrease 
in mortality with prophylactic UFH administration in DIC patients (Jaimes 2009; Levi 
2007). Additionally, heparin carries a significant risk of treatment-associated bleeding. 
The co-administration of AT with heparin in DIC patients has also been investigated as a 
therapeutic approach (Hoffmann 2002; Yang 1994), although co-administration of 
heparin may reduce the efficacy of AT supplementation. 
The doses of heparin used clinically are widely varied depending on the clinical 
scenario. Accordingly, the doses of heparin used in clinical trials and in animal models 
are highly variable (Li 2011). UFH has been administered to sepsis-associated DIC 
patients at doses of 5,000 U subcutaneously twice per day concomitant with APC (Levi 
2007). In a study of UFH as a therapy for DIC, UFH was administered at a dose of 
12,000 IU for a 24-hour period (Jaimes 2009). For a 70 kg standard man, a dose of 
10,000 IU of UFH per day would correspond to a dose of 143 IU/kg. Multiple animal 
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studies of UFH in DIC have used UFH at doses in the range of 100-400 IU/kg/day 
(Gonda 1993; Iba 2009; Li 2011; Mohri 1994).  
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CHAPTER TWO 
STATEMENT OF PURPOSE 
Sepsis, defined by the Society of Critical Care Medicine in 2016 as “life 
threatening organ dysfunction due to a dysregulated host response to infection” (Singer 
2016) is a severe clinical condition that contributes significantly to morbidity and 
mortality in the United States and worldwide. A significant fraction of patients 
hospitalized with sepsis develop coagulation anomalies, ranging from slight perturbations 
in laboratory values to a severe systemic coagulation disorder known as disseminated 
intravascular coagulation (DIC). DIC is characterized, paradoxically, by both bleeding 
and thrombosis. Inappropriate and widespread activation of the coagulation cascade leads 
to microvascular thrombosis, causing, vascular occlusion, ischemia, and ultimately 
resulting in multiple organ dysfunction. This inappropriate coagulation activity consumes 
platelets and coagulation factors through a process often referred to as “consumptive 
coagulopathy”, placing patients at risk for severe and potentially fatal bleeding. 
Development of DIC leads to a significantly elevated risk of death in septic patients. The 
molecular pathophysiology of sepsis-associated DIC is complex, and much remains to be 
understood about the development and treatment of this disease.  
Under normal physiologic conditions, blood flow and hemostasis is maintained 
though an intricate balance between the coagulation cascade, endogenous anticoagulants, 
and the fibrinolytic system. In highly pro-inflammatory states, such as sepsis, these 
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processes can become dysregulated through interactions with the host immune and 
inflammatory apparatus. Platelet activation and endothelial dysfunction activation or 
damage can also contribute to the development of a systemic prothrombotic state and 
subsequent DIC. Current practice for the diagnosis of DIC is based on scoring systems, 
most commonly the one defined by the International Society of Thrombosis and 
Hemostasis (ISTH) (Taylor, Toh, Hoots, Wada, & Levi, 2001), which incorporates the 
clinical laboratory parameters platelet count and prothrombin time (PT) or international 
normalized ratio (INR) as well as the thrombosis markers fibrinogen and D-Dimer. While 
this diagnostic approach utilizes readily available laboratory assays, it does not provide 
insight into the molecular aspects of sepsis-associated DIC. Factors including bacteria 
and bacterial virulence factors, host immune and inflammatory response, endothelial 
damage or activation, platelet activation, and the interactions of these processes with 
coagulation, fibrinolysis, and endogenous anticoagulants are all involved in the 
development of sepsis-associated DIC. Assessment of biomarkers representative of the 
numerous processes underlying the development of DIC using plasma samples 
acquired from septic patients may provide greater insight into the molecular 
pathogenesis of DIC. Development of a diagnostic or investigational test panel with 
parameters representative of the complex pathophysiology of DIC may provide improved 
diagnostic or prognostic information for patients. Additionally, this work will provide an 
improved method for the evaluation of animal models used to study DIC and potential 
therapeutic agents. 
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 Current standard of care for the treatment of sepsis-associated DIC is focused on 
elimination of the underlying infection through antibiotic administration accompanied by 
supportive measures such as mechanical ventilation and vasopressor administration. No 
specific treatments are used for the coagulopathy in DIC. Development of therapies 
specific for DIC is made difficult by the dual risks for thrombosis and bleeding, both of 
which may be exacerbated by the administration of any hemostatically active substance.  
While traditional anticoagulants are capable of inhibiting thrombosis in DIC 
patients, these drugs carry a significant risk of severe bleeding in this already susceptible 
patient population. Conversely, while replacement of depleted platelets and coagulation 
factors could prevent DIC-associated bleeding, this could also add fuel to the fire of 
ongoing thrombus formation. Due to the risk of bleeding associated with anticoagulant 
therapy, targeting of therapeutics to the patients with the greatest potential for benefit 
from treatment is a priority. 
A potential therapeutic approach to preventing thrombosis without causing 
bleeding in DIC patients is replacement of endogenous anticoagulants, particularly 
antithrombin (AT) and thrombomodulin (TM), which become depleted during disease. 
Therapy with both AT (Allingstrup 2016; Gando 2006; Iba 2016; Iba 2012; Kienast 
2006; Tagami 2015; Warren 2001) and recombinant TM (Hayakawa 2016; Hoppensteadt 
2014; Ito 2015; Moll 2004; Ogawa 2011; Saito 2007; Takazono 2014; Vincent 2013; 
Yamakawa 2015; Yamakawa 2011; Yamakawa 2013) has been evaluated in clinical trials 
for this application. In addition to their function as endogenous anticoagulants, both AT 
and rTM have additional functions that are poorly understood but may be highly 
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beneficial to DIC patients (Hagiwara 2010; Iba 2014; Iba 2014; Nagato 2009; Nakahara 
2013; Shi 2008; Shimomura 2016; Tawara 2016). Despite the risk of bleeding, heparin is 
also of interest for this application due to both its anticoagulant and non-anticoagulant 
properties (Ding 2011; do Toit 1991; Jaimes 2009; Kienast 2006; Pernerstorfer 1999; 
Yang 1994). An understanding of the antithrombotic, anti-inflammatory, and other 
mechanisms by which rTM, AT, and heparin may modulate the pathogenesis of 
sepsis-associated DIC may improve the use of these therapeutic agents, including 
targeting to the appropriate patient population, as well as lay groundwork for 
design and testing of future therapeutics for sepsis-associated DIC.  
An improved understanding of the modulation of not only coagulation but also 
other processes such as inflammation, response to infection, and endothelial and platelet 
damage or activation, is necessary for optimal understanding, development and 
implementation of these agents. Assessment of drug impact on these factors through 
biomarkers selected based on human pathophysiology and validated in an animal model 
may be an important step in this direction.  
It is the purpose of this dissertation to identify biomarkers representative of 
multiple aspects of the molecular pathophysiology of DIC, validate the potential 
relevance of relevant markers through the use of animal models, and assess the 
response of these factors to treatment with recombinant thrombomodulin, 
antithrombin, and heparin in order to better understand the mechanism of action of 
these therapeutic agents. Investigation of the molecular pathophysiology of sepsis-
associated DIC in patient samples with respect to numerous factors involved in disease 
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development and subsequent validation of these findings in an experimental model will 
contribute to an improved understanding of the pathogenesis of this disease. Furthermore, 
this will improve the understanding of the full mechanism of therapeutic agents with 
potential application in DIC, leading to improved treatment outcomes for sepsis-
associated DIC patients. 
Specific Aims 
Specific Aim 1: To understand the molecular pathogenesis of sepsis-associated 
DIC by profiling plasma biomarkers of inflammation, infection, endothelial function, and 
platelet function as well as hemostatic dysregulation and assessing their relevance to 
disease progression and outcome. 
Aim 1A: To assess the relationship between INR, aPTT, and coagulation factor 
levels in patients with sepsis-associated DIC and compare this relationship with that 
observed in patients receiving warfarin anticoagulation. 
Aim 1B: To measure a panel of biomarkers in plasma from a cohort of patients 
with well-defined sepsis and DIC and determine the association of these markers with 
DIC scores and mortality. 
Aim 1C: To develop an algorithm based on a combination of biomarkers to 
predict clinical outcome in patients with sepsis associated DIC. 
Specific Aim 2: To modify and validate an in vivo animal model of sepsis-
associated DIC to understand the pathophysiology and pharmacological modulation of 
this disease process. 
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Specific Aim 3: To assess the effects and mechanism of action of therapeutic 
modulation on the pathogenesis of sepsis and sepsis-associated DIC. 
Significance 
Sepsis associated disseminated intravascular coagulation (DIC) is a severe clinical 
scenario with high prevalence and high mortality. The pathophysiology of sepsis-
associated DIC is complex and involves dysregulation of multiple systems, which is not 
fully captured by current clinical diagnosis and evaluation protocols. Furthermore, 
therapeutic options for the treatment of DIC are limited, with no specific treatments 
currently approved in the United States. A comprehensive approach to the understanding 
of the molecular pathophysiology of sepsis-associated DIC, its replication in animal 
models, and its pharmacologic modulation will provide useful information for improved 
clinical management of this syndrome.  
 Although DIC is diagnosed on the basis of coagulation dysfunction, this disease 
involves numerous other processes including inflammation, immunity, platelet and 
endothelial dysfunction, and dysregulation of endogenous anticoagulants. These factors 
are not reflected in current assessments of sepsis-associated DIC. By assessing a 
combination of biomarkers representative of multiple aspects of the pathophysiology of 
sepsis-associated DIC in a cohort of patients with sepsis and well-characterized 
coagulopathy, this project will contribute to an improved understanding of this disease 
process. Additionally, this biomarker profile will also provide a framework for the 
evaluation of the relevance of animal models and the mechanism of investigational drugs.  
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Animal models for sepsis are widely used, and development of coagulopathy has 
been reported in several sepsis model systems. However, this coagulopathy is often 
poorly defined. Furthermore, the physiological relevance of these models in terms of not 
only coagulation or inflammation but also endogenous anticoagulants, endothelial 
damage, and other factors has not been comprehensively evaluated and compared to 
human patients. By comparing an animal model with a well-defined patient cohort, this 
project will provide improved validation of animal models for DIC. 
 Therapeutics for DIC represent a critical unmet medical need. As with all 
anticoagulant drugs, these therapies carry a risk of severe bleeding, and previous trials of 
anticoagulant agents in the sepsis population have proven largely unsuccessful, due in 
part to this elevated bleeding risk. However, analyses of subgroups of patients from 
larger trials have shown that the benefits of these agents may outweigh the risks in the 
population of patients with the most severe coagulopathy, suggesting that improved 
targeting of drugs to patients with specific pathologies may lead to improved outcomes. 
An improved understanding of the mechanisms of recombinant thrombomodulin, 
antithrombin, and heparin for the treatment of sepsis-associated DIC will be gained 
through analysis of the effects of these drugs on the molecular pathophysiology of the 
disease in a validated animal model. This will contribute to better application of therapy 
to the most appropriate patients, maximizing benefit while minimizing risk.  
Clinical Implications 
 The work presented in this dissertation has the potential to contribute to both the 
diagnosis and the treatment of patients with sepsis-associated DIC.  
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By examining the association of biomarkers with the severity of coagulopathy, 
this work may aid in the development of an improved diagnostic approach for DIC. 
Furthermore, this work includes a novel approach to the development of an algorithm for 
the prediction of outcome in this patient population. Improved diagnosis and prognostic 
prediction is important for the appropriate administration of care to these patients. 
Currently, drugs for sepsis-associated DIC represent an unmet medical need. This 
dissertation includes studies on the mechanism of action of rTM, AT, and UFH as drugs 
with potential use in sepsis-associated DIC. This will contribute not only to an improved 
understanding of the optimal use of these agents, but also to the development of future 
treatments for this disease.  
The improvement in diagnosis and prognostic prediction and the better 
understanding of the mechanism of action of potential therapies for sepsis-associated DIC 
are significant individually, but may have greater significance when combined. Previous 
clinical studies of treatments for DIC have shown that these potential therapeutic agents 
are not without risk and may have a favorable risk-benefit profile in some patients but not 
others. A combination of physiologically relevant approaches to patient identification 
with a better understanding of the mechanism of action of rTM, AT, and UFH will aid in 
the optimal administration of patients with the greatest potential to benefit from therapy.  
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CHAPTER THREE 
MATERIALS AND METHODS 
Materials 
Coagulation Reagents 
Prothrombin Time (PT) and Fibrinogen. Recombiplastin (Instrumentation 
Laboratory, Bedford, MA) was used for the measurement of PT and the calculation of 
fibrinogen level. This reagent contains lyophilized recombinant human tissue factor and 
synthetic phospholipids and has an IS value of 1.0.  
Activated Partial Thromboplastin Time (aPTT). Platelin (Diagnostica Stago, 
Parsippany NJ) was used as the aPTT reagent. This reagent contains purified 
phospholipids and micronized silica as an activator. 0.025 M CaCl2 was used to recalcify 
the citrated plasma.  
Thrombin Time (TT). Human thrombin (Enzyme Research Laboratories, South 
Bend, IN) was diluted to 5 U/ml in 0.02 M CaCl2 and was used in the Thrombin Time 
test.  
Thromboelastography (TEG). TEG cups and pins were purchased from 
Haemonetics (Braintree, MA). 0.025 M CaCl2 was used to recalcify samples and initiate 
clot formation. 
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Drugs 
Recombinant Thrombomodulin. Thrombomodulin is used clinically for the 
treatment of DIC in Japan and is currently in a global phase III clinical trial for this 
application. Recombinant human thrombomodulin (rTM or ART-123) was provided by 
Asahi Kasei Pharma (Tokyo, Japan). rTM was aliquoted at a concentration of 2.5 mg/ml 
and stored at -80ºC prior to use. 
Antithrombin. Antithrombin concentrate is used clinically to treat patients with 
antithrombin deficiency and is approved in Japan for the treatment of patients with DIC. 
Antithrombin was purchased from Baxter Healthcare Corporation (Deerfield, IL). AT 
was reconstituted at a concentration of 125 U/ml, aliquoted, and stored at -80ºC prior to 
use. 
Heparin. Unfractionated heparin (UFH) is a widely used anticoagulant with 
many clinical applications, including prevention and treatment of thrombosis and 
cardiovascular surgery. Heparin sodium for injection (lot 6012617, expiration date 
8/2018) was purchased from Fresenius Kabi (Lake Zurich, IL). UFH was acquired in a 10 
ml vial and stored at room temperature prior to use. The stock concentration of heparin 
was 1,000 U/ml, and heparin was diluted in saline to a concentration of 200 U/ml prior to 
injection.  
Plasma Samples 
Factor Deficient Plasmas. Human plasma deficient in specific coagulation 
factors or associated proteins is commonly used as a reagent for specialized functional 
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coagulation testing. These plasmas are commercially available in lyophilized form. 
Lyophilized protein C deficient plasma was purchased from Diagnostica Stago 
(Parsippany, NJ). Lyophilized plasmas deficient in Factor VII, Factor IX, and Factor X, 
were purchased from Aniara (Westchester, Ohio). Plasmas were reconstituted according 
to the manufacturer’s instruction for use in functional coagulation testing. 
Whole Blood. Whole blood was drawn from apparently healthy volunteer donors 
under an IRB approved protocol (LU# 9191051098). Blood was drawn using standard 
phlebotomy technique into tubes containing 3.2% sodium citrate. All donors provided 
informed consent and a maximum of 40 ml of blood was drawn from each donor.  
Normal Human Plasma. Pooled normal human plasma for use in coagulation 
assays was purchased from George King Biomedical (Overland, KS). Each pool 
contained citrated plasma from 30 or more donors and was certified to return normal 
values on standard coagulation tests including PT, aPTT, and fibrinogen and to have 
levels of coagulation Factors II, V, VII, VIII, IX, X, XI, and XII within the normal range. 
Plasma was aliquoted and stored at -80ºC prior to use. 
Individual Patient Samples. Samples from individual patients or healthy 
volunteers were collected as described below.  
Individual healthy controls. Frozen, citrated plasma samples from apparently 
healthy individuals were purchased from George King Biomedical (Overland KS). These 
samples were drawn from 25 male and 25 female volunteers, ages 19-54, with a mean 
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age of 32. All volunteers were non-smokers, non-medicated, and of geographically 
diverse origins. Plasma was aliquoted and stored at -80ºC prior to use. 
De-identified patient samples. De-identified plasma samples were collected from 
the clinical laboratory at Loyola University Medical Center under an IRB approved 
protocol (LU #9192052016). Samples were collected from among specimens ready for 
discard and no modification was made to patient care due to this sample collection. 
Limited information was available to accompany each specimen including diagnosis and 
treatment.  
De-identified, citrated plasma samples were collected from patients in the initial 
phase of warfarin therapy (n = 100) and from patients with diagnosed sepsis and 
suspected DIC (n = 78) using this protocol. Plasma was aliquoted and stored at -80ºC 
prior to use. 
Utah sepsis cohort plasma samples. Plasma samples from adult patients with 
sepsis and suspected DIC were collected between 2008 and 2012 under an IRB-approved 
protocol by Matthew Rondina, MD at the University of Utah Medical Center as described 
in the literature (Rondina 2011; Rondina 2012; Rondina 2015). Samples were collected 
from adult patients in the intensive care unit (ICU) at the University of Utah Hospital or 
an associated community hospital at ICU admission as well as on ICU days 4 and 8 for 
patients remaining in the ICU at those times. Sample collection was approved by the 
Internal Review Board (IRB) at the University of Utah (IRB_0029495), and all patients 
enrolled in the study provided informed consent. 
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In order to qualify for enrollment in this study, patients were required to meet the 
criteria for SIRS and have an identified focus of infection. SIRS was defined as the 
presence of 2 or more of the following: (1) temperature < 36ºC or > 38ºC, (2) heart rate > 
90 beats per minute, (3) respiratory rate > 20 breaths per minute or PaCO2 < 32 mmHg, 
(4) white blood cell count ≥ 12,000 or ≤ 4,000 cells/mm3 or > 10% bands.  
Patients were excluded from the study if they had received a blood transfusion 
within the past 4 months, platelet transfusion within the past 14 days, or platelet count of 
less than 20 K/μl. Patients were also excluded from this study if they had a pre-existing 
disorder affecting platelet number or function, including idiopathic thrombocytopenic 
purpura, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, end-stage 
liver disease, myeloproliferative disorders, multiple myeloma, Waldenstrom’s 
macroglobulinemia, end-stage renal disease requiring hemodialysis, or inherited platelet 
disorders such as Bernard-Soulier syndrome, gray platelet syndrome, May-Hegglin 
anomaly, Wiskott-Aldrich syndrome, Glanzmann thrombasthenia, Chediak-Higashi 
syndrome, Hermansky-Pudlak syndrome, or thrombocytopenia-absent radius syndrome.  
Blood was collected into 3.2% sodium citrate and centrifuged to prepare platelet 
poor plasma. Plasma was collected, aliquoted, and stored at -80ºC prior to analysis. 
Transfer of samples and accompanying de-identified clinical information to Loyola was 
approved by the Loyola University Chicago IRB (LU Number 207958). Samples were 
shipped to Loyola University Chicago on dry ice and stored at -80ºC prior to analysis. 
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Baseline (day 0) samples and accompanying data were available from 103 
patients. 57 patients had day 4 samples and data available and 30 had day 8 samples and 
data available. 
Assays for Biomarker Analysis 
Assays for Human Proteins. Commercially available enzyme linked 
immunosorbent assays (ELISAs) were used to quantitate the levels of proteins in human 
plasma samples. All assays were specific for human proteins and were performed 
according to the manufacturer’s instructions. Assays used and their manufacturers are 
listed in Table 5.   
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Table 5: Sources of Assay Kits for Human Plasma Proteins 
 
Marker Manufacturer 
D-Dimer 
Hyphen BioMed  
(Neuville-Sur-Oise, France) 
 
Microparticle Tissue Factor (MP-TF) 
Microparticles (MP) 
Platelet Factor 4 (PF4) 
von Willebrand Factor (vWF) 
Tissue Factor (TF) 
Factor VII (Zymutest) 
Factor IX (Zymutest) 
Factor X (Zymutest) 
PAI-1 Stago Asserachrom  
(Asnieres-Sur-Sene, France) Tissue Factor Pathway Inhibitor (TFPI) 
CD40L R&D Systems  
(Minneapolis, MN) Angiopoietin 2 (Ang-2) 
Endocan 
Lunginnov  
(Lille, France) 
High Mobility Group Box 1 Protein (HMGB-1) 
LifeSpan BioSciences  
(Seattle, WA) 
Nucleosomes (Cell Death Assay) 
Roche Diagnostics  
(Indianapolis, IN) 
Procalcitonin 
Abcam  
(Cambridge, United Kingdom) 
Prothrombin Fragment F1.2 
Dade Behring-Siemens  
(Erlangen, Germany) 
IL-2 
IL-4 
IL-6 
IL-8 
IL-10 
VEGF 
IFNγ 
TNFα 
IL-1α 
IL-1β 
MCP-1 
EGF 
Randox 
(Antrim, UK) 
Cytokine High Sensitivity Assay Kit 
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Assays for Rat Proteins. Commercially available ELISAs specific for rat 
proteins were used to quantitate protein levels in rat plasma. Assays and their 
manufacturers are listed in Table 6.  
Table 6. Sources of ELISA Kits for Rat Plasma Proteins 
Assay Manufacturer 
Rat Histone H3 ELISA Kit (Sandwich ELISA) LifeSpan BioSciences  
(Seattle, WA) Rat Procalcitonin ELISA Kit 
Rat IL-10 Quantikine ELISA Kit 
R&D Systems  
(Minneapolis, MN) 
ZYMUTEST Rat PAI-1 Antigen 
Hyphen BioMed  
(Neuville-Sur-Oise, France) 
Rat IL-6 ELISA 
Abcam 
(Cambridge, United Kingdom) 
Nucleosomes (Cell Death Assay) 
Roche Diagnostics  
(Indianapolis, IN) 
 
Instruments 
ACL-Elite. An ACL-ELITE coagulation analyzer (Instrumentation Laboratories, 
Bedford, MA) was used for standardized clinical coagulation tests including PT, aPTT, 
and fibrinogen measurements. This instrument uses an optical method to detect clot 
formation in a plasma sample. The required materials for use of this instrument, including 
rotors, sample cups, reference emulsion, and cleaning solution, were also purchased from 
Instrumentation Laboratories. 
ST-4. An ST-4 Coagulation Analyzer (Diagnostica Stago, Parsippany, NJ) was 
used for specialized coagulation tests, including determination of Protein C, Factor VII, 
Factor IX, and Factor X activity levels and measurement of PT and aPTT in whole blood 
or rat plasma. This instrument uses a mechanical method to evaluate clot formation in a 
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plasma or whole blood sample. The required materials for use of this instrument, 
including cuvettes and stir balls, were also purchased from Diagnostica Stago 
SpectraMax Plus. A SpectraMax Plus Absorbance Microplate Reader 
(Molecular Devices, Sunnyvale, CA), which was used in conjunction with SoftMax Pro 
software for measurement of optical density for ELISA assays. A Randox Evidence 
Investigator (Randox, London, UK), was used for biochip analysis. 
Animals 
Male Sprague-Dawley rats (275-500g, Charles River Laboratories, Wilmington, 
MA) were used in the rat cecal ligation and puncture (CLP) model of sepsis. Prior to 
participation in experiments, rats were allowed an acclimation period of at least 72 hours 
following arrival into the animal care facility. Rats were pair housed using standard 
rodent husbandry procedures in the Comparative Medicine Facility (CMF) at Loyola 
University Medical Center. Rats received unrestricted access to water and a standard 
rodent diet.  
Studies were performed under a protocol approved by the Institutional Animal 
Care and Use Committee (IACUC) (IACUC #2017009, LU #209143, 175 rats approved 
for use). All animal studies were carried out in compliance with the guidelines set forth 
by the IACUC at the Loyola University Medical Center and the Principles of Laboratory 
Animal Care (National Institutes of Health, 1985).  
107 
 
 
Methods 
Global Clotting Assays 
Prothrombin Time (PT). Prothrombin time (PT) is a commonly performed 
clinical laboratory test which measures the overall functionality of factors involved in the 
extrinsic pathway of coagulation, particularly Factor VIIa and Factor Xa. PT is based on 
the time to clot after recalcified plasma has been activated by tissue factor. PT is often 
reported as International Normalized Ratio (INR), which relates the patient’s PT to the 
standard PT measured using a given laboratory’s specific instrument and reagent. This 
test is commonly used clinically to monitor warfarin therapy as well as to assess the 
global function of the coagulation cascade. 
In human plasma, PT was measured using standard operating protocols on an 
ACL-ELITE coagulation analyzer (Instrumentation Laboratory, Bedford, MA). 
Recombiplastin (Instrumentation Laboratory, Bedford, MA) was used as the PT reagent. 
This instrument uses an automated optical method to detect clot formation in a plasma 
sample. The maximal clotting time detectable using this instrument was 300 seconds. 
This instrument performed automated calculation of INR.  
In whole blood and rat plasma, PT was measured using standard operating 
procedures on an ST-4 Coagulation Analyzer (Diagnostica Stago, Parsippany, NJ). This 
device uses a mechanical method to determine the time required for clot formation. 100μl 
of whole blood or 50 μl of plasma was warmed to 37º in a cuvette with a metal mixing 
ball for 100 seconds. 100 μl of Dade Innovin PT reagent (Siemens Healthcare 
Diagnostics, Newark, DE) was added and the time to clot development was recorded.  
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Activated Partial Thromboplastin Time (aPTT). The activated partial 
thromboplastin time (aPTT) is a standard clinical laboratory test that assesses the function 
of the intrinsic pathway of the coagulation cascade (Factors I, II, V, VIII, IX, X, XI and 
XII). aPTT is based on the time to clot after recalcified plasma has been activated by a 
platelet substitute consisting of purified phospholipids as well as a micronized silica 
activator. This test is commonly used to monitor heparin therapy as well as to evaluate 
global function of the coagulation cascade.  
In human plasma, aPTT was measured using standard operating protocols on an 
ACL-ELITE coagulation analyzer (Instrumentation Laboratory, Bedford, MA). This 
instrument uses an optical method to detect clot formation in a plasma sample. Either 
Platelin (Stago, Parsippany, NJ) or Triniclot (Diagnostica Stago, Parsippany, NJ) was 
used as the aPTT reagent along with 0.025 M CaCl2 in order to recalcify the citrated 
plasma. 
In whole blood, aPTT was measured using standard operating procedures on an 
ST-4 Coagulation Analyzer (Diagnostica Stago, Parsippany, NJ). This device uses a 
mechanical method to determine the time required for clot formation. For aPTT, 50 μl of 
sample was incubated with 50μl of Triniclot aPTT reagent (Diagnostica Stago, 
Parsippany, NJ) for 300 seconds at 37ºC. 50μl of CaCl2 was added to initiate coagulation 
and the time to clot formation was recorded.  
Thrombin Time (TT). Thrombin (TT) is a clot based assay in which the time 
required for the conversion of fibrinogen to fibrin following the addition of a known 
amount of thrombin to plasma is recorded.  
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In human plasma, TT was measured using standard operating protocols on an 
ACL-ELITE coagulation analyzer (Instrumentation Laboratory, Bedford, MA). This 
instrument uses an optical method to detect clot formation in a plasma sample. Thrombin 
was used at a concentration of 5 U/ml diluted in 0.02 M CaCl2. 
In whole blood, TT was measured using standard operating procedures on an ST-
4 Coagulation Analyzer (Diagnostica Stago, Parsippany, NJ), which uses a mechanical 
method to determine the time required for clot formation. 100μl of whole blood was 
incubated with a metal stir bar for 100 seconds at 37ºC. 50μl of thrombin at 200 U/ml 
diluted in 0.02 M CaCl2 was then added and the time until clot formation recorded.  
Thromboelastography (TEG). Thromboelastography (TEG) is used to evaluate 
coagulation in whole blood. In addition to assessing coagulation function, TEG assesses 
platelet function, clot strength, and fibrinolysis. Whole blood is placed into a cup that 
rotates slowly around a sensor pin, around which a clot forms. Multiple parameters 
describing clot formation are recorded. The reaction time (R time) represents the time 
from the initiation of the test until clot formation is first detected. The K time is 
representative of the speed of clot formation and is the time between the first detectable 
clot formation (R time) and until the tracing reaches a size of 20 mm. The angle, which is 
the tangent of the curve at the K time, provides similar information to the K time. The 
MA is the maximal amplitude, which is a measure of clot strength.  
Thromboelastography was performed on whole blood using a TEG 5000 system. 
304μl citrated blood and 36μl of drug was added to each sample cup. 20μl of 0.02M 
110 
 
 
CaCl2 was then be added to recalcify the sample and initiate clotting. R time, K time, 
maximum amplitude (MA), and angle were recorded.  
Fibrinogen. In human plasma, fibrinogen concentration was measured using 
standard operating protocols on an ACL-ELITE coagulation analyzer (Instrumentation 
Laboratory, Bedford, MA). This method computes a derived fibrinogen concentration 
based on the prothrombin time utilizing a calibration curve created from standards with 
known fibrinogen concentrations. Recombiplastin (Instrumentation Laboratory, Bedford, 
MA) was used as the PT reagent. 
Coagulation Factor Activity Levels. Functional levels of individual coagulation 
factors were measured in plasma samples using an ST-4 coagulation analyzer as 
described below.  
Factor VII activity. Factor VII activity level was measured in plasma samples 
using a modified one-step PT assay. Clot formation in this test was evaluated 
mechanically using an ST4 Coagulation Analyzer (Diagnostica Stago, Parsippany, NJ).  
Patient samples were diluted 1:10 in Owren’s Veronal Buffer. 50μl of Factor VII 
deficient plasma (Aniara, Westchester, OH) and 50μl of diluted patient plasma sample 
were warmed to 37ºC in a cuvette with a metal mixing ball for 180 seconds. 100μl of 
Dade Innovin PT reagent (Siemens Healthcare Diagnostics, Newark, DE) was added and 
the time to clot development was recorded. Factor VII level was calculated in each 
sample relative to normal human plasma based on a standard curve.  
Factors IX and X Activity. Factor IX and X activity levels were measured in 
plasma samples using a modified one-step aPTT assay. Clot formation in this test was 
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evaluated mechanically using an ST4 Coagulation Analyzer (Diagnostica Stago, 
Parsippany, NJ).  
Patient samples were diluted 1:20 in Owren’s Veronal Buffer. 50μl of diluted 
sample, 50μl of aPTT reagent, and 50μl of Factor IX or X deficient plasma (Aniara, 
Westchester, OH) were warmed to 37ºC in a cuvette with a metal mixing ball for 5 
minutes. 50μl of CaCl2 was added and the time to clot development was recorded. Factor 
IX and X levels were calculated in each sample relative to normal human plasma using a 
standard curve. 
Protein C Activity. Functional levels of Protein C were measured using a clot-
based assay performed using an ST4 coagulation analyzer (STACLOT, Diagnostica 
Stago, Parsippany, NJ). Patient and control plasmas were diluted 1:10 in Owren Koller 
Buffer. 50 μl of diluted sample, 50 μl of Protein C deficient plasma (Diagnostica Stago, 
Parsipanny, NJ) and 50 μl of Protein C activator (Diagnostica Stago, Parsipanny, NJ) 
were incubated in a sample cuvette with a metal mixing ball for 180 seconds at 37ºC. 
50μl of 0.2 M CaCl2 was added to each sample, initiating the clotting reaction. Time to 
clot formation was recorded as the time at which the metal ball was prevented from 
moving.  
Protein C level, measured as percent of normal value, was calculated from the 
time to clot for each sample based on a standard curve. The standard curve consisted of 
dilutions of normal human pooled plasma at 100%, 75%, 50%, 25%, 12.5%, and 0%, 
diluted 1:10 in Owren Koller buffer. Clotting time had an inverse relationship with 
Protein C activity level.  
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Biomarker Analysis 
ELISA Assays. Biomarker levels were measure in human and rat plasma samples 
using the commercially available enzyme linked immunosorbent assay (ELISA) kits 
listed in Table performed according to the manufacturer’s instructions. An illustration of 
the general principle of an ELISA is shown in Figure 7. 
Although the specific protocol varies for each assay, all ELISAs share a common 
principle. Each assay kit included a 96-well microtiter plate coated with an antibody 
specific to the desired analyte. Appropriately diluted sample was incubated in the plate 
and the analyte bound to the plate-bound antibody. The plate was washed to remove 
nonspecifically bound proteins. A secondary antibody against a distinct epitope on the 
analyte was then added. This secondary antibody was conjugated to an enzyme. 
Following additional washing, a substrate was added to the plate, producing a color 
change proportional to the amount of bound enzyme. The color change reaction was 
stopped through the addition of an acidic solution. Precise timing was maintained 
between the addition of the substrate and the addition of the stop solution using a 
stopwatch to ensure accuracy. Optical density at the specified wavelength was measured 
using a spectrophotometer and SoftMaxPro software (Molecular Devices, Sunnyvale, 
CA).  
Each ELISA plate included a standard curve run in duplicate, generated using 
standards of known concentration included in the assay kit. This was used to generate a 
calibration curve relating measured optical density (OD) values to protein concentration 
using a linear equation. This curve was used to calculate the protein concentration in each 
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sample or control. In addition to internal controls included in each kit, pooled normal 
human plasma (NHP) and pooled pathological human plasma samples were included on 
each plate to monitor inter-assay variation. Patient and control samples were run in 
singlicate. Samples with an optical density exceeding that of the highest calibration point 
were diluted and rerun. Samples with an optical density value resulting in a calculated 
analyte concentration of less than zero were recorded as having a concentration of 0.  
 
 
Figure 7. Overview of the Principle of an ELISA Assay. A plasma sample is added to 
an antibody-coated microplate well. The analyte in the sample then binds to the antibody, 
and an enzyme-conjugated secondary antibody binds to the bound analyte. The addition 
of a substrate leads to color change proportional to the amount of bound enzyme (shown 
as a change from white to yellow). The addition of an acidic solution stops this reaction 
(shown as a color change from yellow to blue). The absorbance is then red at the 
appropriate wavelength and the concentration of protein of interest is calculated based on 
calibration curve. 
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Randox Biochip. A Randox Cytokine and Growth Factors High-Sensitivity Array 
assay kit was used to quantify IL-2, IL-4, IL-6, IL-8, IL-10, VEGF, IFNγ, TNFα IL-α, 
IL-1β MCP-1, and EGF (Randox, London, UK). This allowed quantification of all factors 
in a single patient sample simultaneously using a sandwich chemiluminescent 
immunoassay. 
Each biochip provided in the kit contained 12 test regions, each with a different 
immobilized antibody specific to a different cytokine. The chip was incubated with 100μl 
of plasma sample. After washing, conjugate consisting of horse radish peroxidase-
labeled, analyte-specific antibody was incubated with the chip. Increased level of a bound 
cytokine caused increased binding of conjugate and thus increased chemiluminescent 
signal emitted upon activation of the signal reagent. The luminescent signal generated in 
each region of the biochip was translated into analyte concentration by the Randox 
Evidence Investigator using a calibration curve generated based on controls of known 
concentration.  
Animal Models 
Cecal Ligation and Puncture Model. Cecal ligation and puncture (CLP) was 
performed in rats to model sepsis and associated DIC. This is useful for studies of 
treatments for sepsis and DIC as it creates a polymicrobial infection with significant 
inflammation, similar to many clinically observed scenarios. The severity of disease 
achieved through use of this model can be modified by altering the amount of the cecum 
ligated, the size and number of punctures, and the amount of fluid resuscitation given. 
Two variants of the CLP model were approved for use by the IACUC, one for the 
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production of moderate disease and on for the production of mild disease. Due to the 
success of the moderate disease protocol, the mild disease approach was not used.  
The CLP protocol used in these studies was based on that published by Rittirsch 
et. al (Rittirsch 2008) and was similar to that used and described by others (Cuenca 2010; 
Heuer 2004; Heur 2004; Hubbard 2005; Inoue 1991; Kim 2000; Laudes 2002; Otero-
Anton 2001; Qiu 2001; Ravindranath 2007; Rittirsch 2007; Rittirsch 2008; Schabbauer, 
2012; Yang1994). Critical steps in the CLP procedure are shown in Figure 8. Male 
Sprague-Dawley rats were anesthetized by administration of 2-3% isoflurane. Anesthesia 
was initiated by placing rats in an anesthesia induction chamber and maintained 
throughout pre-operative procedures and surgery through the use of an individual nose 
cone. Once the rat was fully anesthetized, protective eye drops were applied, the rat was 
positioned on its back, the abdomen was shaved, and the skin was cleansed with 
alternating betadine and alcohol wipes (Figure 8a). SR-Buprenorphine was administered 
subcutaneously at a dose of 1 mg/kg in order to ensure adequate analgesia. Rats were 
kept on a heating pad or under a heat lamp to maintain appropriate body temperature 
during pre-surgical procedures, surgery, and during recovery. All surgical equipment was 
autoclaved prior to use. A separate surgical pack, sterile gloves, and sterile drape were 
used for each rat.  
To perform the CLP procedure, a midline incision was made through the skin and 
muscle layers (Figure 8b) and the cecum exposed (Figure 8c). Moderate disease was 
produced by ligation of 50% of the cecum with a 2-0 silk suture (Figure 8d). The 
proximal portion of the cecum was returned to the abdomen and a single through-and-
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through puncture with an 18 gauge needle was made through at the midpoint of the distal 
ligated portion of the cecum (Figure 8e). Appropriate anatomical landmarks were noted 
for each rat to ensure model consistency. Following puncture, a small droplet of feces 
was extruded from each puncture and the cecum was returned to the abdomen. For 
animals undergoing sham surgery, an incision through the skin and muscle layers was 
made, but no ligation or puncture of the cecum was performed. The peritoneum was 
closed using a 5-0 Vicryl monofilament suture and a simple interrupted stitch (Figure 8f) 
and the skin was closed using wound clips (Figure 8g).  
Following surgery, rats were kept under a heating lamp and monitored during 
recovery from anesthesia. Rats also received 8ml saline each via subcutaneous injection. 
Appropriate analgesia was maintained post surgically by subcutaneous injection with SR-
Buprenorphine at a dose of 1 mg/kg every 24 hours.  
Rats were followed for up to 3 days (72 hours) following CLP procedure. 
Symptoms of sepsis manifested less than 24 hours following CLP. During the 72 hours 
post CLP, drugs were administered according to the experimental protocol. Blood was 
collected via cardiac puncture and rats were euthanized 72 hours following surgery.  
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Figure 8. Images of Critical Steps in the CLP Procedure. (a) shaving and 
disinfection of the abdomen (b) midline incision through the skin and muscle layers (c) 
exteriorization of the cecum (d) ligation of 50% of the cecum (e) single through-and-
through puncture of the cecum with an 18-gauge needle (f) closure of the muscle layer 
with simple interrupted sutures (g) closure of the skin with wound clips 
 
Drug Administration. Drugs were administered to rats following induction of 
sepsis using the CLP procedure. Although drugs are often administered at the time of 
CLP in research settings, this does not best replicate a clinical scenario in which drugs are 
administered to treat disease that has already developed. An alternative approach, and the 
approach that was selected for these studies, is the administration of drug 24 hours 
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following surgery(Li 2007 ; Uolla 2002; Wang 2004; Yang 2004; Yin 2005), which 
allows adequate time for the development of sepsis.  
24 hours following CLP surgery, rTM, AT, UFH, or saline were administered to 
septic rats intravenously via tail vein injection at clinically relevant doses, with an 
additional dose of drug administered 24 hours later. Rats were euthanized and blood was 
collected 72 hours following CLP. The experimental protocol is schematized in Figure 9 
and drug doses and experimental groups are show in Table 7.  
rTM is administered clinically at a dose of 60 μg/kg/day (Ogawa 2011; Saito 
2007; Vincent 2013; Yamakawa 2015; Yamakawa 2011; Yamakawa 2013) (0.06 
mg/kg/day). However, the IC50 value of rTM on thrombin generation is much higher in 
rat plasma than in human plasma, and significantly higher doses of rTM must be used in 
rats. 1mg/kg is a commonly used dose of rTM in rat studies (Aoki 1994; Aoki 1994; 
Gonda 1993; Hagiwara 2010; Iba 2013; Mohri 1994; Nagato 2009) and was the dose 
selected for use in this protocol.  
AT is typically administered to sepsis and DIC patients at doses of 3000 IU/day or 
1500 IU/day (Allingstrup 2016; Iba 2016; Iba 2012). Assuming a 70 kg “standard man”, 
this corresponds to a dose of 43 IU/kg/day or 21 IU/kg/day, with lower doses achieved in 
heavier patients. In these studies, AT was administered to rats with CLP-induced DIC at a 
dose of 50 IU/kg to model the effects of AT at clinically achievable levels. 
Heparin is used clinically at a wide range of doses depending on the clinical 
scenario. Accordingly, the doses of heparin used in clinical trials and in animal models 
are highly variable(Li 2011). Dosages vary further depending on the type of heparin used 
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and the route of administration. For these studies, UFH was administered to rats at a dose 
of 25 IU/kg in order to achieve an effect with minimal risk of bleeding. 
Table 7. Experimental Groups for Rat CLP and Drug Administration 
Procedure Agent Dose N 
None (control) N/A N/A 10 
CLP N/A N/A 22 
Sham N/A N/A 6 
CLP rTM 1 mg/kg 8 
CLP Antithrombin 50 IU/kg 5 
CLP Antithrombin 125 IU/kg 9 
CLP Heparin 70 IU/kg 5 
CLP Heparin 25 U/kg 10 
The untreated CLP group includes rats that died within 24 hours of surgery and therefore 
did not receive drug treatment. 
 
 
Figure 9. Schematic of Experimental Protocol for Rat CLP and Drug 
Administration. Drugs and analgesics are administered 24 and 48 hours following 
surgery, allowing time for the development of sepsis prior to drug administration. All 
animals were euthanized 72 hours following the surgical procedure, at which time blood 
was collected via cardiac puncture.  
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Blood Collection via Cardiac Puncture. At the time of sacrifice, rats were 
anesthetized via intraperitoneal administration of 90 mg/kg ketamine. Additional 
ketamine was administered as required to achieve complete anesthesia, with an average 
of 123 mg/kg total ketamine administration. Once anesthesia was confirmed, blood was 
collected via cardiac puncture. A needle was inserted immediately below the xiphoid 
process and advanced into the chambers of the heart. 5 ml of blood was collected into a 
syringe and placed immediately into siliconized glass tubes containing 3.8% sodium 
citrate at a ratio of 1 part citrate to 9 parts whole blood. Tubes were mixed well to prevent 
clotting. Rats were euthanized by intracardiac administration of 0.5 ml of Beuthanasia-D 
(390 mg/ml pentobarbital + 50 mg/ml phenytoin).  
Samples were centrifuged at 3000g for 20 minutes, and plasma was aliquoted and 
frozen at -80ºC until analysis. Approximately 2-3 ml of plasma per rat was collected. PT 
was measured in each sample to assess the quality of blood draw. A normal rat PT is 
approximately 8-10 seconds.  
Platelet Counts in Rat Blood. Platelets in whole blood collected from rats were 
counted manually using a hemocytometer. Using the capillary pipette provided in the 
LeukoCheck system, (Biomedical Polymers Inc., Gardner, MA), 20μl of whole blood 
was transferred into the reservoir containing red blood cell lysis buffer and allowed to 
stand for 20 minutes to allow complete lysis of erythrocytes. The lysed and diluted blood 
was then loaded into both sides of a Neubauer Bright-Line Hemocytometer and allowed 
to stand for 10 minutes. Platelets were counted at 40x magnification. Platelets were 
counted in 5 small squares and this number was multiplied by 5 to calculate the total 
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platelet count in whole blood in units of K/μl. Platelet counts were performed in duplicate 
and the average value was recorded.  
Data Processing and Statistical Analysis 
Stepwise Linear Regression Modeling. Stepwise linear regression modeling was 
performed using MATLAB software (Mathworks, Natick, MA). Stepwise linear 
regression is a mathematical modeling approach in which a linear equation incorporating 
relevant predictor variables (i.e. biomarker levels) to predict the value of an output 
variable is developed using an iterative process to predict the value of a response variable 
(i.e. mortality) incorporating only data that significantly alters the model fit.  
Two main approaches are possible for stepwise linear regression modeling. Using 
forward selection, also known as a constant model starting assumption, the initial model 
incorporates no predictor variables. In each iteration of the model, the variable that yields 
the greatest statistically significant improvement in model fit by its addition is added to 
the model. This process is repeated until no variable remains that improves model fit 
when added. Alternatively, backwards elimination, also known as a linear model starting 
assumption, can be used. Using this approach, all predictor variables are initially included 
in the model. With each model iteration, the variable that yields the least significant 
change to the model fit when removed from the model is removed. This process is 
repeated until no variables remain that do not statistically significantly worsen model fit 
when removed 
MATLAB code is shown in Appendix D. Data tables including mortality as the 
response variable and biomarker levels as the predictor values were imported into 
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MATLAB from Microsoft Excel. Models were developed using the “stepwiselm” 
function. Both linear and constant model starting assumptions were used, as specified in 
the results. Model coefficients were recorded and model output value for each patient was 
calculated from the appropriate biomarker levels using Microsoft Excel. Model fit was 
evaluated using ROC analysis in GraphPad Prism using the area under the curve (AUC) 
as the descriptor of model quality. 
Statistical Analysis. The experiments described in this dissertation represent 
multiple techniques, and appropriate data collection and statistical analysis were 
performed for each experiment. Data is presented as mean ± standard deviation (SD) or 
mean ± standard error of the mean (SEM) as specified throughout this document. P < 
0.05 was used as the cutoff for statistical significance, and computed p values are present 
throughout this document. Results were tabulated and stored using Microsoft Excel 
(Microsoft Corporation, Redmond, WA). Statistical analysis was performed and graphs 
were generated using GraphPad Prism (GraphPad Inc., La Jolla, Ca). 
Biomarker levels in patient populations are presented as mean ± SEM. 
Nonparametric statistical tests were used throughout as these tests are more appropriate 
for analysis of data sets with high variability than traditional parametric tests. Differences 
in biomarker levels between two patient groups (i.e. survivors and non-survivors) were 
analyzed using the Mann-Whitney test. Comparisons between three or more groups (i.e. 
sepsis + no DIC, sepsis + non-overt DIC, and sepsis + overt DIC) were analyzed using 
the Kruskal-Wallis one way analysis of variance (ANOVA) followed by Dunn’s multiple 
comparison test. Correlations between factors were analyzed using the Spearman 
123 
 
 
correlation coefficient. Predictive values were analyzed using receiver operator curve 
(ROC) analysis, with the main output for this being the area under the curve (AUC). 
When appropriate, the Chi Square test was also used.  
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CHAPTER FOUR 
RESULTS 
Coagulation Profiling in DIC vs. Warfarin Treated Patients 
 INR is one of the key parameters used clinically to identify patients with sepsis-
associated coagulopathy. In many settings, full diagnostic evaluation for DIC in septic 
patients is not performed, and patients are instead screened for coagulopathy on the basis 
of elevated INR and reduced platelet count. Accordingly, it is important to understand the 
appropriate interpretation of INR in this specific patient population. Prolonged PT or 
elevated INR is generally indicative of a hypocoagulable state; however, patients 
presenting with sepsis-associated DIC and an elevated INR are at risk of complications 
due to both thrombosis and bleeding.  
Elevated PT or INR is often reported in 90% or more of sepsis patients with 
severe disease (Collins 2006; Kinasewitz 2004; Koami 2015). Prolonged PT and elevated 
INR are associated with increased mortality and poor clinical outcome in sepsis patients 
(Dhainaut 2005; Kinasewitz 2004) as well as in other critically ill or injured patient 
populations (MacLeod 2003; Walsh 2010). Elevated PT/INR, typically defined as INR 
≥1.2, is often an inclusion criterion for clinical trials in patients with sepsis and 
coagulopathy (Abraham 2003; Vincent 2013). The majority of the elevated INRs within 
this patient population have been reported to fall into the range of 1.6 to 2.5 
125 
 
 
 
(Walsh 2010). Other changes in global coagulation parameters, including aPTT 
(Bakhtiari 2004; Collins 2006; Daudel 2009; Johansson 2010; Kinasewitz 2004; Koami 
2015) and whole blood clotting ability as measured by thromboelastography (Daudel 
2009; Johansson 2010; Koami 2015), are also often reported in sepsis patients as well as 
in other critically ill patient populations.  
Despite the clear evidence that significant changes to the overall coagulation 
profile occur in sepsis, changes in the levels of individual coagulation factors in sepsis-
associated DIC patients are less well established. Reduced levels of coagulation factors 
including factors II, V, VII, X, and XII compared to normal individuals have been 
reported in sepsis-associated DIC (Collins 2006). However, these results demonstrated no 
discernible relationship to standard coagulation tests and are highly variable between 
studies (Collins 2006; Daudel 2009; Johansson 2010). 
PT/INR was designed to monitor the anticoagulation status in patients treated 
with warfarin and is widely used clinically for this purpose. Warfarin treated patients are 
typically considered appropriately anticoagulated with an INR of between 2 and 3, and 
regular adjustments to drug dosage are made to maintain the INR within this range. A 
study of the relationship of serial INR levels to severe bleeding in patients receiving 
warfarin anticoagulation found that warfarin patients hospitalized with severe bleeding 
showed an elevated INR compared to non-bleeding patients (5.9±5.9 vs. 2.3±0.7) as well 
as higher INRs before the event of the bleed (3.0±1.2 vs. 2.1±0.8) (Kucher 2004) 
The difference in INR levels at which bleeding occurs in warfarin treated and 
sepsis-associated DIC patients as well as the fact that DIC patients with an elevated INR 
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indicative of hypocoagulability experience both thrombotic and bleeding complications 
suggests that the information provided by this common laboratory test may be 
significantly different in these two patient populations. The purpose of this study was to 
compare the relationship of laboratory coagulation tests and levels of individual 
coagulation factors with INR in patients with SAC to the relationships observed in 
warfarin treated patients.  
   Citrated, de-identified plasma samples were collected from the clinical laboratory 
under an IRB approved protocol. Samples were collected from among specimens ready 
for discard and no modification was made to patient care due to this sample collection. 
Limited information regarding diagnosis and treatment was available to accompany each 
sample.  
 Samples were collected from patients receiving warfarin anticoagulation (n=132) 
and patients with sepsis-associated DIC, defined as overt or non-overt DIC by the ISTH 
criteria (n=78). Frozen, citrated plasma samples from healthy individuals, ages 18-55, 
nonsmokers, with no known medical conditions, were purchased from George King 
Biomedical (Overland, KS) and stored at -80ºC prior to analysis.  
 PT, aPTT, and fibrinogen were measured in these samples using previously 
described methods. Additionally, protein and functional levels of coagulation factors VII, 
IX, and X were measured as described in the Materials and Methods section. 
 Statistical analysis was performed using GraphPad Prism software (La Jolla, CA). 
Patients were categorized into groups based on INR levels, with groups for INR of <1.5, 
1.5-1.9, 2-2.9, ≥3. For both patient populations, variability of other factors based on INR 
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was assessed using the Kruskal-Wallis one-way ANOVA and Dunn’s Multiple 
Comparison Test with p<0.05 as the cutoff for significance. Plots of test result or factor 
level versus INR were also created form both patient groups and trendline fit was 
assessed. Spearman correlation coefficients were determined for relationships between 
coagulation factor levels and coagulation test results for both patient groups. 
PT/INR Profiling 
Warfarin treated patients were screened for inclusion in this study on the basis of 
INR measurement to identify only patients compliant with warfarin therapy. Patients with 
an INR of ≥1.2 were included in the study (n=130). The INR range in this population was 
1.2-6.6 with a mean value of 2.1 and a median value of 1.8. 78 patients with sepsis and 
overt or non-overt DIC according to the ISTH criteria were included in this study without 
a requirement for a minimum INR. The INR range in this patient population was 1-8.6 
with a mean value of 1.6 and a median of 1.4. The mean INR was significantly higher in 
the warfarin treated patient population than in the DIC patients (Mann-Whitney test, 
p<0.0001). Scatter plots of INR values in both patient populations are shown in Figure 
10. 
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Figure 10. Scatter Plot of INR Values in DIC Versus Warfarin Treated Patients. 
INR was measured in 100 warfarin treated patients and 78 DIC patients. An INR of ≥ 
1.2 was required for warfarin treated patients to be included in the study in order to 
include only patients actively taking warfarin therapy. DIC patients had sepsis with 
overt or non-overt DIC according to the ISTH criteria. Difference between the two 
groups was assessed using the Mann-Whitney test (p < 0.0001). 
 
aPTT 
Activated partial thromboplastin time (aPTT) was measured in warfarin treated 
patients and DIC patients using standard operating protocols on an ACL-ELITE 
coagulation analyzer, as shown in Table 8 and Figure 11. Overall, significant variation in 
aPTT based on INR was observed in both warfarin treated patients (p=0.019) and DIC 
patients (p<0.0001). For warfarin treated patients, a significant difference was observed 
between patients with a subtherapeutic INR of 1.5-1.9 and patients with a 
supertherapeutic INR ≥3 (p=0.034). In DIC patients, aPTT showed a stepwise increase 
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with increasing INR, although statistical significance was only reached between patients 
with an INR of <1.5 and patients with an INR of 1.5-1.9 (p=0.0001), 2-2.9 (p<0.0001), 
and ≥3 (p=0.0011). Although the aPTT values for patients with an INR of less than 2 
were similar between the two patient populations, the maximum observed aPTTs were 
markedly higher in the DIC patient population than in warfarin treated patients.  
Scatter plots of aPTT vs. INR were also generated for warfarin treated and DIC 
patients, and the fit of linear trendlines were evaluated. For warfarin treated patients, the 
trendline had a poor fit (R2=0.0046) and the slope was not significantly non-zero (p = 
0.44), indicating no consistent relationship between aPTT and INR. For DIC patients, the 
trendline had an R2 of 0.68 and a significantly non-zero slope (p<0.0001), indicating that 
INR and aPTT are strongly related in DIC patients. 
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Figure 11: Relationship of aPTT to INR in Warfarin Treated and DIC Patients. 
aPTT in (a) warfarin treated and (b) DIC patients stratified by INR group. Comparison 
was made using the Kruskal-Wallis one-way ANOVA and Dunn’s multiple 
comparison test with α = 0.05 as the cutoff for significance (indicated by asterisk). 
 
 
Table 8. Relationship of aPTT to INR in Warfarin Treated and DIC Patients  
 
aPTT (s) INR Mean Median SD SEM Range n 
Warfarin 
< 1.5 40.41 38.15 14.9 2.483 24.9-98.7 36 
1.5-1.9 36.79 33.5 13.25 2.179 22.1-91.1 37 
2-2.9 36.56 33.7 9.526 1.545 24.9-66.5 38 
≥ 3 42.74 40.8 10.31 2.365 30.6-66.1 19 
DIC 
< 1.5 33.5 32.9 5.01 0.7387 20.6-44.4 46 
1.5-1.9 43.12 43.4 6.906 1.584 31.1-61.1 19 
2-2.9 59.95 55.1 20.52 6.49 41-115 10 
≥ 3 97.13 92.9 20.09 11.6 79.5-119 3 
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Fibrinogen 
Fibrinogen was measured in 132 warfarin treated patients and 77 DIC patients, as 
shown in Figure 12 and Table 9. Overall, significant variation was observed in warfarin 
treated patients (p=0.0005) but not DIC patients (p=0.075). For warfarin treated patients, 
the difference was significant between patients with an INR of <1.5 and an INR of ≥3 
(p=0.04), an INR of 1.5-1.9 versus an INR of 2-2.9 (p=0.008), and an INR of 1.5-1.9 
versus an INR of ≥3 (p = 0.0077).  
Scatter plots of fibrinogen vs. INR were also generated for warfarin treated and 
DIC patients, and the fit of linear trendlines were evaluated. The trendline fit was poor 
for both warfarin treated (R2=0.054) and DIC (R2=0.084) patients, although the slope was 
significantly non-zero for both patient groups (p=0.0075 for warfarin treated patients and 
0.011 for DIC patients). This indicates that while INR is related to fibrinogen levels in 
both warfarin treated and DIC patients, the relationship is not strong and linear in either 
patient group.  
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Figure 12: Relationship of Fibrinogen to INR in Warfarin Treated and DIC 
Patients. Fibrinogen in warfarin treated and DIC patients stratified by INR group. 
Comparison was made using the Kruskal-Wallis one-way ANOVA and Dunn’s multiple 
comparison test with α = 0.05 as the cutoff for significance.  
 
 
Table 9. Relationship of Fibrinogen to INR in Warfarin Treated and DIC Patients 
 
Fibrinogen  
(mg/dl) 
INR Mean Median SD SEM Range 
Warfarin 
< 1.5 447 420 237.9 39.1 97-999 
1.5-1.9 414.7 361 221.5 36.41 94-999 
2-2.9 554.7 582 200.7 32.13 124-999 
≥ 3 590.2 588 164.8 37.82 312-999 
DIC 
< 1.5 563.9 516 246.3 36.31 159-999 
1.5-1.9 477.9 473 188.9 43.34 130-782 
2-2.9 338.7 223 253 84.35 62-692 
≥ 3 352.3 195 321.3 185.5 140-722 
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Coagulation Factors 
The levels of coagulation factors VII, IX, and X were measured in warfarin 
treated and DIC patients as well as in a population of 50 healthy controls, as shown in 
Figure 13. Immunologic levels of all factors were determined using commercially 
available ELISA methods while functional levels were determined using clot-based 
methods. Coagulation factor levels in both the warfarin and DIC patient populations were 
compared to the levels in the healthy control group. Both functional and antigenic levels 
of all three factors were found to be significantly reduced in both warfarin treated and 
DIC patients compared to healthy controls.  
The relationship of coagulation factor level to INR was assessed for each factor in 
both the DIC and warfarin treated patients. Differences in factor levels based on INR 
group were assessed using the Kruskal-Wallis ANOVA for non-parametric data with 
α=0.05 as the cutoff for significance. Differences between individual groups were 
analyzed using Dunn’s multiple comparison test. 
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Figure 13. Antigenically and Functionally Determined Levels of Coagulation 
Factors in Warfarin Treated and DIC Patients Compared to Healthy Controls. For 
each factor, comparison was made between healthy controls and warfarin treated patients 
and healthy controls and DIC patients using the Mann-Whitney t test with p < 0.05 as 
the cutoff for significance (indicated by asterisk).  
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Factor VII. Statistical significance was not achieved for comparison of protein 
levels of Factor VII between INR groups for either patient group. Significant variation in 
functional Factor VII based on INR was seen in both patients treated with warfarin 
(p<0.0001) and DIC patients (p=0.0004) (Figure 14 and Table 10). For patients treated 
with warfarin, significant differences were observed for patients with an INR of <1.5 vs. 
2-2.9 (p<0.0001), <1.5 vs. >3 (p<0.0001), 1.5-1.9 vs. 2-2.9 (p=0.033), and 1.5-1.9 vs. >3 
(p<0.0001). For DIC patients, the difference was only significant for patients with INRs 
of < 1.5 vs. 1.5-1.9. The linear fit of FVII vs. INR was also evaluated. The fit was 
reasonably strong for warfarin treated patients (R2=0.42) with a significantly non-zero 
slope (p<0.0001), suggesting a direct relationship between FVII and INR, but poor for 
SAC patients (R2=0.018) with a not significantly non-zero slope (p=0.84), indicating no 
direct relationship of FVII to INR in this patient population. 
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Figure 14. Relationship of FVII levels to INR in Warfarin Treated and DIC 
Patients. Protein (A and B) and functional (C and D) levels of FVII in warfarin treated 
and DIC patients stratified by INR group. Comparison was made using the Kruskal-
Wallis one-way ANOVA and Dunn’s multiple comparison test with α=0.05 as the 
cutoff for significance (indicated by *)  
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Table 10. Relationship of Protein and Functional Levels of Factor VII to INR in Warfarin Treated and DIC Patients 
 
 
INR 
Warfarin Treated Patients DIC Patients 
Mean Median SEM Mean Median SEM 
Factor VII 
Antigen (%) 
< 1.5 59.4 60.3 4.4 58.9 57.4 3.5 
1.5-1.9 54.5 52.6 6.4 60.0 56.7 6.4 
2-2.9 49.2 47.8 4.3 45.9 47.8 5.4 
≥ 3 41.0 47.0 6.4 86.2 98.1 14.0 
Factor VII 
Functional (%) 
< 1.5 59.0 59.3 3.1 101.7 104.3 3.4 
1.5-1.9 48.7 46.9 3.0 72.2 72.8 4.1 
2-2.9 37.0 34.8 2.1 93.2 85.9 16.1 
≥ 3 20.2 19.6 3.5 88.4 112.5 28.6 
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Factor IX. For Factor IX (Figure 15 and Table 11), comparable results were 
observed for both functional and antigenic factor levels. Significant variation in 
functional FIX based on INR was seen in warfarin treated (p<0.0001) but not DIC 
patients (p=0.61). For warfarin treated patients, significant differences in functional 
levels of Factor IX were observed for patients with an INR of <1.5 vs. 2-2.9 (p=0.0008), 
<1.5 vs. ≥3 (p=0.0004), 1.5-1.9 vs. 2-2.9 (p=0.045), and 1.5-1.9 vs. ≥3 (p<0.0092). The 
linear fit was reasonably poor for both warfarin treated patients (R2=0.17) and DIC 
patients (R2=0.095), with a significantly non-zero slope for both populations (p<0.0001 
for warfarin treated patients and p=0.006 for DIC patients). 
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Figure 15. Relationship of FIX levels to INR in Warfarin Treated and DIC 
Patients. Protein (A and B) and functional (C and D) levels of FIX in warfarin treated 
and DIC patients stratified by INR group. Comparison was made using the Kruskal-
Wallis one-way ANOVA and Dunn’s multiple comparison test with α=0.05 as the 
cutoff for significance (indicated by *)  
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Table 11. Relationship of Protein and Functional Levels of Factor IX to INR in Warfarin Treated and DIC Patients 
 
 
INR 
Warfarin Treated Patients DIC Patients 
Mean Median SEM Mean Median SEM 
Factor IX 
Antigen (%) 
< 1.5 85.4 88.6 4.2 82.3 84.8 3.1 
1.5-1.9 72.6 73.8 4.9 72.3 77.0 3.4 
2-2.9 66.7 70.8 4.7 80.0 80.2 7.4 
≥ 3 53.5 55.6 4.1 74.9 81.9 13.8 
Factor IX 
Functional 
(%) 
< 1.5 85.4 88.6 4.2 82.3 84.8 3.1 
1.5-1.9 72.6 73.77 4.9 78.3 77.0 3.4 
2-2.9 66.4 70.8 4.7 80.0 80.2 7.4 
≥ 3 53.5 55.6 4.1 74.8 81.9 13.8 
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Factor X. As with Factor IX, comparable results were observed for the functional 
and antigenic levels of Factor X (Figure 16 and Table 12). Significant variation in 
functional FX based on INR was seen in both warfarin treated patients (p<0.0001) and 
DIC patients (p=0.0003). For warfarin treated patients, significant differences in 
functional Factor X levels were observed for patients with an INR of <1.5 vs. 2-2.9 
(p<0.0001), <1.5 vs. >3 (p<0.0001), 1.5-1.9 vs. 2-2.9 (p=0.0005), and 1.5-1.9 vs. >3 
(p<0.0001). For DIC patients, significant differences in functional Factor X levels were 
observed for patients with an INR <1.5 vs. 1.5-1.9 (p=0.002) and < 1.5 vs. >3 (p=0.036). 
The linear fit was reasonably good for warfarin treated patients (R2=0.51), suggesting a 
direct relationship between FX and INR but poor for SAC patients (R2=0.14), indicating 
no direct relationship between these factors, with a significantly non-zero slope for both 
populations (p<0.0001 for warfarin treated patients and p=0.0007 for DIC patients).  
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Figure 16. Relationship of FX Levels to INR in Warfarin Treated and DIC 
Patients. Protein (A and B) and functional (C and D) levels of FX in warfarin treated 
and DIC patients stratified by INR group. Comparison was made using the Kruskal-
Wallis one-way ANOVA and Dunn’s multiple comparison test with α=0.05 as the 
cutoff for significance (indicated by *)  
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Table 12. Relationship of Protein and Functional Levels of Factor X to INR in Warfarin Treated and DIC Patients  
 
 
INR 
Warfarin Treated Patients DIC Patients 
Mean Median SEM Mean Median SEM 
Factor X Antigen 
(%) 
< 1.5 71.7 78.8 4.9 78.3 76.5 2.6 
1.5-1.9 65.6 63.5 3.9 72.9 76.0 4.0 
2-2.9 54.3 57.7 3.3 78.1 84.7 6.5 
≥ 3 43.5 38.8 4.3 78.5 91.4 23.2 
Factor X 
Functional 
(%) 
< 1.5 65.4 71.6 3.3 91.3 92.1 1.8 
1.5-1.9 46.7 47.1 2.9 76.7 80.0 3.3 
2-2.9 24.2 20.4 2.5 86.3 84.3 5.8 
≥ 3 9.0 10.4 0.9 61.7 53.1 9.9 
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Correlations Between Factor Levels and Global Coagulation Tests 
Correlations between levels of all factors were analyzed for both the warfarin 
treated and DIC patient groups. Spearman correlation coefficients were analyzed with 
α=0.05 as the cutoff for significance. Correlation coefficients for warfarin treated patients 
are shown in Table 13 and coefficients for DIC patients are shown in Table 14. Non-
significant correlations are indicated as NS, and correlation coefficients are listed and 
highlighted in light blue for all significant correlations. Strong correlations (Spearman 
r≥0.4) are indicated with bold text and dark blue highlighting.  
The observed patterns of correlations were markedly different for warfarin treated 
patients and DIC patients. For warfarin treated patients, significant and a strong 
correlation was observed between INR and both functional and antigenic levels of the 
coagulation factors. Correlations were stronger with functional factor levels than with 
antigenic factor levels. In this patient population, the levels of Factors VII, IX, and IX 
were highly correlated with each other as well. Strong correlations were also seen 
between antigenic and functional levels of all three coagulation factors. In contrast, fewer 
correlations were observed overall in DIC patients, and the observed correlations were 
overall weaker. A correlation was observed between INR and aPTT in the DIC patients, 
whereas no correlation was observed in the warfarin treated patients. In the DIC patients, 
both INR and aPTT correlated significantly with the functional, but not antigenic, levels 
of Factors VII, IX, and X, with the strongest correlations observed with functional Factor 
X for both tests. Fewer correlations between levels of coagulation factors were observed 
in DIC patients than in warfarin treated patients. The only strong correlation observed 
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between coagulation factors in DIC patients was between the functional and antigenic 
levels of Factor X. Functional and antigenic levels of FVII and FIX showed no 
correlations with each other.  
 The results of the comparison between patients with DIC and patients receiving 
warfarin therapy demonstrated that the same INR value describes distinct scenarios of 
coagulation dysfunction in these two patient populations. INR is one of the key 
parameters used to identify patients with DIC. In studies that do not utilize the full 
definition of DIC, identification of patients with sepsis-associated coagulopathy is often 
made solely on the basis of elevated INR and reduced platelet count. However, INR was 
not associated with a consistent pattern of underlying coagulopathy in patients with 
sepsis-associated DIC. Therefore, other tests or biomarkers may provide a more accurate 
description of the coagulopathy in DIC patients than INR.   
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Table 13. Correlations among Coagulation Factors in Warfarin Treated Patients 
 
 INR FIB aPTT 
FVII 
Ant. 
FVII  
Func. 
FIX  
Ant. 
FIX 
Func. 
FX  
Ant. 
FX  
Func. 
INR  0.32 NS -0.22 -0.66 -0.39 -0.50 -0.46 -0.85 
FIB 0.32  NS NS NS 0.30 NS NS -0.23 
aPTT NS NS  -0.27 -0.22 -0.31 -0.40 NS NS 
FVII 
Ant. 
-0.22 NS NS  0.62 0.48 0.29 0.49 NS 
FVII 
Func. 
-0.66 NS -0.22 0.62  0.54 0.47 0.50 0.46 
FIX 
Ant. 
-0.39 0.30 -0.31 0.48 0.54  0.52 0.57 0.37 
FIX 
Func. 
-0.50 NS -0.40 0.29 0.47 0.52  0.35 0.34 
FX Ant. -0.46 NS NS 0.49 0.50 0.57 0.35  0.48 
FX 
Func. 
-0.85 -0.23 NS NS 0.46 0.37 0.34 0.48  
 
Table 14. Correlations among Coagulation Factors in DIC Patients 
 
 INR FIB aPTT 
FVII 
Ant. 
FVII 
Func. 
FIX 
Ant.  
FIX  
Func. 
FX  
Ant. 
FX 
Func. 
INR  -0.28 0.84 NS -0.39 NS -0.22 NS -0.50 
FIB -0.28  -0.30 NS NS NS NS NS NS 
aPTT 0.84 -0.30  NS -0.26 NS -0.34 NS -0.41 
FVII 
Ant. 
NS NS NS  NS -0.32 NS NS NS 
FVII 
Func. 
-0.39 NS -0.26 NS  0.26 NS NS 0.39 
FIX 
Ant. 
NS NS NS -0.32 0.26  NS 0.30 0.23 
FIX 
Func. 
-0.22 NS -0.34 NS NS NS  NS 0.26 
FX 
Ant. 
NS NS NS NS NS 0.30 NS  0.54 
FX 
Func. 
-0.50 NS -0.41 NS 0.39 NS 0.26 0.54  
 
147 
 
 
Biomarker Profiling of Utah Cohort Patient Plasma Samples 
 In order to gain a better understanding of the pathophysiology underlying the 
coagulation dysfunction in patients with sepsis-associated DIC, biomarkers representative 
of hemostasis, infection, inflammation, endothelial function, and platelet function were 
measured in a cohort of patients with sepsis and well-defined DIC of variable severity. 
These biomarkers were assessed for association with both the severity of coagulation 
dysfunction and mortality as well as for the ability to predict outcome alone or in 
combination with other biomarkers. Based on the lack of association of INR with a 
predictable pattern of coagulation dysfunction, it was hypothesized that biomarkers other 
than commonly measured hemostatic parameters would provide insight into the 
underlying pathophysiology of DIC and describe the severity of ongoing coagulation 
dysfunction. Due to the complex pathophysiology of sepsis-associated DIC, it was 
hypothesized that a combination of biomarkers would provide superior descriptive or 
predictive ability than a single biomarker.  
Patient Cohort Baseline Characteristics  
Plasma samples were collected from Utah cohort patients according to the 
protocols detailed in the Materials and Methods section of this dissertation. Samples were 
collected at the University of Utah Hospital and an associated community hospital and 
transferred to Loyola University Chicago under IRB approved protocols. Patient 
treatment was not altered as a result of participation in this study, and all patients 
provided informed consent.  
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Plasma samples were collected from 103 patients with sepsis, defined as meeting 
SIRS criteria with an identified focus of infection, at the time of ICU admission. 
Subsequent samples were collected from 46 patients remaining in the ICU on day 4 and 
21 patients remaining in the ICU on day 8. Basic demographic information for this 
patient cohort, including known comorbidities, is shown in Table 15.  
The basic demographics of this patient cohort are typical and appropriate for 
patients with sepsis. Sepsis is a disease with many causes that can affect patients of any 
age. This is reflected in the broad age range of patients, ranging from 18 to 90. The mean 
age of 57.1 ± 18.6 years describes a predominantly middle aged population and is typical 
of sepsis cohorts in the literature. The mean BMI (31.2) describes an obese patient, and 
76% of patients are classified as either overweight or obese (BMI ≥25). The cohort is 
split fairly evenly between males and females (53.4% male vs. 46.6% female), and racial 
and ethnic makeup of this cohort (84.5% white) is typical of the geographic area in which 
these samples were collected.  
Comorbidities analyzed in this patient cohort include conditions that may affect 
coagulation status and thus the development of DIC, particularly active cancer and 
cirrhosis. Both of these conditions occurred with low frequency (5.8%) in this patient 
population. The most prevalent recorded comorbidity in this patient cohort was 
hypertension, reported in 45.6% of patients.  
Patient care was not modified as a part of this study, and patients received 
antibiotics as well as appropriate supportive treatments as deemed appropriate by the 
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medical team. Patients also received routine thromboprophylaxis at the discretion of the 
medical team, typically unfractionated heparin. Use of anticoagulants in addition to this 
routine thromboprophylaxis was minimal. Warfarin therapy was reported in 5.8% of 
patients. There was no reported use of direct thrombin inhibitors, direct anti-Xa agents, or 
low molecular weight heparin.  
Table 15. Baseline Characteristics of the Utah Patient Cohort 
 
Characteristic Mean ± Standard Deviation 
Age (Years) 57.1 ± 18.6 
Weight (kg) 89.5 ± 27.4 
BMI 31.2 ± 0.89 
Characteristic  N (%) 
Gender  
Male 48 (46.6%) 
Female 55 (53.4%) 
Race  
White 87 (84.5%) 
Black 2 (1.9%) 
Hispanic 9 (8.7%) 
American Indian 2 (1.9%) 
Other  1 (1%) 
Cardiovascular Disease 22 (21.4%) 
Diabetes 26 (25.2%) 
Congestive Heart Failure 9 (8.7%) 
Cirrhosis 6 (5.8%) 
Hypertension 47 (45.6%) 
Pulmonary Disease 17 (16.5%) 
Recent or Active Cancer 6 (5.8%) 
Recent Surgery 23 (22.3%) 
Recent Transfusion 7 (6.8%) 
 
Disease Severity and Patient Outcomes 
Outcome and disease severity information for the Utah patient cohort is shown in 
Table 16. The primary measure of outcome in this patient population was 28 day 
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mortality. This cohort was comprised of 88 survivors and 15 non-survivors, resulting in 
an overall 28-day mortality rate of 14.6%.  
Severity of illness was further described through the requirement for vasopressors 
and mechanical ventilation as well as the Sequential Organ Failure Assessment (SOFA) 
and Acute Physiology and Chronic Health Evaluation (APACHE-II) scores at baseline. 
Septic shock, defined as the requirement for a vasopressor at baseline, was present in 46 
patients (44.7%), and 48 patients (46.6%) required ventilator support. 
The SOFA score describes organ failure in terms of both number of failing organ 
systems and severity of failure of each system. The SOFA scoring algorithm, included in 
Appendix C, assigns points based on clinically measurable values describing the 
dysfunction of organs including the lungs, liver, and kidneys, as well as the 
cardiovascular, hemostatic, and central nervous systems. An increasing score describes 
increasingly severe organ failure. A healthy individual with no underlying conditions 
leading to serious organ dysfunction is expected to have a SOFA score of zero. Elevated 
scores correlate with increasing ICU mortality, in-hospital mortality, and length of ICU 
stay. In this patient population, the SOFA score was 5.9 ± 3.7 (mean ± SD).  
The APACHE-II score was computed in patients at the time of ICU admission. 
The APACHE II score is designed to be applied to patients within 24 hours of admission 
to the intensive care units, with higher scores in the range from 0 to 71 correlating with 
severe disease and elevated risk of death. The scoring algorithm for the APACHE II 
score is shown in Appendix C. In this patient cohort, the APACHE II score was 17.4 ± 
7.3 (mean ± SD). 
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As a part of the study protocol under which these samples were collected, patients 
received additional monitoring for thrombosis throughout their hospital stay. In addition 
to recording symptomatic events including pulmonary embolism (PE), myocardial 
infarction (MI), or thromboembolic stroke, surviving patients received ultrasonographic 
assessment for asymptomatic DVT at the time of hospital discharge. No factors measured 
in this dissertation showed significant association with thrombosis diagnosed at 
discharge. However, the thrombi identified through this protocol may have developed 
significantly later in the course of hospitalization in the presence of risk factors other than 
sepsis. Without additional patient information, these thrombi cannot be said to be 
associated specifically with sepsis or DIC.  
Table 16. Outcome and Disease Severity Information 
 
Outcome N (%) 
28-Day Mortality 15 (14.6%) 
Septic Shock (Day 0) 46 (44.7%) 
Ventilator Use (Day 0) 48 (46.6%) 
In-Hospital Thrombosis (Total) 25 (24.3%) 
PE 2 
MI 1 
Stroke 2 
DVT 10 
Other/Unknown 10 
Clinical Disease Severity Score  Mean ± SD 
SOFA Score (Day 0) 5.9 ± 3.7 
APACHE II Score 17.4 ± 7.3 
 
DIC Score Stratification 
In this cohort, the DIC score was calculated for all patients using the ISTH 
scoring algorithm for DIC. This scoring system assigns points for abnormal values of 
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platelet count, INR, D-Dimer, and fibrinogen, and is shown both in Table 3 as well as in 
Appendix C. The presence of a predisposing condition for DIC, such as sepsis, cancer, 
trauma, or toxin exposure is a prerequisite for the use of this scoring algorithm. In this 
cohort, all patients were diagnosed with sepsis, fulfilling this requirement. Using this 
scoring system, a score of 5 or greater was classified as sepsis + overt DIC, a score of 3-4 
was categorized as sepsis + non-overt DIC, and a score of 2 or lower was categorized as 
sepsis + no DIC.  
Distribution of DIC scores is shown in Table 17. At baseline, 20 patients had 
sepsis + no DIC, 59 patients had sepsis + non-overt DIC, and 24 patients had sepsis + 
overt DIC. The relative prevalence of the degrees of DIC remained relatively constant 
between day 0 and day 4; however, on day 8, no patients remaining in the ICU had overt 
DIC.  
Table 17. DIC Score Distribution 
 
 All 
Patients 
Sepsis + No 
DIC 
Sepsis + Non-Overt 
DIC 
Sepsis + Overt 
DIC 
DIC Score Any 0-2 3-4 ≥5 
Day 0 (n) 103 20 59 24 
Day 4 (n) 57 11 36 10 
Day 8 (n) 30 8 22 0 
 
The association of mortality, shock and ventilator use with the severity of DIC 
was assessed using the Chi Square test. Although the prevalence of septic shock and 
mortality appeared to increase progressively with increasing severity of DIC, this 
difference was not statistically significant. Changes in SOFA and APACHE II scores 
based on DIC score category were evaluated using the Kruskal-Wallis One-Way 
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ANOVA. SOFA score showed significant variation based on DIC score category, 
indicating increased organ failure in patients with the most severe coagulopathy, while 
the APACHE II score did not. SOFA score describes organ failure in terms of both 
number of failing organ systems and degree of failure of each system. This score 
accounts for respiratory, hepatic, cardiovascular, central nervous system, and renal 
function as well as platelet count as a measure of coagulation function. The APACHE II 
score also includes similar parameters describing several physiological systems. 
However, platelet count is not included in the APACHE II score and coagulation function 
and liver function are not directly evaluated, which may contribute to the lack of 
association with DIC score. Outcome and illness severity information based on DIC score 
category is shown in Table 18.  
Table 18. Outcome and Severity of Illness Based on DIC Score Category 
 
 All 
Patients 
Sepsis +  
No DIC 
Sepsis +  
Non-Overt DIC 
Sepsis +  
Overt DIC 
P 
Value 
Shock 44  5  28  13  0.12 
Ventilator 48 10  25  13  0.59 
Mortality 15 2  7  6  0.25 
SOFA  
Mean ± SD 
5.9 ± 3.7 4.2 ± 2.8 5.8 ± 3.9 7.5 ± 3.1 0.011* 
APACHE II 
Mean ± SD 
17 ± 7.3 16 ± 6.3 17 ± 7.8 19 ± 6.8 0.37 
 
Association of Biomarker Levels with Severity of Illness 
The biomarkers measured in this dissertation can be divided into five general 
categories: hemostatic (platelets, INR, fibrinogen, D-Dimer, F1.2, and PAI-1), infection 
(nucleosomes, HMGB-1, and procalcitonin), inflammatory (IL-2, IL-4, IL-6, IL-8, IL-10, 
VEGF, IFNγ, TNFα, IL-1α, IL-1β, MCP-1, EGF, and IL-6:IL-10 Ratio), endothelial 
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(TFPI, Protein C, endocan, Ang-2, and vWF), and platelet (CD40L, PF4, MP, and MP-
TF).  
In order to determine the relationships between biomarker levels and organ 
dysfunction, Spearman correlation coefficients were calculated between each biomarker 
and the SOFA and APACHE II scores with p<0.05 as the cutoff for significance.  
The requirement for supportive therapies including a ventilator to maintain 
adequate gas exchange and vasopressors to maintain blood pressure are indicators of poor 
clinical status. Information regarding vasopressor type or dose was not available for most 
patients, and thus more in-depth analysis regarding the association of outcome or 
biomarkers with varied severity of shock could not be performed. Differences in baseline 
biomarker levels on the basis of ventilator or vasopressor use were assessed using the 
Mann-Whitney t-test with p<0.05 as the cutoff for significance.  
Hemostatic Biomarkers. Baseline levels of hemostatic biomarkers indicating 
ongoing thrombosis or coagulation dysfunction showed significant association with organ 
failure. As shown in Table 19, SOFA score correlated significantly with platelet count (p 
< 0.001, r = -0.36), D-Dimer (p = 0.035, r = 0.21), and INR (p = 0.043, r = 0.20). The 
APACHE II score correlated significantly with platelet count (p = 0.026, r = -0.22).  
No significant differences in platelet count, INR, fibrinogen, D-Dimer, F1.2, or 
PAI-1 levels at baseline were observed on the basis of ventilator use or shock, suggesting 
that while coagulation dysfunction may be involved in the development of global organ 
failure, it is not a major contributor to shock or respiratory dysfunction. 
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Table 19. Association of Hemostatic Biomarkers with Severity of Illness 
 
  
  
Spearman Correlation 
Coefficients 
Mann-Whitney Test p 
Value 
APACHE II 
Score 
SOFA 
Score 
Ventilator Vasopressor 
D-Dimer 0.16 0.21 0.36 0.07 
F1.2 0.13 0.12 0.19 0.61 
PAI-1 0.09 0.04 0.11 0.10 
INR 0.12 0.20 0.44 0.28 
Platelets -0.22 -0.36 0.16 0.08 
Fibrinogen -0.03 -0.02 0.26 0.71 
 
For APACHE II and SOFA scores, Spearman correlation coefficients are shown. 
Significant correlations (p<0.05) are highlighted in blue. For ventilator and vasopressor 
use, Mann-Whitney Test p value is shown for comparison of biomarker levels between 
patients receiving or not receiving ventilator or vasopressor support. Light blue denotes 
significance (p<0.05). 
 
Infection and Inflammation Biomarkers. As shown in Table 20, the presence of 
inflammation and infection was significantly associated with organ failure. SOFA score 
correlated significantly with IL-6 (p = 0.008, r = 0.26) IL-8, (p = 0.001, r = 0.32), IL-10 
(p = 0.022, r = 0.23), MCP-1 (p = 0.001, r = 0.23), and TNFα (p = 0.025, r = 0.22). This 
highlights the association between widespread, generalized inflammation, and organ 
failure. In contrast, the only infection marker to show significant association with organ 
failure was procalcitonin (p = 0.030, r = 0.28).  
Levels of MCP-1 and HMGB-1 were significantly elevated in patients requiring 
ventilator support at baseline. Procalcitonin, IL-6, IL-8, TNFα, and MCP-1 were 
significantly elevated in patients requiring vasopressors.  
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Table 20. Association of Infection and Inflammation Biomarkers with Severity of 
Illness 
 
  
  
Spearman Correlation 
Coefficients 
Mann-Whitney Test p 
Value 
APACHE II 
Score 
SOFA 
Score 
Ventilator Vasopressor 
Nucleosomes 0.06 -0.07 0.21 0.82 
HMGB-1 -0.08 -0.07 0.05 0.29 
Procalcitonin 0.21 0.28 0.84 <0.0001 
IL-2 0.07 0.06 0.81 0.49 
IL-4 -0.02 0.01 0.99 0.21 
IL-6 0.09 0.26 0.08 0.01 
IL-8 0.19 0.32 0.05 0.04 
IL-10 0.05 0.23 0.53 0.06 
VEGF -0.04 0.00 0.07 0.12 
IFNγ -0.06 0.01 0.34 0.54 
TNFα 0.02 0.22 0.45 0.004 
IL-1α 0.12 0.14 0.82 0.96 
IL-1β 0.04 0.11 0.38 0.13 
MCP-1 0.10 0.33 0.03 0.02 
EGF -0.12 -0.17 0.98 0.09 
IL-6:IL-10 0.03 0.17 0.21 0.15 
 
For APACHE II and SOFA scores, Spearman correlation coefficients are shown. 
Significant correlations (p<0.05) are highlighted in blue. For ventilator and vasopressor 
use, Mann-Whitney Test p value is shown for comparison of biomarker levels between 
patients receiving or not receiving ventilator or vasopressor support. Light blue denotes 
significance (p<0.05). 
 
Somewhat surprisingly, MCP-1 showed the strongest association of any measured 
inflammatory marker with indicators of clinical status and organ failure, including SOFA 
score, as well as ventilator and vasopressor use. Although previous investigations of 
MCP-1 in sepsis and DIC have been limited, it has been suggested that elevated MCP-1 
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may contribute to the development of shock and organ dysfunction through increased 
vascular leakage.  
Endothelial Biomarkers. As shown in Table 21, markers of endothelial function 
showed minimal associations with organ failure or disease severity. Statistically 
significant but weak correlation was seen between SOFA score and protein C (p = 0.024, 
r = -0.22). APACHE II score showed no significant correlation with any endothelial 
biomarker.  
Minimal associations were observed between the endothelial markers and the 
presence of shock or ventilator use. Ang-2 was significantly elevated in patients requiring 
vasopressor support. vWF was significantly elevated in patients requiring mechanical 
ventilation. This low degree of association between endothelial markers and disease 
severity is somewhat surprising, as previous studies have demonstrated associations 
between endothelial damage and organ failure.  
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Table 21. Association of Endothelial Biomarkers with Severity of Illness 
 
  
  
Spearman Correlation 
Coefficients 
Mann-Whitney Test p 
Value 
APACHE II 
Score 
SOFA 
Score 
Ventilator Vasopressor 
TFPI 0.10 0.00 0.45 0.55 
Protein C -0.15 -0.22 0.11 0.25 
Endocan 0.19 -0.02 0.63 0.35 
Ang-2 0.05 0.14 0.22 <0.0001 
vWF -0.14 -0.12 0.0006 0.22 
 
For APACHE II and SOFA scores, Spearman correlation coefficients are shown. 
Significant correlations (p<0.05) are highlighted in blue. For ventilator and vasopressor 
use, Mann-Whitney Test p value is shown for comparison of biomarker levels between 
patients receiving or not receiving ventilator or vasopressor support. Light blue denotes 
significance (p<0.05). 
 
Platelet Biomarkers. As shown in Table 22, multiple associations were observed 
between the levels of platelet function markers and organ failure. SOFA score correlated 
significantly with PF4 (p < 0.001, r = -0.43) and microparticles (p = 0.011, r = -0.26). 
APACHE II score correlated significantly with CD40L (p = 0.003, r = -0.29) and PF4 (p 
< 0.001, r = -0.37). Notably, PF4, vWF, MP, MP-TF, and CD40L were all elevated in 
sepsis and DIC patients compared to healthy controls despite the reduction in platelet 
count. However, negative correlations between platelet function markers and SOFA, 
MODS, and APACHE II scores were observed, indicating an inverse relationship 
between the levels of these markers and the degree of organ failure. PF4 was significantly 
elevated in patients requiring mechanical ventilation. No other differences in platelet 
markers were observed on the basis of vasopressor or ventilation status. 
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Table 22. Association of Platelet Biomarkers with Severity of Illness 
 
  
  
Spearman Correlation 
Coefficients 
Mann-Whitney Test p 
Value 
APACHE II 
Score 
SOFA 
Score 
Ventilator Vasopressor 
CD40L -0.29 -0.18 0.44 0.51 
MP -0.05 -0.26 0.81 0.20 
MP-TF 0.18 0.16 0.55 0.69 
PF-4 -0.37 -0.43 0.02 0.15 
 
For APACHE II and SOFA scores, Spearman correlation coefficients are shown. 
Significant correlations (p<0.05 are highlighted in blue). Light blue denotes a correlation 
coefficient of <0.4 while dark blue denotes a coefficient of ≥0.4. For ventilator and 
vasopressor use, Mann-Whitney Test p value is shown for comparison of biomarker 
levels between patients receiving or not receiving ventilator or vasopressor support. Light 
blue denotes significance (p<0.05). 
 
Association of Biomarkers with DIC Score at Baseline 
As previously described, the ISTH DIC score was calculated in all sepsis patients, 
and patients were divided into three groups based on this score. Patients with a score of 
0-2 were classified as “No DIC”, patients with a score of 3-4 were classified as “Non-
Overt DIC”, and patients with a score of 5 or greater were classified as “Overt DIC”. 
Overt DIC describes a scenario of severe, decompensated coagulopathy with marked 
perturbations to multiple aspects of the hemostatic system. Non-overt DIC represents a 
heterogeneous phenotype, with a variable degree and manifestation of coagulopathy. 
Patients in the no DIC category were still severely ill with sepsis; however, these patients 
did not have significant coagulation dysfunction. Differences in biomarker levels 
between the three groups and from the healthy control cohort were assessed using the 
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Kruskal-Wallis ANOVA with Dunn’s multiple comparison test and p < 0.05 as the cutoff 
for significance. Markers were measured in 50 healthy individuals as well as in samples 
from 20 patients with no DIC, 59 patients with non-overt DIC, and 24 patients with overt 
DIC. 
Hemostatic Biomarkers. Platelet count, fibrinogen, INR and D-Dimer are 
included in the DIC scoring algorithm, and therefore are expected to vary significantly 
with DIC score. This variation was observed with D-Dimer, where significant differences 
were seen not only between the healthy controls and all patient groups but also between 
patients with sepsis without DIC and those with either non-overt or overt DIC. INR, 
platelet count, and fibrinogen were not measured in the healthy control population. 
However, both INR and platelet count, as expected, showed significant variation based 
on DIC score category. In contrast, fibrinogen showed no variation on the basis of DIC 
status. While in severe coagulopathy, fibrinogen levels may decrease as fibrinogen is 
converted into an insoluble fibrin clot, this phenomenon was not generally observed in 
this patient cohort. Fibrinogen is an acute phase reactant and is secreted by the liver under 
inflammatory conditions. In patients with sepsis, this increased fibrinogen release in 
response to inflammation appears to overcome the consumption due to coagulation, even 
in patients with severe coagulopathy. Accordingly, fibrinogen may not be an appropriate 
marker to use in the evaluation of coagulation status in this patient population.  
The fibrinolysis regulator PAI-1 was significantly elevated in all categories of 
sepsis patients compared to healthy controls, but did not vary within the sepsis population 
based on DIC status. The thrombin generation marker F1.2 was only elevated in patients 
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with overt or non-overt DIC compared to healthy controls; the elevation in F1.2 in 
patients with sepsis without DIC was not statistically significant. Data is shown in Figure 
17 and in Table 42 in Appendix B.  
A 
 
B 
 
C 
 
D
 
E
 
F
 
Figure 17. Baseline Hemostatic Biomarker Levels Stratified by DIC Score. 
Significance calculated between groups using the Kruskal-Wallis ANOVA with 
Dunn’s multiple comparison test and p<0.05 as the cutoff for significance (indicated by 
*). Data is shown as mean ± SEM.  
 
Infection and Inflammation Biomarkers. Numerous markers of infection and 
inflammation showed significant variation within the sepsis patient cohort based on DIC 
score category. Data is shown in Figure 18 and 19 and in Tables 43-44 in Appendix B.  
Biomarkers of infection demonstrated a distinct association with coagulopathy. 
Nucleosomes showed significant elevation only in patients with overt DIC compared to 
healthy controls and to patients with sepsis without DIC. Septic patients without DIC 
showed no elevation in nucleosome levels. Although HMDB-1 trended towards 
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increasing levels with increasing severity of DIC, significant differences were only 
observed between healthy controls and all patient groups. This may be a function of 
limited statistical power due to the size of the patient cohort, as when analyzed separately 
from healthy controls (data not shown), differences in HMGB-1 levels were seen 
between patients with non-overt DIC and overt DIC. Procalcitonin demonstrated the 
greatest distinction between levels of coagulopathy. In addition to significant elevations 
compared to healthy controls in all sepsis patients regardless of DIC status, procalcitonin 
was also significantly elevated in both non-overt and overt DIC compared to sepsis alone. 
This supports the role of infection response, including infection-related nuclear material, 
in the molecular pathogenesis of DIC.  
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Figure 18. Baseline Infection Biomarker Levels Stratified by DIC Score. 
Significance calculated between groups using the Kruskal-Wallis ANOVA with 
Dunn’s multiple comparison test and p<0.05 as the cutoff for significance (indicated by 
*). Data is shown as mean ± SEM. 
 
Inflammatory cytokines, including the IL-6:IL-10 ratio which was calculated as a 
means to evaluate the balance between pro- and anti-inflammatory processes ongoing 
within a single patient, were significantly elevated in sepsis patients compared to healthy 
controls regardless of coagulation status. The exception to this elevation was IL-1β, 
which did not show elevation in the sepsis + no DIC group compared to controls. 
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Variation within sepsis patients based on DIC score was observed only for IL-8, which 
was significantly elevated in overt DIC compared to no DIC, and EGF, which was 
reduced in overt DIC compared to both no DIC and non-overt DIC. If analyzed without 
the inclusion of the healthy control population (data not shown), the increases in non-
overt and overt DIC reached statistical significance in comparison to no DIC for IL-8, IL-
8, and TNFα. Additional significant differences were noted for IL-10 in overt DIC 
compared to no DIC and in IL-1β and MCP-1 in non-overt DIC compared to overt DIC.  
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Figure 19. Baseline Inflammatory Biomarker Levels Stratified by DIC Score. 
Significance calculated between groups using the Kruskal-Wallis ANOVA with 
Dunn’s multiple comparison test and p<0.05 as the cutoff for significance (indicated by 
*). Data is shown as mean ± SEM. 
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Endothelial Biomarkers. Significant variation of levels of endothelial 
biomarkers based on DIC score was observed, as shown in Figure 20 and in Table 45 in 
Appendix B.  
Protein C is known to be implicated in the pathogenesis of sepsis-associated DIC, 
and decreased levels are generally associated with poor outcome. In this cohort, protein C 
was decreased in sepsis patients compared to healthy controls regardless of coagulation 
status. Additionally, protein C showed a significant decrease in patients with overt DIC 
compared to patients with sepsis and no DIC. This corroborates prior research regarding 
Protein C in sepsis-associated coagulopathy. Depletion of this endogenous anticoagulant 
contributes to the development of coagulopathy in sepsis patients, and this pathway is a 
major therapeutic target. In contrast, another endogenous anticoagulant, TFPI, showed no 
significant variation based on DIC status, although it was elevated in patients with sepsis 
compared to healthy controls regardless of DIC score. TFPI release is induced by heparin 
therapy. All patients enrolled in this study received prophylactic doses of UFH; no 
additional UFH or LMWH use was reported, therefore this treatment does not represent a 
confounding factor for TFPI levels in this cohort.  
Ang-2 also varied significantly based on DIC status, with significant elevation in 
patients with overt DIC compared to those with sepsis and no DIC as well as significant 
elevations in all patient groups compared to healthy controls. Both endocan and vWF 
were elevated in sepsis patients compared to controls regardless of DIC status; however, 
no variation was seen within sepsis patients based on DIC status.  
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Figure 20. Baseline Endothelial Biomarker Levels Stratified by DIC Score. 
Significance calculated between groups using the Kruskal-Wallis ANOVA with 
Dunn’s multiple comparison test and p<0.05 as the cutoff for significance (indicated by 
*). Data is shown as mean ± SEM. 
 
Platelet Biomarkers. Although a trend towards changes in platelet markers was 
seen between patients in the different DIC score categories, no significant differences in 
CD40L, MP, MP-TF, or PF4 were observed based on DIC score status. Significant 
elevation in all platelet markers was observed in all groups compared to the healthy 
controls. Although platelets may be significantly activated in sepsis and therefore secrete 
high levels of platelet-derived biomarkers, this increase in biomarker level may be 
confounded by the depletion of platelets due to consumptive coagulopathy in severe DIC. 
The contrasting findings of elevated platelet function markers in sepsis despite reduced 
platelet count with inverse relationships between platelet function markers and SOFA 
scores are in line with these unclear observations about platelet function markers in 
sepsis-associated DIC. Data is shown in Figure 21 and in Table 46 in Appendix B.  
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Figure 21. Baseline Platelet Biomarker Levels Stratified by DIC Score. 
Significance calculated between groups using the Kruskal-Wallis ANOVA with 
Dunn’s multiple comparison test and p<0.05 as the cutoff for significance (indicated by 
*). Data is shown as mean ± SEM 
 
Association of Baseline Biomarkers with Mortality 
The 28 day mortality in this patient cohort was 14.6% (88 survivors and 15 non-
survivors). Information on time to mortality was not available. Differences in baseline 
biomarker levels between survivors and non-survivors were evaluated using the Mann-
Whitney t-test with p<0.05 as the cutoff for significance. The predictive power of each 
biomarker for mortality was evaluated using receiver operating curve (ROC) analysis; the 
area under the curve (AUC) is reported as the quantification of this analysis. Using this 
analytical technique, an AUC value of 0.5 for a biomarker represents no ability to predict 
outcome while an AUC value of 1.0 represents ability to perfectly predict outcome with 
100% sensitivity and 100% specificity. 
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Hemostatic Biomarkers. Baseline levels of hemostatic biomarkers were poor 
predictors of mortality in the sepsis patient population. Of the measured hemostatic 
markers, only PAI-1 showed a significant difference between survivors and non-
survivors (p=0.015). Elevated PAI-1 has the potential to increase mortality in patients 
with DIC by preventing the fibrinolytic breakdown of clots in the microvasculature. This 
may increase vascular occlusion and lead to organ dysfunction out of proportion with the 
amount of thrombosis as quantified by D-Dimer, coagulation factor, or platelet levels. 
Interestingly, none of the markers typically used to describe coagulopathy in septic 
patients (INR, platelet count, D-Dimer, or fibrinogen) showed significant differences 
between survivors and non-survivors. Although the DIC score itself is not designed to 
predict mortality, the lack of association of these markers with patient outcome suggests 
that this scoring system may be missing important parameters. The AUC values for 
prediction of mortality with these markers were also poor, with values of 0.61 for 
platelets, 0.60 for INR, 0.51 for fibrinogen, 0.60 for D-Dimer, and 0.54 for F1.2. The 
predictive value for PAI-1 was slightly better, with an AUC of 0.70. Data is shown in 
Figure 22 and in Table 47 in Appendix B.   
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Figure 22. Association of Baseline Hemostatic Biomarker Levels with Survival. 
Significance calculated between groups using the Mann-Whitney test with p<0.05 as 
the cutoff for significance (indicated by *). Data is shown as mean ± SEM.  
 
Infection and Inflammation Biomarkers. Significant associations were 
observed between markers of infection and mortality. Both HMGB-1 (p=0.031, 
AUC=0.67) and procalcitonin (p=0.0005, AUC=0.77) were significantly elevated in non-
survivors compared to survivors, as shown in Figure 23 and in Table 48 in Appendix B. 
The elevation of HMGB-1 and procalcitonin in non-survivors demonstrates that infection 
and infection response are major determinants of patient outcome. Furthermore, 
procalcitonin had the highest AUC for the prediction of mortality of any biomarker 
measured in this study. While procalcitonin is not a therapeutic target, its predictive 
ability is important to recognize as procalcitonin is available as a clinical laboratory test 
and would therefore be relatively simple to incorporate into a new algorithm for 
evaluation of patients with sepsis or DIC. While a weaker predictor than procalcitonin, 
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HMGB-1 may be a direct mechanistic link between infection response and the 
physiological dysfunction that ultimately results in death. Despite the association of 
nucleosomes with severity of coagulopathy, the elevation of nucleosomes in non-
survivors compared to survivors was not statistically significant and showed a poor 
predictive value (AUC = 0.58). This suggests that while infection is a critical determinant 
of both development of coagulopathy and patient outcome, different aspects of this 
response may play distinct physiological roles.  
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Figure 23. Association of Baseline Infection Biomarker Levels with Survival. 
Significance calculated between groups using the Mann-Whitney test with p<0.05 as 
the cutoff for significance (indicated by *). Data is shown as mean ± SEM. 
 
Of the measured inflammatory markers, IL-6 (p = 0.02, AUC = 0.70) and IL-8 (p 
= 0.015, AUC = 0.70) were significantly elevated in non-survivors compared to 
survivors. Predictive values for mortality for all other inflammatory cytokines were 
relatively poor (IL-2, 0.52; IL-4, 0.55; IL-10, 0.58; VEGF, 0.57; IFNγ, 0.54; TNFα, 0.52; 
IL-1α, 0.60; IL-1β, 0.58; MCP-1, 0.56; EGF, 0.58, IL-6:IL-10 Ratio, 0.61). Data is 
shown in Figure 24 and in Table 49 in Appendix B.   
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Figure 24. Association of Baseline Inflammatory Biomarker Levels with Survival. 
Significance calculated between groups using the Mann-Whitney test with p<0.05 as 
the cutoff for significance (indicated by *). Data is shown as mean ± SEM. 
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Endothelial Biomarkers. Significant association was seen between markers of 
endothelial function and mortality. TFPI (AUC=0.55) and vWF (AUC=0.58) showed no 
significant variation based on survival. However, significant variation was seen for the 
remainder of the endothelial markers. In contrast to almost all other evaluated markers, 
Protein C showed a significant reduction in non-survivors compared to survivors 
(p=0.0093, AUC=0.71). Both endocan (p=0.025, AUC=0.58) and Ang-2 (p=0.001, 
AUC=0.76) were significantly elevated in non-survivors compared to survivors. Data is 
shown in Figure 25 and in Table 50 in Appendix B.   
A 
 
B 
 
C 
 
                      D 
 
E  
 
Figure 25. Association of Baseline Endothelial Biomarker Levels with Survival. 
Significance calculated between groups using the Mann-Whitney test with p<0.05 as 
the cutoff for significance (indicated by *). Data is shown as mean ± SEM. 
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Platelet Biomarkers. Overall, minimal associations were observed between 
markers of platelet function and patient outcome. Only PF4 showed a significant 
association with mortality (p=0.016, AUC=0.70), with significantly lower levels 
observed in non-survivors compared to survivors. All other platelet biomarkers had weak 
predictive values for mortality (CD40L, 0.55; MP, 0.53; MP/TF, 0.62). Data is shown in 
Figure 26 and in Table 51 in Appendix B.   
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Figure 26. Association of Baseline P1atelet Biomarker Levels with Survival. 
Significance calculated between groups using the Mann-Whitney test with p<0.05 as 
the cutoff for significance (indicated by *). Data is shown as mean ± SEM. 
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Association of Biomarkers with DIC Score and Mortality on ICU Days 4 and 8 
 On Day 4, 57 patients remained in the ICU. Of the 46 patients who left the ICU 
before this time, 4 died and the remaining 42 were transferred to other units or 
discharged. Of the 57 patients remaining in the ICU on day 4, 11 had no DIC, 26 had 
non-overt DIC, and 10 had overt DIC. At this time, only D-Dimer and Protein C showed 
a significant association with DIC score category. 47 survivors and 10 non-survivors 
remained in the ICU on day 4. Significant elevations were observed in IL-6 (p=0.028), 
IL-8 (p=0.005) and endocan (p=0.025) at this time point. Data for day 4 biomarker levels 
is shown in Tables 52-56 and 62-66 in Appendix B. 
 On Day 8, 24 survivors and 6 non-survivors remained in the ICU. Of these, 8 had 
no DIC and 22 had non-overt DIC; no patients had overt DIC on day 8. Accordingly, 
comparisons were only made between patients with sepsis and patients with non-overt 
DIC. Significance between these two patient groups was calculated using the Mann-
Whitney t test with p<0.05 as the cutoff for significance. Protein C and IL-2 were 
significantly reduced in patients with non-overt DIC compared to patients with no DIC. 
The reduction in protein C in patients with more severe coagulopathy is consistent with 
previous findings and with knowledge about the role of protein C in the pathophysiology 
of DIC. Significant elevations were observed in D-Dimer, procalcitonin, IL-6, IL-8, IL-
10, MCP-1, MP/TF, endocan, and Ang-2 in patients with non-overt DIC compared to 
patients with sepsis and no DIC. The increase in the number of biomarkers demonstrating 
an association with DIC status on day 8 may be due to the decrease in the number of 
patient groups due to the absence of overt DIC patients at this time point. The elevations 
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in IL-6 (p=0.008) and IL-8 (p=0.009) that were observed on days 0 and 4 persisted on 
day 8. Additionally, on day 8, a significant elevation in D-Dimer (p=0.029) as well as a 
significant reduction in protein C (p=0.025) in non-survivors compared to survivors, 
suggesting a major role for coagulation dysfunction in determining outcome in patients 
remaining in the ICU at this time point. Data for Day 8 biomarker levels are shown in 
Tables 57-61 and 67-71 in Appendix B. 
Association of Biomarkers with Platelet Count 
 Throughout this study, the association between markers of platelet function and 
outcome was relatively weak. However, numerous studies have demonstrated that the 
platelet response in sepsis and DIC is integral to the pathophysiology of this disease. The 
association of factors generated or released by platelets with clinical status and outcome 
may be confounded by the consumption of platelets during the coagulopathy 
characteristic of sepsis-associated DIC. Recently, significant associations were 
demonstrated between levels of platelets and hemostatic, inflammatory, and endothelial 
markers in patients with sepsis-associated coagulopathy (Claushuis 2016). In line with 
this analysis, patients were divided into groups based on platelet count on ICU Day 0 of 
<100 K/μl (n=21), 100-149 K/μl (n=20), or ≥150 K/μl (normal range; n = 61). The 
normal range for platelet count is 150-400 K/μl. Patients with a platelet count of 100-149 
K/μl have thrombocytopenia; however, a platelet count within this range does not pose a 
significant bleeding risk. For patients with a typical platelet count of close to 150 K/μl, a 
platelet count within the 100-149 K/μl range may not represent a significant drop in 
platelet count. A platelet count of <100 K/μl indicates a marked drop in platelets from the 
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normal range and may lead to an increased risk of bleeding. A platelet count of <50 K/μl 
indicates a markedly increased bleeding risk; however, only 3 patients fell within this 
range in this cohort and thus these patients could not be analyzed separately. Differences 
in biomarker levels between these patient groups were quantified using the Kruskal-
Wallis one-way ANOVA with Dunn’s multiple comparison test and p<0.05 as the cutoff 
for significance.  
Hemostatic Biomarkers. Of the hemostatic biomarkers, only INR and fibrinogen 
showed a significant association in platelet count, with an elevated INR observed in 
patients with a platelet count of 100-149 K/μl compared to those with a platelet count of 
≥150 K/μl. Fibrinogen was significantly elevated in patients with a platelet count of ≥150 
K/μl compared to those with a platelet count of >100 K/μl. No significant differences 
were observed in D-Dimer, F1.2, or PAI-1. Data is shown in Figure 27 and in Table 72 in 
Appendix B.  
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Figure 27. Baseline hemostatic biomarker levels in patients stratified by platelet 
count. Significance calculated between groups using the Kruskal-Wallis ANOVA with 
Dunn’s multiple comparison test and p<0.05 as the cutoff for significance (indicated by 
*). Data is shown as mean ± SEM.  
 
Infection and Inflammation Biomarkers. Of the infectious biomarkers, only 
procalcitonin showed significant variation based on platelet count. Patients with a platelet 
count of <100 K/μl or 100-149 K/μl had significantly elevated levels of procalcitonin 
compared to those with a platelet count within the normal range. This demonstrates an 
association between infection, as quantified by procalcitonin, and thrombocytopenia. 
Data is shown in Figure 28 and in Table 73 in Appendix B.  
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Figure 28. Baseline Infection Biomarker Levels in Patients Stratified by Platelet 
Count. Significance calculated between groups using the Kruskal-Wallis ANOVA 
with Dunn’s multiple comparison test and p<0.05 as the cutoff for significance 
(indicated by *). Data is shown as mean ± SEM.  
 
Of the inflammatory biomarkers, VEGF, TNFα, and EGF showed significant 
variation based on platelet count. The highest levels of VEGF and EGF were observed in 
patients with platelet counts of ≥150 K/μl, with significant differences between patients 
with platelet counts of ≥150 K/μl and <100 K/μl for both factors and for ≥150 K/μl and 
100-149 K/μl for EGF. Conversely, the highest levels of TNFα were observed in patients 
with platelet counts of <100 K/μl. Data is shown in Figure 29 and in Table 74 in 
Appendix B  
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Figure 29. Baseline Inflammatory Biomarker Levels in Patients Stratified by 
Platelet Count. Significance calculated between groups using the Kruskal-Wallis 
ANOVA with Dunn’s multiple comparison test and p<0.05 as the cutoff for 
significance (indicated by *). Data is shown as mean ± SEM. 
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Endothelial Biomarkers. Protein C and Ang-2 showed significant variation 
based on platelet count. Protein C was significantly reduced in patients with a platelet 
count of 100-149 K/μl compared to those with a platelet count of ≥150 K/μl. Ang-2 
increased with decreasing platelet count, with significant differences observed between 
those with a normal platelet count and those with mild or severe thrombocytopenia. Data 
is shown in Figure 30 and in Table 75 in Appendix B.  
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Figure 30. Baseline Endothelial Biomarker Levels in Patients Stratified by Platelet 
Count. Significance calculated between groups using the Kruskal-Wallis ANOVA 
with Dunn’s multiple comparison test and p<0.05 as the cutoff for significance 
(indicated by *). Data is shown as mean ± SEM.  
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Platelet Biomarkers. Patients with sepsis-associated DIC have significantly 
elevated levels of several biomarkers associated with platelet activity. However, these 
same patients often have significantly reduced platelet counts due to consumption, which 
may confound the utility of these platelet biomarkers. Levels of some markers of platelet 
activity may be the most elevated in patients with platelet counts in the normal range of 
≥150 as patients with severely depleted platelet levels may not be able to release these 
markers into circulation at high levels from their depleted pool of platelets. Alternatively, 
platelet markers may show the greatest elevation in patients with significantly reduced 
platelet counts (<100 K/μl if factors are released at high levels during platelet 
consumption. Furthermore, a combination of these two processes may contribute to the 
level of each biomarker in a given patient.  
CD40L and MP increased with increasing platelet count, with statistically 
significant differences between patients with normal platelet counts of ≥150 K/μl 
compared to those of <100 K/μl for both parameters and for patients with a platelet count 
of ≥150 K/μl compared to those with a platelet count of 100-149 K/μl for MP. The trend 
observed for PF4 was more complex, with the highest level of PF4 measured in patients 
with platelets of 100-149 K/μl and significant differences between 100-149 K/μl and 
<100 K/μl and between ≤150 K/μl and <100 K/μl. Data is shown in Figure 31 and in 
Table 76 in Appendix B.  
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Figure 31. Baseline Platelet Biomarker Levels in Patients Stratified by Platelet 
Count. Significance calculated between groups using the Kruskal-Wallis ANOVA 
with Dunn’s multiple comparison test and p<0.05 as the cutoff for significance 
(indicated by *). Data is shown as mean ± SEM.  
 
Changes in Biomarker Levels over Time 
Several methods were used to analyze the change in biomarker levels over time 
within a given patient. For each marker in each patient, changes between baseline and 
day 4 levels were analyzed in terms of direct change (day 4 level minus baseline level), 
ratio of day 4 to baseline, and percent change from baseline to day 4. These parameters 
were calculated in the 37 survivors and 9 non-survivors with complete data at both 
baseline and day 4. Ratio and percent change could not be calculated in all patients due to 
undetectably low concentrations of factors in some samples, resulting in the presence of a 
zero in the denominator.  
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Using the direct comparison (subtraction method) approach, significant 
differences were observed between survivors and non-survivors for CD40L and protein 
C. When analyzed using the day 4 to baseline ratio and the percent change from baseline 
to day 4, significant differences were observed between survivors and non-survivors for 
VEGF and protein C. Contrary to previous studies, greater increases in protein C levels 
were seen in non-survivors than in survivors throughout the course of hospitalization. 
This is in direct contrast to previous reports that have demonstrated that increasing levels 
of protein C is a favorable prognostic indicator in sepsis-associated DIC. This may be due 
to the initial lower levels of protein C in non-survivors compared to survivors, allowing 
for a greater possible increase in these patients between baseline measurement and 
normal physiological levels. 
Potential Confounding Factors 
Age is one of the most significant confounding factors for biomarker analysis. 
Previous studies have demonstrated that older patients with sepsis have distinct 
biomarker profiles compared to younger patients, and that the associations between 
biomarkers and outcome may vary based on patient age (Opal, Girard, & Ely, 2005; 
Rondina 2015). Accordingly, the correlation between baseline biomarker level and age 
was calculated. Significant associations were seen between age and platelets (p=0.018, 
r=-0.23), INR (p=0.009, r=0.26), procalcitonin (p=0.024, r=0.22), VEGF (p=0.033, r=-
0.21) IFNγ, (p=0.031, r=-0.21), endocan (p<0.001, r=0.35), and Ang-2 (p=0.005, r=0.28).  
For further analysis, patients were divided into two categories based on age <65 
vs. ≥65 years. Although aging is a continuous process with no universal cutoff point, the 
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use of 65 as a cutoff point was selected on the basis of similar analyses (Baldwin 2013; 
Martin 2006; Opal 2005; Rondina 2015). There were 66 patients younger than 65 and 37 
patients older than 65. Data for markers with significant variation based on age or 
survival is shown in Figure 32. Significant differences were found based on age in INR 
(higher in the elderly, p=0.017), VEGF (lower in the elderly, p=0.020), Protein C (lower 
in the elderly, p=0.0057), and endocan (higher in the elderly, p=0.0004) using the Mann-
Whitney t test with p<0.05 as the cutoff for significance.  
In order to evaluate the potential interactions between age, survival, and 
biomarker levels, patients were subdivided into four groups; survivors younger than 65 
(n=60), survivors aged 65 or older (n=27), non-survivors younger than 65 (n=6), and 
non-survivors aged 65 or older (n=9). Interaction between age and survival for each 
biomarker was assessed using an ordinary 2-way ANOVA with p<0.05 as the cutoff for 
significance.  
For TFPI, significant variation was seen based on both age (p<0.0001) and 
survival category (p=0.002), with a statistically significant interaction between the two 
(p<0.0001). Nucleosomes varied significantly based on survival (p=0.033), but not on 
age. Procalcitonin varied significantly based on age (p=0.0001) and survival (p<0.0001), 
with a significant interaction between the two (p=0.0006). IL-6 varied significantly based 
on survival (p=0.017) but not age. IL-8 varied significantly based on age (p=0.028) and 
survival (p=0.004), with a significant interaction between the two (p=0.012). IL-6:IL-10 
ratio varied significantly based on survival (p=0.015) but not age. PAI-1 varied 
significantly based on both age (p=0.020) and survival (p=0.0004), with no significant 
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interaction between the two (p=0.098). Endocan varied significantly based on survival 
(p=0.016) but not age. Ang-2 varied significantly based on both age (p=0.0124) and 
survival (p=0.0001), with a significant interaction between the two (p=0.002). PF-4 
varied significantly based on survival (p=0.027) but not age. Other markers did not show 
any significant variation based on age or survival when analyzed in this manner.  
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Figure 32. Biomarker Levels Showing Significant Difference by Two-Way 
ANOVA when Subdivided by Age <65 vs. Age ≥65 and Survival or Non-Survival. 
Data is shown as mean ± SEM.  
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Additional confounding factors include gender and BMI as well as comorbidities 
including history of hypertension, recent surgery, recent or active cancer, cirrhosis, 
pulmonary disease, congestive heart failure, diabetes, and cardiovascular disease were 
also analyzed. Differences between categorical variables were assessed using the Mann-
Whitney t test, and correlations between biomarker levels and continuous variables (age 
and BMI) were assessed using Spearman correlation coefficients, summarized in Table 
23. No significant differences were seen in the Day 0 levels of any biomarkers based on 
history of hypertension (present in 47 patients) or recent surgery (present in 23 patients). 
BMI showed no significant correlations with any analyzed variable. F1.2, IL-2, IL-4, IL-
6, IL-8, IL-1β, MCP-1, EGF, HMGB-1, MP, MP/TF, and PF4 did not show any 
relationship with any analyzed confounding variable.  
Of particular interest in any condition involving coagulation is liver function, as 
many coagulation factors are produced in the liver, and patients with liver dysfunction 
may not produce normal levels of some coagulation factors and related proteins. In this 
cohort, 6 patients had cirrhosis. These patients showed significant reductions in 
fibrinogen (p=0.031) and VEGF (p=0.044) compared to patients without cirrhosis. 
The comorbidity with the greatest association with biomarker levels was history 
of pulmonary disease. D-Dimer (p=0.006), IFNγ (p=0.018), IL-10 (p=0.012), 
nucleosomes (p=0.044), and TNFα (p=0.040) were significantly elevated in patients 
without pulmonary disease compared to those with pulmonary disease (17 patients).  
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Common comorbidities included history of cardiovascular disease (22 patients) 
and diabetes (26 patients). Fibrinogen was significantly increased and (p=0.019) protein 
C significantly reduced (p=0.014) in patients with a history of cardiovascular disease 
compared to those without.IL-1α (p=0.013) and TFPI (p=0.021) were significantly 
elevated in patients with diabetes compared to non-diabetic patients (26 patients). 
Several markers showed significant differences in patients with low-frequency 
comorbidities. vWF was significantly elevated (p=0.039) was seen in patients with recent 
or active cancer compared to those without (6 patients). IFNγ (p=0.035) was significantly 
elevated in patients with CHF compared to those without (9 patients). CD40L (p=0.0182) 
and fibrinogen (p=0.0380) were significantly reduced in patients with history of recent 
transfusion compared to those without (7 patients). 
IL-1α (p=0.041) and TFPI (p=0.041) were higher in males than in females. PAI-1 
(p=0.005) and platelets (p=0.025) were higher in females than in males. 
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Table 23. Association of Biomarkers with Comorbid Conditions  
 
Marker Age Sex Cancer CHF Cirrhosis CVD Diabetes Pulmonary Transfusion 
D-Dimer 0.10 0.23 0.21 0.34 0.30 0.85 0.63 0.01 0.44 
PAI-1 -0.08 0.01 0.65 0.97 0.79 0.66 0.45 0.78 0.29 
INR 0.26 0.98 0.89 0.15 0.48 0.31 0.02 0.33 0.28 
Platelets -0.23 0.03 0.17 0.65 0.09 0.84 0.61 0.21 0.23 
Fibrinogen -0.01 0.23 0.63 0.47 0.03 0.02 0.93 0.89 0.04 
Nucleosomes 0.05 0.58 0.09 0.24 0.46 0.32 0.75 0.04 0.51 
Procalcitonin 0.22 1.00 0.11 0.65 0.29 0.66 0.83 0.45 0.59 
IL-10 -0.11 0.77 0.76 0.34 0.55 0.26 0.69 0.01 0.54 
VEGF -0.21 0.92 0.38 0.35 0.04 0.32 0.94 0.85 0.79 
IFNγ -0.21 0.62 0.58 0.03 0.66 0.60 0.40 0.02 0.69 
TNFα 0.05 0.46 0.18 0.36 0.59 0.96 0.45 0.04 0.78 
IL-1α -0.08 0.04 0.34 0.58 0.98 0.32 0.01 0.50 0.20 
TFPI 0.16 0.04 0.57 0.56 0.64 0.87 0.02 0.91 0.37 
Protein C -0.23 0.99 0.56 0.16 0.57 0.01 0.12 0.60 0.51 
Endocan 0.35 0.15 0.40 0.12 0.92 0.68 0.44 0.91 0.49 
Ang-2 0.28 0.89 0.44 0.69 0.44 0.96 0.37 0.09 0.34 
vWF 0.19 0.08 0.04 0.78 0.30 0.65 0.49 0.36 0.61 
CD40L -0.07 0.80 0.34 0.28 0.39 0.35 0.75 0.32 0.02 
Spearman r value (age) and Mann-Whitney test p values (all other markers) for the relationship of biomarker levels to comorbidities. 
Significant relationships (p<0.05) are highlighted in blue. BMI, history of hypertension or recent surgery showed no associations with 
biomarker level and were not included in this table.   
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Correlations 
Correlations between baseline biomarker levels were assessed using Spearman 
correlation coefficients with p<0.05 as the cutoff for significance. A correlation matrix 
relating each measured biomarker to each other biomarker was generated and is shown 
split into separate tables for hemostatic markers (D-Dimer, F1.2, PAI-1, INR, platelets, 
and fibrinogen), infection markers (nucleosomes, HMGB-1, and procalcitonin), 
inflammatory markers (IL-2, IL-4, IL-6, IL-8, IL-10, VEGF, IFNγ, TNFα, IL-1α, IL-1β, 
MCP-1, and EGF), endothelial markers (TFPI, Protein C, endocan, Ang-2, and vWF), 
and platelet markers (CD40L, MP, MP-TF, and PF4). Correlation coefficients are shown 
in Tables 24-28 with significant correlations highlighted in blue. Significant correlations 
with an r<0.4 are highlighted in light blue whereas correlations with an r≥0.4 are 
highlighted in dark blue.  
Hemostatic biomarkers, shown in Table 24, correlated moderately with each other 
as well as with biomarkers of infection, inflammation, and endothelial function. PAI-1 
did not correlate with any other measured hemostatic marker, suggesting that PAI-1 is 
involved in an independently regulated process relevant to patient outcome in sepsis-
associated DIC. As anticipated based on prior analysis of the relationship of platelet 
counts with platelet-associated biomarkers, platelets correlated strongly with CD40L, 
MP, and PF4.  
The infection markers nucleosomes, HMGB-1, and procalcitonin, shown in Table 
25, correlated moderately with each other. Surprisingly, nucleosomes and HMGB-1 had 
minimal relationships to the classic inflammatory markers, with the exception of weak 
191 
 
 
but significant correlations between nucleosomes and IL-8 and HMGB-1 and IL-1β. In 
contrast, procalcitonin, an indicator but not a physiological mediator of infection, 
correlated strongly with numerous inflammatory markers including IL-6, IL-8, IL-10, 
TNFα, and MCP-1 as well as D-Dimer and Ang-2. Procalcitonin exhibited the greatest 
degree of correlation of any single biomarker, also correlating with hemostatic markers, 
including a strong correlation with D-Dimer, and endothelial markers, including a strong 
correlation with Ang-2. 
Inflammatory markers, shown in Table 26, correlated strongly with each other; 
the majority of strong correlations between biomarkers were observed among 
inflammatory biomarkers. In addition to the previously mentioned strong correlations 
with procalcitonin, the inflammatory markers demonstrated significant but weak 
correlations with hemostatic markers, endothelial markers, and platelet markers. The 
majority of these correlations were focused in a few inflammatory cytokines, particularly 
IL-6, IL-8, IL-10, TNFα and MCP-1. This suggests that analysis of a small number of 
biomarkers with association with coagulopathy or mortality (i.e. IL-6, IL-8, or IL-10) 
may be sufficient to describe the inflammatory status of a patient with sepsis and DIC.  
Endothelial biomarkers correlated significantly but weakly with each other and 
showed relatively few strong correlations with anything else, as shown in Table 27. The 
exceptions to this were a strong relationship between Protein C and INR, strengthening 
the association between low Protein C levels and coagulopathy, strong associations 
between Ang-2 and HMGB-1 and procalcitonin, and a strong negative association 
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between endocan and VEGF. Virtually no associations were seen between endothelial 
and platelet markers.  
Platelet count showed limited associations with other factors, as shown in Table 
28. With the exception of the previously mentioned strong correlation of platelet count 
with CD40L, MP, and PF4, the only other strong correlations observed were between 
VEGF and CD40L and between MP and EGF. Minimal associations were seen between 
platelet markers and endothelial markers, infection markers, and hemostatic parameters.  
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Table 24. Spearman Correlation Coefficients for Hemostatic Markers 
 
  D-Dimer F1.2 PAI-1 INR Platelets Fibrinogen 
D-Dimer   0.46 0.17 0.11 -0.27 0.03 
F1.2 0.46  0.17 -0.15 -0.01 -0.12 
PAI-1 0.17 0.17  0.08 0.19 -0.06 
INR 0.11 -0.15 0.08  -0.30 -0.11 
Platelets -0.27 -0.01 0.19 -0.30  0.26 
Fibrinogen 0.03 -0.12 -0.06 -0.11 0.26   
Nucleosomes 0.34 0.19 0.29 0.17 -0.14 0.04 
HMGB-1 0.19 0.18 0.09 0.16 -0.18 0.10 
Procalcitonin 0.47 0.29 0.18 0.24 -0.35 0.02 
IL-2 0.13 0.11 -0.14 -0.04 -0.03 0.01 
IL-4 -0.04 -0.02 -0.11 0.05 -0.07 0.01 
IL-6 0.34 0.12 0.28 0.33 -0.03 0.21 
IL-8 0.34 0.13 0.39 0.32 -0.16 0.06 
IL-10 0.36 0.32 0.31 0.17 -0.21 -0.09 
VEGF 0.12 0.17 0.14 -0.15 0.45 0.41 
IFNγ 0.05 0.21 0.10 0.01 -0.09 -0.06 
TNFα 0.31 0.33 0.12 0.16 -0.28 -0.02 
IL-1α 0.15 0.08 -0.23 -0.05 -0.15 0.01 
IL-1β 0.25 0.20 0.03 0.13 -0.05 0.11 
MCP-1 0.23 0.22 0.25 0.30 -0.14 0.09 
EGF -0.01 0.02 0.13 -0.22 0.58 0.25 
IL-6:IL-10 0.11 -0.12 0.05 0.20 0.12 0.36 
TFPI 0.21 0.15 0.26 0.06 -0.04 -0.11 
Protein C -0.22 -0.13 -0.11 -0.49 0.26 -0.10 
Endocan 0.16 -0.02 0.19 0.27 -0.22 -0.30 
Ang-2 0.32 0.01 0.16 0.38 -0.39 -0.01 
vWF 0.31 -0.01 -0.06 0.15 -0.22 0.18 
CD40L -0.05 -0.01 0.13 0.02 0.40 0.15 
MP -0.10 -0.06 0.26 0.01 0.58 0.10 
MP-TF 0.24 -0.04 0.11 0.19 -0.13 0.03 
PF4 -0.09 0.03 0.05 0.00 0.42 0.12 
Spearman correlations are shown. Significant correlations (p<0.05 are highlighted in 
blue). Light blue denotes a correlation coefficient of <0.4 while dark blue denotes a 
coefficient of ≥0.4  
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Table 25 Spearman Correlation Coefficients for Infection Markers 
 
  Nucleosomes HMGB-1 Procalcitonin 
D-Dimer 0.34 0.19 0.47 
F1.2 0.19 0.18 0.29 
PAI-1 0.29 0.09 0.18 
INR 0.17 0.16 0.24 
Platelets -0.14 -0.18 -0.35 
Fibrinogen 0.04 0.10 0.02 
Nucleosomes   0.25 0.31 
HMGB-1 0.25  0.28 
Procalcitonin 0.31 0.28   
IL-2 -0.07 -0.03 0.11 
IL-4 -0.19 -0.03 0.19 
IL-6 0.19 0.14 0.41 
IL-8 0.24 0.17 0.41 
IL-10 0.18 0.07 0.45 
VEGF -0.02 0.04 -0.11 
IFNγ -0.08 -0.12 0.16 
TNFα 0.03 0.14 0.52 
IL-1α 0.00 -0.01 0.12 
IL-1β 0.07 0.19 0.37 
MCP-1 0.16 0.14 0.46 
EGF -0.16 -0.09 -0.26 
IL-6:IL-10 
Ratio 
0.02 0.12 0.09 
TFPI 0.21 0.20 0.18 
Protein C -0.17 -0.17 -0.29 
Endocan 0.37 0.02 0.21 
Ang-2 0.17 0.43 0.62 
vWF 0.26 0.19 0.30 
CD40L 0.04 0.10 -0.08 
MP 0.05 0.12 -0.14 
MP-TF 0.25 0.03 0.17 
PF4 0.05 0.06 -0.16 
Spearman correlations are shown. Significant correlations (p<0.05 are highlighted in 
blue). Light blue denotes a correlation coefficient of <0.4 while dark blue denotes a 
coefficient of ≥0.4  
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Table 26. Spearman Correlation Coefficients for Inflammatory Markers 
 
  IL-2 IL-4 IL-6 IL-8 IL-10 VEGF IFNγ TNFα IL-1α IL-1β MCP-1 EGF IL-6:10 
D-Dimer 0.13 -0.04 0.34 0.34 0.36 0.12 0.05 0.31 0.15 0.25 0.23 -0.01 0.11 
F1.2 0.11 -0.02 0.12 0.13 0.32 0.17 0.21 0.33 0.08 0.20 0.22 0.02 -0.12 
PAI-1 -0.14 -0.11 0.28 0.39 0.31 0.14 0.10 0.12 -0.23 0.03 0.25 0.13 0.05 
INR -0.04 0.05 0.33 0.32 0.17 -0.15 0.01 0.16 -0.05 0.13 0.30 -0.22 0.20 
Platelets -0.03 -0.07 -0.03 -0.16 -0.21 0.45 -0.09 -0.28 -0.15 -0.05 -0.14 0.58 0.12 
Fibrinogen 0.01 0.01 0.21 0.06 -0.09 0.41 -0.06 -0.02 0.01 0.11 0.09 0.25 0.36 
Nucleosomes -0.07 -0.19 0.19 0.24 0.18 -0.02 -0.08 0.03 0.00 0.07 0.16 -0.16 0.02 
HMGB-1 -0.03 -0.03 0.14 0.17 0.07 0.04 -0.12 0.14 -0.01 0.19 0.14 -0.09 0.09 
PCT 0.11 0.19 0.41 0.41 0.45 -0.11 0.16 0.52 0.12 0.37 0.46 -0.26 0.12 
IL-2   0.28 -0.03 0.05 0.08 0.10 0.51 0.26 0.28 0.46 0.06 0.09 -0.04 
IL-4 0.28  0.22 0.20 0.13 0.02 0.23 0.33 0.29 0.47 0.27 0.04 0.15 
IL-6 -0.03 0.22  0.61 0.50 0.30 0.07 0.38 0.04 0.42 0.68 -0.06 0.77 
IL-8 0.05 0.20 0.61  0.57 0.19 0.09 0.49 0.06 0.31 0.66 -0.07 0.31 
IL-10 0.08 0.13 0.50 0.57  0.08 0.28 0.57 0.11 0.36 0.61 -0.16 -0.07 
VEGF 0.10 0.02 0.30 0.19 0.08  -0.01 0.04 0.14 0.09 0.14 0.55 0.36 
IFNγ 0.51 0.23 0.07 0.09 0.28 -0.01  0.46 0.12 0.41 0.30 0.06 -0.09 
TNFα 0.26 0.33 0.38 0.49 0.57 0.04 0.46  0.06 0.49 0.64 -0.09 0.08 
IL-1α 0.28 0.29 0.04 0.06 0.11 0.14 0.12 0.06  0.18 0.03 0.04 -0.01 
IL-1β 0.46 0.47 0.42 0.31 0.36 0.09 0.41 0.49 0.18  0.53 0.01 0.24 
MCP-1 0.06 0.27 0.68 0.66 0.61 0.14 0.30 0.64 0.03 0.53  -0.06 0.35 
EGF 0.09 0.04 -0.06 -0.07 -0.16 0.55 0.06 -0.09 0.04 0.01 -0.06   0.14 
IL-6:IL-10 -0.04 0.15 0.77 0.31 -0.07 0.36 -0.09 0.08 -0.01 0.24 0.35 0.14  
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  IL-2 IL-4 IL-6 IL-8 IL-10 VEGF IFNγ TNFα IL-1α IL-1β MCP-1 EGF IL-6:10 
TFPI -0.08 0.06 0.11 0.13 0.11 -0.18 -0.03 0.09 -0.12 0.13 0.18 -0.09 -0.06 
Protein C -0.06 0.05 -0.36 -0.30 -0.18 -0.07 -0.11 -0.18 0.02 -0.13 -0.36 0.23 -0.28 
Endocan -0.06 0.09 0.13 0.13 0.00 -0.44 -0.01 0.06 -0.15 0.18 0.15 -0.30 0.01 
Ang-2 -0.12 0.08 0.38 0.37 0.36 -0.18 -0.05 0.39 -0.05 0.19 0.37 -0.34 0.16 
vWF 0.01 0.09 0.19 0.26 0.12 0.07 -0.03 0.32 -0.15 0.12 0.20 -0.13 0.17 
CD40L -0.02 -0.14 0.14 0.17 -0.06 0.41 -0.12 -0.10 -0.17 -0.05 0.06 0.37 0.23 
MP -0.19 -0.05 0.03 -0.15 -0.21 0.28 -0.21 -0.27 -0.18 -0.08 -0.09 0.62 0.14 
MP-TF 0.02 -0.01 0.17 0.25 0.03 0.04 0.00 0.05 -0.17 0.00 0.08 -0.11 0.12 
PF4 -0.23 -0.02 -0.06 -0.09 -0.23 0.21 -0.10 -0.15 -0.24 -0.18 -0.11 0.30 0.04 
Spearman correlations are shown. Significant correlations (p<0.05 are highlighted in blue). Light blue denotes a correlation coefficient 
of <0.4 while dark blue denotes a coefficient of ≥0.4 
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Table 27. Spearman Correlation Coefficients for Endothelial Markers 
 
  TFPI Protein C Endocan Ang-2 vWF 
D-Dimer 0.21 -0.22 0.16 0.32 0.31 
F1.2 0.15 -0.13 -0.02 0.01 -0.01 
PAI-1 0.26 -0.11 0.19 0.16 -0.06 
INR 0.06 -0.49 0.27 0.38 0.15 
Platelets -0.04 0.26 -0.22 -0.39 -0.22 
Fibrinogen -0.11 -0.10 -0.30 -0.01 0.18 
Nucleosomes 0.21 -0.17 0.37 0.17 0.26 
HMGB-1 0.20 -0.17 0.02 0.43 0.19 
Procalcitonin 0.18 -0.29 0.21 0.62 0.30 
IL-2 -0.08 -0.06 -0.06 -0.12 0.01 
IL-4 0.06 0.05 0.09 0.08 0.09 
IL-6 0.11 -0.36 0.13 0.38 0.19 
IL-8 0.13 -0.30 0.13 0.37 0.26 
IL-10 0.11 -0.18 0.00 0.36 0.12 
VEGF -0.18 -0.07 -0.44 -0.18 0.07 
IFNγ -0.03 -0.11 -0.01 -0.05 -0.03 
TNFα 0.09 -0.18 0.06 0.39 0.32 
IL-1α -0.12 0.02 -0.15 -0.05 -0.15 
IL-1β 0.13 -0.13 0.18 0.19 0.12 
MCP-1 0.18 -0.36 0.15 0.37 0.20 
EGF -0.09 0.23 -0.30 -0.34 -0.13 
IL-6:IL-10 -0.06 -0.28 
28 
0.01 0.16 0.17 
TFPI   0.24 0.34 0.28 0.08 
Protein C 0.24  -0.18 -0.29 -0.26 
Endocan 0.34 -0.18  0.28 0.10 
Ang-2 0.28 -0.29 0.28  0.33 
vWF 0.08 -0.26 0.10 0.33   
CD40L -0.02 0.07 -0.19 -0.12 0.03 
MP 0.08 0.15 -0.01 -0.14 -0.16 
MP-TF 0.03 -0.14 0.21 0.11 0.32 
PF4 0.08 0.17 -0.08 -0.16 0.13 
Spearman correlations are shown. Significant correlations (p<0.05 are highlighted in 
blue). Light blue denotes a correlation coefficient of <0.4 while dark blue denotes a 
coefficient of ≥0.4 
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Table 28. Spearman Correlation Coefficients for Platelet Markers 
 
  CD40L MP MP-TF PF4 
D-Dimer -0.05 -0.10 0.24 -0.09 
F1.2 -0.01 -0.06 -0.04 0.03 
PAI-1 0.13 0.26 0.11 0.05 
INR 0.02 0.01 0.19 0.00 
Platelets 0.40 0.58 -0.13 0.42 
Fibrinogen 0.15 0.10 0.03 0.12 
Nucleosomes 0.04 0.05 0.25 0.05 
HMGB-1 0.10 0.12 0.03 0.06 
Procalcitonin -0.08 -0.14 0.17 -0.16 
IL-2 -0.02 -0.19 0.02 -0.23 
IL-4 -0.14 -0.05 -0.01 -0.02 
IL-6 0.14 0.03 0.17 -0.06 
IL-8 0.17 -0.15 0.25 -0.09 
IL-10 -0.06 -0.21 0.03 -0.23 
VEGF 0.41 0.28 0.04 0.21 
IFNγ -0.12 -0.21 0.00 -0.10 
TNFα -0.10 -0.27 0.05 -0.15 
IL-1α -0.17 -0.18 -0.17 -0.24 
IL-1β -0.05 -0.08 0.00 -0.18 
MCP-1 0.06 -0.09 0.08 -0.11 
EGF 0.37 0.62 -0.11 0.30 
IL-6:IL-10 0.23 0.14 0.12 0.04 
TFPI -0.02 0.08 0.03 0.08 
Protein C 0.07 0.15 -0.14 0.17 
Endocan -0.19 -0.01 0.21 -0.08 
Ang-2 -0.12 -0.14 0.11 -0.16 
vWF 0.03 -0.16 0.32 0.13 
CD40L   0.32 0.05 0.30 
MP 0.32  0.00 0.45 
MP-TF 0.05 0.00  0.13 
PF4 0.30 0.45 0.13   
Spearman correlations are shown. Significant correlations (p<0.05 are highlighted in 
blue). Light blue denotes a correlation coefficient of <0.4 while dark blue denotes a 
coefficient of ≥0.4 
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The most notable markers to emerge from this study are the biomarkers of 
infection. The relationship between these markers, particularly between nucleosomes and 
HMGB-1, is of interest as it may provide information regarding the source of these 
markers in the circulation. To assess this association, patients were divided into tertiles 
based on HMGB-1 levels. Data is shown in Figure 33. The highest tertile included 
patients with HMGB-1 in the range of 7.11-86.77 ng/ml. The middle tertile included 
patients in the range of 4.16-7.10 ng/ml. The lowest tertile included patients in the range 
of from 0.18-4.15 ng/ml. For each group, n=34. Differences in nucleosome levels based 
on HMGB-1 tertile were assessed using the Kruskal-Wallis test with Dunn’s multiple 
comparison test and p<0.05 as the cutoff for significance. Significant variance was seen 
in nucleosome levels based on HMGB-1 levels (p=0.019), with significance reached 
between the 1st and 2nd tertiles (p=0.020). The significant but relatively weak relationship 
between nucleosomes and HMGB-1 supports the related physiological role of these 
molecules; however, it also suggests that there is some independent regulation of these 
factors.  
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Figure 33. Relationship of Nucleosomes to HMGB-1. Patients were divided into 
tertiles based on HMGB-1 levels (n=34 per tertile). Differences in nucleosome levels 
by tertile were assessed using the Kruskal-Wallis One-Way ANOVA with Dunn’s 
multiple comparison test and p<0.05 as the cutoff for significance. Significant 
differences in nucleosome levels were seen between the highest tertile (HMGB-1 
between 7.11 and 86.88 ng/ml) and the middle tertile (HMGB-1 between 4.16-7.10 
ng/ml). 
 
Stepwise Linear Regression Modeling 
 Stepwise linear regression modeling using MATLAB software was performed in 
order to create an algorithm for the prediction of mortality in patients with sepsis and 
sepsis-associated DIC. Stepwise linear regression is a computational technique in which 
an iterative algorithm is employed to construct an equation to predict the value of a 
“response variable” based on a subset of “predictor variable” selected by the algorithm 
from among all input “predictor values”. Two starting assumptions are possible for this 
model; a “constant” starting assumption in which all predictor variables are assumed to 
be included in the model or a “linear” starting assumption in which no predictor variables 
are assumed to be included in the model. With a constant starting assumption, variables 
are added to the model if inclusion yields a statistically significant improvement to model 
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fit. This process continues until no variables remain which improve the fit of the model 
when added. Using a linear starting assumption, variables are removed from the model if 
elimination does not significantly change model fit, and this process is repeated until no 
variables remain that can be removed without altering model fit.  
 The output of this process is an equation composed of a constant term and 
coefficients for each included predictor variable. This equation is used to predict the 
value of the response variable for a given patient. Model performance was assessed using 
receiver operating curve (ROC) analysis.   
 MATLAB code is shown in Appendix D. Data tables defining mortality as the 
response variable and baseline biomarker levels as the predictor values were imported 
into MATLAB from Microsoft Excel. Models were developed using the “stepwiselm” 
function. Both linear and constant model starting assumptions were used as specified in 
the data analysis. Predictive equations generated using the linear starting assumption 
included more terms than those generated using the constant assumption. Model 
coefficients were recorded and model output value for each patient was calculated from 
the appropriate biomarker levels  
Two different approaches were used for the prediction of mortality in the Utah 
cohort. In the first approach, only measured biomarkers (levels of D-Dimer, F1.2, PAI-1, 
INR, platelets, fibrinogen, nucleosomes, HMGB-1, procalcitonin, IL-2, IL-4, IL-6, IL-8, 
IL-10, VEGF, IFNγ, TNFα, IL-1α, IL-1β, MCP-1, EGF, IL-6:IL-10 Ratio, TFPI, Protein 
C, endocan, Ang-2, vWF, CD40L, MP, MP-TF, and PF4) were included. In the second 
approach, the additional clinical parameters of DIC score, hemoglobin, white blood cell 
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count, BMI, age, MODS score, and SOFA score, and APACHE-II score were included in 
the analysis. Accordingly, four different models were generated: linear starting 
assumption and biomarkers alone, linear starting assumption and biomarkers plus clinical 
data, constant starting assumption and biomarkers alone, and constant starting assumption 
and biomarkers plus clinical data. 
As shown in Table 29, models were successfully generated for the prediction of 
mortality in Utah cohort patients using this approach. All four models generated using 
this approach had greater predictive value (AUC of 0.84-0.95) than any individual 
biomarker in this patient cohort (maximum individual AUC=0.77 for procalcitonin). 
Furthermore, the models generated using this approach incorporated biomarkers 
representative of multiple physiological systems and processes.  
The best model was generated using a constant starting assumption and 
biomarkers alone. This model included 5 variables: procalcitonin, representative of 
infection; VEGF and the IL-6:IL-10 ratio, representative of inflammation; endocan, 
representative of endothelial function; and PF4, representative of platelet activation. The 
overall AUC for prediction of mortality using this model was 0.87. The inclusion of 
clinical variables did not improve AUC; the model generated using the constant starting 
assumption and biomarkers plus clinical data had an AUC value of 0.84. This model 
supported previous results on the importance of infection response to the disease 
progression and outcome of sepsis and DIC; both procalcitonin and white blood cell 
count, markers of infection response, were included in this model. The models generated 
using the linear starting assumption showed some improvement in predictive value over 
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the constant starting assumption model, with the biomarker alone model producing an 
AUC of 0.95 and the biomarker plus clinical model producing an AUC of 0.89. Despite 
the high predictive value of these model, the practical utility of these models is limited by 
the inclusion of in excess of 10 biomarkers.  
The results of this modeling analysis support the hypothesis that while a single 
biomarker cannot accurately predict outcome in this complex patient population, a 
combination of biomarkers representative of multiple physiological systems will have 
improved predictive value. The model generated using the constant starting assumption 
and biomarker data alone provides a superior predictive value for outcome than any 
single measured biomarker and accounts for the activity of multiple physiological 
systems. This model should be further validated in additional patient cohorts. 
204 
 
 
Table 29. Stepwise Linear Regression Modeling for Prediction of Mortality in All 
Utah Sepsis Cohort Patients 
 
Components Assumption Components Coefficient AUC 
Biomarkers Constant 
Intercept -1.9E-3 
0.87 
Procalcitonin 4.1E-5 
VEGF 2.6E-3 
IL-6:IL-10 Ratio 8.5E-4 
Endocan 0.010 
PF4 -1.6E-3 
Biomarkers 
+ Clinical 
Constant 
Intercept -0.27 
0.84 
APACHE II 9.8E-3 
WBC 0.013 
Procalcitonin 4.47E-5 
Biomarkers Linear 
Intercept 0.13 
0.95 
D-Dimer -8.6E-6 
PCT 4.3E-5 
MCP1 -2.5E-4 
EGF 0.016 
IL-6:IL-10 Ratio 1.2E-3 
PAI-1 1.3E-3 
CD40L 1.2E-4 
Protein C -1.5E-3 
Endocan 9.7E-3 
PF4 -9.8E-4 
HMGB-1 3.8E-3 
MP -4.6E-3 
Biomarkers 
+ Clinical 
Linear 
Intercept -0.11 
0.89 
WBC 0.015 
D-Dimer -1.0E-5 
PCT 4.3E-5 
EGF 0.011 
IL-6:IL-10 Ratio 8.8E-4 
PAI-1 1.1E-3 
CD40L 1.2E-4 
Endocan 9.5E-3 
PF4 -1.1E-3 
MP -4.6E-3 
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A difficulty in designing tools to predict outcome in patients with sepsis is the 
heterogeneity of the patient population. For example, different factors may contribute to 
mortality in patients with sepsis who develop coagulopathy compared to patients who do 
not. Accordingly, patients were subdivided based on DIC score and separate models for 
the prediction of mortality were generated for patients with sepsis + no DIC, sepsis + 
non-overt DIC, and sepsis + overt DIC. These models are described in Table 30, Table 
31, and Table 32. 
This approach is limited by the low number of patients in each category, 
particularly the low number of non-survivors. The models generated using this approach 
have extraordinarily high predictive value for this patient cohort, but would not be 
expected to be generalizable to a larger population. However, this analysis does serve as 
proof of concept of the potential utility of developing different predictive models for 
sepsis patients on the basis of coagulation status.  
The largest group of patients when subdivided on the basis of coagulopathy is 
sepsis + non-overt DIC, encompassing a total of 59 patients including 7 non-survivors 
and 52 survivors. The model generated for this patient group using biomarkers only and a 
constant starting assumption, shown in Table 31, is very similar to that generated using 
the total patient population, also including procalcitonin, VEGF, IL-6:IL-10 ratio, and 
PF4 but excluding endocan.  
The groups of patients with no DIC and with overt DIC were significantly smaller 
than the non-overt DIC group. 20 patients had no DIC, including 18 survivors and 2 non-
survivors. 24 patients had overt DIC, including 6 non-survivors and 18 survivors. Models 
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generated on the basis of these patients’ data incorporated different markers than those 
generated from the total cohort or non-overt DIC patients.  
 
Table 30. Stepwise Linear Regression Modeling for Prediction of Mortality in 
Patients with Sepsis Alone 
 
Components Assumption Components Coefficient AUC 
Biomarkers 
 
Biomarkers 
+ Clinical 
Constant 
Intercept 0.19 
1 
INR -0.14 
IL-8 0.013 
VEGF -2.4E-3 
TNFα -2.4E-3 
Protein C -1.9E-3 
HMGB-1 0.035 
Biomarkers 
 
Biomarkers 
+ Clinical  
Linear 
Intercept -0.40 
1 
F1.2 5.8E-5 
IL-10 0.026 
VEGF -5.0E-3 
IFNγ -0.21 
IL-1α -0.82 
IL-1β 0.30 
MCP-1 -4.8E-4 
EGF 0.036 
MP-TF -0.37 
IL-6:IL-10 
Ratio 
-3.5E-3 
PAI-1 -1.8E-3 
CD40L 3.2E-4 
Endocan 0.033 
Ang2 7.8E-6 
PF4 4.2E-4 
HMGB-1 0.047 
vWF 1.5E-3 
MP -5.7E-3 
Incorporation of clinical data in addition to biomarkers did not result in the generation of 
a distinct model for patients with sepsis alone using either the linear or constant starting 
assumption. 
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Table 31. Stepwise Linear Regression Modeling for Prediction of Mortality in 
Patients with Non-Overt DIC 
 
Components Assumption  Components Coefficient AUC 
Biomarkers Constant 
Intercept -0.010 
0.94 
Procalcitonin 8.5E-5 
VEGF 3.8E-3 
IL-6:IL-10 Ratio 1.4E-3 
PF4 -1.9E-3 
Biomarkers Linear 
Intercept -1.7 
1 
INR 0.95 
F1.2 -3.9E-4 
Procalcitonin 1.3E-4 
IL-2 -0.037 
IL-10 -6.5E-3 
IL-1α -0.015 
IL-1β 0.034 
EGF 0.023 
MP-TF 0.34 
CD40L 2.1E-4 
Endocan 0.012 
PF4 1.5E-3 
MP -8.7E-3 
Clinical Constant 
Intercept -0.87 
0.99 
SOFA 0.043 
WBC 0.019 
Nucleosomes 0.01 
PCT 6.2E-5 
IL-6:IL-10 Ratio 1.7E-3 
Protein C 3.2E-3 
Clinical Linear 
Intercept -1.6 
1 
WBC 0.020 
Platelets 1.5E-3 
INR 0.81 
Procalcitonin 1.2E-4 
IL-2 -0.045 
IL-10 -0.011 
IL-1β 0.045 
EGF 0.027 
Endocan 0.016 
PF4 -3.6E-4 
MP -0.012 
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Table 32. Stepwise Linear Regression Modeling for Prediction of Mortality in 
Patients with Overt DIC  
Components Assumption  Components Coefficient AUC 
Biomarkers Constant 
Intercept 0.20 
1 
TFPI -5.8E-3 
Procalcitonin 3.4E-5 
IL-4 0.17 
TNFα -0.051 
MCP1 -7.2E-4 
PAI-1 4.6E-3 
HMGB-1 0.017 
MP 2.9E-3 
Clinical Constant 
Intercept -0.68 
1 
Age 7.7E-3 
Nucleosomes -3.9E-3 
IL-6:IL-10 Ratio 2.0E-3 
PAI-1 2.6E-3 
Protein C -2.6E-3 
Endocan 8.4E-3 
HMGB-1 0.025 
Biomarkers 
 
Biomarkers + 
Clinical Data 
Linear 
Intercept 0.94 
1 
PCT -5.9E-5 
IL-8 2.1E-3 
IL-10 4.0E-3 
VEGF -0.026 
IFNγ -8.1E-3 
TNFα 0.22 
IL-1α 1.6 
IL-1β -0.26 
MCP1 -5.2E-4 
EGF -0.14 
MP-TF 0.45 
PAI-1 -5.4E-3 
CD40L 1.1E-3 
Protein C -0.027 
Endocan 6.1E-3 
Ang2 -9.96E-6 
PF4 7.0E-3 
HMGB-1 0.034 
vWF -6.9E-3 
MP 0.028 
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In vitro Coagulation Profiles of rTM, AT, and UFH 
 Endogenous anticoagulants including AT and rTM have been pursued as 
treatments for DIC in part due to the reduced potential for bleeding with these drugs 
when compared to traditional anticoagulants, such as heparin. These drugs may only 
prevent pathological coagulation without interfering with the normal hemostatic process 
to the same degree as heparin.  
Prior to testing the effects of rTM, AT, and heparin in an animal model of sepsis, 
the relative anticoagulant effects of rTM, AT, and heparin were compared in vitro in 
human whole blood and plasma and in rat plasma. rTM was supplemented into plasma at 
concentrations from 0.625-10 μg/ml and in whole blood at concentrations from 1.25-5 
μg/ml. This is representative of the circulating level of rTM in the management of 
patients with sepsis-associated DIC, which is typically within the range of 0.5-1.5 μg/ml 
(Moll 2004; Vincent 2013). Heparin was used at concentrations of 0.0625-1 U/ml in 
plasma and 0.125-0.5 U/ml in whole blood. For similar indications, therapeutic levels of 
heparin range from 1.5-5.0 μg/ml (0.15-0.5 U/ml) in blood. Antithrombin was used at 
concentrations of 0.0625-1 U/ml in plasma and 1.25-5 U/ml in whole blood. In DIC, 
therapeutic blood levels of AT range from 1-2.5 U/ml (Choi 2014; Kienast 2006).  
Clotting 
 The anticoagulant effects of rTM, AT, and heparin on plasma based coagulation 
tests were assessed in vitro in both human and rat plasma using physiologically relevant 
drug concentrations. Endogenous anticoagulants such as AT and rTM have been pursued 
as treatments for DIC in part due to the reduced potential for bleeding with these drugs 
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when compared to traditional anticoagulants, such as heparin. PT was used to assess the 
effect of the drugs on the extrinsic pathway and aPTT was used to assess the effect of the 
drugs on the intrinsic pathway.  
The results of in vitro clotting tests in human samples are shown in Table 33. All 
tests were performed in citrated plasma from healthy normal volunteers. Drugs were 
supplemented into blood at the specified concentrations. Data is shown as the mean of 
two independent experiments. Both rTM and AT had minimal anticoagulant activity in in 
vitro clot formation as measured by PT and aPTT at physiologically relevant blood 
concentrations. At supertherapeutic concentrations, prolongation of clotting times was 
minimal. Heparin showed strong anticoagulant activity, producing maximum results in 
the aPTT and lesser prolongations in PT. This was expected, as aPTT is used clinically to 
monitor heparin therapy and PT is not sensitive to heparin treatment.  
As shown in Table 34, the modulation of coagulation by rTM, AT, and UFH in rat 
plasma is comparable to that in human plasma. Drugs were supplemented in pooled 
plasma from healthy rats at the specified concentrations. No elevation in PT was present 
as a result of supplementation with rTM, AT, or UFH. UFH supplementation caused a 
dose-dependent increase in aPTT, while neither rTM nor AT supplementation increased 
aPTT. 
 
  
 
 
 
2
1
1
 
Table 33. Comparison of rTM, AT, and UFH in Clotting Tests in Human Whole Blood 
Recombinant Thrombomodulin Antithrombin Heparin 
Concentration PT (s) aPTT (s) Concentration PT (s) aPTT (s) Concentration PT (s) aPTT (s) 
10 μg/ml   1 U/ml 18.6 49.3 1 U/ml 25.1 300 
5 μg/ml 16.5 80.4 0.5 U/ml 16.4 42.8 0.5 U/ml 20.8 270.9 
2.5 μg/ml 15.9 61.4 0.25 U/ml 16.2 42.6 0.25 U/ml 16.6 120.8 
1.25 μglml 15.9 53 0.125 U/ml 15.9 42.3 0.125 U/ml 16.4 73.3 
0.625 μg/ml 15.8 47 0.0625 U/ml 15.0 41.3 0.0625 U/ml 15.9 49.1 
0 μg/ml 15.6 37.3 0 U/ml 15.9 37.3 0 U/ml 15.6 37.3 
Drugs were supplemented into whole blood acquired from healthy volunteers at the specified concentrations. Data is shown as the 
mean of two independent experiments. The maximum reported time for aPTT is 300 seconds. 
 
Table 34. Comparison of rTM, AT, and UFH in Clotting Tests in Rat Plasma 
Recombinant Thrombomodulin Antithrombin Heparin 
Concentration PT (s) aPTT (s) Concentration PT (s) aPTT (s) Concentration PT (s) aPTT (s) 
10 μg/ml 9.7 27.8 1 U/ml 9.4 20.0 1 U/ml 9.6 91.4 
5 μg/ml 10.0 23.9 0.5 U/ml 9.3 21.3 0.5 U/ml 9.5 35.2 
2.5 μg/ml 9.4 21.7 0.25 U/ml 9.4 20.9 0.25 U/ml 9.7 24.0 
1.25 μglml 9.5 21.1 0.125 U/ml 9.2 20.5 0.125 U/ml 9.2 21.2 
0.625 μg/ml 8.9 21.2 0.0625 U/ml 9.0 20.5 0.0625 U/ml 9.5 20.2 
0 μg/ml 9.5 20.2 0 U/ml 9.5 20.2 0 U/ml 9.5 20.2 
Drugs were supplemented into pooled plasma from healthy rats at the specified concentrations. 
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Thromboelastography 
Thromboelastography (TEG) was used to assess the anticoagulant activity of 
rTM, AT, and UFH in human whole blood. R time, K time, angle, and maximum 
amplitude were recorded as methods to describe clot formation. R is reflective of the time 
required for clot formation to start; a longer R time indicates greater anticoagulant 
activity. K time is the interval between clot initiation and the time that amplitude reaches 
20 mm in size and is a descriptor of the speed of clot formation. The angle provides 
similar information to the K time and is the angle of the tangent to the 
thromboelastograph curve at the K time; a wider angle describes faster clot formation. 
Maximum amplitude (MA) is the maximum size reached by the clot and describes clot 
strength.  
Thromboelastography was used to compare the anticoagulant properties of rTM, 
AT, and UFH at concentrations ranging from 0-5μg/ml for rTM, 0-5 μg/ml for UFH, and 
0-5 U/ml for AT. Four concentrations of each drug were run simultaneously in the blood 
of a single donor. The same donor was used for all three drugs. Thromboelastography 
plots and tabulated data is shown in Figure 34. 
Heparin demonstrated strong anticoagulant properties at all doses, with an R time 
greater than 60 minutes and no K time, angle, or maximum amplitude computed within 
the time limit. AT also demonstrated anticoagulant properties at higher drug 
concentrations. In contrast, the anticoagulant effects of rTM were minimal, even at the 
highest utilized concentration of 5 μg/ml. This suggests that rTM may have an improved 
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safety profile in the treatment of sepsis-associated DIC due to a reduced risk of bleeding 
compared to AT and heparin.   
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Figure 34. Comparison of Anticoagulant Properties of rTM, AT, and UFH via 
Thromboelastography. (A-C) Plots showing the anticoagulant properties of AT, 
UFH, and rTM in whole blood as measured via thromboelastography in the blood of a 
single donor. (D-G) Graphs of thromboelastograph parameters of UFH, AT, and rTM. 
# indicates that parameter could not be measured at a given concentration as clot 
formation within the allocated time frame was insufficient.  
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In order to compare the anticoagulant effects of rTM, AT, and heparin in a single 
donor, one concentration of each drug and a saline control was run simultaneously in a 
single donor. Three combinations of drug doses were used, and each set of dosages was 
repeated with three individual donors. The time allotted for clot formation in each test 
was limited to one hour. Data is show in Figures 35-38  
Direct comparisons were performed between AT at 5 U/ml, rTM at 2.5μg/ml, 
heparin at 2.5μg/ml, and saline control in 3 donors. Direct comparisons were also 
performed in 3 donors between AT at 2.5 U/ml, rTM at 2.5 μg/ml, and heparin at 1.25 
μg/ml saline. A third set of comparisons was performed in 3 donors between AT at 1.25 
μ/ml, rTM at 1.25 μg/ml, heparin at 1.25 μg/ml, and saline.  
As shown in Figure 35, heparin demonstrated the greatest prolongation in R time, 
with clot formation only occurring in under one hour with a heparin concentration of 1.25 
μg/ml. AT treatment led to R time prolongation, with no clot formation detected within 
the time limit at an AT concentration of 5 U/ml. The R time prolongation observed with 
rTM was minimal.  
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Figure 35. R Times of rTM, AT, and UFH Treated Whole Blood. Data is shown as 
mean ± SD of three independent experiments with blood collected from individual 
donors. For conditions in which no clot formed within the time limit, R time is shown 
as 60 minutes. 
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As shown in Figures 36-38, clot formation was slow in all heparin treated 
samples, resulting in no measureable K times, angles, or maximum amplitudes. Clot 
formation in AT treated samples was also accelerated, with no measurable K time, angle, 
or maximum amplitude at the highest dose of 5 U/ml. rTM showed minimal, if any, 
slowing of clot formation at all evaluated doses.  
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Figure 36. K times of rTM, AT, and UFH Treated Whole Blood. Data is shown as 
mean ± SD of three independent experiments with blood collected from individual 
donors. # indicates that no clot was formed within the time limit of one hour for a 
given condition. 
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Figure 37. Angles of rTM, AT, and UFH Treated Whole Blood. Data is shown as 
mean ± SD of three independent experiments with blood collected from individual 
donors. # indicates that no clot was formed within the time limit of one hour for a 
given condition.  
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Figure 38. Maximum Amplitudes of rTM, AT, and UFH Treated Whole Blood. 
Data is shown as mean ± SD of three independent experiments with blood collected 
from individual donors. # indicates that no clot was formed within the time limit of one 
hour for a given condition.  
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Animal Models 
 The cecal ligation and puncture (CLP) model, described previously, was 
performed in rats to induce sepsis and concomitant coagulopathy. The purpose of this 
study was to evaluate the effects of treatment with rTM, AT, and UFH on the molecular 
pathophysiology of DIC. Accordingly, it was important to develop a model system in 
which rats developed sepsis and coagulopathy but survived for at least 72 hours to allow 
for drug administration and blood collection.  
Biomarkers were selected for analysis in rat plasma on the basis of findings in 
human plasma. Platelet count was selected as the primary marker of hemostatic status in 
the rats, with a reduction in platelet count indicative of consumptive coagulopathy. PT 
was tested in all samples in order to ensure that samples collected were plasma rather 
than serum. PAI-1 was also measured. Due to the traumatic nature of the cardiac puncture 
blood draw and the associated activation of coagulation, other coagulation parameters 
could not be reliably measured. Procalcitonin was the strongest individual predictor of 
outcome in the Utah patients, demonstrated a significant association with severity of 
coagulopathy, and is an established biomarker of infection; accordingly, procalcitonin 
was measured in rats to confirm and monitor infection. IL-10 was included as a measure 
of the anti-inflammatory processes ongoing to oppose pro-inflammatory activation. The 
drugs studied are hypothesized to have non-anticoagulant activity mediated partly 
through interaction with nuclear material. Nucleosomes were measured as a tool to 
analyze these properties. Weight loss was also monitored as an indicator of general health 
status.  
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Validation of the CLP Model for Sepsis and DIC 
In order to validate this model system, CLP was performed in 22 rats according to 
the protocol described previously. Of these rats, 2 (9.1%) died within 72 hours. All rats 
showed signs of illness including subdued behavior 24 hours following surgery. All rats 
received appropriate analgesia throughout the experimental procedure. Sham surgery, in 
which an incision was made through the skin and muscle layers but no ligation or 
puncture of the cecum occurred, was performed in 6 rats, all of which survived.  
Blood was collected via cardiac puncture 72 hours following surgery from CLP 
and sham rats. As shown in Figure 39, changes in biomarker levels consistent with 
sepsis-associated coagulopathy occurred. The significant elevation in procalcitonin in the 
CLP group compared to the sham group (p=0.038) is indicative of infection in CLP rats. 
The reduction in platelets in the CLP group (p=0.013) is indicative of the development of 
consumptive coagulopathy in addition to infection in these rats. CLP rats also 
demonstrated significant elevation in IL-10 (p=0.002) and nucleosomes (p=0.011) 
compared to sham rats, consistent with results seen in human sepsis and DIC patients. No 
significant differences in PAI-1 were noted between sham and CLP rats (p=0.74). CLP 
rats also exhibited significant weight loss over the 72 hour period, with a higher percent 
loss of body weight than sham operated animals (p=0.012). No rats lost more than 12% 
of pre-surgical body weight through the course of this study. 
These results validate this model in terms of the development of sepsis and DIC 
with characteristics similar to those observed in human patients. Furthermore, the 
mortality in this model was sufficiently low to facilitate study of drug mechanisms.  
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Figure 39. Validation of rat CLP Model of Sepsis and DIC. CLP was performed in 
22 rats and sham surgery in 6 rats. Biomarker analysis was performed in 16 CLP rats 
and 5 sham rats for which significant activation of coagulation did not occur during 
blood draw. Groups were compared using the Mann-Whitney t test with p<0.05 as the 
cutoff for significance (indicated by *). Data is shown as mean ± SEM. 
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Comparison of rTM, AT, and UFH in Rats with CLP-Induced Sepsis and DIC 
The mechanisms of action of rTM, AT, and UFH were studied in rats with CLP-
induced sepsis and DIC. All drugs were administered intravenously via bolus injection 
into the tail vein at 24 and 48 hours following surgery. This replicated a realistic clinical 
scenario in which drugs are not administered until after a patient presents with sepsis and 
coagulopathy. Blood was collected for analysis 72 hours following surgery (24 hours 
after the second drug dose).  
Two doses of UFH were originally selected for analysis. Heparin is administered 
in studies of sepsis and DIC at an extremely wide range of doses (Li 2011). The goal in 
selecting a dose of UFH for use in this study was to maximize the potential non-
anticoagulant effect while minimizing bleeding risk. UFH was administered to 5 rats at a 
high dose of 70 IU/kg. One rat died between 30 and 48 hours following surgery (6 to 24 
hours following the administration of the first dose of heparin). Blood was visible in the 
nares, and necropsy revealed significant bleeding into the gastrointestinal tract. Heparin 
dose was reduced to 25 IU/kg for the subsequent 10 rats, all of which survived for 72 
hours. As shown in Figure 40, no significant differences in biomarker levels were 
detected between rats treated with 70 or 25 IU/kg UFH. Due to the minimized risk of 
bleeding complications, 25 IU/kg UFH was selected as the dose for further analysis. 
Heparin treatment resulted in significant reduction in nucleosomes in rats treated with 25 
IU/kg UFH compared to CLP alone (p=0.004) and in IL-10 in rats treated with either 25 
IU/kg (p=0.0098) or 70 IU/kg (p=0.028) compared to CLP alone. The reduction in PCT 
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in heparin treated rats was not statistically significant (Kruskal-Wallis ANOVA p=0.060). 
No changes in platelet count, weight loss, or PAI-1 were observed in heparin treated rats.  
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Figure 40. Comparison of High and Low Dose UFH in the Treatment of Sepsis 
and DIC. Data represents rats from which plasma was successfully collected treated 
with CLP (n=16), CLP + 25 IU/kg UFH (n=9), and CLP + 70 IU/kg UFH (n=4) 
Groups were compared using the Kruskal-Wallis One-Way ANOVA with Dunn’s 
Multiple Comparison Test and p<0.05 as the cutoff for significance (indicated by *). 
Data is shown as mean ± SEM. 
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Two doses of AT were also tested in the treatment of rats with sepsis-associated 
DIC. A low dose of 50 IU/kg was used to achieve clinically relevant blood 
concentrations. A clinically validated dose of 3000 IU/day (Allingstrup 2016; Iba 2016; 
Iba 2012) in a 70kg “standard man” corresponds to a dose of 43 IU/kg. However, it is 
hypothesized that higher doses of AT may be necessary to achieve anti-inflammatory 
effects (Uchiba 1998); AT is commonly administered to rats at doses of 125 IU/kg or 
higher (Uchiba 1998; Yamashiro 2001; Yang 1994). 5 rats were treated with 50 IU/kg 
AT and 9 with 125 IU/kg; all survived for 72 hours. 
As shown in Figure 41, no significant differences were noted between rats treated 
with 50 IU/kg or 125 IU/kg AT. Although bleeding complications with AT have been 
reported, none were observed. 125 IU/kg was used in further analysis in order to 
maximize the ability to detect non-anticoagulant effects. Treatment with both high and 
low dose AT resulted in a reduction in nucleosomes and reduced weight loss.  
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Figure 41. Comparison of High and Low Dose AT in the Treatment of Sepsis and 
DIC. Data represents rats from with plasma was successfully collected treated with 
CLP (n=16), CLP + 50 IU/kg AT (n=5), and CLP + 125 IU/kg AT (n=8) Groups were 
compared using the Kruskal-Wallis One-Way ANOVA with Dunn’s Multiple 
Comparison Test and p<0.05 as the cutoff for significance (indicated by *). Data is 
shown as mean ± SEM. 
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 rTM was used at the single dose of 1 mg/kg throughout this study. This is higher 
than the 60 μg/kg dose at which rTM is typically administered in clinical trials in 
humans. However, previous studies have demonstrated that higher doses of rTM are 
required to achieve comparable effects in rats, and 1 mg/kg is a commonly accepted dose 
in both the original pre-clinical development of rTM and in more recent work (Gonda 
1993; Hagiwara 2010; Iba 2013; Mohri 1994; Nagato 2009). rTM was administered to 11 
rats at a dose of 1 mg/kg; 3 rats (27%) died within 72 hours. 
 In order to compare the mechanisms of rTM, AT, and UFH, the levels of the 
selected biomarkers were compared between rats treated with one concentration of each 
drug as well as CLP rats without drug and sham operated rats. As shown in Figure 42, no 
drugs led to a significant change in platelet count (Kruskal-Wallis ANOVA p=0.090), 
suggesting that drug treatment led to at best incomplete resolution of coagulopathy. 
Significant variation in procalcitonin based on treatment condition was observed 
(Kruskal-Wallis ANOVA p=0.040); however, significance was not reached between any 
individual treatment groups. All drugs showed drastic reductions in nucleosomes (rTM, 
p=0.031; AT, p=0.016, UFH, p=0.028) compared to untreated rats. UFH exhibited the 
greatest effects, also leading to significant reduction in both IL-10 (p=0.046) and PAI-1 
(p=0.035). In contrast, AT treatment led to a reduction in weight loss (p=0.034). No 
changes in PT or aPTT were present  between any groups. 
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Figure 42. Comparison of rTM, AT, and UFH in the Treatment of CLP-Induced 
Sepsis and DIC. Data represents rats from which plasma was successfully collected 
from sham (n=5), CLP (n=16), 1 mg/kg rTM (n=7), 125 IU/kg AT (n=8), and 25 IU/kg 
UFH (n=9) groups. Groups were compared using the Kruskal-Wallis One-Way 
ANOVA with Dunn’s Multiple Comparison Test and p<0.05 as the cutoff for 
significance (indicated by *). Data is shown as mean ± SEM.  
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CHAPTER FIVE 
DISCUSSION 
Sepsis is a severe systemic response to infection, defined by a pathological and 
overwhelming immune and inflammatory response. Although a robust immune response 
is necessary to overcome infection, the response seen in sepsis can have detrimental 
effects on the host. The inappropriate immune response in sepsis has both quantitative 
aspects, typically characterized by elevated plasma cytokine levels, and qualitative 
aspects, such as changes in the function of neutrophils and other immune cells. Sepsis 
may progress to septic shock, in which hypotension and hypoperfusion contribute to the 
failure of multiple organ systems. Furthermore, sepsis can lead to coagulation 
dysfunction, which contributes significantly to morbidity and mortality. 
Sepsis-associated disseminated intravascular coagulation (DIC) is a serious and 
often fatal medical condition occurring as a complication of sepsis which causes 
significant morbidity and mortality worldwide. DIC is the severe manifestation of a 
spectrum of coagulation disorders which occur secondary to sepsis. This disorder is 
characterized by both thrombotic and hemorrhagic complications. At present, DIC is 
identified in sepsis patients on the basis of the consumptive coagulopathy characteristic 
of this disease. Inappropriate and widespread coagulation consumes platelets and 
coagulation factors, resulting in measurable decreases in platelet count and fibrinogen 
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levels and elevation of the INR due to the consumption of coagulation proteins. Fibrin 
split products or D-Dimer are also measured and reflect the presence and ongoing 
breakdown of thrombi in the circulation. Given the current lack of specific therapeutic 
agents for DIC, this diagnostic scheme may be sufficient. However, it does not account 
for the underlying pathophysiology of DIC or the ways in which this may influence 
standard laboratory test results. When drugs for the treatment of DIC do become 
available, an improved diagnostic approach will be necessary to identify patients most 
likely to benefit from therapies and to monitor the effectiveness of treatment. An 
improved understanding of the underlying molecular pathophysiology of DIC may 
contribute to both the development of drugs for this disease and the identification of 
patients who will benefit from treatment.  
In order to better understand the pathophysiology of sepsis-associated 
coagulopathy, a systematic approach taking into account all of the processes contributing 
to the development of this disease—not only the resulting coagulation dysfunction—is 
required. Both sepsis and DIC are complex clinical scenarios with pathophysiology 
encompassing all aspects of the blood and vasculature. This includes not only coagulation 
and inflammatory processes but also the response to infection as well as endothelial and 
platelet activation. While this complicates the modeling of this disease process, it also 
means that the blood and the factors it contains provide a window through which to 
understand this disease. Many biomarkers have been evaluated for their utility in 
understanding and diagnosing sepsis, and numerous reviews have been written on this 
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topic (Biron, Ayala, & Lomas-Neira, 2015; Paulus, Jennewein, & Zacharowski, 2011; 
Pierrakos & Vincent, 2010; Sims, Nguyen, & Mayeux, 2016). However, analysis of the 
association of these factors with well-defined coagulopathy is often lacking. Furthermore, 
these biomarkers may also be useful in the validation of the physiological relevance of 
animal models for sepsis-associated DIC.  
An improved understanding of the molecular pathophysiology of sepsis-
associated DIC will also provide information for the development and implementation of 
therapeutics for this disease. One of the guiding principles of medicine is “first, do no 
harm”. The opposing risks for thrombosis and bleeding in this patient population make 
the development of a drug to treat coagulopathy without causing harm difficult. Any 
anticoagulant drug may carry significant bleeding risk in this already vulnerable patient 
population, while any treatment designed to promote coagulation and prevent bleeding 
may fuel ongoing coagulation.  
In addition to exogenous anticoagulants such as heparin, potential treatments for 
DIC include the replacement of endogenous anticoagulants such as thrombomodulin, 
antithrombin, and protein C. Under normal physiological circumstances, these proteins 
serve to prevent excessive or inappropriate coagulation. However, these factors become 
depleted or dysregulated in DIC. These factors are also pleiotropic, with cytoprotective 
and anti-inflammatory effects in addition to their major hemostatic functions. Two 
endogenous anticoagulants, antithrombin (AT) and recombinant thrombomodulin (rTM) 
are currently approved for use in the treatment of DIC in Japan, where post-approval 
studies have demonstrated efficacy in sepsis-associated DIC, particularly in more severe 
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cases (Kienast 2006; Umemura 2016; Yamakawa 2015). However, AT in particular may 
be associated with an elevated risk of bleeding. A previously investigated endogenous 
anticoagulant, activated protein C (APC) was approved for use in patients with sepsis-
associated coagulopathy and subsequently withdrawn from the market due to serious 
bleeding events. Post hoc analyses of the clinical trials for APC have demonstrated that 
patients with the most severe disease may have benefitted while patients with less severe 
disease may have experienced adverse events (Dhainaut 2004; Kienast 2006). 
Accordingly, an understanding of the additional mechanisms of action of these drugs in 
conjunction with an improved understanding of the pathophysiology of DIC may 
contribute to optimal targeting of treatments to patients who will benefit the most from 
intervention.  
Thus, the purpose of this dissertation was twofold. First, a wide array of 
biomarkers were assessed in the plasma of a cohort of patients with sepsis and strictly 
defined coagulopathy. This allowed for the evaluation of the association of these markers 
with both mortality and the degree of coagulopathy and the identification of markers 
representative of multiple aspects of disease that were relevant to outcome. Secondly, 
three potential therapeutics for DIC, recombinant thrombomodulin, antithrombin, and 
heparin, were compared in vitro for their anticoagulant effects and in vivo in a rat model 
of sepsis-associated DIC in order to provide insight into the actions of these agents in the 
setting of this disease.  
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Coagulation Profiling in DIC vs. Warfarin Treated Patients 
The initial identification of patients with sepsis-associated DIC is commonly 
based on the presence of an elevated INR. As a component of the DIC scoring algorithm, 
INR is by definition associated with the severity of DIC, as was observed in the Utah 
patient cohort. Elevated INR is often associated with poor outcome or increased mortality 
in sepsis patients (Dhainaut 2005; Kinasewitz 2004) as well as in other critically ill 
patient populations (MacLeod 2003; Walsh 2010), although no association between INR 
and mortality was seen in the Utah patient cohort. As INR is one of the key parameters 
used clinically to identify patients with sepsis-associated DIC, it is important to 
understand the appropriate interpretation of this measure in this patient population. 
Prolonged PT or elevated INR is generally indicative of a hypocoagulable state. In 
patients receiving warfarin anticoagulant therapy, the degree of INR elevation is 
indicative of the degree of anticoagulation resulting from treatment and is used to guide 
therapy and maintain an appropriate balance between thrombotic and bleeding risks. 
However, DIC patients with an elevated INR are at risk of complications due to both 
thrombosis and bleeding. This leads to the hypothesis that the same INR result does not 
indicate the same status of the coagulation cascade in DIC patients compared to warfarin-
treated patients. In order to better understand the appropriate interpretation of INR in DIC 
patients, the relationship between INR, other global coagulation tests, and coagulation 
factor levels was compared in patients with sepsis-associated DIC to patients receiving 
warfarin anticoagulation. In addition to PT, aPTT, and fibrinogen, functional and protein 
levels of Factors VII, IX, and X were measured. Although warfarin also effects Factor II, 
234 
 
 
it is the slowest of the coagulation factors to respond to warfarin therapy. Therefore, 
Factor II would be expected to remain unaltered in patients with warfarin levels within 
the therapeutic range and was not included in this study.  
Markedly different relationships between INR and other laboratory coagulation 
tests and coagulation factor levels were observed in DIC patients compared to patients 
receiving warfarin anticoagulation. In DIC patients, increased INR was associated with 
increased aPTT. This supports the hypothesis that the coagulation dysfunction indicated 
by a given INR level is different in warfarin treated patients, where changes in INR are 
the result of a targeted disruption to the coagulation cascade, than in DIC patients, where 
an elevated INR is indicative of a more diffuse insult to the coagulation system.  
Functional and antigenic levels of coagulation factors VII, IX, X were decreased 
in both warfarin treated and DIC patients compared to healthy controls. However, the 
pattern of decrease in factor levels was markedly different between the two patient 
groups. In warfarin treated patients, the decrease in factor levels corresponded strongly 
with an increase in INR. In contrast, the factor levels in DIC patients were uniformly low 
across all INR levels; additional increases in INR did not correspond with an additional 
drop in coagulation factor levels.  
When correlations between all coagulation tests and factor levels were assessed, 
strikingly different patterns were observed in DIC and warfarin treated patients. In 
warfarin treated patients, functional and antigenic levels of Factors VII, IX, and X 
showed strong correlations with each other. The highly correlated levels of coagulation 
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factors in these patients are a reflection of the unified mechanism by which warfarin 
inhibits coagulation. These factors also correlate strongly with INR, the test designed to 
monitor the effects of warfarin on the coagulation cascade. In contrast, minimal 
significant correlations were observed between coagulation factors in DIC patients. 
While coagulation factor levels were overall decreased compared to healthy controls in 
this patient population, the patient to patient variation in the nature of this decrease was 
high, indicated by the lack of correlation between factor levels. Furthermore, the levels of 
individual coagulation factors were not predictable based on INR in the DIC patient 
cohort.  
These results support the hypothesis that the meaning of an elevated INR is 
substantially different in warfarin treated patients than in DIC patients. In warfarin 
treated patients, an elevated INR suggests a uniform and predictable reduction in the 
detectable and functional levels of multiple coagulation factors without an accompanying 
alteration in the other global coagulation parameter of aPTT. In this patient population, 
elevated INR is solely a measure of a specific type of hypocoagulability induced by 
warfarin in order to prevent thrombotic complications. In contrast, an elevated INR in 
DIC patients provides different information and is accompanied by global coagulation 
dysfunction, suggested by the strong correlation between elevated INR and elevated 
aPTT in this patient population. This demonstrates that unlike warfarin anticoagulation, 
DIC has strong effects on both the extrinsic and intrinsic pathways of the coagulation 
cascade. However, this alteration in coagulation is not accompanied by predictable or 
consistent changes in levels of individual coagulation factors in this patient population. . 
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Despite the elevation of both INR and aPTT in DIC patients, INR remains the superior of 
the two tests for diagnosis of sepsis-associated coagulopathy due to its standardization 
between clinical sites. In DIC patients, elevated INR is accompanied not only by bleeding 
risk but also by thrombosis in this patient population, a risk that is not demonstrable by 
analysis of traditional hemostatic parameters.  
This study underscores the need for an improved understanding of the relationship 
of hemostatic laboratory parameters to the ongoing coagulation processes and the 
associated risks of both bleeding and thrombosis specific to the DIC patient population. 
Furthermore, this demonstrates that the coagulation tests available in the clinical 
laboratory may not provide an accurate description of the nature or severity of the 
coagulopathy in patients with sepsis-associated DIC. Additional hemostatic parameters as 
well as biomarkers representing the processes that lead to the development of 
coagulopathy such as infection response and endothelial dysfunction must be analyzed 
for their association with the severity of coagulopathy. This understanding has 
implications for both the diagnosis of patients with sepsis-associated DIC and the 
development and administration of safe and effective treatments for these patients. 
Biomarker Profiling of Utah Cohort Patient Plasma Samples 
In order to understand the molecular pathogenesis of sepsis-associated DIC, 
biomarkers of hemostatic dysregulation, inflammation, infection, endothelial function, 
and platelet function were measured in the plasma of patients with sepsis and associated 
DIC. The results of these studies, summarized in Table 35, supported the hypothesis that 
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a combination of biomarkers representative of multiple physiological systems would 
provide greater insight into the pathophysiology and outcome of sepsis-associated DIC 
than markers of a single system. Biomarkers representative of multiple physiological 
systems were relevant to all studied aspects of disease, including organ failure, severity 
of coagulation dysfunction, and association with mortality. However, inflammation and 
coagulation were particularly relevant to organ failure whereas infection response and 
coagulation function were particularly relevant to severity of coagulopathy and mortality. 
Furthermore, the use of biomarkers representative of multiple physiological systems 
permitted the development of predictive algorithm for patient outcome. This algorithm 
incorporated procalcitonin (a biomarker of infection), VEGF and the IL-6:IL-10 ratio 
(biomarkers of inflammation), endocan (a biomarker of endothelial function), and PF-4 (a 
biomarker of platelet function). The predictive ability of this algorithm was superior to 
that of any individual biomarker.  
Procalcitonin, a biomarker of infection, was associated with organ failure, 
severity of coagulopathy, and mortality outcome. While associations were present 
between all systems and organ failure, severity of DIC, and mortality, organ failure was 
predominantly associated with biomarkers of hemostasis (D-Dimer, INR, and platelet 
count) and inflammation (IL-6, IL-8, IL-10, TNFα, and MCP-1) whereas severity of 
coagulopathy and mortality were predominately associated with biomarkers of infection 
(nucleosomes, HMGB-1, and procalcitonin) and endothelial function (protein C, 
endocan, and Ang-2).  
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Disease severity and patient outcome were predominately associated with changes 
in levels of biomarkers representing infection and endothelial function. These findings 
support the hypothesized roles of infection response (particularly as characterized by the 
presence of extracellular nuclear material) and endothelial function in the molecular 
pathogenesis of sepsis-associated DIC and promote further study of these systems, 
particularly with respect to their involvement in the response to treatment.  
Throughout this study, procalcitonin demonstrated the most significant 
association with patient clinical status and outcome. Procalcitonin was the only marker to 
demonstrate associations with organ failure, severity of coagulopathy, and mortality as 
well as to be included in the predictive algorithm for outcome. While procalcitonin is 
well established as an indicator of ongoing infectious processes, this study also identified 
a significant association between procalcitonin and the severity of coagulopathy. 
Procalcitonin is clinically available as a laboratory test and is used as an indicator of 
whether a systemic inflammatory process is infectious or sterile in origin. This would 
facilitate the inclusion of procalcitonin in any testing panel for use in patients with sepsis 
or DIC. Nucleosomes and HMGB-1 levels were individually weaker markers than 
procalcitonin in terms of ability to distinguish survivors from non-survivors. However, in 
addition to diagnostic relevance, both HMGB-1 and nucleosomes have the mechanistic 
relevance to the development of DIC through their pro-coagulant, pro-inflammatory, and 
endothelial damaging properties and may be involved in the response to treatment with 
heparin, rTM (Iba 2014; Nakahara 2013; Osada 2017), or AT (Iba 2017). Therefore, 
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these nuclear factors should be included in further studies of both the pathophysiology 
and treatment of DIC. 
Endothelial markers also demonstrated particularly strong associations with 
severity of coagulopathy and with outcome. Protein C is well documented to play a role 
in the pathophysiology of sepsis-associated DIC, and the protein C pathway is a major 
therapeutic target in this disease. Ang-2 also emerged as strongly associated with both 
severity of coagulopathy and mortality, representing a new potential avenue for study in 
this disease process.  
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Table 35. Summary of Utah Cohort Biomarker Profiling Results 
 
Marker 
Significant Association Included in Predictive Model 
SOFA DIC 
Mortality  
(AUC) 
Constant 
AUC=0.87 
Linear 
AUC=0.95 
D-Dimer 0.21 Yes No (0.60) No Yes 
F1.2 0.12 Yes No (0.54) No No 
PAI-1 0.04 No Yes (0.70) No Yes 
INR 0.20 Yes No (0.60) No No 
Platelets -0.36 Yes No (0.61) No No 
Fibrinogen -0.02 No No (0.51) No No 
Nucleosomes -0.07 Yes No (0.58) No No 
HMGB-1 -0.07 No Yes (0.67) No Yes 
Procalcitonin 0.28 Yes Yes (0.77) Yes Yes 
IL-2 0.06 No No (0.52) No No 
IL-4 0.01 No No (0.55) No No 
IL-6 0.26 No Yes (0.70) No No 
IL-8 0.32 Yes Yes (0.70) No No 
IL-10 0.23 No No (0.58) No No 
VEGF 0.00 No No (0.57) Yes No 
IFNγ 0.01 No No (0.54) No No 
TNFα 0.22 No No (0.52) No No 
IL-1α 0.14 No No (0.60) No No 
IL-1β 0.11 No No (0.58) No No 
MCP-1 0.33 No No (0.53) No Yes 
EGF -0.17 Yes No (0.58) No Yes 
IL-6:IL-10 0.17 No No (0.61) Yes Yes 
TFPI 0.00 No No (0.55) No No 
Protein C -0.22 Yes Yes (0.71) No Yes 
Endocan -0.02 No Yes (0.58) Yes Yes 
Ang-2 0.14 Yes Yes (0.76) No No 
vWF -0.12 No No (0.58) No No 
CD40L -0.18 No No (0.55) No Yes 
MP -0.26 No No (0.53) No Yes 
MP-TF 0.16 No No (0.62) No No 
PF-4 -0.43 No Yes (0.70) Yes Yes 
Spearman correlation coefficients shown for relationship with SOFA score. Significant 
correlations are highlighted in blue with bold text. Significant association with DIC score 
or mortality determined on the basis of significant difference between survivors and non-
survivors or significant difference between patient groups based on DIC score.  
241 
 
 
Patient Cohort Baseline Characteristics 
 The Utah patient cohort samples used throughout this study were collected from 
consenting adult patients following IRB approved protocols. The enrollment criteria used 
to define sepsis for the purpose of this cohort are well defined (Levy 2003) and are the 
criteria most commonly used in the literature to define sepsis (Alhamadi 2015; Bozza 
2007; Claushuis 2016; Collins 2006; Davis 2010; Hovinga 2007; Ioakeimidou 2017; 
Jones 2009; Kaplan 2015; Livaditi 2006; Mihajlovic 2014; Ogura 2014; Ricciuto 2011; 
Rondina 2015; Scherpereel 2006; Siner 2009; Soriano 2005; Sunden-Cullberg 2005; van 
der Heijden 2009; Wildhagen 2015). The most recent guidelines for the diagnosis of 
sepsis (Singer 2016) were published after the collection of all patient samples and the 
initialization of this study. Based on available information, it was not possible to 
determine which patients in this cohort met the SEPSIS-3 guidelines for the diagnosis of 
sepsis. As the focus of the studies in this dissertation is not sepsis epidemiology but rather 
the pathogenesis of the associated DIC, this cohort was appropriate for this analysis. 
 The demographics of this cohort are within the range typical for sepsis patients in 
the literature. This includes the age distribution (57 ± 18.5 years, mean ± SD) and the 
gender balance (46.6% male) (Abraham 2003; Chen 2012; Claushuis 2016; Fisher 2016; 
Jones 2009; Yaroustovsky 2013). The racial and ethnic composition of this cohort is 
reasonable for the region in which the samples were collected. The highest prevalence 
comorbidities in this cohort included hypertension (45.6%), diabetes mellitus (25.2%), 
and cardiovascular disease (21.4%), all of which are common medical conditions. History 
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of recent surgery was also highly prevalent in this cohort (22.3%). This is reasonable, as 
sepsis often develops as a complication of surgery.  
Association of Biomarkers with Organ Failure 
The severity of organ failure, quantified by SOFA score, was associated with 
changes in markers of hemostasis (D-Dimer, INR, and platelets), infection 
(procalcitonin), inflammation (IL-6, IL-8, IL-10, TNFα, and MCP-1), endothelial 
function (protein C) and platelet function (PF-4). While organ failure was predominately 
associated with inflammation and coagulation dysfunction, this demonstrates that 
infection, endothelial function, and platelet function also play a role in this process.  
The severity of disease, quantified by mortality as well as through clinical scoring 
systems such as SOFA and APACHE II are highly variable based on factors such as 
study inclusion criterial, standard of care, and variability between institutions and 
services. The overall 28-day mortality of patients included in this cohort, 14.6%, is 
relatively low, as mortality in sepsis is often estimated at greater than 20%. However, 
many studies reporting high mortality are designed to enroll only patients with severe 
sepsis or septic shock, both of which are associated with increased mortality. Numerous 
studies enrolling patients with sepsis have reported mortality of under 20% (Abraham 
2005; Davis 2010; Gogos 2000; Rondina 2015; Scherpereel 2006; Sunden-Cullberg 
2005). Similarly, the SOFA and APACHE II scores were at the low end of the range 
typically reported for cohorts of sepsis patients. Many studies enrolling sepsis patients 
report mean SOFA scores between 6 and 9 and mean APACHE II scores between 18 and 
25 (Alhamadi 2015; Bozza 2007; Davis 2010; Jones 2009; Ogura 2014; Park 2016; Siner 
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2009; Sunden-Cullberg 2005; Wildhagen 2015). In this cohort, the SOFA score was 5.9 ± 
3.7 (mean ± SD) and the APACHE II score was 17.4 ± 7.3 (mean ± SD). Insufficient 
information about the causative pathogen was available to allow for analyses based on 
pathogen type.  
The severity of coagulopathy was significantly associated with organ failure, as 
quantified by SOFA score. DIC is well established to lead to increased organ failure in 
sepsis patients (Okabayashi 2004). The formation of microthrombi in the vasculature can 
lead directly to organ failure. Additionally, the status of the hemostatic system as 
measured by platelet count is included in the SOFA score.  
A strong association was also observed between organ failure and inflammation. 
SOFA score correlated significantly with IL-6, IL-8, IL-10, MCP-1, and TNFα. Notably, 
this association was not present between SOFA score and the infection markers, 
nucleosomes and HMGB-1.  
Of the inflammatory cytokines, MCP-1 exhibited the most notable association 
with the severity of illness. In addition to correlating significantly with SOFA score, 
MCP-1 was significantly elevated in patients who required vasopressor or ventilator 
support compared to those who did not. Although MCP-1 is relatively less studied than 
other inflammatory cytokines in the context of sepsis, it has been suggested that MCP-1 
may contribute to the development of septic shock and subsequent organ failure through 
increased vascular leakage, mediated by effects on endothelial tight junctions. Treatment 
of mice with either LPS or CLP-induced sepsis with a blocker of MCP-1 synthesis was 
244 
 
 
shown to reduce liver and lung injury, as quantified by myeloperoxidase (MPO) levels 
(Ramnath 2008).  
The associations of hemostatic and endothelial biomarkers with organ failure 
were relatively weak, and association with ventilator or vasopressor use was minimal. 
Somewhat surprising was the degree of association between platelet biomarkers and 
organ failure. It is interesting to note that these relationships were inverse, despite the 
overall elevation of these biomarkers. This suggests that the involvement of platelets and 
platelet-associated factors in sepsis and associated DIC may be highly variable through 
the time course of disease, as platelets progress from activation to consumption.  
The main limitation of the relatively mild sepsis and low mortality rate in this 
patient cohort was the limited statistical power this provides for the comparison of 
survivors to non-survivors, particularly when the cohort was further subdivided based on 
other factors such as DIC score. This may explain the lack of association between DIC 
score and mortality in this patient cohort. Numerous studies have demonstrated an 
association between DIC score and mortality; however, no such association was observed 
in this patient population. Other studies have also seen no significant increase in mortality 
among DIC patients compared to non-DIC sepsis patients (Okabayashi 2004). 
 Surviving patients in this cohort were assessed for the presence of thrombosis at 
the time of hospital discharge using ultrasound of the venous system. Major thrombotic 
events including PE, MI, or thromboembolic stroke were also reported. No associations 
were noted between baseline levels of any measured biomarker and thrombosis at or prior 
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to discharge. The thrombosis identified through this protocol, most commonly 
asymptomatic DVT, is distinct from the sepsis-associated coagulopathy that is the focus 
of this study, which typically manifests as microthrombi and bleeding due to the 
consumption of platelets and coagulation factors. Thrombosis is common in hospitalized 
patients due to a combination of immobilization-induced stasis with other predisposing 
factors including inflammation and the presence of interventional devices in the 
vasculature. Without further information regarding the complicated hospital courses of 
the patients involved in this study, no further analysis of factors associated with this 
outcome can be performed.  
Association of Biomarker Levels with DIC Score 
This study examined the relationship of biomarkers representing hemostasis, 
infection, inflammation, endothelial function, and platelet function with the severity of 
DIC in a cohort of patients with sepsis and well defined coagulopathy. The severity of 
coagulation dysfunction, quantified by DIC score, was associated with markers of 
hemostasis (D-Dimer, INR, and platelet count), infection (nucleosomes and 
procalcitonin), inflammation (IL-8 and EGF), and endothelial function (protein C and 
Ang-2). While multiple systems are involved in the development of coagulation 
dysfunction, this demonstrates that the processes underlying the development of DIC may 
be distinct from those classically associated with sepsis. In particular, extracellular 
nuclear material released into the circulation as a component of the response to infection 
as well as the function of the endothelium contribute to DIC and should therefore be 
addressed in the evaluation and treatment of this disease. 
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The Utah cohort is composed of patients with sepsis and DIC defined according 
to well-established criteria. While the overall severity of illness, as defined by 28-day 
mortality, SOFA score, and APACHE-II score was relatively mild, patients were well 
distributed in terms of severity of DIC. Using the ISTH criteria, 19.4% of patients were 
diagnosed with no DIC, 57.3% with non-overt DIC, and 23.3% with overt DIC. This 
distribution of DIC scores enables analysis of the association of biomarker levels with the 
severity of coagulopathy. 
DIC was strictly defined and patients were subdivided into three groups based on 
DIC score. Many studies categorize patients as either overt DIC (ISTH score ≥5) or no 
DIC (ISTH score <5) (Bakhtiari 2004; Cauchie 2006; Dhainaut 2004; Jesmin 2012; Joo 
2010; Kim 2015; Park 2016; Seo 2009). In these studies, non-overt DIC (ISTH score 3-4) 
is not treated as an independent category. This results in a highly heterogeneous patient 
population in the no DIC category, resulting in reduced ability to identify factors 
associated with the development of severe coagulation dysfunction. Separation of 
patients with non-overt DIC from those who do not demonstrate coagulation dysfunction 
(ISTH score ≤2), as was performed in this study, is required for improved understanding 
of factors involved in the development of coagulation dysfunction. Furthermore, post hoc 
analysis of clinical trials has demonstrated that patients with overt DIC may respond 
differently to treatments than patients with less severe manifestations of coagulopathy 
(Dhainaut 2004; Shakoory 2016). In this study, 57.3% of patients had non-overt DIC at 
baseline.  
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 The majority of measured biomarkers were significantly elevated in all patient 
groups compared to the healthy control group, regardless of coagulation status. Sepsis 
represents a severe dysfunction of all major physiological systems; this was reflected in 
changes in markers of hemostasis, infection, inflammation, platelet activity, and 
endothelial function in all patients. Notable differences were apparent in markers of 
infection and endothelial function not only on the basis of sepsis but also on the basis of 
severity of DIC.  
Among the markers of infection, both nucleosomes and procalcitonin were 
significantly elevated in patients with overt DIC compared to those with less severe 
coagulopathy. Although this trend was also apparent for HMGB-1, statistical significance 
was not achieved.  
Procalcitonin was significantly elevated in both overt and non-overt DIC patients 
compared to patients with sepsis alone. Unlike many of the other markers measured in 
this study, there is no hypothesized direct role for procalcitonin in the development of 
coagulopathy. Under normal physiological conditions, procalcitonin is produced by the 
parafollicular cells of the thyroid as the precursor to the hormone calcitonin, which is 
involved in calcium homeostasis. The mechanism increase in circulating procalcitonin 
under infectious circumstances is not fully understood, although expression of 
procalcitonin in numerous tissues has been demonstrated in response to LPS and IL-1β 
(Riedel, 2012). In animal models, circulating levels of procalcitonin have been shown to 
correlate well with the quantity of bacteria administered (Becker 2010; Nylen 1998; 
Steinwald 1999). However, procalcitonin is widely studied in sepsis and accepted as a 
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means to distinguish infectious conditions from non-infectious inflammatory states such 
as SIRS (Annane 2005; Biron 2015; Harbarth 2001; Livaditi 2006; Pierrakos 2010; 
Riedel 2012; Riedel 2011; Wacker 2013; Wunder 2004; Zakariah 2008). The association 
of procalcitonin with the severity of coagulopathy in addition to the presence of infection 
supports the importance of infection in the development of coagulopathy. As 
procalcitonin is readily available as a laboratory test in the hospital setting, further study 
of the relationship of procalcitonin to DIC may have the potential to improve DIC 
diagnosis with minimal logistical challenges.  
Nucleosomes represent a more novel biomarker in the field of sepsis and DIC 
than procalcitonin. In this study, nucleosomes showed a significant association with 
coagulopathy but not with sepsis alone. No difference in nucleosome levels was apparent 
between patients with sepsis and no or non-overt DIC and the healthy control group. 
However, nucleosomes were significantly elevated in patients with sepsis and overt DIC 
compared to both healthy controls and patients with sepsis and no DIC. Both histones and 
DNA, the constituent parts of nucleosomes, have been shown to have direct procoagulant 
and prothrombotic properties in addition to effects on platelets, the endothelium, and 
inflammation. The elevation of nucleosomes only in patients with overt DIC supports the 
involvement of nucleosomes or processes that they represent in the development of 
coagulopathy. 
The association of procalcitonin and nucleosomes with DIC is largely 
independent of general inflammatory processes. Of the inflammatory cytokines, only IL-
8 and EGF showed significant variation based on coagulation status in addition to overall 
249 
 
 
elevation in sepsis. This points as infection rather than inflammation as the major driver 
of the development of DIC in sepsis patients. Although the relationship between 
inflammation and coagulation is bi-directional, evidence in the literature points towards 
infection and infection-related neutrophil activity as a mediator of coagulation (Massberg 
2010; McDonald 2017) as opposed to the converse. Platelets activated with LPS but not 
those activated with traditional platelet activators have been shown to stimulate NET 
formation (Clark 2007). This is evolutionary advantageous as it can trap bacteria and 
reduce bacterial dissemination throughout the body. However, as evidenced in DIC, it 
can also be detrimental to the host if coagulation occurs to excess.  
Endothelial dysfunction also demonstrated significant association with the 
development of DIC. This is logical from a pathophysiological perspective, as endothelial 
damage is cited in Virchow’s Triad as one of the main requirements for thrombosis. The 
variation of protein C based on DIC score is expected as the role of this endogenous 
anticoagulant in the pathophysiology of DIC is well accepted. Protein C was notable in 
this study as the only biomarker to maintain an association with DIC status throughout 
the course of hospitalization.  
Ang-2 also demonstrated a significant association with DIC, with elevation in 
overt DIC patients compared to sepsis and no DIC. Ang-2 has not previously been 
strongly associated with coagulopathy in sepsis patients, although an association of Ang-
2 with coagulopathy in trauma patients has been noted (Ganter 2008). Ang-2 has been 
more strongly tied to regulation of endothelial barrier function (Gallagher 2008; Parikh 
2006) and the development of respiratory dysfunction in critically ill patients (Gallagher 
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2008; Kumpers 2008; Lin 2015; Parikh 2006). Ang-2 acts as an antagonist to Ang-1 at 
the Tie2 receptor on the endothelial cell surface. While Ang-1 promotes vascular stability 
and preserves cell-cell contacts, Ang-2 acts in opposition to these effects. In addition to 
Ang-2, Ang-1 and the Ang-Tie system may represent a new avenue of study in sepsis-
associated DIC.  
Association of Biomarkers with Mortality 
 Mortality was associated with changes in the levels of markers of hemostasis 
(PAI-1), infection (HMGB-1 and procalcitonin), inflammation (IL-6 and IL-8), 
endothelial function (protein C, endocan, and Ang-2), and platelet function (PF-4). Sepsis 
is commonly described as a disease of excessive inflammation with potential associated 
coagulation dysfunction. However, biomarkers of infection and endothelial function 
demonstrated a greater degree of association with mortality than inflammatory or 
hemostatic markers. These endothelial and inflammatory markers were also strongly 
associated with the severity of coagulopathy. This shows that infection and endothelial 
function in addition to inflammation and hemostatic function are relevant to disease 
progression and outcome in patients with sepsis-associated DIC and therefore must be 
considered in the diagnosis, evaluation, and treatment of these patients 
 Procalcitonin was significantly elevated in non-survivors compared to survivors 
and demonstrated the best predictive value for outcome of any measured biomarker 
(AUC = 0.77). This supports previous research demonstrating elevated procalcitonin in 
non-survivors compared to survivors of sepsis (Harbarth 2001; Wunder 2004) and further 
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validates procalcitonin as a valuable biomarker in sepsis and DIC. HMGB-1 was also 
significantly elevated in non-survivors compared to survivors, although the predictive 
value was lower than procalcitonin (AUC = 0.67). This is similar to the observations of 
the association of infection biomarkers with DIC. HMGB-1 may contribute to both 
thrombosis and inflammation (Ito 2006; Stark 2016) and is a potential therapeutic target 
in DIC (Suda 2006; H. Yang 2004). While the associations of procalcitonin, 
nucleosomes, and HMGB-1 with severity of coagulopathy and patient mortality indicate 
the relevance of infection response to the pathophysiology of sepsis-associated DIC, 
further questions are raised regarding the specific roles of HMGB-1, nucleosomes, and 
other nuclear components and the optimal application of this information. Additionally, 
this suggests that special attention should be paid to the potential interactions of 
therapeutics for DIC with these nuclear materials. 
Several endothelial markers also emerged as strong predictors of mortality. 
Protein C was significantly reduced in non-survivors compared to survivors. Protein C is 
the most studied endothelial factor in sepsis-associated DIC, and reductions in protein C 
levels have previously been associated with poor outcome in patients with sepsis and DIC 
(Bouchard 2015; Collins 2006; LaRosa 2006a, 2006b; Macias & Nelson, 2004; Shorr 
2010; Shorr 2008). Furthermore, the protein C pathway is a promising therapeutic target. 
Protein C functions as an endogenous anticoagulant as well as performing other anti-
inflammatory functions, including the destruction of extracellular histones. Protein C 
depletion leads in the loss of these antithrombotic and cytoprotective functions, resulting 
in increased severity of coagulopathy and increased mortality. Surprisingly, Ang-2 
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demonstrated the highest predictive value for mortality of the measured endothelial 
markers, superior to protein C (AUC = 0.71). Ang-2 is predominately involved in the 
maintenance of endothelial cell barrier function. Increased Ang-2 is associated with 
increased intracellular gap formation. Sepsis patients already suffer from hypotension, 
shock, and impaired perfusion; increased loss of fluid into the intravascular space further 
impairs perfusion and increases mortality. Elevated Ang-2 has been implicated in the 
development of respiratory dysfunction, another contributor to mortality. The 
mechanisms by which Ang-2 may contribute to hemostatic dysfunction remain unclear. 
This suggests Ang-2 and the Ang-Tie system is a new avenue for investigation in the 
molecular pathophysiology of sepsis and DIC. A third endothelial marker, endocan, was 
also elevated in non-survivors compared to survivors, underscoring the importance of 
endothelial function to this disease.  
Despite the accepted association between the development of DIC and increased 
mortality in sepsis patients, none of the markers used in the diagnosis of DIC (INR, 
platelet count, D-Dimer, or fibrinogen) demonstrated significant association with 
mortality. The only hemostatic marker to differ between survivors and non-survivors was 
PAI-1. Unlike fibrinogen, platelets, and INR, which are modified in disease due to 
consumption, or D-Dimer, which is produced as a consequence of thrombus breakdown, 
PAI-1 may be a cause rather than an effect of DIC. When released from platelets or the 
endothelium, PAI-1 inhibits fibrinolysis by inhibiting tissue plasminogen activator. 
Significantly elevated PAI-1 may prevent the breakdown of thrombi in the 
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microcirculation, magnifying the end-organ damage resulting from even mild 
coagulopathy. PAI-1 is reduced by treatment of DIC patients with rTM (Saito 2007).  
Differences between survivors and non-survivors were also present in the 
inflammatory markers IL-6 and IL-8 and the platelet marker PF-4 (AUC = 0.70 for all). 
Although the predictive values for these markers are weaker than those seen for infection 
and endothelial markers, this supports the hypothesis that all systems contribute to the 
development of sepsis and DIC and may provide significant insight into disease 
pathophysiology. The strong predictive values present in markers of endothelial function 
and infection response indicate that these systems should be a focus for the development 
of therapeutics. However, no single biomarker demonstrated exceptionally strong 
predictive value for outcome in this complex and heterogeneous disease. Procalcitonin 
demonstrated the best predictive value for outcome in this patient population and, 
measurement of procalcitonin is therefore useful as a single rapid indicator of patient 
prognosis. However, improved information is provided when a combination of 
biomarkers are used. The predictive algorithm developed in this study incorporated 
biomarkers of infection (procalcitonin), inflammation (VEGF and the IL-6:IL-10 ratio), 
endothelial function (endocan) and platelet function (PF-4) and provided improved 
predictive value over procalcitonin alone.  
The development of a predictive algorithm employing a combination of 
biomarkers may provide improved predictive ability. Alternatively, separate analysis of 
the association of biomarkers with outcome based on patient DIC status may provide 
improved predictive ability in conjunction with a deeper understanding of the underlying 
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pathology associated with different levels of coagulopathy. Due to the small number of 
non-survivors, particularly amongst patients with sepsis and no DIC, this analysis was not 
performed in this patient cohort.  
Association of Biomarkers with Platelet Count 
 Platelet-related biomarkers demonstrated the least degree of association of with 
severity of illness and outcome of any biomarker category. However, platelet depletion is 
a major characteristic of sepsis-associated DIC, as circulating platelets are reduced due 
consumptive coagulopathy. Reduced platelet count is included in the ISTH algorithm for 
the diagnosis of DIC, and thrombocytopenia in conjunction with elevated INR is 
commonly used as a screening test for sepsis-associated coagulopathy. Analysis of the 
association of the level of platelet biomarkers with platelet count revealed that the 
circulating levels of these biomarkers are largely controlled by platelet depletion.  
 The interpretation of levels of factors released by platelets in patients with sepsis 
and DIC is complicated by the dual processes of platelet activation and platelet 
consumption. Activated platelets may secrete factors at high levels. However, this effect 
may be cancelled out by sufficient reduction in platelet number. However, it is important 
to understand platelet function in sepsis and DIC, as platelets are involved not only in 
hemostasis but also in the response to infection. Previous analyses (Claushuis 2016) have 
shown that sepsis patients with severe thrombocytopenia demonstrate a different 
molecular profile than those with platelet counts within the normal range. Accordingly, 
patients were divided into groups of normal platelet count (≥150 K/μl), mild 
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thrombocytopenia (100-149 K/μl), and moderate to severe thrombocytopenia (<100 
K/μl). 
 Procalcitonin displayed the most striking association with platelet count of any 
biomarker. The elevation of PCT in patients with platelets of <100 K/μl or 100-149 K/μl 
compared to those within the normal range highlights the association of infection with 
platelet depletion. Ang-2 also displayed a dramatic increase in patients` with reduced 
platelet counts compared to those within normal limits. This emphasizes the importance 
of endothelial function and the response to infection in sepsis-associated coagulopathy.  
 Platelet depletion was also reflected in the association with hemostatic markers. 
The increases in INR and decrease in fibrinogen observed in patients with reduced 
platelet counts are reflective of the same consumptive process. 
 The association of platelet count with classical markers of inflammation was 
relatively limited. The clearest associations with platelet count were VEGF and EGF, 
both of which were higher in patients with normal platelet counts than those with 
thrombocytopenia. As both of these factors are released by activated platelets, this pattern 
is also likely reflective of platelet depletion.  
 The relationship of platelet biomarkers to platelet count was largely dictated by 
platelet depletion. CD40L and MP were both significantly reduced in patients with 
reduced platelet counts compared to those within the normal range. The reduction of 
these markers in patients with dramatically reduced platelet counts indicates that the 
degree of platelet consumption in these patients overcomes the increased secretion of 
these markers by activated platelets. The relatively limited association of platelet 
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biomarkers with organ failure, severity of DIC, and mortality is attributable to this same 
process rather than to a lack of involvement of platelet-related factors in disease 
pathophysiology. Measurement of platelet factors at an earlier time point may provide 
insight into the disease progression of patients who are likely to develop coagulopathy, as 
dramatic platelet activation precedes platelet depletion. Measurement of platelet count at 
both early and late time points in disease would also allow for analysis of not only 
platelet count but change in a patient’s platelet count over time. Due to the wide range of 
normal platelet counts (150-400 K/μl), some patients who have experienced a drop in 
platelet count of more than 50% may still be classified as having a normal platelet count, 
whereas some patients with only minor drops in platelet count may be classified as 
thrombocytopenic. Further study of this phenomenon should occur in patients with more 
detailed information available regarding the timing of the onset of illness.  
Biomarkers on Days 4 and 8 and Changes Over Time 
 Analysis of the relationships of biomarkers at ICU days 4 and 8 to DIC score and 
mortality revealed few associations. Protein C showed persistent associations with DIC 
score on days 4 and 8. Furthermore, changes in the level of protein C over time were also 
associated with survival. This supports the relevance of protein C to disease 
pathophysiology and the potential utility of this biomarker as a means to assess response 
to therapy.  
 Persistent elevations in IL-6 and IL-8 on days 4 and 8 were seen in non-survivors 
compared to survivors. This highlights the relevance of ongoing pro-inflammatory 
processes to mortality in this patient cohort.  
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Potential Confounding Factors 
 Prior to selection of a biomarker panel for use in animal studies or incorporation 
into a predictive algorithm, it was important to understand the influence of potential 
confounding factors on these biomarkers. No known comorbidity interferes with the 
utility of any of the biomarkers analyzed in this study in the evaluation and understanding 
of sepsis-associated DIC. 
 Special attention was paid to age as a potential confounding factor, as age can 
significantly change both baseline characteristics and response in disease. Furthermore, 
previous studies have demonstrated that age may change not only the biomarker profile 
seen in patients but also the association of this profile with patient outcome (Rondina 
2015). This information is particularly relevant in sepsis and DIC, which affects patients 
of all ages. In this patient cohort, correlations between age and biomarker level were 
relatively week, although associations were present for several biomarkers. The strongest 
correlation (r=0.35) was observed for endocan, which was also significantly elevated in 
patients with age ≥65 compared to younger patients. When analyzed via two-way 
ANOVA, procalcitonin, IL-8, and Ang-2 showed significant differences based on both 
age and survival as well as a significant interaction factor. For these factors, the increases 
in non-survivors compared to survivors was more pronounced in younger patients than 
those with age ≥65. Additionally, this blunting of the increase in these markers in older 
patients may have implications for disease outcome in elderly patients and interfere with 
the use of some of these biomarkers. 
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 Common and significant medical conditions were also analyzed for association 
with biomarker levels. History of pulmonary disease, which was present in 17 patients, 
was associated with the highest number of biomarkers. Compared to patients without a 
history of pulmonary disease, these patients had reduced D-Dimer, IFNγ, IL-10, 
nucleosomes, and TNFα. However, this should not interfere with the use of these 
markers.  
Correlations Between Biomarkers 
 Many correlations were seen between the analyzed biomarkers. From this 
analysis, several groups of biomarkers emerge as potentially independently regulated 
although associated with patient outcome. For example, PAI-1, which varied significantly 
based on mortality, did not correlate with other hemostatic biomarkers and showed no 
strong correlation with any measured biomarker.  
 The highest concentration of correlations was among the inflammatory markers. 
While inflammation is critical to the pathogenesis of sepsis and to the development of 
DIC in sepsis patients, this suggests that inflammation may be monitored effectively 
through a small number of biomarkers.  
 Through this analysis, biomarkers of infection emerge as particularly important 
parameters and a new direction for research in the field of sepsis-associated DIC. While 
these factors were strongly associated with both mortality and the severity of 
coagulopathy, nucleosomes and HMGB-1 were relatively independent of the 
inflammatory processes. In contrast, procalcitonin, an indicator of infection but not a 
mediator of infection response, showed the most correlations and the strongest 
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correlations overall with any biomarkers. Procalcitonin showed associations with 
hemostatic markers, including a strong correlation with D-Dimer, strong correlations with 
several inflammatory markers including IL-6, IL-8, IL-10, TNFα and MCP-1, and 
correlations with endothelial markers including a strong correlation with Ang-2. 
However, procalcitonin showed no association with platelets; the only association 
between infection biomarkers and platelets was a weak correlation between nucleosomes 
and MP-TF. Infection may lead to generalized inflammation which in turn contributes 
bidirectionally to coagulopathy; however, infection was more strongly associated with 
endothelial function supporting the involvement of these factors not only with infection 
and inflammation but also with the development of the endothelial and coagulation 
dysfunction.  
 Platelet biomarkers demonstrated relatively limited relationships with other 
biomarkers with the exception of strong correlation with platelet counts. While platelets 
certainly play a role in the ongoing processes, this suggests that monitoring platelet count 
alone may provide sufficient information about this status in sepsis-associated DIC 
patients.  
 A specific association that may be of note for the biomarkers is the one seen 
between nucleosomes and HMGB-1. Both nucleosomes and HMGB-1 may be released 
into circulation as a part of NETosis; however, this is not the only mechanism of release 
for HMGB-1, which may also be released by endothelial cells. Patients with the highest 
levels of HMGB-1 using tertile analysis also had elevated levels of nucleosomes 
compared to patients with lower HMGB-1 levels. The platelet factors are more complex 
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in this patient population due to the consumption of platelets in DIC. Platelets may 
become strongly activated by the ongoing infection and release several factors, but may 
also be depleted to such an extent that this ability becomes exhausted. Additional 
information regarding the time course of illness is required to facilitate analysis of the 
relationship of platelet activation and depletion with disease development. 
Stepwise Linear Regression Modeling 
 The aim of this analysis was to develop an algorithm based on a combination of 
biomarkers to predict clinical outcome in patients with sepsis-associated DIC. This aim 
was based on the hypothesis that a combination of biomarkers representative of multiple 
physiological processes would provide better predictive ability for outcome in sepsis 
patients than a single biomarker. A predictive equation for outcome was developed, 
incorporating procalcitonin, VEGF, IL-6:IL-10 ratio, endocan, and PF-4. As 
hypothesized, biomarkers representative of multiple physiological systems were 
incorporated into this algorithm, which exhibited a predictive value for mortality superior 
to that of any individual biomarker.  
 The stepwise linear regression modeling approach used in this aim was valuable 
because it provided an unbiased method to select the optimal biomarkers for the 
prediction of outcome and did not rely on preconceived ideas about the potential utility of 
each biomarker. This unbiased approach is valuable in a complex pathophysiological 
scenario such as sepsis-associated DIC, as the model is developed to be mathematically 
optimal rather than to conform to current knowledge about the utility of each parameter. 
This approach has been used successfully to predict outcome in other complex disease 
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processes such as pediatric intensive care unit patients (Hon 2017), kidney transplant 
patients (Dahle 2015), and in patients following the hip fracture repair (Durand 2018).  
 The models developed in this study represent an improvement over many 
previously developed models as they incorporate markers not only of a single aspect of 
disease, such as inflammatory cytokines (Andaluz-Ojeda 2012) but of multiple 
pathophysiological processes.  
 The models generated using stepwise linear regression are summarized in Table 
36. These models support the hypothesis that multiple markers representative of different 
physiological systems are required predict outcome in patients with sepsis and DIC.  
 The most successful and robust model generated using this approach is that 
incorporating biomarkers only (excluding clinical data) and based on a constant starting 
assumption. This model incorporated 5 variables representative of 6 biomarkers 
(procalcitonin, VEGF, the IL-6:IL-10 ratio, endocan, and PF-4) and had an overall AUC 
for prediction of mortality of 0.87, greater than the value of any individual biomarker. 
Although other models generated based on a linear starting assumption achieved a greater 
AUC value (0.95), inclusion of 12 terms representing 13 biomarkers in this model is 
prohibitive for practical implementation in either the clinical or research setting.  
 The incorporation of clinical data into the predictive model did not yield an 
improvement in predictive ability compared to models incorporating biomarkers alone. 
The model generated using both biomarkers and clinical data and a constant starting 
assumption displayed the weakest predictive value of the four models (AUC=0.84). 
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Additionally, the APACHE-II score incorporated in this model is itself a complicated 
parameter representing the measurement of numerous laboratory values.  
 Procalcitonin emerged as the most useful marker (highest predictive value) in the 
analysis of the individual biomarkers, and was included in all four models developed for 
the total sepsis patient population, further emphasizing the importance of infection 
response to disease pathophysiology. Although the procalcitonin itself is not an 
antimicrobial factor, procalcitonin release has been shown in animal models to be 
proportional to bacterial load (Becker 2010; Nylen 1998; Steinwald 1999) and is widely 
accepted as a biomarker of bacterial infection. Notably, the most commonly included 
clinical parameter was white blood cell count (WBC). Elevated WBC is often used 
clinically as an indicator of infection. This further emphasizes the importance of infection 
response in the pathophysiology of DIC. 
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Table 36. Summary of Stepwise Linear Regression Model Results 
 
Marker 
Included in Predictive Model 
Biomarkers 
Constant 
AUC=0.87 
Biomarkers 
Linear 
AUC=0.95 
Clinical 
Constant 
AUC=0.84 
Clinical 
Linear 
AUC=0.89 
D-Dimer No Yes No Yes 
F1.2 No No No No 
PAI-1 No Yes No Yes 
INR No No No No 
Platelets No No No No 
Fibrinogen No No No No 
Nucleosomes No No No No 
HMGB-1 No Yes No No 
Procalcitonin Yes Yes Yes Yes 
IL-2 No No No No 
IL-4 No No No No 
IL-6 No No No No 
IL-8 No No No No 
IL-10 No No No No 
VEGF Yes No No No 
IFNγ No No No No 
TNFα No No No No 
IL-1α No No No No 
IL-1β No No No No 
MCP-1 No Yes No No 
EGF No Yes No Yes 
IL-6:IL-10 Yes Yes No Yes 
TFPI No No No No 
Protein C No Yes No No 
Endocan Yes Yes No Yes 
Ang-2 No No No No 
vWF No No No No 
CD40L No Yes No Yes 
MP No Yes No Yes 
MP-TF No No No No 
PF-4 Yes Yes No No 
APACHE II N/A N/A Yes No 
WBC N/A N/A Yes Yes 
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 Sepsis is a heterogeneous disease, and biomarker levels vary greatly between 
patients. Therefore, it is probable that different model components contribute to model 
output to different degrees for different patient depending on individual pathophysiology. 
By incorporating markers representative of different aspects of pathophysiology, the 
model may be applicable to the broadest set of patients with reasonable accuracy.   
 Different factors may contribute to mortality in patients who develop severe 
coagulopathy compared to those who do not develop significant coagulopathy. Therefore, 
the development of separate predictive algorithms for outcome based on the severity of 
coagulation disorder as defined by DIC score is a rational approach to model 
improvement. In this study, the number of patients in each DIC score subgroup present a 
significant limitation to this line of inquiry, and models produced using these small 
sample sizes are unlikely to be fully generalizable. However, extremely accurate 
(AUC=1) algorithms for the prediction of mortality were developed when patients were 
divided on the basis of DIC score. Although the practicality of these specific models may 
be limited, this study provides a proof of concept for the development of separate 
predictive algorithms for patients with different severities of coagulopathy. 
 Although these models do not provide information about the role of any marker in 
the molecular pathogenesis of sepsis or DIC, identification of markers commonly 
included in the models may provide insight into processes contributing substantially to 
patient outcome. The importance of infection response was further emphasized in models 
generated for patients with different severities of DIC by the common inclusion of 
HGMB-1.  
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Limitations 
Several limitations were observed in the analysis of the Utah patient cohort, 
primarily with regards to sample size and availability of clinical information for the Utah 
patient cohort.  
 A cohort of approximately 100 patients is typical in many published studies of 
sepsis patients, with the exception of large clinical trials (Angus 2007; Chen 2012; Davis 
2010; Delabranche 2013; Gogos 2000; Kranidioti 2009). However, this may provide 
limitations in statistical power when patients are subdivided into multiple groups. In 
particular, this limited the ability to analyze associations with mortality separately for 
patients with sepsis + no DIC, sepsis + non-overt DIC, and sepsis + overt DIC. 
Furthermore, the number of available patient samples decreased dramatically between 
day 0 (n=103) and day 4 (n=57), with further decreases by day 8 (n=30). This reduction 
in sample size reduces the statistical power for identifying differences in biomarker level 
on the basis of DIC score or patient outcome. Furthermore, patients were lost to follow-
up due to both death and recovery, changing the overall characteristics of this cohort and 
limiting the utility of the analysis of change in biomarker levels over time. 
A second limitation of this cohort is the lack of certain types of clinical 
information. Insufficient information was available to permit analysis of the prophylactic 
dose of heparin administered, type and dose of vasopressor, other treatments (i.e. 
antibiotics), length of hospitalization prior to either discharge or death, and pathogen 
type. Precise information regarding the time course of disease development relative to the 
timing of blood draw placed limitations on the analysis of time-dependent phenomena, 
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such as the activation and subsequent depletion of platelets or the changes in biomarker 
levels over time.  
With the exception of protein C, protein antigen levels, not functional levels, were 
measured as a part of this study. Accordingly, only quantitative changes in biomarker 
level, not qualitative changes in protein function, were analyzed.  
In vitro Coagulation Profiles of Thrombomodulin, Antithrombin, and Heparin 
 Currently, no specific treatments are available for DIC in the United States. 
Therapy is limited to supportive care and treatment (i.e. antibiotics) to eliminate the 
underlying infection. Safe and effective treatments for DIC represent an unmet 
therapeutic need. Recombinant thrombomodulin (rTM), antithrombin (AT) and 
unfractionated heparin (UFH) represent three potential therapeutic approaches for this 
patient population. Prior to in vivo examination of the mechanism of action of drug 
mechanism of action, in vitro comparison of the relative anticoagulant activity of these 
drugs is required in order to address potential safety concerns. In contrast to the strong 
anticoagulant activity displayed by UFH, rTM and AT displayed mild and moderate 
anticoagulant activity, respectively. This indicates that rTM and AT may display an 
improved safety profile in humans and may act substantially via non-anticoagulant 
mechanisms. 
Treatment with an anticoagulant or antithrombotic drug is associated with a risk 
of bleeding. Under normal circumstances, this can range from mild (i.e. epistaxis or 
menorrhagia) to severe and potentially fatal (i.e. intracranial hemorrhage). Patients with 
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DIC are at an elevated risk of bleeding in the absence of an anticoagulant drug, and 
therefore particular care must be taken when administering a drug with anticoagulant 
properties to this patient population. Accordingly, an understanding of the anticoagulant 
profiles of drugs for the treatment of DIC is important before in vivo administration. 
Direct comparison of drugs can be accomplished through in vitro coagulation testing. 
These experiments demonstrate that heparin is a strong anticoagulant while AT provides 
moderate anticoagulation in vitro and rTM possesses minimal anticoagulant properties in 
vitro.  
The comparisons made between the three drugs in this study were all performed 
in whole blood at physiologically relevant concentrations. rTM was supplemented into 
human whole blood and rat plasma at concentrations from 0.625-10 μg/ml. This is 
representative of the circulating level of rTM in the management of patients with sepsis-
associated DIC, which is typically within the range of 0.5-1.5 μg/ml (Moll 2004; Vincent 
2013). Heparin was supplemented in human whole blood and rat plasma at 
concentrations of 0.0625-1 U/ml. For similar indications, therapeutic levels of heparin 
range from 1.5-5.0 μg/ml (0.15-0.5 U/ml) in blood (Jaimes 2009; Liu 2014). 
Antithrombin was used at concentrations of 0.0625-1 U/ml in human whole blood and rat 
plasma. In DIC, therapeutic blood levels of AT range from 1-2.5 U/ml (Choi 2014; 
Kienast 2006).  
Similar results were obtained using PT and aPTT. aPTT is designed to monitor 
heparin therapy, and heparin produced maximal results on this test in human plasma at 
low concentrations. In comparison, the effects of rTM and AT on these assays was 
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minimal, even at supertherapeutic doses. The heparin-induced increase in PT was 
relatively low, as PT is not designed to monitor pathways affected by heparin. Neither 
rTM nor AT dramatically increased PT, demonstrating low anticoagulant effects for these 
drugs. Comparable results were obtained using both human blood and rat plasma, 
validating the use of these drugs in the rat model. 
Unlike PT and aPTT, which assess specific components of the coagulation 
cascade, TEG provides a measure of the global effect of a drug on coagulation. The 
pattern of anticoagulation suggested by TEG is the same as that shown using PT and 
aPTT. Heparin strongly inhibits clot formation at low concentration while rTM displays a 
minimal anticoagulant effect throughout the analyzed coagulation range. AT displayed 
intermediate anticoagulant properties. This suggests that while antithrombotic activity 
may be important for the function of rTM, the mechanism of action of this drug is not 
limited to anticoagulation.  
Animal Models of Sepsis and DIC 
Validation of the CLP Model for Sepsis and DIC 
In order to study the effects of rTM, AT, and UFH in vivo¸ a physiologically 
relevant, validated animal model of sepsis-associated DIC was employed. A rat cecal 
ligation and puncture model (CLP) was standardized for use for this purpose. This model 
is appropriate for use in the study of drugs for the treatment of sepsis-associated DIC on 
the basis of its physiological relevance. Active bacterial infection and coagulation 
dysfunction were confirmed by significant elevations in procalcitonin and significant 
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reductions in platelet count, respectively. Furthermore, the elevations in IL-10 and 
nucleosomes detected in CLP rats are consistent with pathophysiological changes in 
human disease.  
Several modeling approaches for sepsis exist and can be divided into two general 
categories: the injection of toxins (most commonly LPS) or the induction of systemic 
infection (i.e. CLP). The CLP model here replicated a clinical scenario of polymicrobial 
infection with gut flora, resulting in systemic inflammation and hemostatic dysfunction, 
and in which treatment was not administered until after the development of disease. The 
presence of active infection is important, as factors involved in the response to infection 
(i.e. nucleosomes) are important to the pathogenesis of sepsis-associated DIC and may be 
affected by treatment with rTM, AT, or UFH. In contrast, the injection of LPS produces 
only a transient sepsis-like scenario, which does not allow for administration of drugs 
after the development of disease or for the study of all drug mechanisms of action.  
The rat CLP protocol used in this study led to the development of sepsis and 
coagulopathy while maintaining a sufficiently low mortality rate (9% in the untreated 
CLP group) to allow for study of the results of drug treatment. This is appropriate, as the 
aim of this study was not to evaluate changes in outcome but rather changes in 
pathophysiology secondary to drug treatment. The pathophysiological changes seen in 
the CLP rats were consistent with those observed in human sepsis patients and validate 
this model system for use in the study of drug mechanisms of action.   
270 
 
 
In the initial validation studies, procalcitonin was measured as an indicator of 
bacterial infection in order to validate the development of sepsis in CLP rats. 
Procalcitonin was undetectable in the majority of sham-operated rats and was 
significantly elevated in the CLP group. This indicates the presence of an active bacterial 
infection as a result of the CLP procedure. The rats in the CLP group also experienced 
significant weight loss compared to sham-operated controls, which is established as an 
indicator of illness in this model (Breuille 1999; Brooks 2007; Nemzeck 2004)  
Platelets were counted as an indicator of hemostatic status. Significant reduction 
in platelets was observed in CLP rats compared to sham-operated controls, indicating the 
development of consumptive coagulopathy in these rats.  
A limited number of additional biomarkers were selected for analysis due to the 
small blood volume of a rat and the availability of methods for the detection of rat 
proteins. The correlations between biomarkers observed in the Utah cohort patients 
justified the selection of a single biomarker or small number of biomarkers representative 
of each process. Although both infection response and endothelial function were 
identified as critical contributors to the pathogenesis of sepsis-associated DIC, this 
analysis was focused on infection response and inflammation. The traumatic nature of the 
cardiac blood puncture blood draw led to significant coagulation activation and prevented 
the accurate measurement of some hemostatic parameters. PT was measured and samples 
that failed to clot excluded from further analysis as serum. Nucleosomes, IL-10, and PAI-
1 were selected for analysis in rat samples. IL-6 and histone H3 could not be detected in 
these samples. It is possible that these mediators do not persist in the blood to the 72 hour 
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time point (Miki 2015). Although TNFα is often measured in studies of sepsis, it was not 
included in this study as it peaks early and transiently in sepsis (Kinasewitz 2004) and 
therefore would not be expected to be detectable at the 72 hour time point.  
Nucleosomes were selected for inclusion in this analysis not only as a biomarker 
of infection response but as a potential mediator of coagulation dysfunction in septic 
patients with therapeutic implications. rTM, AT, and UFH are hypothesized to have non-
anticoagulant activity mediated through interactions with extracellular nuclear 
components, such as nucleosomes. Therefore, an elevation in nucleosomes consistent 
with that seen in human disease, such as that observed in CLP rats compared to sham-
operated controls, is required for the study of the mechanism of action of these agents.  
IL-10 was selected as a classic inflammatory marker. In the Utah cohort, IL-10 
was significantly elevated in sepsis patients and correlated strongly with other notable 
inflammatory markers, including IL-6, IL-8, IFNγ, and MCP-1, making it appropriate for 
use in this analysis. The significant elevation in IL-10 in CLP rats compared to sham-
operated controls is consistent with the pathophysiology seen in humans and further 
validates this model system.  
PAI-1 was selected for inclusion in this study on the basis of reports suggesting 
PAI-1 as a potential means to monitor rTM therapy. However, although PAI-1 was 
detected in the rat plasma; the elevation of PAI-1 in the CLP group compared to sham 
operated controls was not statistically significant.  
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Comparison of Heparin, rTM, and AT in Rats with CLP-Induced Sepsis and DIC 
 This study compared the non-anticoagulant effects of rTM, AT, and UFH in rats 
with CLP-induced sepsis and coagulopathy. The underlying hypothesis was that each of 
the three drugs would exhibit a distinct pattern of non-anticoagulant effects, including 
ant-inflammatory effects and neutralization of circulating nuclear material. Therefore, the 
primary goal in this study was not to compare drug efficacy as quantified by reduction in 
mortality but to understand the interactions of these drugs with factors identified as 
important in human sepsis patients. Treatment with rTM, AT, and UFH resulted in a 
significant reduction in nucleosome levels, showing that interaction with extracellular 
nuclear material is a component of the mechanism of action of each of these agents. UFH 
displayed additional anti-inflammatory effects, with UFH treatment also resulting in a 
significant reduction in IL-10. AT treatment led to additional effects that were not 
quantified in terms of anti-inflammatory activity, resulting in a lessening of weight loss. 
An improved understanding of the non-anticoagulant mechanisms of rTM, AT, and UFH 
may have significant implications for the optimal clinical implementation of these drugs.  
 The approach taken in this study has several advantages. Models of sepsis 
associated DIC are highly variable, and thus a head-to-head comparison is required to 
gain accurate information regarding comparative effects of rTM, AT, and UFH. 
Furthermore, the approach used in this study is highly replicative of the clinical scenarios 
in which these drugs would be employed. Previous studies have demonstrated reduction 
in infection-related factors such as nucleosomes, histones, cfDNA, and HMGB-1 in 
response to treatment with rTM or AT in LPS injection models (Iba, Miki, Hashiguchi, 
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Yamada, & Nagaoka, 2014; Iba, Miki, hasiguchi, Tabe, & Nagaoka, 2014; Takehara 
2017). While this provides in vivo support for the interactions of rTM or AT with these 
factors, it does not address the consequences of active bacterial infection on these 
interactions. NETosis, and therefore the release of nuclear material into blood, 
contributes to bacterial clearance (Araujo 2016; Czaikoski 2016; Yost 2016); modulation 
of nuclear factors by therapeutic agents may be significantly altered in the presence of 
live bacteria.  
 The drug administration protocol used in this study replicates the clinical scenario 
typical of sepsis-associated DIC. In numerous animal studies of treatments for sepsis and 
DIC, drugs are administered at the time of or prior to the induction of sepsis. However, in 
the clinical setting drugs for sepsis are administered after the development of disease. In 
this study, drugs were administered 24 hours after the CLP procedure, allowing time for 
the development of sepsis and DIC. Drug doses were also selected to balance clinical 
relevance with the potential to detect non-anticoagulant effects. The purpose of this study 
was not the generation of a dose-response curve for the non-anticoagulant effects of each 
drug but rather the comparison of the effects of rTM, AT, and UFH. Accordingly, a 
single drug dose was selected for comparison for each drug.  
 rTM was evaluated at a single dose of 1 mg/kg. This is higher than the dose of 60 
μg/kg at which this drug is administered to humans. However, rats have been reported to 
require a higher dose of rTM than humans to elicit a comparable response. In rats, 1 
mg/kg is a commonly used dose, both in the initial preclinical studies (Gonda 1993; 
Mohri 1994) and in more recent work (Hagiwara 2010; Iba 2013; Nagato 2009). 
274 
 
 
 Antithrombin was administered at two doses; 50 IU/kg, replicating a clinically 
utilized dose of 3000 IU in a human, and a higher dose of 125 IU/kg, which is commonly 
used in studies of this drug in rats and may be required to achieve anti-inflammatory 
effects (Iba 2014; Iba 2014; Uchiba 1998; Yamashiro 2001; Yang 1994). Although it is 
hypothesized that higher doses of AT may be required to achieve anti-inflammatory 
effects, no significant differences were observed between the two doses in this study, and 
AT was administered at 125 IU/kg to the majority of rats. This high dose of AT did not 
result in any detectable bleeding. 
 UFH is used clinically at a wide range of doses dependent on indication. The 
range of doses that have been used in animal studies of sepsis is well reviewed by Li et. 
al. and ranges over several orders of magnitude. This high-dose heparin treatment of 
septic animals typically results in increased mortality (Li 2011). Low doses of UFH were 
selected for this study, as these doses may be more appropriate in this disease state. Of 
the 5 rats that received 70 IU/kg UFH, one died within 24 hours of drug administration. 
Blood was visible in the nares and necropsy revealed the presence of a significant amount 
of blood in the GI tract, suggesting that heparin-induced bleeding was the cause of death 
in this rat. All other rats were treated with UFH at 25 IU/kg, and no mortality was seen at 
this dose. No significant differences in biomarker level were apparent between rats on the 
basis of heparin dose. Treatment with heparin at 25 U/kg resulted in a significant 
decrease in both nucleosomes and IL-10 compared to untreated rats. 
When directly compared, rTM, AT, and UFH displayed distinct anti-
inflammatory profiles in rats with CLP-induced sepsis and coagulopathy. All three drugs 
275 
 
 
caused a significant reduction in nucleosomes compared to untreated rats. UFH treatment 
caused a reduction in IL-10, while AT led to a reduction in weight loss. The reduction in 
circulating nucleosomes caused by rTM, AT, and UFH treatment in a model involving 
active bacterial infection is the most notable finding of this study. The results of the 
biomarker profiling studies in the Utah cohort as well as a growing body of literature 
have identified circulating nuclear material as a contributor to the pathophysiology of 
sepsis-associated DIC and a potential therapeutic target. 
This finding further validates the importance of extracellular nuclear material to 
the mechanism of action of rTM. In vitro, rTM has been shown to bind to histones 
(Nakahara 2013) and HMGB-1 (Abeyama 2005) in a protein C independent manner and 
to inhibit histone-induced platelet aggregation. rTM may also contribute to histone 
clearance through the activation of protein C, which degrades histones in its active form 
(Xu 2009). The effect of protein C on nucleosomes, however, are less clear; in a 
retrospective analysis of plasma from children with meningococcal sepsis treated with 
protein C, no reduction in nucleosome levels was observed in treated children (Zeerleder 
2012). Interestingly, histones may also decrease the antithrombotic efficacy of rTM by 
inhibiting TM-dependent activation of protein C (Ammollo 2011). This study 
demonstrates that rTM administration leads to a reduction in circulating nucleosomes as 
well as circulating free histones.  
Heparin may reduce circulating nucleosomes by binding to both nucleosomes and 
histones as well as inducing nucleosome breakdown by releasing histones from 
chromatin (Fuchs 2010; Napirei 2009). Histones bind to heparin as well as endogenous 
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glycosaminoglycans (GAGs) including heparin sulfate (Henriquez 2002). Heparin has 
also been shown to bind to histone-DNA complexes (van Bruggen 1996). The influence 
of heparin treatment on not only histones but also nucleosomes is important to establish, 
as different structures of histones, DNA, and nucleosomes may have different 
procoagulant and proinflammatory processes (Noubouossie 2017). 
Heparin has been shown to inhibit histone-induced platelet interaction both in in 
vitro platelet aggregations and in a mouse model of histone-induced thrombocytopenia 
(Fuchs, Bhandari, & Wagner, 2011). A major concern with the use of heparin in patients 
with sepsis-associated DIC is the risk of bleeding, which was also apparent in the rat 
model. However, several non-anticoagulant heparins have also been shown to possess 
anti-histone or anti-nucleosome properties both in vitro and in vivo (Ammollo 2011; van 
Bruggen 1996; Wildhagen 2014; Zhang 2014). Non-anticoagulant heparins may provide 
an approach to target circulating nuclear material and other inflammatory factors in sepsis 
and DIC patients without causing a significant risk of bleeding. 
In comparison to rTM and heparin, little is known about the potential interaction 
of AT with nucleosomes or other nuclear components. This study demonstrates that AT 
treatment also leads to a reduction in circulating nuclear material. A large proportion of 
the anti-inflammatory activity of AT is mediated through its anticoagulant activity, with 
reduced coagulation resulting in reduced inflammation (J. H. Levy, Sniecinski, Welsby, 
& Levi, 2016). As demonstrated in this experiment, AT does have additional activity 
including the reduction of circulating nucleosomes. In contrast to rTM and UFH, this is 
likely due to the regulation of processes upstream of NETosis. The coagulation 
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independent anti-inflammatory activities of AT are mediated largely through the 
upregulation of prostacyclin and the inhibition of leukocyte adhesion, migration, cytokine 
production, and chemotaxis (Hoffmann 2002; Levy 2016; Roemisch 2002; Souter 2001). 
As treatment of platelets with prostacyclin reduces platelet-induced NET formation 
(Carestia 2016), AT-induced prostacyclin release may reduce the amount of nucleosomes 
released into the circulation. AT also binds to the syndecan-4 receptors on neutrophils, 
reducing activity (Opal 2002).  
The co-administration of low-dose heparin as DVT prophylaxis may explain the 
lack of anti-inflammatory effects in human trials of AT and may reduce the utility of 
these findings. Heparin is an AT-dependent anticoagulant; co-administration of heparin 
with AT results in enhanced heparin-AT binding and anticoagulant activity while 
inhibiting coagulation-independent actions of AT (Hoffmann 2002; Opal 2002; Roemisch 
2002).  
Despite discussion in the literature of additional anti-inflammatory effects of 
rTM, none were observed in this study. Only heparin demonstrated significant reduction 
in generalized inflammation, as assessed through IL-10.  
No drug significantly reduced procalcitonin, although a trend towards 
procalcitonin reduction with heparin was seen. The continued elevation of procalcitonin 
is likely a reflection of persistent bacterial infection; rTM, AT, and UFH do not have 
antibiotic properties. In this study, rats were not treated with antibiotics, and thus 
resolution of the bacterial infection was not anticipated. 
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AT treatment was also associated with reduced weight loss. Sepsis is associated 
with the development of a catabolic state, and weight loss in a CLP model is expected 
and an indicator of illness (Breuille 1999; Brooks 2007; Nemzeck 2004).  
This study demonstrates that rTM, AT, and UFH have distinct non-anticoagulant 
activity profiles in sepsis-associated DIC. UFH demonstrated additional anti-
inflammatory activity in comparison with rTM and AT, leading to a reduction in IL-10 
levels as well as nucleosomes. However, UFH is a powerful anticoagulant associated 
with a high bleeding risk in DIC. Both animal studies and clinical trials have thus far 
failed to show a reduction in mortality with heparin treatment in DIC.  
The reduction in circulating nucleosome levels induced by treatment with rTM, 
AT, and UFH underscores the importance of infection-related nuclear material in sepsis-
associated DIC. This material should be included in future clinical and mechanistic 
studies in order to better understand the pathophysiology of DIC, develop improved 
therapeutic agents, and identify patients for treatment.  
Clinical Implications 
 The results presented in this dissertation have clinical implications with respect to 
both the diagnosis and treatment of patients with sepsis-associated DIC. These studies 
demonstrate that INR, the most commonly used parameter in the identification and 
classification of patients with sepsis-associated coagulopathy, does not provide a 
consistent description of the ongoing coagulation dysfunction in these patients. The 
results of the biomarker profiling in the Utah cohort patients show that alternative 
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approaches, such as measurement of extracellular nuclear material or factors associated 
with endothelial dysfunction, provide more pathophysiolgically relevant insight into 
disease progression. Furthermore, the results of the mathematical modeling in this patient 
cohort provide an approach to predict mortality in sepsis patients, which may be 
important to guide appropriate therapy.  
 The in vitro and in vivo studies of thrombomodulin, antithrombin, and heparin 
provide insight into the mechanisms of action of these potential therapeutic agents. The in 
vitro studies demonstrate that the anticoagulant activity, and therefore the anticipated 
associated bleeding risk, of rTM and AT is minimal in comparison to that of UFH. The 
results from the in vivo studies demonstrate that all three drugs act through non-
anticoagulant mechanisms, including reducing the levels of circulating nuclear material. 
This may provide a means to target therapy with patients with the highest potential to 
respond to therapy.  
Conclusion 
The aims of this dissertation were (1) to understand the molecular pathogenesis of 
sepsis-associated DIC by profiling plasma biomarkers of inflammation, infection, 
endothelial function, and platelet function as well as hemostatic dysregulation and assess 
their relevance to disease progression and outcome, (2), to develop and validate an in vivo 
animal model of sepsis-associated DIC, and (3) to assess the effects and mechanism of 
action of therapeutic modulation on the pathogenesis of sepsis-associated DIC.  
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Evaluation of biomarkers of hemostasis, inflammation, infection, endothelial 
function, and platelet function in the Utah patient cohort revealed that all systems are 
associated with organ failure, severity of coagulopathy, and mortality. However, 
inflammation and hemostasis are more strongly associated with organ failure, whereas 
infection (including extracellular nuclear material) and endothelial function are more 
strongly associated with severity of coagulopathy and outcome.  
A predictive algorithm for outcome was developed which incorporated 
biomarkers of infection, inflammation, endothelial function, and platelet function and had 
superior predictive value to any individual marker. The rat cecal ligation and puncture 
model used in these studies included the infection and coagulation dysfunction that define 
sepsis-associated DIC, and further replicates the inflammatory and infection response 
profile observed in human patients. Finally, rTM, AT, and UFH were shown to have 
distinct activity profiles in terms of both in in vitro coagulation testing and in vivo 
modulation of disease pathophysiology.   
Sepsis-associated DIC is a complex syndrome that involves not only hemostatic 
dysfunction but also inflammation, infection response, and endothelial and platelet 
function. The patient cohorts included in this dissertation demonstrated dysfunction of all 
aspects of hemostasis, including global coagulation testing, individual coagulation 
factors, endogenous anticoagulants, the fibrinolytic system, as well as the endothelium 
and platelets. Although DIC is defined on the basis of coagulopathy, the results presented 
in this dissertation demonstrate that other factors, including inflammation, infection 
response, and endothelial function are associated with both the severity of coagulopathy 
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and with patient mortality. Further study is warranted in order to elucidate the cause and 
effect relationship between coagulation, inflammation, infection response, and 
endothelial activation.  
In conclusion, the results presented in this dissertation provide significant insight 
into the molecular pathogenesis of sepsis-associated disseminated intravascular 
coagulation and its pharmacologic modulation.  
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CHAPTER SIX 
SUMMARY 
This dissertation is focused on the molecular pathophysiology of sepsis-associated 
disseminated intravascular coagulation (DIC) and its pharmacologic modulation. These 
studies included extensive exploration of the hemostatic, inflammatory, infection 
response, endothelial function, and platelet function profiles of human sepsis patients. 
Three drugs—recombinant thrombomodulin (rTM), antithrombin (AT), and 
unfractionated heparin (UFH) were evaluated in vitro and in vivo, for their anticoagulant 
and anti-inflammatory effects in this disease. The results from the major experimental 
protocols included in this dissertation are summarized below.  
Coagulation Profiling in DIC vs. Warfarin Treated Patients 
 1. The international normalized ratio (INR) is commonly used to describe the 
coagulation status of both DIC patients and patients receiving warfarin for therapeutic 
anticoagulation. The underlying cause of the coagulation dysfunction is fundamentally 
different in these two patient populations; accordingly, INR may provide different 
information in these different patient populations. In order to analyze these differences, 
the global coagulation tests INR, aPTT, and fibrinogen as well as protein and functional 
levels of coagulation Factors VII, IX, and X were measured in a cohort of patients 
receiving warfarin anticoagulation and in a cohort of patients with sepsis and  overt or 
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non-overt DIC defined by the ISTH scoring algorithm. In order to better understand 
the pathophysiology underlying the elevation of INR in patients with sepsis-
associated DIC, the relationship of individual coagulation factors and other global 
coagulation tests to INR was compared in patients with DIC to warfarin-treated 
patients.  
 2. In DIC patients, increased INR was associated with a progressive increase 
in aPTT, whereas no such pattern was apparent in warfarin-treated patients. This 
suggests that an elevated INR in DIC patients is reflective of global coagulation 
dysfunction, while in warfarin-treated patients, this finding reflects a targeted dysfunction 
of the extrinsic pathway.  
 3. Functional and protein levels of Factors VII, IX, and X were reduced in both 
warfarin treated and DIC patients compared to healthy controls. In warfarin treated 
patients, Factors VII, IX, and X decreased progressively with increasing INR, 
demonstrating a predictable and regular relationship between coagulation factor 
level and INR in warfarin-treated patients. In contrast, no predictable pattern of 
association between coagulation dysfunction as measured by INR and levels of 
individual coagulation factors was detected in DIC patients. 
 4. Distinct patterns of correlations were seen between coagulation factors and 
global coagulation tests in warfarin-treated patients compared to patients with 
sepsis-associated DIC. In warfarin treated patients, strong correlations were present 
between the levels of individual coagulation factors and INR, but not with fibrinogen or 
284 
 
 
 
aPTT. In contrast, very few strong correlations were present in DIC patients in the levels 
of global coagulation tests as opposed to among individual coagulation factors. This 
confirms that the coagulation deficit described by an elevated INR in DIC patients is 
fundamentally different than that described by a comparable INR in warfarin-treated 
patients.  
Biomarker Profiling in Utah Cohort Patients 
 1. A panel of biomarkers was evaluated in plasma samples collected from 103 
patients with sepsis and well-defined DIC (the Utah cohort). These biomarkers were 
selected to represent several distinct physiological systems: hemostasis, infection 
response, inflammation, endothelial function, and platelet function. Hemostatic 
function was represented by D-Dimer, F1.2, PAI-1, INR, platelet count, and fibrinogen. 
Infection response was represented by nucleosomes, HMGB-1, and procalcitonin. 
Inflammation was represented by IL-2, IL-4, IL-6, IL-8, IL-10, VEGF, IFNγ, TNFα, IL-
1α, IL-1β, MCP-1, EGF, and the IL-6:IL-10 ratio. Endothelial function was represented 
by TFPI, protein C, endocan, Ang-2, and vWF. Platelets were represented by CD40L, 
PF-4, MP, and MP-TF. 
2. Organ failure was quantified using the SOA score. Hemostatic and 
inflammatory biomarkers demonstrated strong associations with organ failure. This 
supports the traditional model of sepsis as a syndrome in which organ failure occurs 
subsequent to overwhelming inflammation. Hemostatic biomarkers were also associated 
with organ failure, supporting the role of coagulation dysfunction in the development of 
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organ failure. The associations between endothelial or platelet function and organ failure 
were less pronounced.  
 3. In order to quantify the associations between the severity of coagulation 
function and the status of each physiological systems, patients were subdivided into three 
groups on the basis of the ISTH scoring algorithm for DIC. At baseline, 20 patients had 
sepsis + no DIC (ISTH score ≤2), 59 had sepsis + non-overt DIC (ISTH score 3-4), and 
24 had sepsis + overt DIC (ISTH score ≥5). In addition to hemostatic parameters 
included in the DIC score (platelet count, INR and D-Dimer), DIC status demonstrated 
strong associations with both infection response and endothelial function. This 
suggests that these processes play a critical role in the development of coagulation 
dysfunction in sepsis patients and should therefore be addressed with respect to the 
diagnosis, prognostic prediction, and response to therapy in these patients. The 
established infection marker procalcitonin varied significantly based on the severity of 
coagulopathy. Additionally, nucleosomes, a component of the nuclear material released 
into the circulation due to NETosis, showed significant variation based on DIC status. Of 
the endothelial markers, both the endogenous anticoagulant protein C and the regulator of 
vascular permeability Ang-2 demonstrated significant variation based on DIC status. 
Only hemostatic markers used in the calculation of the DIC score (platelets, INR, and D-
Dimer) showed significant variation based on DIC status. Fibrinogen, the fourth 
component of the DIC score, did not vary significantly based on DIC status, nor did F1.2 
or PAI-1. Variations in inflammatory cytokines based on DIC status were limited to IL-8 
and EGF, and no platelet biomarkers demonstrated significant association with the degree 
286 
 
 
of coagulation dysfunction. This demonstrates a contrast between the systems involved in 
organ failure and those associated with coagulopathy.  
 4. The primary outcome measure in this patient cohort was 28-day mortality. The 
overall mortality rate among the Utah cohort patients was 14.6%. Association of 
biomarkers with mortality was quantified in two ways; the difference between survivors 
and non-survivors, and predictive value as quantified by the area under the receiver 
operating curve (AUC). Association of biomarkers was quantified both in terms of 
difference between survivors and non-survivors as well as predictive value, quantified by 
the area under the receiver operating curve (AUC). Procalcitonin was significantly 
elevated in non-survivors compared to survivors and provided the strongest predictive 
value of any individual biomarker (AUC=0.77). Infection markers demonstrated 
strong associations with mortality as well as with coagulation dysfunction. In 
addition to procalcitonin, the nuclear protein HMGB-1 was significantly elevated in non-
survivors compared to survivors (AUC=0.67). Endothelial markers also demonstrated 
strong associations with mortality in addition to the severity of coagulation 
dysfunction. Although the endogenous anticoagulant protein C was unsurprisingly 
reduced in non-survivors compared to survivors (AUC=0.81), the strongest predictive 
value for mortality among endothelial markers was found for Ang-2 (AUC=0.76). 
Endocan, an indicator of endothelial activation, was also significantly elevated in non-
survivors compared to survivors. The only variation in hemostatic biomarkers identified 
on the basis of survival was PAI-1; none of the factors included in the DIC score 
demonstrated an association with survival. Limited relationships were observed between 
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mortality and inflammation or platelet function. The inflammatory cytokines IL-6 and IL-
8 as well as the platelet factor PF-4 were significantly elevated in non-survivors 
compared to survivors. Overall, this suggests that infection response and endothelial 
function are significant factors in both the development of coagulation dysfunction 
and in patient outcome. However, inflammatory and coagulation factors more 
traditionally associated with sepsis are the key contributors to organ failure.  
 5. A computational approach was used in order to generate an algorithm to 
predict mortality outcome in sepsis patients. This algorithm incorporated 
procalcitonin, VEGF, IL-6:IL-10 ratio, endocan, and PF-4, thereby representing 
infection, inflammation (including both endogenous pro- and anti- inflammatory 
processes), endothelial function, and platelet activation and had better predictive 
ability for outcome than any individual biomarker. Stepwise linear regression 
modeling was used to generate models for outcome prediction in sepsis patients using an 
unbiased approach to biomarker selection. These models supported the hypothesis that 
sepsis is a complex disease best described not by a single biomarker but rather by a 
combination of biomarkers representative of multiple physiological systems. The best 
model created using this approach incorporated only biomarkers and was based on a 
constant starting assumption. Although the model generated using the linear starting 
assumption had a better predictive value (AUC=0.95 vs. 0.87 for the constant assumption 
model), the constant assumption model was judged to be optimal on the basis of the more 
limited number of biomarkers included.  
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In vitro Coagulation Profiles of Thrombomodulin, Antithrombin, and Heparin 
 1.  Recombinant thrombomodulin (rTM), antithrombin (AT) and unfractionated 
heparin (UFH) are all drugs of interest for the treatment of sepsis-associated DIC. These 
drugs were selected for use in this disease on the basis of their antithrombotic activity, 
mediated through distinct mechanisms. These drugs may also provide benefit through 
anti-inflammatory mechanisms in DIC. Patients with DIC experience an elevated risk of 
bleeding, especially when treated with anticoagulant agents. Accordingly, the 
understanding of the relative anticoagulant properties of drugs selected for use in this 
population is required. The anticoagulant profiles of rTM, AT, and UFH were compared 
in vitro at physiologically relevant concentrations in whole blood and citrated plasma 
acquired from healthy human volunteers.  
2. In the aPTT and TT clotting tests, UFH demonstrated maximal anticoagulant 
activity even at low concentrations. In comparison, the clotting time prolongation by rTM 
and AT was minimal.  The PT test is not designed to measure UFH activity; however, 
UFH still demonstrated greater anticoagulant activity in this test than either rTM or AT. 
In comparison to UFH, a known strong anticoagulant, rTM and AT exhibited 
minimal overall anticoagulant activity in clotting tests. 
3. Thromboelastography was used to compare the global anticoagulant effects of 
rTM, AT, and UFH, with results similar to those seen in the clotting tests. UFH 
demonstrated strong overall anticoagulant activity, even at low concentrations. rTM 
demonstrated minimal anticoagulant activity, even at supertherapeutic 
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concentrations, indicating that while this drug possesses antithrombotic activity, it is not 
anticoagulant and therefore would not be expected to be associated with a markedly 
elevated risk of bleeding. AT demonstrated intermediate anticoagulant activity, with 
marked alterations present in thromboelastographic parameters present at high 
concentrations. This indicates that mechanisms other than direct anticoagulation 
may be at play in the resolution of DIC seen clinically with treatment with rTM or 
AT. 
In vivo Studies 
 1. A cecal ligation and puncture (CLP) model of sepsis and coagulopathy was 
used in rats. This model was designed to yield sepsis and coagulopathy with low 72 hour 
mortality to allow for effective analysis of the drug mechanism of action. Elevated levels 
of procalcitonin in CLP rats compared to sham-operated controls confirmed the 
presence of active infection. The significant reduction in platelet count in CLP-
operated rats compared to sham-operated controls confirmed the presence of 
coagulation dysfunction. The significant increase in IL-10 demonstrated 
inflammation similar to that observed in human disease. Furthermore, nucleosomes 
were significantly elevated in CLP rats compared to sham-operated controls. This is 
consistent with the findings in human disease and further emphasizes the relevance 
of role of nuclear material to sepsis and DIC.  
 2. The anti-inflammatory effects of rTM, AT, and UFH were compared using the 
rat CLP model of sepsis and coagulopathy described above. Drug treatment did not result 
290 
 
 
in a reduction in procalcitonin, indicating that treatment with these agent does not lead 
directly to infection resolution. Treatment with rTM, AT, or UFH did lead to a 
significant reduction in nucleosome level. Due to the potential involvement of 
nuclear material including nucleosomes in the pathogenesis of DIC, this provides an 
anti-inflammatory mechanism by which rTM and AT may contribute the reduction 
in the pathophysiology observed in sepsis. UFH demonstrated additional anti-
inflammatory activities, also leading to a significant reduction in IL-10. However, UFH 
treatment was associated with the potential for fatal bleeding complications.  
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CHAPTER SEVEN 
CONCLUSIONS 
 Sepsis-associated disseminated intravascular coagulation (DIC) is a complex 
clinical condition with high mortality. This disease is characterized by the overwhelming 
inflammatory response to infection characteristic of sepsis as well as the consumptive 
coagulopathy that defines DIC. Patients with DIC experience both thrombotic and 
bleeding complications. Treatments for DIC represent an unmet therapeutic need; 
currently, no treatments are approved in the United States for this indication. 
The purpose of this dissertation was twofold. In order to test the hypothesis 
that DIC would be best described by a combination of biomarkers representative of 
multiple physiological processes, a wide array of biomarkers, representative of 
hemostasis, inflammation, infection, endothelial function, and platelet function, 
were measured in the plasma of a cohort of patients with sepsis and strictly defined 
coagulopathy. The relationship of these markers, and the physiological systems they 
represent, with severity of illness, severity of coagulopathy, and patient outcome was 
assessed. Based on this data, an algorithm to predict mortality in sepsis patients was 
developed, incorporating parameters representative of inflammation, infection, 
endothelial function, and platelet function. Furthermore, the relationship of the 
status of the coagulation cascade to global coagulation function in DIC patients was 
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assessed. Secondly, thrombomodulin, antithrombin, and heparin were studied for 
use in DIC. In vitro coagulation testing was performed to determine the relative 
anticoagulant effects of these drugs. Furthermore, additional anti-inflammatory 
effects of these agents were studied in a rat cecal ligation and puncture model of 
sepsis-associated DIC in order to test the hypothesis that each of these drugs has a 
distinct set of anticoagulant and non-anticoagulant actives. 
The initial identification of patients with sepsis-associated DIC is often based on 
the presence of an elevated INR. Elevated INR is typically indicative of a hypocoagulable 
state; however, DIC patients with an elevated INR are at risk of complications due to 
both thrombosis and bleeding. Therefore, it was hypothesized that the coagulation 
dysfunction resulting in INR elevation is substantially different in DIC patients than in 
patients with other causes of INR elevation such as warfarin anticoagulation. In order to 
better understand the appropriate interpretation of INR in DIC patients, the 
relationship between INR, other global coagulation tests, and coagulation factor 
levels were compared in patients with sepsis-associated DIC to patients receiving 
warfarin anticoagulation. In contrast to warfarin treated patients, where elevated 
INR was associated with a uniform and predictable reduction in coagulation factor 
levels, no predictable pattern of coagulation dysfunction was associated with INR 
elevation in sepsis-associated DIC patients.  
Sepsis is defined as an “overwhelming inflammatory response to infection”, and 
DIC is currently defined on the basis of reactive coagulation dysfunction. However, 
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inflammation and coagulation dysfunction are not the only factors at play in this disease. 
The response to infection, particularly the expulsion of nuclear material into the 
extracellular environment, endothelial function, including the production or loss of 
endogenous anticoagulants, and platelet function also contribute to the pathogenesis of 
DIC. It was hypothesized that assessment of biomarkers representative of the numerous 
processes underlying the development of DIC using plasma samples acquired from septic 
patients would provide greater insight into the molecular pathogenesis of DIC. The 
results of the studies carried out in this dissertation supported the hypothesis that a 
combination of biomarkers representative of multiple physiological systems would 
provide greater insight into the pathophysiology of sepsis-associated DIC than 
markers of a single system. Inflammation and coagulation demonstrated the 
greatest degree of association with organ failure. However, infection response, 
including extracellular nuclear material, and endothelial function, were associated 
with the severity of coagulation dysfunction and patient mortality to a greater 
degree than inflammation, hemostatic markers, or platelet function.  
The identification of patients with the most severe disease is important to target 
treatments with potential associated risks to patients with the greatest potential for 
benefit. To this end, a method to predict mortality in patients with sepsis and DIC would 
be beneficial. Stepwise linear regression modeling was used to generate an algorithm to 
predict mortality in sepsis patients and to test the hypothesis that a combination of 
biomarkers representative of multiple physiological processes would provide better 
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predictive ability for outcome in sepsis patients than a single biomarker. A predictive 
equation for mortality in sepsis patients was generated. This equation predicts 
mortality in sepsis patients based on levels of procalcitonin, VEGF, IL-6:IL-10 ratio, 
endocan, and PF-4. As hypothesized, this algorithm incorporated biomarkers 
representative of multiple physiological systems including infection response 
(procalcitonin), the balance between pro- and anti-inflammatory processes (IL-6:IL-
10 ratio), endothelial function (endocan), and platelet function (PF-4). Furthermore, 
this equation demonstrated a better predictive value for mortality than any 
individual biomarker.  
Safe and effective treatments for DIC represent an unmet therapeutic need. 
Recombinant thrombomodulin (rTM), antithrombin (AT) and unfractionated 
heparin (UFH) represent potential therapeutic approaches for this indication. An 
understanding of the antithrombotic, anti-inflammatory, and other mechanisms by 
which rTM, AT, and heparin may modulate the pathogenesis of sepsis-associated 
DIC may improve the use of this therapeutic agent, including targeting to the 
appropriate patient population, as well as lay groundwork for design and testing of 
future therapeutics for sepsis-associated DIC.  
The risk of bleeding associated with any anticoagulant treatment in DIC is of 
significant concern. Accordingly, the relative anticoagulant activity of rTM, AT, and 
UFH was compared in vitro in both human and rat plasma using both clotting tests and 
thromboelastography. rTM exhibited minimal anticoagulant ability, in contrast to the 
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strong anticoagulation caused by UFH. AT exhibited intermediate anticoagulant 
activity.  
 In order to better understand the mechanisms by which rTM, AT, and UFH exert 
their activities, the effects of these drugs were studied in vivo. A physiologically relevant 
rat cecal ligation and puncture (CLP) model was used, and drugs were administered to 
rats with established bacterial infections. rTM, AT, and UFH all demonstrated anti-
nucleosome effects in a rat model of sepsis-associated DIC. Furthermore, UFH 
exhibited additional anti-inflammatory activity, while AT therapy resulted in 
lessened weight loss. These non-anticoagulant mechanisms may contribute substantially 
to the efficacy of these drugs in sepsis-associated DIC. 
 The work presented in this dissertation contribute to an improved understanding 
of the molecular pathogenesis of sepsis-associated DIC and its modulation by potential 
therapeutic agents. This work included both focused analysis of the status of the 
coagulation system in patients with sepsis-associated DIC as well as integrated 
analysis of numerous biomarkers representative of multiple physiological systems. 
Furthermore, this dissertation presents a mathematical approach designed to 
predict mortality in patients with sepsis, which has clinical implications as a 
potential means to identify patients who will benefit most from treatment.  The 
results in both human samples and animal models identify infection response, 
particularly the presence of nuclear material in the extracellular environment, as an 
important component of the pathophysiology of DIC. The demonstration of the 
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reduction in circulating nuclear material due to treatment with rTM, AT, and UFH 
has implications for the further clinical development of these drugs.    
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APPENDIX A 
IRB AND IACUC APPROVAL INFORMATION 
 
Acquisition of Utah DIC samples  
LU #207958  
Approved 9/15/2015 
University of Utah IRB Approval: IRB_00029495 
Title: Novel Markers of Sepsis and Venous Thromboembolism in Patients with 
Sepsis-Associated Coagulopathy 
 
Acquisition of de-identified patent plasma samples  
IRB #9192051098  
Approved 5/10/1998, continuing approval granted 5/24/2016 
 Continuing approval granted 5/24/2016 
 Title: Loyola Plasma Bank 
 
Blood Draw from Healthy Human Volunteers 
 LU# 9191051098 
 Approved 5/1/1998, continuing approval granted 8/24/2017 
 Title: Normal Donor Blood Collection 
 
Rat Cecal Ligation and Puncture Model  
IACUC #2017-009, LU#209143 
Approved 4/3/2017 
175 rats approved 
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APPENDIX B 
SUPPLEMENTAL DATA TABLES (TABLES 37-76) 
 
 
  
 299 
 
 
Table 37. Hemostatic Biomarker Data in Utah Cohort Patients Compared to 
Healthy Controls 
 
Biomarker Patient Group Mean Median SD SEM Range 
D-Dimer 
(ng/ml) 
Healthy Controls 76 57 71 10 0-249 
Day 0 6,398 5,153 5,870 578 0-36,567 
Day 4 5,603 4,192 4,390 581 335-16,496 
Day 8 5,879 3,681 4,285 782 758-15,283 
F1.2 
(pmol/l) 
Healthy Controls 151 136 60 8.5 83-397 
Day 0 365 232 556 55 39-5,285 
Day 4 468 351 319 42 62-1,309 
Day 8 296 253 190 35 76-746 
PAI-1  
(pg/ml) 
Healthy Controls 7 0.025 13 1.9 0-54 
Day 0 66 38 71 7 0-357 
Day 4 60 45 63 8.4 0-325 
Day 8 47 45 49 8.9 0-173 
INR 
Day 0 1.6 1.4 0.55 0.054 1-5.2 
Day 4 1.5 1.3 0.41 0.054 1-3.2 
Day 8 1.3 1.3 0.18 0.033 1.1-2 
Platelets 
(k/μl) 
Day 0 189 181 101 10 23-571 
Day 4 218 180 137 18 21-680 
Day 8 312 291 167 32 98-737 
Fibrinogen 
(mg/dl) 
Day 0 638 616 254 25 133-1,449 
Day 4 602 627 202 27 153-1,063 
Day 8 635 609 203 37 252-1,269 
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Table 38. Infection Biomarkers in Utah Cohort Patients Compared to Healthy 
Controls 
 
Biomarker Patient Group Mean Median SD SEM Range 
Nucleosomes 
(Units) 
Healthy Controls 7 4.8 6.4 0.93 3.7-36 
Day 0 13 8.2 19 1.9 0-119 
Day 4 23 13 26 3.5 0-136 
Day 8 18 13 21 3.8 0-77 
HMGB-1 
(ng/ml) 
Healthy Controls 1.4 0.13 4.9 0.69 0.04-23 
Day 0 9.1 5.3 13 1.3 0.18-87 
Day 4 8 6.3 7.9 1 0.44-44 
Day 8 8.3 6.3 6.5 1.2 2.3-29 
Procalcitonin 
(pg/ml) 
Healthy Controls 18 11 23 3.2 0-98 
Day 0 1,810 663 3,210 316 8-21,162 
Day 4 1,266 243 3,111 412 7.6-22,162 
Day 8 699 243 1,650 301 5.6-8,751 
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Table 39. Inflammation Biomarkers in Utah Cohort Patients Compared to Healthy 
Controls 
 
Biomarker Patient Group Mean Median SD SEM Range 
IL-2 
(pg/ml) 
Healthy Controls 1.1 0 1.8 0.26 0-6.3 
Day 0 3.4 2.5 3 0.29 0-22 
Day 4 5.5 2.5 9.6 1.3 0-56 
Day 8 3.6 2.5 2.6 0.47 1.6-12 
IL-4 
(pg/ml) 
Healthy Controls 1.3 1.4 1.1 0.16 0-6.7 
Day 0 2.8 2.6 1.4 0.13 0-9.7 
Day 4 3.3 2.5 3 0.4 0.94-18 
Day 8 2.7 2.5 1.6 0.29 1.2-10 
IL-6  
(pg/ml) 
Healthy Controls 1.2 0.94 1.2 0.18 0.25-7.3 
Day 0 165 44 252 25 0-857 
Day 4 82 28 150 20 3.4-764 
Day 8 78 28 157 29 0.63-764 
IL-8 
(pg/ml) 
Healthy Controls 2.6 2.6 0.89 0.13 0.98-5.7 
Day 0 41 12 106 10 0-708 
Day 4 30 16 48 6.3 3.4-317 
Day 8 39 16 60 11 3-278 
IL-10  
(pg/ml) 
Healthy Controls 0.68 0.6 0.36 0.052 0-2.1 
Day 0 16 2.8 78 7.7 0-758 
Day 4 4.6 3 4.2 0.56 0.67-17 
Day 8 5.7 3 13 2.3 0.75-72 
VEGF 
(pg/ml) 
Healthy Controls 4.8 4.6 1.3 0.19 2.1-7.8 
Day 0 28 20 37 3.6 0-339 
Day 4 39 29 35 4.6 3.2-188 
Day 8 29 29 34 6.2 3.7-184 
IFNγ 
(pg/ml) 
Healthy Controls 0.17 0 0.31 0.045 0-1.8 
Day 0 7.3 0.41 50 4.9 0-507 
Day 4 1.2 0.42 2.3 0.3 0-12 
Day 8 0.65 0.42 0.49 0.09 0-2 
TNFα  
(pg/ml) 
Healthy Controls 1.7 1.8 1 0.15 0-6.6 
Day 0 6 4.1 7.2 0.71 0-57 
Day 4 5.2 4.3 4.5 0.59 0.74-29 
Day 8 4.6 4.3 3 0.54 0.84-15 
IL-1α  
(pg/ml) 
Healthy Controls 0.1 0.1 0.11 0.015 0-0.53 
Day 0 0.76 0.31 3.6 0.36 0-37 
Day 4 1.1 0.31 3.1 0.41 0.15-23 
Day 8 1.1 0.31 3.4 0.62 0.1-19 
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Biomarker Patient Group Mean Median SD SEM Range 
IL-1β 
(pg/ml) 
Healthy Controls 0.79 0 1.2 0.18 0-5.6 
Day 0 2.3 1.3 2.3 0.23 0-11 
Day 4 2.8 1.7 3.9 0.51 0.65-25 
Day 8 2.2 1.7 1.6 0.3 0.6-6.6 
MCP-1 
(pg/ml) 
Healthy Controls 89 90 27 3.9 30-150 
Day 0 337 259 257 25 0-802 
Day 4 304 226 212 28 61-802 
Day 8 247 226 173 32 36-802 
EGF 
(pg/ml) 
Healthy Controls 1.4 1.3 1.2 0.17 0-5.4 
Day 0 6.4 4.6 6.2 0.61 0-46 
Day 4 9.5 5.6 10 1.4 1.3-50 
Day 8 8.2 5.6 13 2.3 1.5-56 
IL-6:IL-10 
Ratio 
Healthy Controls 1.8 1.3 2.1 0.31 0.38-15 
Day 0 41 13 70 6.9 0-460 
Day 4 27 9.1 52 6.9 0.55-301 
Day 8 15 9.8 18 3.2 0.59-93 
 
All biomarkers showed significant differences (Mann-Whitney t test, p <0.05) from the 
healthy control population at each time point. Biomarkers were measured in 50 healthy 
controls, 103 patients on Day 0, 57 patients on Day 4, and 30 patients on Day 8. 
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Table 40. Endothelial Biomarker Data in Utah Cohort Patients Compared to 
Healthy Controls  
 
Biomarker Patient Group Mean Median SD SEM Range 
TFPI 
(ng/ml) 
Healthy Controls 61 59 19 2.7 24-106 
Day 0 104 90 72 7.1 4.8-423 
Day 4 89 65 88 12 24-671 
Day 8 87 66 61 11 32-337 
Protein C 
(%) 
Healthy Controls 98 94 18 2.5 71-142 
Day 0 61 52 49 4.8 0-309 
Day 4 57 58 27 3.6 9.7-113 
Day 8 77 58 35 6.4 32-147 
Endocan 
(ng/ml) 
Healthy Controls 1.9 0.85 4.5 0.63 0.17-25 
Day 0 10 6.2 9.5 0.93 1.4-60 
Day 4 9.1 5.3 11 1.4 1.4-50 
Day 8 9.2 5.3 7.9 1.4 1.5-27 
Ang-2 
(pg/ml) 
Healthy Controls 1869 1566 1070 151 503-5,538 
Day 0 15,236 8,435 19,130 1,894 650-13,6317 
Day 4 7,302 5,156 8,639 1,274 48-53,240 
Day 8 10,065 5,156 13,454 2,936 448-61,010 
vWF 
(%) 
Healthy Controls 93 93 19 2.7 59-131 
Day 0 246 251 71 7 107-379 
Day 4 249 253 77 10 38-398 
Day 8 255 253 65 12 154-374 
 
All biomarkers showed significant differences (Mann-Whitney t test, p <0.05) from the 
healthy control population at each time point. Biomarkers were measured in 50 healthy 
controls, 103 patients on Day 0, 57 patients on Day 4, and 30 patients on Day 8.  
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Table 41. Platelet Biomarker Data in Utah Cohort Patients Compared to Healthy 
Controls  
 
Biomarker Patient Group Mean Median SD SEM Range 
Platelets 
(k/μl) 
Day 0 189 181 101 10 23-571 
Day 4 218 180 137 18 21-680 
Day 8 312 291 167 32 98-737 
CD40L 
(pg/ml) 
Healthy Controls 75 70 95 13 0-625 
Day 0 378 236 588 58 0-4756 
Day 4 594 335 627 83 0-2733 
Day 8 624 335 921 168 0-3796 
MP  
(nM) 
Healthy Controls 13 11 12 1.7 0-62 
Day 0 38 31 29 2.9 2.4-159 
Day 4 54 32 50 6.7 2.8-208 
Day 8 49 32 50 9.1 11-225 
MP-TF 
(pg/ml) 
Healthy Controls 0.34 0.25 0.3 0.042 0-1.1 
Day 0 1.1 0.84 0.94 0.092 0.06-7.4 
Day 4 1.2 0.95 0.94 0.12 0-5.1 
Day 8 1.1 0.95 0.87 0.16 0.12-4.6 
PF4 
(ng/ml) 
Healthy Controls 18 18 5.9 0.91 8-35 
Day 0 77 64 35 3.5 15-169 
 
All biomarkers showed significant differences (Mann-Whitney t test, p <0.05) from the 
healthy control population at each time point. Biomarkers were measured in 50 healthy 
controls, 103 patients on Day 0, 57 patients on Day 4, and 30 patients on Day 8, with the 
exception of PF4, which was not measured in patient samples from Day 4 or Day 8.
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Table 42. Baseline Hemostatic Biomarker Levels Stratified by DIC Score 
 
Biomarker Patient Group Mean Median SD SEM Range 
D-Dimer 
(ng/ml) 
Healthy Controls 76 57 71 10 0-249 
No DIC 1,355 1,188 1,113 249 0-3,171 
Non-Overt DIC 6,972 6,312 4,987 649 423-27,871 
Overt DIC 9,189 6,232 7,615 1,554 1,041-36,567 
F1.2 
(pmol/l) 
Healthy Controls 151 136 60 8.5 83-397 
No DIC 242 189 193 43 39-812 
Non-Overt DIC 335 256 276 36 47-1,699 
Overt DIC 540 232 1049 214 63-5,285 
PAI-1 
(pg/ml) 
Healthy Controls 7 0.025 13 1.9 0-54 
No DIC 49 31 48 11 0-176 
Non-Overt DIC 70 39 67 8.7 6.1-256 
Overt DIC 70 30 95 19 0-357 
INR 
No DIC 1.5 1.2 0.96 0.21 1-5.2 
Non-Overt DIC 1.4 1.4 0.18 0.023 1.1-2.3 
Overt DIC 1.9 1.8 0.56 0.12 1.2-3.2 
Platelets 
(K/μl) 
No DIC 243 221 87 19 85-433 
Non-Overt DIC 205 185 95 12 59-571 
Overt DIC 104 81 71 15 23-295 
Fibrinogen 
(mg/dl) 
No DIC 662 650 269 60 221-1,449 
Non-Overt DIC 660 626 231 30 298-1,428 
Overt DIC 567 518 291 59 133-1,404 
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Table 43. Baseline Infection Biomarker Levels Stratified by DIC Score 
Biomarker Patient Group Mean Median SD SEM Range 
Nucleosomes 
(Units) 
Healthy Controls 7 4.8 6.4 0.93 3.7-36 
No DIC 6.3 5.1 6.3 1.4 0-23 
Non-Overt DIC 11 8.6 14 1.8 0-86 
Overt DIC 23 9.7 31 6.3 0-119 
HMGB-1 
(ng/ml) 
Healthy Controls 1.4 0.13 4.9 0.69 0.04-23 
No DIC 5.6 4.8 3.5 0.77 2.5-18 
Non-Overt DIC 9 5.1 15 1.9 0.18-87 
Overt DIC 12 7.5 14 2.8 3.3-66 
Procalcitonin 
(pg/ml) 
Healthy Controls 18 11 23 3.2 0-98 
No DIC 1,309 88 4,700 1,051 8-21,162 
Non-Overt DIC 1,484 687 1,743 227 18-6,493 
Overt DIC 3,028 1,182 4,214 860 83-18,965 
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Table 44. Baseline Inflammatory Biomarker Levels Stratified by DIC Score 
 
Biomarker Patient Group Mean Median SD SEM Range 
IL-2 
(pg/ml) 
Healthy Controls 1.1 0 1.8 0.26 0-6.3 
No DIC 2.9 2.3 1.8 0.41 0-8.3 
Non-Overt DIC 3.4 2.6 3.4 0.44 0-22 
Overt DIC 3.5 2.3 2.7 0.55 0-11 
IL-4 
(pg/ml) 
Healthy Controls 1.3 1.4 1.1 0.16 0-6.7 
No DIC 2.5 2.4 0.65 0.14 1.5-3.9 
Non-Overt DIC 3 2.7 1.6 0.21 0-9.7 
Overt DIC 2.7 2.5 1.1 0.22 1.1-5.5 
IL-6 
(pg/ml) 
Healthy Controls 1.2 0.94 1.2 0.18 0.25-7.3 
No DIC 56 15 168 37 1.9-764 
Non-Overt DIC 197 72 271 35 0-857 
Overt DIC 176 80 244 50 0.27-764 
IL-8 
(pg/ml) 
Healthy Controls 2.6 2.6 0.89 0.13 0.98-5.7 
No DIC 11 5.1 17 3.8 1.7-70 
Non-Overt DIC 43 13 103 13 0-708 
Overt DIC 61 16 147 30 0.51-708 
IL-10 
(pg/ml) 
Healthy Controls 0.68 0.6 0.36 0.052 0-2.1 
No DIC 2.5 1.8 2.4 0.53 0.69-11 
Non-Overt DIC 7.9 2.9 17 2.2 0-101 
Overt DIC 47 4.3 159 32 0.45-758 
VEGF 
(pg/ml) 
Healthy Controls 4.8 4.6 1.3 0.19 2.1-7.8 
No DIC 24 18 19 4.2 5.5-92 
Non-Overt DIC 33 23 45 5.9 0-339 
Overt DIC 20 13 17 3.4 3.2-65 
IFNγ 
(pg/ml) 
Healthy Controls 0.17 0 0.31 0.045 0-1.8 
No DIC 0.6 0.41 0.59 0.13 0-2.7 
Non-Overt DIC 3.7 0.45 8.4 1.1 0-38 
Overt DIC 22 0.4 103 21 0.24-507 
TNFα 
(pg/ml) 
Healthy Controls 1.7 1.8 1 0.15 0-6.6 
No DIC 5.7 2.6 12 2.7 0.74-57 
Non-Overt DIC 6.3 4.7 6.3 0.82 0-36 
Overt DIC 5.5 6.2 2.5 0.5 0.76-9.4 
IL-1α 
(pg/ml) 
Healthy Controls 0.1 0.1 0.11 0.015 0-0.53 
No DIC 0.29 0.28 0.084 0.019 0.16-0.49 
Non-Overt DIC 1.1 0.28 4.8 0.62 0-37 
Overt DIC 0.42 0.35 0.29 0.06 0.15-1.6 
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Biomarker Patient Group Mean Median SD SEM Range 
IL-1β 
(pg/ml) 
Healthy Controls 0.79 0 1.2 0.18 0-5.6 
No DIC 1.2 1 0.56 0.12 0.6-2.9 
Non-Overt DIC 2.8 1.5 2.7 0.35 0-11 
Overt DIC 2.2 1.5 1.9 0.39 0.65-7.5 
MCP-1 
(pg/ml) 
Healthy Controls 89 90 27 3.9 30-150 
No DIC 185 166 122 27 7.6-523 
Non-Overt DIC 380 310 279 36 0-802 
Overt DIC 360 288 244 50 1.3-802 
EGF 
(pg/ml) 
Healthy Controls 1.4 1.3 1.2 0.17 0-5.4 
No DIC 7.5 7.7 5.1 1.1 1.6-23 
Non-Overt DIC 7.3 5.7 7.2 0.93 0-46 
Overt DIC 3.2 2 2.1 0.44 1.4-10 
IL-6:IL-10 
Ratio 
Healthy Controls 1.8 1.3 2.1 0.31 0.38-15 
No DIC 13 7 16 3.7 0.97-69 
Non-Overt DIC 52 17 78 10 0-460 
Overt DIC 36 12 72 15 0.11-344 
 
 
  
 309 
 
 
Table 45. Baseline Endothelial Biomarker Levels Stratified by DIC Score 
 
Biomarker Patient Group Mean Median SD SEM Range 
TFPI 
(ng/ml) 
Healthy Controls 61 59 19 2.7 24-106 
No DIC 95 81 58 13 32-285 
Non-Overt DIC 104 94 69 8.9 4.8-423 
Overt DIC 110 89 90 18 11-407 
Protein C 
(%) 
Healthy Controls 98 94 18 2.5 71-142 
No DIC 80 71 62 14 0-309 
Non-Overt DIC 59 51 40 5.3 2.5-309 
Overt DIC 48 41 52 11 2.7-277 
Endocan 
(ng/ml) 
Healthy Controls 1.9 0.85 4.5 0.63 0.17-25 
No DIC 7 5.1 6.4 1.4 1.4-24 
Non-Overt DIC 9.8 7.4 7.3 0.95 2-34 
Overt DIC 14 6.5 14 3 1.9-60 
Ang-2 
(pg/ml) 
Healthy Controls 1,869 1,566 1,070 151 503-5,538 
No DIC 8,343 5,754 11,187 2,501 961-53,612 
Non-Overt DIC 11,736 82,74 10,563 1,387 650-44,167 
Overt DIC 29,440 17,618 30,732 6,273 
1,816-
136,317 
vWF 
(%) 
Healthy Controls 93 93 19 2.7 59-131 
No DIC 205 183 63 14 107-349 
Non-Overt DIC 260 271 69 9 111-370 
Overt DIC 247 251 73 15 122-379 
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Table 46. Baseline Platelet Biomarker Levels Stratified by DIC Score 
Biomarker Patient Group Mean Median SD SEM Range 
Platelets 
(k/μl) 
No DIC 243 221 87 19 85-433 
Non-Overt DIC 205 185 95 12 59-571 
Overt DIC 104 81 71 15 23-295 
CD40L 
(pg/ml) 
Healthy Controls 75 70 95 13 0-625 
No DIC 476 197 1,032 231 5-4,756 
Non-Overt DIC 412 259 478 62 0-2,923 
Overt DIC 213 148 187 38 13-659 
MP 
(nM) 
Healthy Controls 13 11 12 1.7 0-62 
No DIC 47 36 35 7.7 16-159 
Non-Overt DIC 39 34 29 3.9 2.4-138 
Overt DIC 28 23 20 4.2 2.8-93 
MP-TF 
(pg/ml) 
Healthy Controls 0.34 0.25 0.3 0.042 0-1.1 
No DIC 0.79 0.74 0.58 0.13 0.06-2.3 
Non-Overt DIC 1.1 0.87 0.93 0.12 0.24-7.4 
Overt DIC 1.4 1.1 1.1 0.23 0.41-5.2 
PF4 
(ng/ml) 
Healthy Controls 18 18 5.9 0.91 8-35 
No DIC 82 65 38 8.4 38-169 
Non-Overt DIC 78 66 35 4.7 31-164 
Overt DIC 68 56 32 6.7 15-137 
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Table 47. Association of Baseline Hemostatic Biomarker Levels with Survival 
Biomarker Group Mean Median SD SEM Range AUC 
D-Dimer 
(ng/ml) 
Survivors 6,210 4,781 6,090 652.9 0-36,567 
0.60 Non-
Survivors 
7,211 5,499 4,593 1,186 
181-
15,752 
F1.2 
(pmol/l) 
Survivors 371 223 598.8 64.2 39-5,285 
0.54 Non-
Survivors 
311.9 235 198.8 51.34 96-825 
PAI-1 
(pg/ml) 
Survivors 55.53 35.54 59.24 6.351 0-252.4 
0.70 Non-
Survivors 
114.3 106.8 97.81 25.25 7.53-357.5 
INR 
Survivors 1.563 1.42 0.577 0.06186 1-5.22 
0.60 Non-
Survivors 
1.594 1.5 0.379 0.09475 1.17-2.77 
Platelets 
(k/μl) 
Survivors 194.7 182 103.7 11.12 23-571 
0.61 Non-
Survivors 
153.1 140 72.79 18.8 36-272 
Fibrinogen 
(mg/dl) 
Survivors 628 619 236.8 25.54 133-1,404 
0.51 Non-
Survivors 
693.5 574 338.1 84.51 324-1,449 
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Table 48. Association of Baseline Infection Biomarker Levels with Survival 
Biomarker Group Mean Median SD SEM Range AUC 
Nucleosomes 
(Units) 
Survivors 11.25 8 16.7 1.795 0-118.9 
0.58 
Non-Survivors 22.93 15.6 27.3 7.038 0-85.6 
HMGB-1 
(ng/ml) 
Survivors 8.35 4.775 12.3 1.325 0.18-86.77 
0.67 
Non-Survivors 13.36 7.185 16.3 4.063 2.87-65.67 
Procalcitonin 
(pg/ml) 
Survivors 1213 433.7 1,708 183.1 8-9,083 
0.77 
Non-Survivors 5031 2425 6,550 1691 93.5-21,162 
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Table 49. Association of Baseline Inflammatory Biomarker Levels with Survival 
Biomarker Group Mean Median SD SEM Range AUC 
IL-2 
(pg/ml) 
Survivors 3.374 2.43 3.104 0.3328 0-21.61 
0.52 
Non-Survivors 3.091 2.49 2.093 0.5403 1.6-9.83 
IL-4 
(pg/ml) 
Survivors 2.763 2.56 1.35 0.1447 0-9.71 
0.55 
Non-Survivors 2.946 2.49 1.193 0.3081 1.15-5.5 
IL-6 
(pg/ml) 
Survivors 135.4 41.61 225 24.12 0-857.1 
0.70 
Non-Survivors 294.3 150 319.3 82.45 0.27-764 
IL-8 
(pg/ml) 
Survivors 25.92 9.98 49.42 5.298 0-273 
0.70 
Non-Survivors 83.62 36.06 176.9 45.66 0.51-708 
IL-10 
(pg/ml) 
Survivors 14.18 2.8 81.25 8.711 0-758 
0.58 
Non-Survivors 20.26 2.97 61.09 15.77 0.45-240.8 
VEGF 
(pg/ml) 
Survivors 25.37 20.51 18.97 2.034 0-91.55 
0.57 
Non-Survivors 43.32 14.06 85.05 21.96 6.11-338.8 
IFNγ 
(pg/ml) 
Survivors 8.219 0.41 54.5 5.843 0-507 
0.54 
Non-Survivors 2.108 0.37 6.41 1.655 0.24-25.26 
TNFα 
(pg/ml) 
Survivors 5.825 4.09 7.005 0.7511 0-56.54 
0.52 
Non-Survivors 5.109 6.11 2.933 0.7573 0.76-9.73 
IL-1α 
(pg/ml) 
Survivors 0.8346 0.28 3.952 0.4237 0-37.11 
0.60 
Non-Survivors 0.3727 0.36 0.1347 0.03478 0.16-0.69 
IL-1β 
(pg/ml) 
Survivors 2.19 1.3 2.183 0.234 0-10.95 
0.58 
Non-Survivors 2.635 1.37 2.318 0.5985 0.91-8.83 
MCP-1 
(pg/ml) 
Survivors 322.9 224.8 249.2 26.71 0-802 
0.53 
Non-Survivors 390.2 302.1 284 73.33 1.31-802 
EGF 
(pg/ml) 
Survivors 6.297 4.91 4.947 0.5304 0-27.53 
0.58 
Non-Survivors 7.443 2.63 11.22 2.897 1.4-45.86 
IL-6:IL-10 
Ratio 
Survivors 33.96 12.8 49.11 5.265 0-234.8 
0.61 
Non-Survivors 81.31 16.61 136.2 35.18 0.6-460.3 
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Table 50. Association of Baseline Endothelial Biomarker Levels with Survival 
Biomarker Group Mean Median SD SEM Range AUC 
TFPI  
(ng/ml) 
Survivors 96.2 87.5 57.1 6.1 4.8-407.4 
0.55 
Non-Survivors 141.3 94.9 121.9 31.5 39.1-422.6 
Protein C 
(%) 
Survivors 56.5 53.1 26.1 2.8 0-128 
0.71 
Non-Survivors 37.2 34.4 19.5 5.2 2.7-67.1 
Endocan 
(ng/ml) 
Survivors 9.0 5.5 7.9 0.8 1.4-37.6 
0.58 
Non-Survivors 16.5 13.1 14.8 3.8 2.3-59.7 
Ang-2 
(pg/ml) 
Survivors 12,539 7,413 14,277 1,540 650-66,180 
0.76 
Non-Survivors 30,165 19,300 33,385 8,620 1,812-136,317 
vWF 
(%) 
Survivors 246.5 251 70.17 7.523 107-379 
0.58 
Non-Survivors 239.7 219 79.38 20.5 122-345 
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Table 51. Association of Baseline Platelet Biomarker Levels with Survival 
Biomarker Group Mean Median SD SEM Range AUC 
Platelets 
(k/μl) 
Survivors 194.7 182 103.7 11.12 23-571 
0.61 
Non-Survivors 153.1 140 72.79 18.8 36-272 
CD40L 
(pg/ml) 
Survivors 380.3 243 604 64.76 0-4,756 
0.55 
Non-Survivors 385.6 163 518.3 133.8 3-1,931 
MP 
(nM) 
Survivors 38.61 30.92 29.85 3.277 2.75-159.4 
0.53 
Non-Survivors 34.19 28.07 25.3 6.325 2.35-93.4 
MP/TF 
(pg/ml) 
Survivors 1.062 0.83 0.9971 0.1069 0.06-7.4 
0.62 
Non-Survivors 1.153 1.13 0.5411 0.1397 0.41-2.1 
PF4 
(ng/ml) 
Survivors 79.55 64.96 36.33 3.964 15.37-169.3 
0.70 
Non-Survivors 58.93 55.55 19.22 5.136 41.43-119.1 
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Table 52. Day 4 Hemostatic Biomarker Levels Stratified by DIC Score 
Biomarker Group Mean Median SD SEM Range 
D-Dimer 
(ng/ml) 
No DIC 3,057 1,819 3,455 1,042 335-12,509 
Non-Overt DIC 5,837 4,193 4,440 740 787-16,496 
Overt DIC 7,562 8,302 4,193 1,326 581-12,993 
F1.2 
(pmol/l) 
No DIC 679 518 428 129 103-1,309 
Non-Overt DIC 441 359 281 47 62-1,029 
Overt DIC 329 271 207 65 80-657 
PAI-1 
(pg/ml) 
No DIC 86 45 95 29 0-272 
Non-Overt DIC 46 37 32 5.3 0-120 
Overt DIC 81 54 94 30 14-325 
INR 
No DIC 1.3 1.2 0.12 0.035 1.2-1.5 
Non-Overt DIC 1.4 1.3 0.39 0.066 1-3.2 
Overt DIC 1.8 1.7 0.48 0.15 1.3-2.8 
Platelets 
(k/μl) 
No DIC 214 183 140 42 21-478 
Non-Overt DIC 222 182 119 20 72-534 
Overt DIC 209 131 199 63 63-680 
Fibrinogen 
(mg/dl) 
No DIC 612 657 231 70 233-972 
Non-Overt DIC 593 597 189 31 153-975 
Overt DIC 620 576 234 74 286-1,063 
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Table 53. Day 4 Infection Biomarker Levels Stratified by DIC Score 
Biomarker Group Mean Median SD SEM Range 
Nucleosomes 
(Units) 
No DIC 30 20 25 7.5 6.2-79 
Non-Overt DIC 22 13 29 4.8 0-136 
Overt DIC 18 12 17 5.4 1.5-59 
HMGB-1 
(ng/ml) 
No DIC 6.7 6.6 3 0.96 2.8-13 
Non-Overt DIC 8 5.4 9.5 1.6 0.44-44 
Overt DIC 9.2 8.1 4.3 1.4 4.8-18 
Procalcitonin 
(pg/ml) 
No DIC 827 137 1,424 429 28-4,813 
Non-Overt DIC 850 241 1,266 211 7.6-4,801 
Overt DIC 3,249 705 6,814 2155 77-22,162 
 
  
 318 
 
 
Table 54. Day 4 Inflammatory Biomarker Levels Stratified by DIC Score 
Biomarker Group Mean Median SD SEM Range 
IL-2 
(pg/ml) 
No DIC 3.2 2.1 3.5 1.1 0-13 
Non-Overt DIC 6.6 2.7 12 1.9 0-56 
Overt DIC 4 2.3 4.6 1.5 1.7-17 
IL-4 
(pg/ml) 
No DIC 2.9 2.7 0.96 0.29 2.2-5.3 
Non-Overt DIC 3.7 2.5 3.7 0.61 1-18 
Overt DIC 2.6 2.5 1.5 0.47 0.94-6.5 
IL-6 
(pg/ml) 
No DIC 100 23 184 56 3.4-626 
Non-Overt DIC 67 29 135 22 4.7-764 
Overt DIC 118 73 168 53 5.4-565 
IL-8 
(pg/ml) 
No DIC 52 10 95 29 4.6-317 
Non-Overt DIC 23 15 23 3.9 3.4-100 
Overt DIC 29 18 34 11 4.7-124 
IL-10 
(pg/ml) 
No DIC 5.2 2.4 5.6 1.7 1.1-17 
Non-Overt DIC 4.5 3.1 3.8 0.63 0.97-16 
Overt DIC 4.3 2.7 4.5 1.4 0.67-14 
VEGF 
(pg/ml) 
No DIC 55 46 53 16 9-188 
Non-Overt DIC 37 30 27 4.6 3.7-126 
Overt DIC 29 17 33 10 3.2-114 
IFNγ 
(pg/ml) 
No DIC 0.52 0.27 0.62 0.19 0-2.2 
Non-Overt DIC 1.5 0.51 2.8 0.46 0-12 
Overt DIC 0.9 0.46 1.3 0.4 0-3.8 
TNFα 
(pg/ml) 
No DIC 5.9 3.6 7.8 2.4 1.8-29 
Non-Overt DIC 5 4.5 3.6 0.6 0.74-21 
Overt DIC 4.9 4.9 2.3 0.74 1.6-8.5 
IL-1α 
(pg/ml) 
No DIC 0.36 0.29 0.27 0.08 0.2-1.2 
Non-Overt DIC 0.81 0.33 1.3 0.22 0.18-5.1 
Overt DIC 2.8 0.26 7 2.2 0.15-23 
IL-1β 
(pg/ml) 
No DIC 2.2 1.9 1.5 0.47 0.76-5.1 
Non-Overt DIC 3.2 1.6 4.6 0.77 0.68-25 
Overt DIC 2.2 1.4 2.4 0.77 0.65-8.9 
MCP-1 
(pg/ml) 
No DIC 318 239 200 60 156-802 
Non-Overt DIC 290 222 219 36 61-802 
Overt DIC 335 272 218 69 113-802 
EGF 
(pg/ml) 
No DIC 12 6.3 12 3.8 1.3-44 
Non-Overt DIC 10 6.1 11 1.8 1.4-50 
Overt DIC 4.5 2.2 5 1.6 1.3-17 
 
 
 319 
 
 
Table 55. Day 4 Endothelial Biomarker Levels Stratified by DIC Score 
Biomarker Group Mean Median SD SEM Range 
TFPI 
(ng/ml) 
No DIC 70 64 27 8 42-129 
Non-Overt DIC 81 70 42 6.9 27-192 
Overt DIC 136 63 194 61 24-671 
Protein C 
(%) 
No DIC 76 69 25 7.8 46-113 
Non-Overt DIC 58 61 24 4 9.7-105 
Overt DIC 33 26 19 6.1 13-68 
Endocan 
(ng/ml) 
No DIC 4.5 3.9 2.4 0.73 1.4-8.3 
Non-Overt DIC 8.7 5.3 9.4 1.6 1.4-44 
Overt DIC 16 6.7 17 5.3 2.6-50 
Ang-2 
(pg/ml) 
No DIC 4,688 4,404 3,248 1,027 48-11,316 
Non-Overt DIC 7,886 6,806 9,099 1,517 436-53,240 
Overt DIC 7,829 6,680 7,185 2,272 1,593-24,532 
vWF 
(%) 
No DIC 203 213 99 31 38-353 
Non-Overt DIC 249 248 69 12 123-398 
Overt DIC 291 308 62 20 174-380 
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Table 56. Day 4 Platelet Biomarker Levels Stratified by DIC Score 
Biomarker Group Mean Median SD SEM Range 
Platelets 
(k/μl) 
No DIC 214 183 140 42 21-478 
Non-Overt DIC 222 182 119 20 72-534 
Overt DIC 209 131 199 63 63-680 
CD40L 
(pg/ml) 
No DIC 459 140 684 206 0-2,043 
Non-Overt DIC 672 523 555 93 0-2,150 
Overt DIC 461 208 815 258 0-2,733 
MP 
(nM) 
No DIC 73 57 67 21 5.4-208 
Non-Overt DIC 53 33 43 7.1 7.6-167 
Overt DIC 43 24 58 18 2.8-205 
MP/TF 
(pg/ml) 
No DIC 0.99 0.86 0.63 0.19 0-2.3 
Non-Overt DIC 1.3 0.95 1.1 0.18 0-5.1 
Overt DIC 1.2 1.1 0.65 0.21 0.28-2.4 
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Table 57. Day 8 Hemostatic Biomarker Levels Stratified by DIC Score 
Biomarker Group Mean Median SD SEM Range 
D-Dimer 
(ng/ml) 
No DIC 1,988 2,121 1,105 391 758-3,625 
Non-Overt DIC 7,293 7,105 4,134 881 1,197-15,283 
F1.2 
(pmol/l) 
No DIC 222 231 83 29 87-351 
Non-Overt DIC 322 307 212 45 76-746 
PAI-1 
(pg/ml) 
No DIC 20 18 20 7.2 0-50 
Non-Overt DIC 57 41 53 11 0-173 
INR 
No DIC 1.2 1.2 0.073 0.026 1.1-1.3 
Non-Overt DIC 1.4 1.4 0.18 0.039 1.1-2 
Platelets 
(k/μl) 
No DIC 375 327 203 77 98-737 
Non-Overt DIC 291 250 153 33 102-731 
Fibrinogen 
(mg/dl) 
No DIC 580 520 172 61 443-961 
Non-Overt DIC 655 620 214 46 252-1,269 
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Table 58. Day 8 Infection Biomarker Levels Stratified by DIC Score 
Biomarker Group Mean Median SD SEM Range 
Nucleosomes 
(Units) 
No DIC 9.1 8.5 7.5 2.6 0.8-26 
Non-Overt DIC 21 12 23 5 0-77 
HMGB-1 
(ng/ml) 
No DIC 8.6 6.3 8.2 2.9 2.3-28 
Non-Overt DIC 8.2 6.2 6 1.3 3-29 
Procalcitonin 
(pg/ml) 
No DIC 82 77 60 21 5.6-177 
Non-Overt DIC 923 314 1887 402 6.9-8,751 
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Table 59. Day 8 Inflammatory Biomarker Levels Stratified by DIC Score 
Biomarker Group Mean Median SD SEM Range 
IL-2 
(pg/ml) 
No DIC 6.1 5.8 3.9 1.4 1.7-12 
Non-Overt DIC 2.7 2.5 0.96 0.2 1.6-4.8 
IL-4 
(pg/ml) 
No DIC 3.6 2.9 2.8 0.99 1.5-10 
Non-Overt DIC 2.3 2.2 0.68 0.14 1.2-3.7 
IL-6 
(pg/ml) 
No DIC 5.3 4.5 3.9 1.4 0.63-12 
Non-Overt DIC 104 49 177 38 2-764 
IL-8 
(pg/ml) 
No DIC 6.6 5 3.8 1.4 3-13 
Non-Overt DIC 50 24 66 14 3.1-278 
IL-10 
(pg/ml) 
No DIC 2.2 1.5 1.7 0.62 0.75-5.8 
Non-Overt DIC 7 2.8 15 3.2 0.97-72 
VEGF 
(pg/ml) 
No DIC 17 15 4.2 1.5 12-25 
Non-Overt DIC 33 20 39 8.3 3.7-184 
IFNγ 
(pg/ml) 
No DIC 0.88 0.62 0.6 0.21 0.3-1.7 
Non-Overt DIC 0.57 0.42 0.44 0.093 0-2 
TNFα 
(pg/ml) 
No DIC 3.5 3.5 1.6 0.56 0.84-5.8 
Non-Overt DIC 5 4.4 3.3 0.7 1.5-15 
IL-1α 
(pg/ml) 
No DIC 0.49 0.39 0.3 0.11 0.22-0.92 
Non-Overt DIC 1.3 0.28 4 0.85 0.1-19 
IL-1β 
(pg/ml) 
No DIC 2.8 2.6 1.6 0.57 0.6-5 
Non-Overt DIC 1.9 1.5 1.6 0.34 0.6-6.6 
MCP-1 
(pg/ml) 
No DIC 143 134 85 30 36-245 
Non-Overt DIC 285 259 183 39 40-802 
EGF 
(pg/ml) 
No DIC 6.7 5.5 4.3 1.5 2.1-13 
Non-Overt DIC 8.7 3 15 3.1 1.5-56 
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Table 60. Day 8 Endothelial Biomarker Levels Stratified by DIC Score 
Biomarker Group Mean Median SD SEM Range 
TFPI 
(ng/ml) 
No DIC 62 63 17 6 36-90 
Non-Overt DIC 97 73 69 15 32-337 
Protein C 
(%) 
No DIC 111 121 32 11 65-147 
Non-Overt DIC 65 58 28 5.9 32-136 
Endocan 
(ng/ml) 
No DIC 3.2 2.7 1.6 0.56 1.5-6.4 
Non-Overt DIC 11 9.3 8.2 1.8 1.5-27 
Ang-2 
(pg/ml) 
No DIC 2,154 2,042 737 261 1,072-3,180 
Non-Overt DIC 10,750 8,159 12,888 2,748 448-61,010 
vWF 
(%) 
No DIC 246 251 54 19 182-309 
Non-Overt DIC 258 239 70 15 154-374 
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Table 61. Day 8 Platelet Biomarker Levels Stratified by DIC Score 
Biomarker Group Mean Median SD SEM Range 
Platelets 
(k/μl) 
No DIC 375 327 203 77 98-737 
Non-Overt DIC 291 250 153 33 102-731 
CD40L 
(pg/ml) 
No DIC 400 347 235 83 91-809 
Non-Overt DIC 706 226 1,061 226 0-3,796 
MP 
(nM) 
No DIC 38 32 23 8.3 13-78 
Non-Overt DIC 53 35 56 12 11-225 
MP/TF 
(pg/ml) 
No DIC 0.7 0.56 0.35 0.13 0.48-1.5 
Non-Overt DIC 1.2 0.97 0.96 0.21 0.12-4.6 
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Table 62. Association of Day 4 Hemostatic Biomarker Levels with Survival 
Biomarker Group Mean Median SD SEM Range 
D-Dimer 
(ng/ml) 
Survivors 5,171 4,079 4,160 613 462-16,496 
Non-Survivors 7,238 6,652 5,300 1,676 335-16,325 
F1.2 
(pmol/l) 
Survivors 456 339 326 48 62-1,309 
Non-Survivors 479 419 288 91 156-1,107 
PAI-1 
(pg/ml) 
Survivors 57 40 62 9.1 0-325 
Non-Survivors 68 47 75 24 18-272 
INR 
Survivors 1.5 1.3 0.4 0.059 1-3.2 
Non-Survivors 1.5 1.3 0.49 0.16 1.1-2.8 
Platelets 
(k/μl) 
Survivors 230 197 141 21 21-680 
Non-Survivors 162 130 102 32 63-397 
Fibrinogen 
(mg/dl) 
Survivors 625 646 195 29 153-1,063 
Non-Survivors 491 456 218 69 233-902 
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Table 63. Association of Day 4 Infection Biomarker Levels with Survival 
Biomarker Group Mean Median SD SEM Range 
Nucleosomes 
(Units) 
Survivors 22 13 27 4 0-136 
Non-Survivors 20 17 20 6.4 0-59 
HMGB-1 
(ng/ml) 
Survivors 6.5 6.1 3.9 0.59 0.44-24 
Non-Survivors 11 8 13 4 0.52-44 
Procalcitonin 
(pg/ml) 
Survivors 1,134 189 3,333 491 7.6-22,162 
Non-Survivors 1,624 767 1,936 612 53-4,987 
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Table 64. Association of Day 4 Inflammatory Biomarker Levels with Survival  
Biomarker Group Mean Median SD SEM Range 
IL-2 
(pg/ml) 
Survivors 5.4 2.5 9.6 1.4 0-56 
Non-Survivors 5.9 2.5 10 3.3 1.7-35 
IL-4 
(pg/ml) 
Survivors 3.6 2.6 3.3 0.49 0.94-18 
Non-Survivors 2.3 2.1 0.86 0.27 1-4.1 
IL-6 
(pg/ml) 
Survivors 62 23 123 18 3.4-764 
Non-Survivors 170 65 230 73 17-626 
IL-8 
(pg/ml) 
Survivors 21 14 28 4.1 3.4-126 
Non-Survivors 62 29 92 29 13-317 
IL-10 
(pg/ml) 
Survivors 4 2.9 3.5 0.51 0.67-15 
Non-Survivors 6 3.2 5.7 1.8 1.6-17 
VEGF 
(pg/ml) 
Survivors 41 30 37 5.5 3.2-188 
Non-Survivors 23 19 14 4.4 5.8-44 
IFNγ 
(pg/ml) 
Survivors 1.4 0.46 2.5 0.37 0-12 
Non-Survivors 0.33 0.3 0.28 0.09 0-0.87 
TNFα 
(pg/ml) 
Survivors 5.3 4.2 4.8 0.71 1.5-29 
Non-Survivors 4.2 4.2 2.3 0.73 0.74-8.5 
IL-1α 
(pg/ml) 
Survivors 1.2 0.31 3.4 0.51 0.15-23 
Non-Survivors 0.41 0.25 0.31 0.098 0.22-1.2 
IL-1β 
(pg/ml) 
Survivors 3 1.6 4.3 0.63 0.65-25 
Non-Survivors 1.9 1.6 0.87 0.28 0.91-3.6 
MCP-1 
(pg/ml) 
Survivors 284 222 199 29 65-802 
Non-Survivors 366 271 262 83 61-802 
EGF 
(pg/ml) 
Survivors 11 6.7 11 1.6 1.3-50 
Non-Survivors 5.1 3.3 4.7 1.5 1.4-17 
7 
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Table 65. Association of Day 4 Endothelial Biomarker Levels with Survival 
Biomarker Group Mean Median SD SEM Range 
TFPI 
(ng/ml) 
Survivors 75 63 39 5.8 24-192 
Non-Survivors 152 80 187 59 42-671 
Protein C 
(%) 
Survivors 58 58 28 4.1 9.7-113 
Non-Survivors 53 58 23 7.2 21-86 
Endocan 
(ng/ml) 
Survivors 7.5 5 8.4 1.2 1.4-44 
Non-Survivors 17 12 16 5.1 2.5-50 
Ang-2 
(pg/ml) 
Survivors 6,706 4,443 8,338 1,243 48-53,240 
Non-Survivors 9,817 9,407 6,662 2,107 1,317-24,532 
vWF 
(%) 
Survivors 243 248 73 11 38-380 
Non-Survivors 264 259 93 29 130-398 
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Table 66. Association of Day 4 Platelet Biomarker Levels with Survival 
Biomarker Group Mean Median SD SEM Range 
Platelets 
(k/μl) 
Survivors 230 197 141 21 21-680 
Non-Survivors 162 130 102 32 63-397 
CD40L 
(pg/ml) 
Survivors 666 381 672 99 0-2,733 
Non-Survivors 302 269 230 73 0-777 
MP 
(nM) 
Survivors 60 38 54 8.1 2.8-208 
Non-Survivors 34 27 20 6.2 20-86 
MP/TF 
(pg/ml) 
Survivors 1.2 0.95 0.99 0.15 0-5.1 
Non-Survivors 1 0.81 0.67 0.21 0.28-2.3 
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Table 67. Association of Day 8 Hemostatic Biomarker Levels with Survival 
Biomarker Group Mean Median SD SEM Range 
D-Dimer 
(ng/ml) 
Survivors 4,837 3,468 3,467 708 758-13,167 
Non-Survivors 10,044 10,822 5,021 2,050 1,197-15,283 
F1.2 
(pmol/l) 
Survivors 286 240 190 39 76-746 
Non-Survivors 334 329 204 83 132-683 
PAI-1 
(pg/ml) 
Survivors 40 32 40 8.3 0-173 
Non-Survivors 75 48 72 29 0-165 
INR 
Survivors 1.3 1.3 0.19 0.038 1.1-2 
Non-Survivors 1.4 1.4 0.14 0.058 1.3-1.7 
Platelets 
(k/μl) 
Survivors 314 311 156 33 98-737 
Non-Survivors 306 244 220 90 139-731 
Fibrinogen 
(mg/dl) 
Survivors 641 609 195 40 443-1,269 
Non-Survivors 611 583 254 104 252-947 
 
  
 332 
 
 
Table 68. Association of Day 8 Infection Biomarker Levels with Survival 
Biomarker Group Mean Median SD SEM Range 
Nucleosomes 
(Units) 
Survivors 16 9.2 18 3.6 0-71 
Non-Survivors 26 13 31 13 0-77 
HMGB-1 
(ng/ml) 
Survivors 8.8 6.3 7.1 1.4 2.3-29 
Non-Survivors 6.4 5.8 2.9 1.2 3-9.9 
Procalcitonin 
(pg/ml) 
Survivors 646 126 1,776 363 5.6-8,751 
Non-Survivors 909 654 1,103 450 31-3,052 
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Table 69. Association of Day 8 Inflammatory Biomarker Levels with Survival 
Biomarker Group Mean Median SD SEM Range 
IL-2 
(pg/ml) 
Survivors 3.9 2.7 2.8 0.58 1.6-12 
Non-Survivors 2.7 2.6 0.76 0.31 1.6-3.7 
IL-4 
(pg/ml) 
Survivors 2.8 2.6 1.7 0.35 1.4-10 
Non-Survivors 2.4 2.2 0.95 0.39 1.2-3.7 
IL-6 
(pg/ml) 
Survivors 37 30 41 8.4 0.63-185 
Non-Survivors 243 66 308 126 29-764 
IL-8 
(pg/ml) 
Survivors 21 16 24 4.9 3-116 
Non-Survivors 109 78 102 42 9.8-278 
IL-10 
(pg/ml) 
Survivors 3.3 2.7 2 0.42 0.75-8.5 
Non-Survivors 15 2.5 28 11 1.2-72 
VEGF 
(pg/ml) 
Survivors 23 15 18 3.6 3.7-83 
Non-Survivors 53 30 65 27 8.3-184 
IFNγ 
(pg/ml) 
Survivors 0.71 0.42 0.53 0.11 0.24-2 
Non-Survivors 0.43 0.53 0.25 0.1 0-0.65 
TNFα 
(pg/ml) 
Survivors 4.1 3.9 2.2 0.44 0.84-10 
Non-Survivors 6.7 5.1 4.8 2 1.5-15 
IL-1α 
(pg/ml) 
Survivors 1.3 0.32 3.8 0.78 0.1-19 
Non-Survivors 0.36 0.26 0.21 0.084 0.2-0.64 
IL-1β 
(pg/ml) 
Survivors 2.1 1.6 1.5 0.31 0.6-6.2 
Non-Survivors 2.4 1.7 2.2 0.89 0.84-6.6 
MCP-1 
(pg/ml) 
Survivors 220 231 120 24 36-461 
Non-Survivors 358 281 300 122 40-802 
EGF 
(pg/ml) 
Survivors 7.4 3.5 11 2.3 1.5-56 
Non-Survivors 11 2.7 18 7.4 1.6-47 
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Table 70. Association of Day 8 Endothelial Biomarker Levels with Survival  
Biomarker Group Mean Median SD SEM Range 
TFPI 
(ng/ml) 
Survivors 89 65 67 14 32-337 
Non-Survivors 83 76 32 13 48-132 
Protein C 
(%) 
Survivors 84 76 36 7.3 32-147 
Non-Survivors 50 46 17 7 34-82 
Endocan 
(ng/ml) 
Survivors 8 5.5 7.3 1.5 1.5-25 
Non-Survivors 14 15 9.4 3.8 2.8-27 
Ang-2 
(pg/ml) 
Survivors 7,640 3,180 12,044 2,458 934-61,010 
Non-Survivors 11,730 10,977 10,087 4,118 448-26,908 
vWF 
(%) 
Survivors 8.1 6.3 6.3 1.5 3.1-29 
Non-Survivors 6.4 5.8 2.9 1.2 3-9.9 
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Table 71. Association of Day 8 Platelet Biomarker Levels with Survival 
Biomarker Group Mean Median SD SEM Range 
Platelets 
(k/μl) 
Survivors 314 311 156 33 98-737 
Non-Survivors 306 244 220 90 139-731 
CD40L 
(pg/ml) 
Survivors 523 260 734 150 0-3,468 
Non-Survivors 1,028 412 1,481 605 10-3,796 
MP 
(nM) 
Survivors 48 35 49 10 11-225 
Non-Survivors 54 34 58 23 14-164 
MP/TF 
(pg/ml) 
Survivors 1.1 0.76 0.96 0.2 0.12-4.6 
Non-Survivors 1.1 0.97 0.42 0.17 0.76-1.7 
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Table 72. Association of Baseline Hemostatic Biomarker Levels with Platelet Count 
Biomarker 
Platelets 
(K/μl) 
Mean 
Media
n 
SD SEM Range 
D-Dimer 
(ng/ml) 
< 100 8,945 6,438 8,497 1,854 150-36,567 
100-149 6,908 5,818 3,838 858 305-15,918 
≥ 150 5,285 3,793 5,093 652 0-27,871 
F1.2 
(pmol/l) 
< 100 605 257 1,110 242 63-5,285 
100-149 223 221 117 26 78-512 
≥ 150 325 223 283 36 39-1,699 
PAI-1 
(pg/ml) 
< 100 78 30 100 22 0-357 
100-149 41 25 46 10 1.9-191 
≥ 150 67 44 61 7.8 0-252 
INR 
< 99 1.6 1.5 0.32 0.07 1.2-2.5 
140-149 2 1.6 0.99 0.22 1.2-5.2 
≥ 150 1.4 1.4 0.3 0.039 1-3 
Fibrinogen 
(mg/dl) 
< 100 505 487 222 48 133-1,152 
100-149 656 619 277 64 249-1,404 
≥ 150 666 650 228 29 298-1,449 
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Table 73. Association of Baseline Infection Biomarker Levels with Platelet Count 
Biomarker Platelets (K/μl) Mean Median SD SEM Range 
Nucleosomes 
(Units) 
< 100 21 9.4 29 6.3 0-119 
100-149 15 7 21 4.7 0-88 
≥ 150 9.8 7.8 12 1.6 0-86 
HMGB-1 
(ng/ml) 
< 100 13 6.4 15 3.3 3.2-66 
100-149 7.7 6.3 5.9 1.3 0.18-21 
≥ 150 8.3 4.9 14 1.8 0.65-87 
Procalcitonin 
(pg/ml) 
< 100 3,217 1,995 4,296 937 189-18,965 
100-149 1,718 627 2,312 517 70-8,123 
≥ 150 102 86 71 9.1 4.8-423 
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Table 74. Association of Inflammatory Biomarkers with Platelet Count 
Biomarker Platelets (K/μl) Mean Median SD SEM Range 
IL-2 
(pg/ml) 
< 100 4.7 2.7 5.3 1.1 0-22 
100-149 2.6 2.3 1.5 0.33 0-7.6 
≥ 150 3.1 2.4 2 0.26 0-11 
IL-4 
(pg/ml) 
< 100 3.1 2.5 2 0.43 1.1-9.7 
100-149 2.9 2.8 0.86 0.19 1.5-4.7 
≥ 150 2.6 2.5 1.2 0.15 0-9.7 
IL-6 
(pg/ml) 
< 100 131 52 218 48 1.3-764 
100-149 204 51 276 62 0.27-764 
≥ 150 154 42 246 32 0-857 
IL-8 
(pg/ml) 
< 100 63 16 158 35 4.1-708 
100-149 20 15 23 5.2 0.51-110 
≥ 150 29 7.5 51 6.5 0-238 
IL-10 
(pg/ml) 
< 100 52 4.3 170 37 0.92-758 
100-149 4.4 2.7 5.7 1.3 0.45-27 
≥ 150 5.7 2.6 11 1.4 0-65 
VEGF 
(pg/ml) 
< 100 16 12 12 2.5 4.3-57 
100-149 20 18 14 3 3.2-57 
≥ 150 35 25 45 5.8 0-339 
IFNγ 
(pg/ml) 
< 100 25 0.71 110 24 0.24-507 
100-149 2.1 0.38 6.7 1.5 0-30 
≥ 150 2.8 0.37 7.5 0.96 0-38 
TNFα 
(pg/ml) 
< 100 7.1 7.3 3.4 0.73 1.5-18 
100-149 5 4.3 3.4 0.75 0.74-15 
≥ 150 5.5 3.2 8 1 0-57 
IL-1α 
(pg/ml) 
< 100 0.5 0.36 0.52 0.11 0.15-2.5 
100-149 2.2 0.32 8.2 1.8 0.18-37 
≥ 150 0.37 0.27 0.3 0.039 0-1.6 
IL-1β 
(pg/ml) 
< 100 2.6 1.6 2.8 0.61 0.65-11 
100-149 2.1 1.5 1.8 0.41 0.78-7.8 
≥ 150 2.2 1.3 2.1 0.27 0-9 
MCP-1 
(pg/ml) 
< 100 356 315 223 49 104-802 
100-149 328 291 248 56 1.3-802 
≥ 150 326 207 269 34 0-802 
EGF 
(pg/ml) 
< 100 3.2 2 2.4 0.53 1.3-12 
100-149 4.4 4 2.6 0.59 1.6-11 
≥ 150 8.3 6.6 7.2 0.92 0-46 
IL-6:IL-10 
Ratio 
< 100 19 8.4 27 5.9 0.11-100 
100-149 67 18 94 21 0.6-344 
≥ 150 40 15 69 8.9 0-460 
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Table 75. Association of Baseline Endothelial Biomarker Levels with Platelet Count 
Biomarker Platelets (K/μl) Mean Median SD SEM Range 
TFPI 
(ng/ml) 
< 100 106 92 68 15 11-346 
100-149 101 85 79 18 39-407 
≥ 150 102 86 71 9.1 4.8-423 
Protein C 
(%) 
< 100 58 51 55 12 2.7-277 
100-149 54 44 64 14 0-309 
≥ 150 64 59 41 5.2 2.5-309 
Endocan 
(ng/ml) 
< 100 12 7.5 10 2.2 1.9-38 
100-149 13 6.8 13 3 2.5-60 
≥ 150 8.5 5.3 7.3 0.94 1.4-34 
Ang-2 
(pg/ml) 
< 100 26,696 18,060 30,975 6,759 1,816-13,6317 
100-149 19,897 12,530 19,229 4,300 650-61,808 
≥ 150 9,538 6,892 9,692 1,251 961-53,612 
vWF 
(%) 
< 100 256 260 74 16 128-379 
100-149 274 297 73 16 111-349 
≥ 150 232 244 67 8.6 107-370 
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Table 76. Association of Baseline Platelet Biomarker Levels with Platelet Count 
Biomarker Platelets (K/μl) Mean Median SD SEM Range 
CD40L 
(pg/ml) 
< 100 150 97 152 33 0-659 
100-149 274 249 164 37 57-643 
≥ 150 496 275 730 94 0-4756 
MP 
(nM) 
< 100 20 17 20 4.3 2.8-93 
100-149 29 24 18 4.3 2.4-60 
≥ 150 47 42 31 4 5.6-159 
MP-TF 
(pg/ml) 
< 100 1.2 0.93 0.87 0.19 0.41-3.9 
100-149 1.3 1.1 1 0.23 0.4-5.2 
≥ 150 0.97 0.82 0.93 0.12 0.06-7.4 
PF4 
(ng/ml) 
< 100 51 47 19 4.3 15-107 
100-149 81 67 36 8.2 31-142 
≥ 150 84 66 35 4.6 38-169 
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CLINICAL SCORING SYSTEMS (TABLES 77-82) 
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Table 77. SCCM Definitions for Sepsis and Associated Conditions 
 
Condition Definition 
Bacteremia The presence of viable bacteria in the blood 
Systemic 
inflammatory 
response syndrome 
(SIRS) 
Systemic inflammatory response to a variety of severe clinical 
insults, manifested by two or more of the following conditions: 
 Temperature >38ºC or <36ºC 
 Heart rate >90 BPM 
 Respiratory rate >20 breaths per minute or PaCO2 <32 
mmHg 
 White blood cell count >12,000/mm3, <4,000/mm3, or 
>10% immature forms 
Sepsis 
The systemic response to infection, manifested by two or more 
of the following as a result of the infection: 
 Temperature >38ºC or < 36ºC 
 Heart rate >90 BPM 
 Respiratory rate >30 breaths per minute or PaCO2 <32 
mmHg 
 White blood cell count >12,000/mm3 <4,000/mm3, or 
>10% immature (band) forms 
Severe sepsis 
Sepsis associated with organ dysfunction, hypoperfusion, or 
hypotension, including but not limited to lactic acidosis, 
oliguria, or acute alteration in mental status 
Septic shock 
Sepsis-induced hypotension despite adequate fluid resuscitation 
along with perfusion abnormalities including but not limited to 
lactic acidosis, oliguria, or acute alteration in mental status. 
Patients receiving inotropic or vasopressive agents may not be 
hypotensive at the time perfusion abnormalities are measured 
Sepsis-induced 
hypotension 
Systolic blood pressure <90 mmHg or a reduction of ≥40 mmHg 
from baseline in the absence of other causes of hypotension 
Multiple organ 
dysfunction 
syndrome (MODS) 
Presence of altered organ function in an acutely ill patient such 
that homeostasis cannot be maintained without intervention 
 
Table adapted from (Bone et al., 1992; Levy et al., 2003) 
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Table 78. 2016 SEPSIS-3 Diagnostic Scheme for Sepsis and Septic Shock 
 
Condition  Requirements 
Sepsis 
1. qSOFA ≥2 
a. Respiratory rate ≥ 22/minute 
b. Altered mentation 
c. Systolic blood pressure ≤100 mmHg 
2. SOFA or change in SOFA≥ 2  
Septic Shock 
With a diagnosis of sepsis and despite adequate fluid resuscitation:  
1. Vasopressors required to maintain MAP ≥ 65 mmHg 
2. Serum lactate level > 2 mmol/L 
 
Table adapted from (Singer et al., 2016) 
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Table 79. Sequential Organ Failure Assessment (SOFA) Score 
 
SOFA Score 1 2 3 4 
Respiration 
PaO2/FiO2, mmHg 
<400 <300 
<200 
(with respiratory 
support) 
<100 
(with respiratory 
support 
Coagulation 
Platelets, 103/mm3 
<150 <100 <50 <20 
Liver 
Bilirubin, mg/dl 
(μmol/l) 
1.2-1.9 
(20-32) 
2.0-5.9 
(33-101) 
6.0-11.9 
(102-204) 
>12.0 
(>204) 
Cardiovascular 
Hypotension 
(Doses given in 
μg/kg*min) 
MAP < 
70 
mmHg 
Dopamine ≤ 5 
Or 
dobutamine, 
any dose 
Dopamine > 5 
Or epinephrine 
≤ 0.1 
Or 
norepinephrine 
≤ 0.1 
Dopamine > 15 
Or epinephrine 
> 0.1 
Or 
norepinephrine 
> 0.1 
Central nervous 
system 
Glasgow Coma 
Score 
13-14 10-12 6-9 <6 
Renal 
Creatinine, mg/dl 
(μmol/l) or urine 
output 
1.2-1.9 
(110-
170) 
2.0-3.4 
(171-299) 
3.5-4.9 
(300-440) 
Or <500 ml/day 
>5 
(>440) 
Or <200 ml/day 
 
Table adapted from (Vincent et al., 1996) 
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Table 80. International Society of Thrombosis and Hemostasis (ISTH) Scoring 
System for DIC 
 
Variable Value Points 
Platelets (K/μL) 
>100 0 
50-100 1 
<50 2 
INR 
<1.3 0 
1.3-1.7 1 
>1.7 2 
D-Dimer (ng/mL) 
<400 0 
400-4000 2 
>4000 3 
Fibrinogen (mg/dL) 
>100 0 
<100 1 
Table adapted from (Taylor et. al, 2001). A score of 5 or more is indicative of overt DIC. 
 
Table 81. Japanese Association for Acute Medicine (JAAM) Scoring System for 
Overt DIC 
Variable Value Points 
Systemic Inflammatory Response 
Syndrome (SIRS) Criteria 
≥ 3 1 
0-2 0 
Platelet Count (109/L) 
< 80 or 50% decrease in 24 hours 3 
81-120 or 30% decrease in 24 hours 1 
≥ 120 0 
Prothrombin Time (Patient 
Value/Normal Value) 
≥ 1.2 1 
< 1.2 0 
Fibrinogen/fibrin degradation 
products (mg/L) 
≥ 25 3 
10-24 1 
< 10 0 
Table adapted from (Gando et al., 2006). A score of 4 or more is indicative of DIC.  For 
the purposes of this algorithm, SIRS criteria include (1) temperature > 38ºC or < 36ºC, 
(2) heart rate > 90 beats per minute, (3) Respiratory rate > 20 breaths per minute or 
PaCo2 < 4.3 kPa (4) white blood cell count > 12,000 cells/mm
3, <4,000 cells/mm3, or 
10% bands 
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Table 82. Acute Physiology and Chronic Health Evaluation (APACHE) II Scoring System  
 
Physiological 
Variable 
Points 
+4 +3 +2 +1 0 +1 +2 +3 +4 
Temperature, 
(ºC) 
≥ 41 39-40.9 -- 38.5-38.9 36-38.4 34-35.9 32-33.9 30-31.9 ≤ 29.9 
Mean Arterial 
Pressure 
(mmHg) 
≥ 160 130-159 110-129 -- 70-109 -- 50-69 -- ≤ 49 
Heart Rate 
(BPM) 
≥ 180 140-179 110-139 -- 70-109 -- 55-69 40-54 ≤ 39 
Respiratory 
Rate  
≥ 50 35-49 -- 25-34 12-24 10-11 6-9 -- ≤ 5 
Oxygenation  
(FiO2 ≥ 0.5; use 
A-a DO2) 
≥ 500 350-499 200-349 -- < 200 -- -- -- -- 
Oxygenation  
(FiO2 < 0.5; use 
PaO2, mm Hg) 
-- -- -- -- > 70 61-70 -- 55-60 < 55 
Arterial pH ≥ 7.7 7.6-7.69 -- 7.5-7.59 7.33-7.49 -- 7.25-7.32 7.15-7.24 < 7.15 
Serum Na 
(mmol/L) 
≥ 180 160-179 155-159 150-154 130-149 -- 120-129 111-119 ≤ 110 
Serum K 
(mmol/L) 
≥ 7 6-6.9 -- 5.5-5.9 3.5-5.4 3-3.4 2.5-2.9 -- < 2.5 
Serum 
creatinine 
(mg/dL) 
Double score for 
acute renal failure 
≥ 3.5 2-3.4 1.5-1.9 -- 0.6-1.4 -- < 0.6 -- -- 
Hematocrit (%) ≥ 60 -- 50-59.9 46-49.9 30-45.9 -- 20-29.9 -- < 20 
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Physiological 
Variable 
Points 
+4 +3 +2 +1 0 +1 +2 +3 +4 
White Blood 
Count (1000s) 
≥ 50 -- 20-39.9 15-19.9 3-14.9 -- 1-2.9 -- < 1 
Glasgow Coma 
Score 
Score = 15 minus Glasgow Coma Score 
Age Points 0 points for age < 44 years; 2 points 45-54 years;  3 points 55-64 years; 6 points ≥ 75 years 
Chronic Health 
Status Points 
If immunocompromised or history of severe organ insufficiency: 2 points for elective postoperative patients; 5 
points for non-operative patients or emergency postoperative patients 
Table adapted from (Knaus et. al. 1985) 
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MATLAB CODE FOR STEPWISE LINEAR REGRESSION MODELING 
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% Clear all clears all variables in workspace. 
% Close all closes all open figures 
clear all; close all; 
  
% Set this up the first time you use the program.  Afterwards, you 
% shouldn't have to change these lines again. 
cd('C:\users\scott\desktop\');     % Root directory for patient data 
  
try 
  [filename, pathname] = uigetfile('*.xlsx;*.xls','Select Patient Data 
File','multiselect','off'); 
  if isnumeric(filename) 
    ME1 = MException('Filename:NoFileSelected','No excel file 
selected'); 
    throw(ME1) 
  end 
  
% Imports Excel file containing patient data in following format: 
% Top row - header with column names(biomarkers / clinical variables) 
% First column - Individual sample names 
% Second column - Outcome variable (i.e. mortality) 
% Each column represents a biomarker, each row represents a patient 
   
  fullpath = fullfile(pathname,filename); 
  T = readtable(fullpath,'readrownames',true); 
  [nPatients,nBiomarkers] = size(T); 
  
% Runs the stepwise linear modeling function (output variable mdl) 
% Can specify starting model as 'linear' or 'constant' (2nd term) 
% Can also specify other constraints: categorical variables, variables  
% to exclude, changes to PEnter/PRemove values, etc.  
   
  mdl = stepwiselm(T,'linear','responsevar',1,'upper','linear'); 
   
% Records the names of the markers included in the model 
% (IncludedMarkers), the coefficient table produced by the stepwiselm 
% function (ModelSummary), the estimated coefficients to be used in 
% calculation (CoefficientsEstimate), and the values of the model for 
% each of the patients (PtValues) 
 
  IncludedMarkers = mdl.CoefficientNames;            
  ModelSummary = mdl.Coefficients; 
  CoefficientsEstimate = mdl.Coefficients.Estimate; 
  PtValues = mdl.Fitted; 
   
% Exports model data and results to Excel file with user-determined  
% name. Includes model results with included variables coefficients  
% (Sheet 1)and results table including patient ID, mortality, and  
% calculated value of the model (Sheet 2) 
 
  PtID = T.Properties.RowNames;         % Patient ID Identifiers 
  PtMortality = T.Mortality;            % Mortality value as 1 or 0 
  ResultsTable = table(PtID,PtMortality,PtValues); 
  defaultfilename = 'output.xlsx'; 
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  filename = uiputfile(defaultfilename, 'Specify Output File Name'); 
  writetable(ModelSummary,filename,'Sheet',1,'WriteRowNames',true); 
  writetable(ResultsTable,filename,'Sheet',2); 
   
catch ME1 
  if     strcmp(ME1.identifier,'MATLAB:dlmread:InvalidInputType') 
      error('MATLAB:dlmread:InvalidInputType','Must select at least 
one file'); 
  elseif strcmp(ME1.identifier,'Filename:NoFileSelected') 
      error('Filename:NoFileSelected','Must select at least one 
file'); 
  else       
  disp('The program encountered an error') 
  disp(ME1.identifier); 
  disp(ME1.message); 
  disp(' '); 
  disp([ME1.stack(1).name, ', line: ', num2str(ME1.stack(1).line)]); 
  disp('Type ''dbquit'' or ''return'' to exit debug mode.'); 
  keyboard; 
  error(ME1); 
  end 
end 
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